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Abstract 
 
Protozoan parasites of the genus Plasmodium are the causative agent of malaria.  The 
most severe form of human malaria is caused by P. falciparum, responsible for 
approximately three quarters of a million deaths each year.  One major problem in the 
treatment of malaria is resistance to existing chemotherapies.  Consequently, there is 
an urgent need to identify and validate novel drug targets. 
 
A possible recently identified drug target is the PfNitA protein of P. falciparum which 
contains orthologues in other Plasmodium species but is absent from humans.  The 
gene is annotated as a putative formate-nitrite transporter and orthologues are found 
in a range of prokaryotes as well as the lower eukaryotes algae and fungi.  To 
determine the biological function of the protein, pfnita was expressed in Escherichia 
coli strains lacking the endogenous formate and nitrite transporters.  In order to 
analyse the essentiality of the gene a reverse genetics approach was taken and the 
data discussed.  Results indicate that the PfNitA protein is located in the plasma 
membrane and digestive vacuole of intraerythrocytic parasites suggesting a role in the 
uptake or excretion of metabolites. 
 
A second complexity with regard to treatment is the lack of a vaccine.  A problem in 
crating a vaccine is antigenic variation.  The PIR family of proteins contain a so-called 
hypervariable domain that has led to the suggestion that the family may play a role in 
antigenic variation.  The objective of the work carried out in this thesis was to 
investigate the topology and structure of the PcCir2 protein of Plasmodium chabaudi, 
using E. coli as the expression host.  The topology of Cir2 has been examined by 
means of reporter fusions and overexpression/purification studies undertaken towards 
crystallisation.  As the PcCir2 amino acid sequence does not show significant homology 
to other proteins, structural data may provide insights into potential functional or 
binding domains. 
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1 Introduction 
 
1.1 Overview of Malaria 
The genus Plasmodium consists of single-celled protozoan parasites, of the Phylum 
Apicomplexa, which includes the opportunistic human parasites Toxoplasma gondii and 
Cryptosporidium parvum and parasites of animals such as Babesia spp. and Theileria 
spp.  Plasmodium infects a range of animals including humans, causing the disease 
malaria (Roberts and Janovy, 2006).  There are five species that give rise to health 
concerns in humans.  Four of these are Plasmodium falciparum, P. vivax, P. ovale and 
P. malariae, while the fifth species, P. knowlesi, an Old World monkey malaria 
causative agent, is known to produce human infections in four Asian countries (IAMAT, 
20112).  P. falciparum is the deadliest of the species and is responsible for the majority 
of morbidity and mortality caused by malaria.  The World Health Organisation (WHO)3 
has estimated that half of the world’s population is at risk of infection.  Around 243 
million of those at risk contract the disease each year and more than three quarters of 
a million die.  The disease is widely spread across the globe, but predominantly affects 
developing countries (Figure 1.1). 
 
The term malaria was first coined in Italy as mal aria and translates to bad air, as the 
disease was associated with ‘bad air’ from swamp areas.  However, we know now it is 
not the air from the swamps in which the disease is transmitted, but from the 
mosquitoes which breed in the stagnant water found in such areas.  The transmission 
of malaria can be increased due to certain factors, for example: climate changes, 
political unrest and economic conditions (Packard, 2007). 
 
Malarial fevers have long been associated with particular times of the year in endemic 
countries.  In India malaria was referred to as autumnal fever and was especially 
prevalent after heavy rains.  This correlates to the monsoon season that occurs in 
summer through early autumn, with disease peaking towards the end of the rains.  
Malaria levels can be affected by other circumstances such as political unrest.  Political 
unrest can see displacement of large populations into refugee camps.  Such camps are 
excellent opportunistic breeding grounds for diseases such as malaria as well as 
                                                 
2 http://www.iamat.org/pdf/world_malaria_risk_chart.pdf.  Accessed on 11 July 2012. 
3 http://www.who.int/malaria/en/.  Accessed on 14 February 2012. 
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cholera and dysentery (Packard, 2007). an inevitable consequence of high density 
habitation in unsanitary conditions. 
 
 
Figure 1.1:  Global distribution of malaria.  Map displaying the global distribution of malaria in 2010, 
reproduced from WHO4.  Regions are highlighted by colours related to the number of cases reported.  
Areas with no reported data are represented by a pale grey colour and those with no malaria cases are in 
green. 
 
Malaria typically presents with a periodic fever every 2 or 3 days, the interval 
depending on the species.  Other symptoms may include myalgia, general malaise and 
headaches.  The latter are very mild effects and make it difficult to discern between 
malaria and, for example, the common cold.  If not treated quickly, the infection 
quickly progresses giving rise to the more serious symptoms of malaria5.  These 
include malarial anaemia, lactic acidosis and cerebral infection.  The pathogen has 
evolved ways to avoid the human immune response such as rosetting where infected 
cells stick to uninfected erythrocytes to avoid removal by the spleen and immune 
                                                 
4 http://gamapserver.who.int/mapLibrary/Files/Maps/Global_Malaria_ReportedCases_2010.png.  Accessed 
on 11 July 2012. 
5 http://www.who.int/malaria/en/.  Accessed on 14 February 2012. 
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avoidance through antigenic variation (MacKinnon et al, 2002).  Such immune 
avoidance mechanisms lengthen the infection that in turn increases the associated 
morbidity.  Clearly malaria is a terrible scourge of humans and a major effort in its 
elimination is required. 
 
1.2 Life Cycle of Malaria Parasites 
 
It was the collaboration between Sir Patrick Manson, now heralded as the Father of 
Tropical Medicine, and his young mentee, Sir Ronald Ross, that first elucidated the 
mode of transmission of malaria.  The research work was deemed to be so important 
that Ross was awarded the Nobel Prize in Physiology and Medicine in 1902 (Ross, 
1902).  The liver stage of the life cycle was later revealed and much of the research 
was carried out by Prof. P. C. C. Garnham (Vickerman, 2005).  An individual is infected 
through the bite of an infected female Anopheline mosquito (Figure 1.2, 1).  
Sporozoites from the mosquito’s salivary gland are injected into the skin and make 
their way to the bloodstream.  It has been estimated that 15 – 200 sporozoites are 
injected with each bite (Vanderberg et al, 1977, in Mota and Rodriguez, 2004). 
 
Upon entry into the mammalian host, the sporozoites make use of the circulatory 
system and are transported to the liver (Figure 1.2, 2).  When the parasites reach the 
liver, they actively force their way through many hepatocytes before coming to rest in 
a cell where they form a parasitophorus vacuole (PV) and initiate the infection (Silvie et 
al, 2004).  The sporozoite undergoes an asexual stage of replication known as 
schizogony in which up to 30 000 new cells known as merozoites can be produced 
(Ménard, 2000). 
 
Following liver stage replication, the parasites re-enter the circulation by causing the 
detachment of the hepatocyte from the liver, followed by the budding of parasite filled 
vesicles known as merosomes (Sturm et al, 2006).  The merosome breaks down in the 
blood and many thousands of merozoites are now free to infect the erythrocytes.  
Garnhams’ work demonstrated the hypnozoite stage of the parasite species P. ovale 
and P. vivax (Vickerman, 2005).  The hypnozoites form a latent stage of malaria where 
they lie dormant in liver hepatocytes.  These latent parasites are the cause of malaria 
recrudescence in patients thought to have been cured of the disease. 
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Figure 1.2: Life cycle of the malaria parasite.  The figure illustrates the progression of the parasite 
through the developmental stage in the mosquito, transmission to the human mammalian host and the 
intraerythrocytic developmental cycle (IDC) which causes the clinical disease malaria.   A description of the 
parasites’ life cycle is provided in the following text.  Image taken from the National Institutes of Health 
(USA) website6. 
 
It takes a malaria parasite approximately 30 seconds (s) to invade a red blood cell 
(RBC), offering only a limited opportunity for immunological recognition of the 
merozoite stage parasite.  The parasite goes through a stage of intraerythrocytic 
replication which gives rise to new merozoites (Figure 1.2, 3).  The replicative stage 
sees the parasite start as a ring (due to its distinctive outline) quickly followed by the 
development of a trophozoite.  The trophozoite is particularly metabolically active 
(Tuteja, 2007).  The final stage of the intraerythrocytic developmental cycle (IDC) 
occurs with replication of the parasites in the schizont stage.  The erythrocytic 
schizogony produces a multinucleate cell (16 – 32 nuclei) followed by division into 
daughter cells, which engenders the infective merozoites released from the RBCs.  The 
rupture of the RBCs gives rise to the periodic fevers characteristic of malaria infection.  
Once inside the erythrocytes the parasites cause changes in the RBC membrane 
(RBCm) (Maier, 2009).  Such modifications allow the exchange of materials between 
the parasite and the extracellular medium.  These modifications may also aid the 
                                                 
6 http://www.niaid.nih.gov/topics/malaria/pages/lifecycle.aspx.  Accessed: 11 July 2012. 
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parasite in its evasion of the host immune system (Sections 1.5 and 1.6, respectively).  
The parasites may differentiate into male and female gametocytes representing the 
sexual stage which allows sexual replication in the mosquito (Figure 1.2, 4). 
 
Female macrogametocytes and male microgametocytes are ingested from the human 
circulation when a female Anopheline mosquito feeds on an infected host.  The 
parasites are ingested with the blood meal into the midgut of the mosquito, in the 
midgut, the male gametocyte develops into 4-8 flagellated microgametes while the 
female develops into a spherical macrogamete (Sinden et al, 1978).  Fertilisation of a 
macrogamete forms a zygote, which becomes a motile ookinete (Figure 1.2, 5).  The 
ookinete burrows into the midgut epithelium and forms a cyst or oocyst on the basil 
lamina.  Many sporozoites form in the oocyst through asexual multiplication until they 
are released into the body cavity of the mosquito (Figure 1.2, part 6) (Sinden et al, 
1978).  The sporozoites migrate to the salivary gland of the mosquito where may 
remain for 1 – 2 months until injection into a new host to continue the cycle (Tuteja, 
2007). 
 
1.3 Biochemistry and Cellular Morphology 
 
Although Plasmodium species are eukaryotic cells, they contain a number of unusual 
organelles and biochemical pathways that are absent from the mammalian host.  The 
absence of these pathways in the human cells makes these pathways and organelles 
attractive as potential novel drug targets.  An overview of the organelles present in a 
trophozoite stage parasite is presented in Figure 1.3. 
 
1.3.1 Apicoplast 
The Apicomplexans are the only organisms known to contain an organelle called the 
apicoplast.  The apicoplast is so called from apical complex and chloroplast, and is 
thought to be a relic of algae formed by secondary endosymbiosis (Lim and McFadden, 
2010).  The organelle contains its own 35 kb genome coding for 30 proteins, however 
many of what were once apicoplast genes have been tranferred to the nucleus.  Any 
proteins encoded in the nucleus must be imported to the apicoplast to function.  This 
organelle is surrounded by four membranes and therefore proteins destined for the 
apicoplast must traverse these membranes.  Proteins containing a bipartite signal 
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extension on the N-terminus are targeted to the apicoplast using a typical chloroplast-
entry like peptide that mediates transport (Mullin et al, 2006). 
 
 
 
 
Figure 1.3:  Morphology of the malaria parasite. The figure depicts a trophozoite parasite, and has 
been drawn from electron microscopy images.  The image was taken from Bannister et al (2000).  Of note 
are the plastid (apicoplast) and pigment vacuole (digestive vacuole) which are discussed below. 
 
1.3.2 Digestive vacuole 
The parasite, residing in the RBC acquires certain nutrients by the degradation of 
haemoglobin (Hb) from the ingested erythrocyte cytoplasm.  Between 60 – 80 % of 
the Hb is utilised (Francis et al, 1997).  The ingestion of Hb peaks during the late 
trophozoite and schizont stages (Naughton et al, 2010).  The degradation of Hb occurs 
in an acidic vacuole known as the food or digestive vacuole (DV).  The Hb is 
hydrolysed into two molecules, globin and haem.  The globin is further degraded into 
small peptides and amino acids for use by the parasites in protein synthesis.  The 
haem, which is toxic to the parasite, is packaged into haemozoin.  The haem 
detoxification process is unique to malaria parasites.  In addition, it is thought that the 
parasites may gain iron through this process (Rosenthal and Meshnick, 1996).  The 
acidic pH (5.0 – 5.4) of the food vacuole is not low enough to ensure full breakdown of 
the haemoglobin and therefore various enzymes are also required. A cocktail of 
proteases including aspartic, cysteine, and metallopeptidases are located in the DV and 
play a major role in the hydrolysis of Hb (Drew et al, 2008). 
Introduction Chapter 1 
 
[7] 
 
1.3.3 Carbon metabolism 
It is known that there is a high demand for glucose during the intraerythrocytic stages 
of the parasite (Slavic et al, 2010).  It was previously thought that the parasite lacked 
a functional tricarboxylic acid (TCA) cycle in the intraerythrocytic form.  The main 
energy gain was thought to be through glycolysis with lactate being the major end-
product.  It is now accepted that all the known TCA cycle enzymes are present in the 
genome and are expressed at these stages (Hall et al, 2005).  The TCA cycle still needs 
to be fully characterised in Plasmodium, however new information regarding the details 
of the TCA cycle is becoming apparent, and a novel link between glycolysis and the 
TCA cycle is emerging (Dr. J. Storm and S. Sethia, personal communication).  The 
proposed carbon source for the TCA cycle is not glucose as in most organisms, but 
rather glutamine.  In this regard glutamine is converted to oxoglutarate in the 
cytoplasm and is transported into the mitochondrion, possibly through the putative 
malate:oxoglutarate antiporter (Nozawa et al, 2011 and Olszewski and Llinas, 2011). 
 
The TCA cycle in Plasmodium is believed to consist of two branches, the oxidative 
branch and the reductive branch.  The reductive branch provides acetyl co-enzyme A 
(Olszewski et al, 2010), while the succinyl co-enzyme A produced by the oxidative 
branch is used for haem biosynthesis (Ginsburg, 2010).  Thus, the main source of ATP 
is through glycolysis.  The electron transport chain (ETC) is critical for the parasites 
survival; for example, the anti-malarial atovaquone is an analogue of ubiquinone and 
inhibits the cytochrome bc1 complex in the ETC (Painter et al, 2007).  The ETC in 
asexual parasites is not used to generate ATP.  The enzyme dihydroorotate 
dehydrogenase (DHOD) is utilised in the production of pyrimidines and is essential to 
asexual parasite survival.  Ubiquinone produced by the ETC is the electron acceptor for 
DHOD and is therefore also vital.  Thus the fundamental role of the ETC is in 
pyrimidine biosynthesis (Painter et al, 2007). 
 
Glycolytic intermediates also play a role in the production of ribose-5-phosphate for 
DNA and RNA synthesis.  A certain amount of phosphoenolpyruvate (PEP), instead of 
being converted to pyruvate and lactate, is transported to the apicoplast where the 
parasites’ pyruvate dehydogenase complex uses PEP to generate acetyl co-enzyme A 
(Olszewski and Llinas, 2011).  The energy requirements and carbon metabolism during 
the insect stages of the parasite are unknown.  However, in the gametocyte stages the 
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expression of TCA cycle enzymes is upregulated (Hall et al, 2005).  The sexual stage 
parasites use amino acids and glucose present in the haemolymph of the insect as 
carbon sources. 
 
1.4 Chemotherapy, Vaccines and Vector Control 
 
A major problem in the fight against malaria is the lack of effective and safe 
chemotherapies (White, 2004).  Various chemotherapeutic agents have such severe 
side effects that people are discouraged from using them.  For example the cost 
effective drug mefloquine (Lariam®), in serious cases, can lead to neuropsychiatric 
behaviour and cardiac disorders (Lariam® Data Sheet, Roche) (Figure 1.4).  The safer 
drug Malarone® (GlaxoSmithKline) is unaffordable to most of those who require it, and 
is commonly used by travellers to endemic areas as prophylaxis (Figure 1.4).  
Contributing to the lack of safe and effective drugs is the increasing parasite resistance 
to the cost effective chloroquine (CQ) and antifolate drugs currently used (Hyde, 
2007).  Generally people in malaria endemic areas will suffer from frequent clinical 
attacks.  Most will survive these attacks, however, during such illnesses sufferers are 
unable to attend school or work. 
 
Inappropriate use of chemotherapy is an enormous problem in endemic countries as 
many people cannot afford the complete course of a drug or even purchase their drugs 
on the black market.  Even if affordable from illegal sources, quality cannot be assured.  
Due to the high human morbidity and mortality associated with malaria, and the 
problems that arise from the misuse of existing antimalarial drugs, affordable novel 
chemotherapies and drug targets need to be developed. 
 
1.4.1 Currently used antimalarial chemotherapies 
Artemisinins 
Artemesinin comes from the Chinese medicinal herb Artemisia annua.  Synthesised 
derivatives include arteether, artemether and artesunate.  Artemisinin is a fast acting 
drug used to treat malaria and is active against all stages of the intraerythrocytic 
parasite as well as the transmittable gametocyte.  Artemisinin prevents the progression 
of the disease in an individual and the spread of the disease to others.  It is a short 
acting drug and therefore requires to be given in combination with longer acting drugs 
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(see below).  The mechanism of action is unclear, but the endoperoxide bridge is 
crucial for the antimalarial activity of artemisinin and its derivatives (Valderramos et al, 
2010).  Possibilities for the mode of action of artemesinins include: (i) interaction of 
the peroxide with haem leading to the production of free radicals and (ii) the inhibition 
of protein export and endocytic pathways.  The prospect of artemisinins inhibiting 
PfATP6, a sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) has now been discounted 
(Valderramos et al, 2010).  Artemisinin was useful for treating infection with parasites 
resistant to other drugs, unfortunately resistance is emerging (Krishna et al, 2006). 
 
 
 
 
Figure 1.4:  Anti-malaria chemotherapy.  Mefloquine (Lariam) is a commonly used chemotherapy for 
prophylaxis of malaria though it can have severe side effects.  Malarone® is very an expensive drug with a 
combination of atovaquone and proguanil.  Proguanil (Paludrine) is given in combination with chloroquine 
(Avloclor) as a prophylaxis. A. Clarke personal photographs. 
 
Quinoline Compounds 
Chloroquine (CQ) is a well-known antimalarial compound that targets the blood stages 
of malarial infection.  CQ was first developed as an alternative to quinine.   CQ was for 
decades the first line of defence against malaria but due to widespread acquired 
resistance its use is diminishing.  Notwithstanding, CQ is still included in the WHO 
Essential Medicines7  list for use in the treatment and P. vivax prophylaxis.  However, 
this classification is to be revised in the near future and so its future status is 
uncertain.  CQ is an alkaline drug and accumulates to high concentrations in the food 
                                                 
7 http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf. Accessed on 11 July 2012. 
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vacuole of the parasite.  The drug causes an increase in vacuolar pH of the parasite 
and is thought to prevent the detoxification of haem.  The toxic haem accumulates in 
the cell (Martin et al, 2009a).  Targets other than haem have also been implicated in 
having a role in the antimalarial action of quinolines.  Derivatives of CQ have been 
manufactured with the aim of avoiding the acquired resistance observed in parasites. 
 
Other quinoline compounds presently prescribed include amodiaquine which can be 
used in conjunction with artesunate to treat all malarias, or alone to treat P. vivax, P. 
malariae and P. ovale infections, as well as primaquine which targets the tissue stages 
of the disease and is used for P. vivax and P. ovale7. 
 
Antibiotics 
Currently used antibacterials include tetracycline and its derivative doxycycline.  
Doxycycline is used for prophylaxis, and can be employed for treatment only in 
combination with another drug such as quinine7 as the antibacterial is slow acting.  
Doxycycline inhibits protein synthesis in bacteria, and is thought to elicit its toxic 
effects on the parasites’ apicoplast and mitochondrion and prevents the formation of 
new merozoites (Goodman et al, 2007). 
 
Antifolates 
There are two enzymes in the parasites’ folate biosynthesis pathway that are 
selectively targeted by drugs, namely dihydrofolate reductase (DHFR) and 
dihydropteroate synthase (DHPS).  Pyrimethamine and cycloguanil inhibit Plasmodium 
DHFR.  Despite humans also containing a DHFR enzyme the drugs bind to the 
Plasmodium enzyme with much higher affinity.  The sulfa drugs, sulfadoxine and 
dapsone inhibit DHPS, an enzyme not present in mammalian cells.  The drugs kill the 
parasite cells by interfering with DNA synthesis (Hyde, 2007).  A combination of two 
drugs (one that inhibits each enzyme) is used, for example Lapdap which combines 
chloroproguanil and dapsone, to limit the spread of parasite resistance.  Such 
resistance is now widespread and is caused by mutations in the two enzyme encoding 
genes (Hyde, 2007).  WHO8 recommends that sulfadoxine and pyremethamine are 
                                                 
8 http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf.  Accessed on 11 July 2012. 
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given together with artesunate for treatment of malaria.  Proguanil is prescribed in 
combination with chloroquine as a prophylaxis (Figure 1.4). 
 
Combination Therapy 
It is anticipated that by combining drugs that target different metabolic steps in the 
parasite, the development of resistance will be retarded.  Artemesinin-based 
Combination Therapies (ACT) are being produced.  WHO8 advises that many of the 
drugs used to treat malaria are given in combinations. 
 
Coartem®, an artemether-lumefantrine combination is one such drug.  Artemether is a 
derivative of artemisinin, and lumefantrine is related to chloroquine and quinine 
(Nosten and White, 2007).  The combination of artemether and lumefantrine has been 
added to the WHO list of Essential Medicines8 for both adults and children for the 
treatment of malaria.  Another combination drug marketed is Malarone® (also known 
as Malanil) (Figure 1.4).  This contains a combination of atovaquone and proguanil.  
Atovaquone is an analogue of ubiquinone (part of the ETC) and proguanil inhibits 
dihydrofolate reductase, the two drugs therefore have actions on different metabolic 
pathways of the cell (Hyde, 2007 and Painter et al, 2007). 
 
1.4.2 Progress towards a vaccine 
Humans living in malaria endemic areas become clinically immune to malaria.  Whilst 
clinical immunity protects man from severe forms of the disease, individuals still suffer 
from the milder symptoms of malaria.  Given that clinical immunity can and does 
occur, a vaccine should be feasible (Holder, 2009).  However, it is only after many 
repeated bouts of the disease that immunity develops.  If there is an absence of 
reinfection the protective immunity will diminish. 
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The requirement for a vaccine in addition to other methods of control is accurately 
summarised by Butcher (2007): 
 
“In the absence of protective immunity that a 
vaccine would provide, the populations of 
endemic areas would be vulnerable to any 
new outbreak that might occur”9. 
 
The process of antigenic variation (Section 1.6) severely impedes the production of a 
vaccine against malaria as the parasites are capable of producing a multitude of 
different antigen types that are exposed to the host’s immune system.  Vaccine targets 
should therefore be restricted to proteins that are constitutively expressed throughout 
the life stage (Phillips, 2001) or a multivalent vaccine combining antigens from each of 
the life cycle stages.  
 
There are three sections of the parasite lifecycle (Section 1.2) that could be targeted 
with a vaccine (Hill, 2012):  1. The pre-erythrocytic stage: sporozoites entering the 
blood are prevented from reaching the liver or completing the liver stage of replication.   
2. The asexual merozoite: prevention of the multiplication of the parasite in the blood 
and a reduction of the symptoms.  3. The sexual stage: vaccines that focus on the 
sexual stage are known as transmission blocking vaccines.  These vaccines ideally 
would kill or inhibit the parasite in the mosquito vector (Hill, 2012).  Transmission 
blocking vaccines prevent the parasite from being passed on to other people, but 
would provide no protection to those individuals who take the vaccine.  Transmission 
blocking vaccines may give rise to some ethical issues relating to cost and possible 
side-effects to a vaccine which will not be of benefit to the one taking the vaccine. 
 
Unfortunately P. falciparum does not readily infect laboratory animals. Thus, most of 
the initial work on vaccines is carried out using the rodent malarias, P. yoelii, P. 
berghei and P. chabaudi, and the simian malaria P.  knowlesi.  For example, the MSP-1 
(merozoite surface protein-1), a possible blood stage vaccine, provided rodents with 
protective immunity (Phillips, 2001).  Experiments were carried out using the P. 
falciparum homologue in monkeys that gave protection (Phillips, 2001).  MSP-1 is 
                                                 
9 Directly quoted from Butcher, (2007). 
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involved in the invasion process; other proteins involved in the invasion process may 
make effective vaccine candidates too e.g. AMA-1 (apical membrane antigen-1) 
(Holder, 2009). 
 
1.4.3 Vector control 
“Prevention is better than cure”. (Erasmus)10. 
 
As described in Section 1.2.2, transmission of malaria is through a bite from an 
infected mosquito depositing the parasites in the human body, thus causing the 
infection.  To prevent the spread of malaria, the mosquito vector may be targeted.  
There are many courses of action involving the eradication of the mosquito vector. 
 
One approach to limit the number of mosquitoes, although perhaps controversial, is 
through the use of the insecticides.  The most controversial and perhaps the most 
effective pesticide that was used is dichlorodiphenyltrichloroethane (DDT).  Due to 
environmental issues the use of DDT was banned in many western developed 
countries, as a result of this legislation, the use in developing countries diminished 
(Tren and Bate, 2001).  Adult mosquitoes can be targeted with insecticides within the 
home as after a mosquito has taken a blood meal it tends to rest on the walls or the 
eaves of the house.  The insecticides are therefore applied to the walls and eaves of 
the houses.  To prevent the mosquito coming in contact with human individuals, 
people are advised to sleep under bednets.  The use of bednets treated with 
insecticide has been verified to be more effective than those which have not been 
treated (Lengeler et al, 2006).  However, the nets necessitate retreatment after about 
six months. 
 
Mosquitoes breed in stagnant water.  To cover all areas of open water would 
effectively block off access to the breeding sites but also starve larvae of oxygen 
(Phillips, 2001).  This method is satisfactory for permanent bodies of water but is not 
effective in the rainy season when transient puddles, pools and floods promptly form.  
Such bodies of water can be much worse in rural areas where drainage is often poor 
(Dr. E. Matovu, personal communication) (Figure 1.5). 
                                                 
10 http://www.brainyquote.com/quotes/quotes/d/desiderius148997.html.  Accessed on 1 July 2012. 
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Figure 1.5: Mosquitoes may breed in puddles formed during the rainy season.  A. Clarke 
personal photographs taken in Kampala, Uganda. 
 
Biocontrol is a less well developed mosquito control measure compared to methods 
such as insecticide spraying, but is still applicable for vector control.  Biocontrol of 
mosquito populations can be achieved using fungi and bacteria.  Some biopesticides 
have been described as ‘‘evolution proof’’ because of the delayed death phenotype 
they exhibit (Read et al, 2009).  An ‘‘evolution proof’’ insecticide is described by Read 
et al (2009) as 
 
“an insecticide that kills after the majority of 
mosquito reproduction has occurred but 
before malaria parasites are infectious [to 
mammalian hosts].”11 
 
Possible ‘‘evolution proof’’ insecticides include the entomopathogenic fungi Metarhizium 
anisopliae and Beauveria bassiana (Howard et al, 2010).  The time taken for the fungi 
to kill the mosquitoes is slow enough to allow the mosquitoes to reproduce, limiting the 
selection pressure for resistance to develop.  These two fungi were tested for their 
pathogenicity to pyrethroid sensitive and pyrethroid resistant Anopheles gambiae 
mosquitoes, when applied to bed nets.  The study by Howard et al (2010) 
demonstrated that the pyrethroid resistant mosquitoes were significantly more 
susceptible to infection by the fungi than the pyrethroid sensitive strain.  The 
transformation of fungi strains with the genes of various antimicrobial peptides has 
shown promise in curing malaria in mosquitoes infected with both malaria and the 
fungi (Fang et al, 2011).  The metabolites from pathogenic fungi, such as 
Culicinomyces clavisporus, could be used for IRS or to treat bednets (Singh and 
                                                 
11 Directly quoted from Read et al, (2009). 
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Prakash, 2011), instead of the chemical insecticides that insects are becoming resistant 
to and that are deemed to be detrimental to the environment and human health. 
 
Larval control measures kill the vectors in the early stages before the insects have the 
capacity to transmit diseases.  A recent study evaluated the effects of the application 
of Bacillus sphaericus (Bs) and Bacillus thuringiensis var. israelensis (Bti) to various 
aquatic habitats in Kenya (Mwangangi et al, 2011).  The biweekly treatment with Bs/Bti 
led to the complete eradication of Anopheline larvae from the aquatic test areas.  The 
authors do note, however, that the use of biolarvicides should be used in combination 
with other methods of control to ensure a decrease in the mosquito populations 
(Mwangangi et al, 2011). 
 
Vector control schemes have been effective in the past e.g. in Brazil.  However, it has 
been demonstrated that complacency may develop resulting in the neglect of these 
schemes leading to a recurrence of malaria (Packard, 2007).  Moreover, the collapse of 
these initiatives, either though lack of funding or a breakdown of the programme, can 
lead to an even more devastating effect in the now immunologically naïve populations. 
 
1.5 Transporters 
 
Transport proteins are integral membrane proteins allowing the flow or passage of 
nutrients across biological membranes, for metabolism and use in cellular functions.  
Other transporters are capable of removing waste metabolites and xenobiotics 
including drugs from cells, or translocating them into subcellular compartments.  Many 
drugs use transporter mediated mechanisms of uptake (Dobson and Kell, 2008) and 
such transporters offer the means to selectively target drugs to cells in which they are 
expressed, presenting the opportunity to restrict toxic effects to target cells.  
Consequently it is important to study transporter proteins to improve our knowledge of 
the binding sites, other important sites and interaction with the substrate and 
mechanisms associated with transport, so we can identify novel drugs with effective 
uptake or inhibitors of the transporter.  
 
Membrane permeases can be utilised in two ways when relating to novel 
chemotherapies.  One approach is to block the transporter (e.g. Kang et al, 2005), 
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therefore starving the cell of that particular and perhaps vital nutrient.  The other 
method is to use a transporter to carry a drug into the cell.  If one has a detailed 
understanding of a transporter, specific functional groups can be added to a drug that 
would enhance the uptake by a specific transporter. 
 
 
 
Figure 1.6: Transporters as drug targets.  Schematic illustrating the various ways that a compound 
(D) can be used to target a cell via a transporter.  The red cross represents a compound that can be used 
to block the passage of nutrients into, effectively starving the cell of required compounds (blue arrows).  
Conversely, a drug may also prevent the efflux of waste products, causing a build up of toxic products 
(green arrows).  A transporter may also be used as a vehicle which delivers a chemotherapeutic 
compound into a cell either as a drug (orange triangle) or prodrug (blue square) which is cleaved by 
intracellular enzymes into the active drug (purple triangle).  Source: A. Clarke. 
 
Certain drugs that contain added functional groups will enter via a transporter in the 
form of a prodrug (Kell, 2012).  The use of a prodrug relies on some mechanism in the 
target cell to remove the added motif to convert the drug to the active form.  An 
overview of the means by which transporters can be targeted by chemotherapeutic 
compounds is illustrated by Figure 1.6. 
 
Initially, the malaria genome project (Gardner et al, 2002a) did not identify many 
putative transporters when compared with the number in other eukaryotes.  No ion 
channels were discovered that displayed significant similarity to other eukaryotic ion 
channels.  31 % of Plasmodium proteins were found to contain at least one putative 
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transmembrane domain (TMD) but there was a relatively low percentage of polytopic 
membrane proteins annotated.  In fact, only 2.1 % of Plasmodium genes are known to 
code for transporters or channels (Martin et al, 2009b).  Gardner et al (2002a) stated 
that the low percentage of probable transporter proteins in P. falciparum resembles the 
numbers of transporters present in prokaryotic intracellular organisms.  The relative 
paucity of transport proteins when compared to other organisms implies the transport 
proteins actually present in the P. falciparum genome are important to the organism, 
perhaps even essential given the likely lack of redundancy. 
 
1.5.1 Permeases targeted in other organisms 
Various chemotherapeutic compounds have already been used to target parasite 
transporters.  For example, several drugs used to treat sleeping sickness caused by 
Trypanosoma spp. are carried into the cell by a transporter designated P2 (Barrett and 
Gilbert, 2006).    The transporter recognises an amine moiety present on the anti-
trypanosomal agents melarsoprol and pentamidine, used in the late and early stages of 
trypanosomiasis, respectively.  The P2 transporter can therefore be targeted by adding 
the recognised melamine motif to novel chemotherapeutic compounds (Chollet et al, 
2009).  Ion channels have been successfully targeted by antihelminthic drugs.  
Ivermectin is a drug that is used to treat onchocerciasis and other nematode infections 
(Mycek et al, 2000).  In this regard, ivermectin acts by binding ion channels in the 
open position, allowing the influx of chloride ions and water.  A separate ion channel is 
targeted in the treatment of schistosomiasis by praziquantel (Mycek et al, 2000). 
 
1.5.2 The malaria permeome 
As the malaria genome project (Gardner et al, 2002a) identified surprisingly few 
putative transporters based on classical homology searching, a bioinformatic approach 
using hydropathy plots was taken by Martin et al, (2005) to search for further 
membrane proteins and to assign putative functions to those for which none had been 
assigned based on simple homology searching.  By combining the genome data and 
computer programs that analyse the amino acid sequence using hydropathy plots, the 
number of putative transporters and channels recognised in the genome was vastly 
increased.  Most of the membrane proteins discovered by Martin and colleagues 
(Martin et al, 2005) were thought to be transporters, while others were designated as 
receptors or proteins without a transport function.  Of the proteins assigned a 
Introduction Chapter 1 
 
[18] 
 
transporter function, some had no amino acid sequence similarity to characterised 
transporters and therefore such Plasmodium proteins could not be given a putative 
function.  Certain transporters have been extensively studied in Plasmodium and the 
characteristics of these are discussed below. 
 
1.5.2.1 Folate transport 
Several of the drugs currently used to treat malaria infections act on two enzymes 
DHFR and DHPS that are involved in the folate synthesis pathway.  Forearmed with the 
knowledge that the folate pathway can be clinically targeted it is important to 
investigate other aspects of this pathway such as salvage.  In this regard Wang et al 
(2007) found that 5-MeTHF (the most abundant form of folate in the serum) was taken 
up significantly during the trophozoite stage, but poorly during the ring and schizont 
stages.  The influx of folate into a strain resistant to anti-folates was much more rapid 
than a sensitive strain, demonstrating the folate salvage pathway is of further 
importance to the development of resistant parasites (Wang et al, 2007). 
 
Two P. falciparum folate transporters, PfFT1 and PfFT2 have been described by 
Salcedo-Sora et al, (2011).  The authors used fluorescence microscopy and report that 
both transporters were localised to the parasite plasma membrane (PPM) at all stages 
of the IDC, though intraparasitic staining was also observed.  Both PfFT1 and PfFT2 
proteins were expressed heterologously in Xenopus laevis oocytes or E. coli to analyse 
substrates.  Both proteins transported folate and folate precursors.  5-MeTHF was 
poorly transported by PfFT2 and not by PfFT1 (Salcedo-Sora et al, 2011). 
 
1.5.2.2 Nucleoside and nucleobase transport 
The protein PfNT1/PfENT1 was the first nucleoside transporter described in malaria 
parasites (Carter et al, 2000 and Parker et al, 2000).  This permease is an attractive 
drug target as malaria parasites are unable to synthesise purines de novo and 
therefore rely on uptake from external sources.  The human orthologue is sufficiently 
different adding to the attractiveness of PfNT1 as a drug target.  With the publication 
of the malaria genome (Gardner et al, 2002a) a total of four putative nucleoside/base 
transporters was revealed.  PfNT1 is expressed on the PPM.  The substrate of the 
transporter was investigated by expression in Xenopus oocytes.  However the two 
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research groups studying PfNT1 came to different conclusions (Carter et al, 2000 and 
Parker et al, 2000). 
 
Later studies showed that the transporter could not be knocked out (el Bissati et al, 
2006 and el Bissati et al, 2008) without the addition of high concentrations of 
hypoxanthine to the medium.  The second transporter, PfNT2 was studied by Downie 
et al (2010), the substrate specificity was not determined but the transporter was 
expressed in the endoplasmic reticulum (ER) membrane, which the authors believe is 
suggestive of a novel function in the parasites’ ER. 
 
1.5.2.3 Glucose transport 
Arguably, the best characterised transporter in P. falciparum is the hexose transporter 
(PfHT1).  The PfHT1 transporter was first described by Woodrow et al (1999).  Glucose 
is essential to the developing intraerythrocytic parasite.  The transport of glucose 
increases by 100-fold in infected RBCs compared with uninfected.  Malaria parasites 
metabolise glucose anaerobically by way of glycolysis for energy production (Section 
1.3.3), signifying a high requirement for glucose, especially in the latter stages of the 
erythrocytic cycle. 
 
The PfHT1 transporter was expressed in Xenopus oocytes and shown to transport 
glucose in this heterologous system.  The protein is expressed at high levels during the 
early ring and early trophozoite stages in Plasmodium.  Immunofluorescence studies 
locate the transporter to the PPM confirming the transporter is not exported to the 
erythrocyte (Woodrow et al, 1999).  PfHT1 permease can transport fructose and 
glucose unlike the mammalian glucose transporter, GLUT1 which is only able to 
transport glucose.  The transport of fructose by PfHT1 can be abolished by a single 
amino acid mutational change (Q196N).  The inference is that this mutation is 
responsible for the substrate specificity of PfHT1 (Joët and Krishna, 2004). 
 
A library of inhibitors that blocked the transport of glucose by PfHT1 expressed in 
Xenopus oocytes, were also able to kill P. falciparum and P. vivax.  A 2010 study by 
Slavic and colleagues (Slavic et al, 2010) was designed to knock out the pfht1 gene in 
P. falciparum.  The researchers found that without an episomal copy of the pfht1 gene, 
the native copy could not be deleted, demonstrating that PfHT1 is essential to asexual 
Introduction Chapter 1 
 
[20] 
 
stages of P. falciparum.  Moreover, the P. berghei orthologue, PbHT, could not be 
knocked out in blood stage parasites.  A PbHT-GFP fusion protein was made and 
fluorescence studies confirmed the PPM location of the transporter but also hinted at a 
DV location.  The transporter is expressed throughout the asexual and sexual growth 
stages (Slavic et al, 2010). 
 
1.5.2.4 Glycerol and water transport 
The intraerythrocytic parasite has a high demand for glycerol which is required for 
membrane biogenesis during the later stages of the growth phase as up to 32 new 
merozoites are made.  Glycerol is present in blood plasma and is able to cross the 
erythrocyte membrane by means of passive diffusion although it is unknown if the 
alterations made to the RBCm assist with glycerol uptake.  A single aquaglyceroporin 
has been annotated in the Plasmodium genome, PfAQP (Hansen et al, 2002) and 
PbAQP (Promeneur et al, 2007).  Hansen and colleagues (2002) carried out BLAST 
searches of the plasmoDB database which yielded a single potential aquaporin located 
on chromosome 11 of the parasite.  The P. berghei orthologue was discovered by 
doing a BLAST search of PfAQP in the P. berghei genome database (Promeneur et al, 
2007).  The AQP shows most homology to the glycerol facilitator of E. coli, and the 
orthologue from P. berghei has 62 % conservation with the P. falciparum gene. 
 
Research was carried out on the P. berghei and P. falciparum orthologues.  The protein 
is responsible for the passage of water and glycerol into the parasite, as well as small 
solutes such as urea.  The Plasmodium proteins are the only known family of 
aquaglyceroporins to transport water and glycerol (in Plasmodium) (Newby et al, 
2008).  Utilising fluorescent microscopy techniques, the proteins were localised to the 
PPM.  The P. berghei gene was knocked out (Promeneur et al, 2007) and it is noted 
that it is one of the few Plasmodium transporters capable of being knocked out.  In 
addition, the authors did not observe morphological changes in the Δpbaqp strains.  
However, the growth rate of the Δpbaqp parasites was greatly reduced when 
compared with WT parasites.  This implies there is some glycerol gained during 
glycolysis. 
 
Hedfalk et al (2008) cloned the P. falciparum aquaporin for functional studies.  The 
crystals produced were of many forms making it hard to gain a 3D crystal structure.  
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The crystal structure was then solved by Newby et al (2008).  The latter research 
group used a codon bias to express the pfaqp gene in E. coli.  This was the first time a 
full-length malarial membrane protein had been crystallised. 
 
Two motifs common to aquaglyceroporins are present in the Plasmodium orthologue.  
The two, three amino acid motifs differ in one amino acid (each) compared to other 
orthologues, however when comparing the structural data, the differences were 
compensated for and the overall structure was preserved (Newby et al, 2009).  
Indeed, mutation of the Plasmodium sequence motifs (NLA-NPS) to the conserved 
motifs (NPA-NPA) does not alter the substrate specificity of the pore.  Taken together, 
these data suggest these motifs do not play a role in substrate specificity (Hansen et 
al, 2002). 
 
1.5.2.5 Apicoplast transporters 
There are many transporters present on the apicoplast membranes (Martin et al, 
2009b).  Mullin et al (2006) characterised two transporters that display sequence 
identity with two plant plastid transporters.  These transporters designated PfiTPT and 
PfoTPT were localised to the inner and outer membranes of the apicoplast, 
respectively.  The substrate of these two plastid transporters could not be determined, 
but they are thought to exchange phosphate for carbon compounds (Mullin et al, 
2006). 
 
1.5.2.6 Transporters involved in drug resistance 
Different transporters are involved in uptake and efflux of individual drugs.  This 
means that resistance can come about through a variety of alterations in different 
transporters creating heterogeneity in mechanisms of resistance found in laboratory 
strains used in different studies (e.g. Dd2, 7G8 and HB3).  The three transporters 
implicated in drug resistance are PfCRT (P. falciparum chloroquine resistance 
transporter), PfMDR1 (P. falciparum multi drug resistance 1), and PfMRP (P. falciparum 
multi resistance-associated protein).  These will be briefly discussed below.  On the 
other hand, the role of a fourth transporter, PfNHE (P. falciparum Na+/H+ exporter), in 
drug resistance is unclear (e.g. Bray et al, 1999, and, Roepe and Ferdig, 2009). 
Thus far, only PfCRT has been experimentally shown to confer resistance to CQ.  The 
resistance is thought to be due to a lysine to threonine mutational alteration (K76T). 
Introduction Chapter 1 
 
[22] 
 
The K76T mutation is always observed with some other mutations such as R163S and 
A220S.  In the majority of field isolates the latter mutation was present (Cooper, 
2005).  It has been proposed the other mutations e.g. R163S and A220S are 
compensatory, allowing the transporter to carry out its natural but as yet unknown 
function.  When the K76T mutation was reversed in a CQ resistant strain the parasites 
were susceptible to CQ (Lakshmanan, 2005). 
 
The PfCRT protein was expressed, without putative signal peptides and to a codon 
bias, in Xenopus oocytes, and without these modifications the protein was not 
expressed at the oocyte surface (Martin et al, 2009a).  This 2009 study demonstrated 
that (i) the transport of CQ occurs from a CQ resistant strain, and (ii) no transport 
occurs in the chloroquine sensitive strain.  The resulting data suggests that the mutant 
PfCRT is used to efflux CQ from the DV to the cytoplasm where the drug cannot exert 
its toxic effect (Martin et al, 2009a).  Although the role of PfCRT is yet unknown, the 
transporter is thought to be necessary for parasite survival as it cannot be knocked out 
(Waller et al, 2003). 
 
PfMDR1 has been shown to have a role in drug resistance, but the mechanism (s) has 
not been definitively demonstrated.  Polymorphisms in these permeases lead to the 
transport of different antimalarials e.g. quinine and mefloquine (See Section 1.4.1).  
This polyspecificity implies the transporter can act on various chemotherapies.  
However the manner in which the transporter acts upon the drugs is unknown 
(Sanchez et al, 2010).  When PfMRP was knocked out, the strain displayed a 
heightened sensitivity to antimalarials such as CQ and artemisinin, and had an 
accumulation of glutathione (Raj et al, 2008).  It has been inferred that PfMRP acts as 
an efflux pump.  
 
1.5.2.7 New permeability pathways 
Infected erythrocytes (IE) show an increase in their permeability to various solutes 
including sugars, anions and cations.  This new-found permeability has been ascribed 
to the so called new permeability pathways (NPPs) induced by the parasite.  It is not 
known if the NPP’s are formed from parasite proteins, the host cell proteins or a 
combination of both.  The NPP’s allows the passage of a wide variety of substrates into 
the RBC including sugars, anions and cations.  The parasitophorus vacuole membrane 
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(PVM) is porous and allows the passage of the substrates to reach the PPM.  The 
proposed roles of the NPP include nutrient uptake and end-product removal as well as 
putative roles in cell regulation (Staines et al, 2004). 
 
1.5.3 Formate-nitrite transporter family 
Members of the formate-nitrite transporter (FNT) family (transport protein classification 
2.A.44) are present in a wide range of prokaryotes and some eukaryotic organisms but 
are absent from plant and mammalian genomes.  As the name suggests, the 
transporters are thought to facilitate the passage of the structurally similar anions 
formate and nitrite across membranes.  The FNT proteins typically have 6 – 8 TMDs 
and are between 250 – 400 amino acids in length.  Three conserved FNT motifs are 
present in each orthologous protein.  The members of the FNT family have been 
grouped into 4 clusters (Saier et al, 1999).  Cluster I contains the formate efflux 
transporters, e.g. E. coli FocA, cluster II the formate uptake transporters e.g. 
Methanobacterium formicicum and Methanothermobacter thermautotrophicus, cluster 
III the nitrite permeases e.g. E. coli NirC.  Cluster IV contains the YHL800c gene from 
Saccharomyces cerevisiae, a member of the transporter family but annotated as an 
acetate:proton symporter (Paulsen et al, 1998).  A BLAST12 (protein-protein BLASTP) 
search of the S. cerevisiae YHL800C protein sequence against the Non-redundant 
protein sequences (nr) database unearthed orthologues in the important human 
pathogen Candida albicans and other yeast (Appendix 5).  P. falciparum contains a 
putative FNT of 309 amino acids.  By performing BLASTP searches using the P. 
falciparum predicted protein sequence against other Plasmodium spp. and 
apicomplexan organisms (Appendix 5) it was established that there are orthologues in 
all malaria species sequenced, and apicomplexan parasites other than C. parvum.  The 
P. falciparum orthologue PFC0725c (PlasmoDB13) has been designated PfNitA. 
 
1.5.3.1 Roles of FNT orthologues 
E. coli 
The FocA transporter in E. coli, which is thought to maintain the intracellular formate 
pool, belongs to the FNT family of transporters.  The protein has been shown to 
transport the toxic formate analogue hypophosphite, through this process, mutants 
                                                 
12 http://blast.ncbi.nlm.nih.gov/Blast.cgi.  Accessed on 12 July 2012. 
13 http://plasmodb.org/plasmo/.  Accessed on 12 July 2012. 
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unable to transport hypophosphite were selected.  The resulting mutations caused an 
increase in the levels of intracellular formate, and concomitantly less formate was 
excreted to the growth media (Suppmann and Sawers, 1994). 
 
Formate is an end-product of the anaerobic fermentation of glucose by pyruvate-
formate lyase, up to 33 % of the glucose metabolised ends up as formate (Falke  et al, 
2010).  To prevent acidification of the cytoplasm by formate it is exported from the 
cytoplasm where it is metabolised to carbon dioxide by formate dehydrogenase in the 
periplasm (Suppmann and Sawers, 1994).  Conversely, when the pH of the medium 
becomes acidic (< pH 6.8), formate is transported into the cytoplasm to be 
metabolised into hydrogen and carbon dioxide by the enzyme formate-hydrogen lyase 
(Rossman et al, 1991 and Sawers, 2005).  The closest homologue of FocA is a second 
putative formate transporter, FocB (Andrews, 1997).  The formate transporter proteins 
can be surmised as playing a role in the cellular redox balance (Sawers, 2005). 
 
A third member of the FNT family is present in E. coli, encoded by the nirc gene, the 
product of which is a transporter for nitrite alone, although not the only transporter of 
nitrite (Jia et al, 2009).  NirC functions in the import and export of nitrite.  The uptake 
of nitrite by NirC is 10-fold higher than that of NarK and NarU, two nitrite/nitrate 
transporters (Jia et al, 2009).  The three proteins form part of the nitrate assimilatory 
pathway to produce ammonium for incorporation into amino acids, mainly glutamine 
and glutamate.  NarU and NarK proteins are thought to be antiporters and efflux nitrite 
in exchange for nitrate. E. coli NirC re-imports nitrite to the cytoplasm for reduction to 
ammonium, and subsequent incorporation into amino acids.  NirC is expressed only 
under anaerobic conditions (Clegg et al, 2002).  
 
Salmonella 
The genome of the enteropathogenic bacterium Salmonella enterica (serovar 
Typhimurium) contains a nirc orthologue.  It has been suggested that the transporter 
in this bacterium plays a role in the pathogenicity of the organism (Das et al, 2009).  
The production of nitric oxide (NO) from macrophages was downregulated in wild type 
(WT) bacteria compared to knock-out nirc parasites in the mouse model.  The 
expression of the transporter was upregulated when cells were exposed to nitrite (Das 
et al, 2009).  The inference is that the NirC transporter is used to defend the bacterium 
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from oxidative stress.  The NirC protein from S. typhimurium was overexpressed in E. 
coli and reconstituted into liposomes (Rycovska et al, 2012).  The liposomes containing 
StmNirC (proteoliposomes) were used for electrophysical characterisation to study the 
transport activities of the protein.  The study found that StmNirC acts as a 
nitrite/proton antiporter, and is also capable of transporting nitrate (Rycovska et al, 
2012). 
 
S. typhimurium also encodes a FocA protein.  StFocA was shown to passively transport 
formate at physiological pH values.  However this transport was abolished at low pH 
when the protein underwent structural changes (Lü et al, 2011).  In a more recent 
study (Lü et al, 2012) the FocA permease was found to transport a range of metabolic 
end-products from mixed acid metabolism.  These metabolites included lactate, 
formate and acetate.  In addition to these metabolic end-products, the permease was 
able to transport pyruvate, nitrite, hypophosphite (E. coli section above) and chloride.  
The authors believe that the FNT proteins “should be defined as broad-range 
monovalent anion channels” and that the transportation of products is dependent on 
metabolic processes in the organism (Lü et al, 2012). 
 
Clostridia spp. 
The FNT orthologue from the anaerobic bacterium Clostridium botulinum was 
highlighted by in silico studies as a potential drug target (Koteswara Reddy et al, 
2010).  Czyzewski and Wang (2012) carried out a genetic linkage and phylogenetic 
analysis on 474 bacterial and archaeal orthologues. 
 
The group mapped the homologous proteins depending on metabolic enzymes present 
in the study organism.  The linkage analysis (Figure 1.7) shows the foca genes split 
into two groups, one with a pyruvate-formate lyase operon (pink -pflBA) and a second 
with a formate dehydrogenase operon (pink -fdhAB).  The nirc genes are grouped with 
a nitrite operon (blue), and the novel hydrosulphide ion transporters (FNT3) linked to 
the sulphite reductase operon (green).  The areas in grey have no function based on 
the genetic linkage analysis suggesting these orthologues transport different anionic 
compounds. 
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Figure 1.7:  Genetic linkage analyses of FNT orthologues.  Image reproduced from Czyzewski and 
Wang (2012). 
 
Electroconductance assays were carried out on the protein orthologue from C. difficile 
in order to determine the substrate (Czyzewski and Wang 2012).  The hydrosulphide 
ion, in quantities sufficient for analysis, causes perturbations in the membrane.  
Therefore Czyzewski and Wang (2012) used formate as a substrate with the 
hydrosulphide ion and nitrite as competitors.  The hydrosulphide ion channel (HSC) 
protein was able to transport each of the three substrates demonstrating 
polyspecificity. 
 
Archaea 
Methanogens are formate metabolising archaea.  Formate is used as an electron donor 
in the reduction of carbon dioxide to methane (Schauer et al, 1982).  
Methanobacterium formicicum contain two formate dehydrogenase enzymes, and 
these are co-transcribed with a FNT orthologue gene, fdhc.  The FdhC protein is 280 
amino acids in length and contains 7 putative TMDs.  A BLAST14 search using the FdhC 
amino acid sequence produced a NirC orthologue from S. typhimurium (White and 
Ferry, 1992).  As these archaebacteria can grow on formate as the sole carbon source, 
it is thought that FdhC is a formate uptake transporter. 
 
 
 
                                                 
14 http://blast.ncbi.nlm.nih.gov/Blast.cgi.  Acessed on 11 July 2012. 
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Algae 
The green algae Chlamydomonas reinhardtii has a set of 6 genes coding for FNTs.  
Three of these may be targeted to the plastid membrane and three to the plasma 
membrane (Fernandez and Galvan, 2007).  The protein encoded by Nar1.1 plays a role 
in the transport of nitrite into the plastid by regulation of uptake, and perhaps the 
transport of nitrite per se.  The uptake of nitrite by chloroplasts of Nar1.1 deletion 
strains was much less than in the WT cells (Rexach et al, 2000).   A second FNT gene, 
Nar1.2 was investigated by Mariscal et al (2006).  This study demonstrated that the 
expression of Nar1.1 and Nar1.6 were induced by nitrite, low CO2 induced Nar1.2 
expression.  Nar1.2 was also given the identifier lciA for low carbon induced.  For this 
reason the group investigated the possibility of bicarbonate as a substrate for the 
transporter (Mariscal et al, 2006).  When Nar1.2 was expressed in Xenopus oocytes, 
the uptake of bicarbonate was measured and found to be two-fold higher than in the 
control oocytes.  Nar1.2 transports nitrite at low concentrations as measured by 
membrane depolarisation (Mariscal et al, 2006). 
 
Euglena gracilis 
In a study by Deloménie et al, (2007) investigating the response to environmental 
toxins, the FNT protein from the unicellular protist Euglena gracilis (EgFth) was 
upregulated at the mRNA level in cell lines chronically exposed to the toxin cadmium.  
Cell lines newly exposed to cadmium showed no immediate changes.  The implication 
is that the EgFth protein functions to combat the toxic effects of heavy metals such as 
cadmium.  Conversely however, cells with chronic exposure to the highly toxic 
pesticide pentachlorophenol showed a down-regulation in egfth expression (Deloménie 
et al, 2007). 
 
Yeast 
The YHL008c protein of Saccharomyces cerevisiae belongs to the FNT family and was 
annotated as a monocarboxylate transporter (MCT) as it resembles bacterial formate–
nitrite transporters (Paulsen et al, 1998, in Makuc et al, 2002).    The proteins’ function 
as a MCT was investigated by Makuc et al (2001).  The YHL008c protein was found not 
to be involved in monocarboxylate transport.  A study into chloride (Cl-) homeostasis 
demonstrated that the uptake of Cl- was not prevented by deletion of the gene, but 
was reduced.  The authors suggest a role in a Cl- sensing and activation of a Cl- 
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transporter for the YHL008c protein (Makuc et al, 2001).  A subcellular localisation has 
not been accurately determined for the YHL008c protein.  Nonetheless, studies using 
GFP tagged proteins suggest it is associated with the vacuole (Paulsen et al, 1998, in 
Jennings and Cui, 2008).  The vacuole of S. cerevisiae and other yeast has many roles 
including the storage of solutes and the isolation and degradation of substances 
harmful to the cell. 
 
Fungi 
Aspergillus nidulans contains two transporters for nitrate and nitrite, and a single 
transporter (NitA) for nitrite uptake (Wang et al, 2008 and references therein).  The 
uptake of nitrite was investigated in a mutant strain of A. nidulans lacking the two 
nitrate/nitrite transporter activities.  This double mutant strain transported nitrite at a 
lower rate than the WT cells, however residual uptake was sufficient to sustain growth 
on medium containing nitrite as the sole nitrogen source.  A triple mutant was created 
which included a mutant in the nita gene and the triple mutant was found to be unable 
to grow on nitrite, unless a high concentration of nitrite was available in the growth 
media.  NitA was thus characterised as a low capacity high affinity nitrite transporter 
(Wang et al, 2008).  Formate (formic acid) was assessed as a substrate for A. nidulans, 
but formate was not transported (Dr. S.E. Unkles, personal communication).  
 
Mutagenesis studies have been carried out to establish which amino acids are 
responsible for substrate binding of the NitA protein to nitrite.  The study began by 
selecting four asparagine residues (N122, N173, N214 and N246) that were highly 
conserved and present in the TMDs (Symington, 2009).  Of these residues, two were 
unable to be investigated as they prevented growth of the organism.  Of the other two 
one was not directly involved in nitrite transport.  It was postulated that this amino 
acid could constrict the space for nitrite transport in the pore and it was suggested that 
this residue functions as part of a gate or barrier.  The final asparagine residue (N214) 
is thought to be involved in the binding of nitrite as mutation allowed uptake of only 20 
% nitrite when compared to the WT NitA (Symington, 2009 and Unkles et al, 2012). 
 
The pathogenic plant fungus Cylindrocarpon tonkinense contains an FNT orthologue 
which is proposed to play a role in the process of denitrification (Kim et al, 2010).  
Denitrification is a poorly understood process in fungi.  Under denitrifying conditions, 
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the FNT orthologue was strongly expressed (Kim et al, 2010).  This indicates a role for 
the FNT orthologue in the denitrification process of C. tonkinense possibly through the 
import of formate as an electron acceptor or the efflux of formate produced as a toxic 
by-product. 
 
1.5.3.2 Structural studies 
The FNT orthologues from A. nidulans (NitA) and the thermophilic archaebacterium 
Thermofilum pendens (NirC) were expressed in Pichia pastoris and E. coli, respectively 
(Beckham et al, 2010).  The E. coli FocA was over expressed in E. coli (Falke et al, 
2009).  The quaternary structures of the proteins were studied.  Circular dichroism 
spectrophotometry (CD) provided evidence that all three FNT proteins have a high α-
helical content as suggested by the in silico predictions.  Through size exclusion 
chromatography the A. nidulans NitA was shown to be tetrameric (Beckham et al, 
2010).  Unpublished work using blue native polyacrylamide gel electrophoresis (BN-
PAGE) also suggests that T. pendens NirC is tetrameric (Dr. S.E. Unkles, personal 
communication).  The E. coli FocA protein was confirmed to be pentameric through 
BN-PAGE and western blotting (Falke et al, 2009).  The FNT proteins from four bacteria 
have been crystallised and are given in Table 1.1. 
 
Bacteria strain pH Resolution Reference PDB NUMBER 
Escherichia coli 7.5 2.25 Å Wang et al, 2009a 3KCV 
Vibrio cholerae 7.5 2.13 Å Waight et al, 2010 3KLY 
Salmonella typhimurium 4.0 2.80 Å Lü et al, 2011 3Q7K 
Clostridium difficile 4.5, 7.5, 9.0 3.0, 3.2, 2.2 Å Czyzewski and Wang, 2012 3TDP, 3TDR, 3TDO 
Table 1.1: FNT orthologues with known crystal structures. 
 
Each of the studies confirmed the presence of six TMDs and a cytoplasmic location for 
the N- and C-termini of the proteins.  TMDs 1 – 3 and 4 – 6 were also noted as being 
‘inverted repeats’, while not completely symmetrical.  TMDs 2 and 5 are broken into 
two helices (Figure 1.8).  These two TMDs are constrained through hydrogen bonding 
(Wang et al, 2009a).  The protein forms a pentamer in the membrane.  The overall 
structure of the FNT protein is thought to resemble that of aquaporins and glycerol 
facilitators. 
 
The large central pore formed by the five monomers is too large to act as a selectivity 
filter for a channel or contain a substrate binding site for a transporter (Waight et al, 
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2010).  The size of the pore suggests the central pore does not facilitate the transport 
of formate, and indeed the central pore is filled with lipids from the bilayer.  The pore 
formed by each individual monomer is believed to be the location where the substrate 
passes through the membrane and is illustrated by Figure 1.8.  The protein is 
suggested to be a channel rather than a transporter as no gate-like structure is 
present. 
 
(A)      (B) 
 
Figure 1.8: 3D Model of FocA monomer.  (A) a model of the FocA crystal structure as viewed from the 
periplasmic side illustrating the central pore where the substrate (formate) passes through.  The numbers 
relate to the transmembrane domains.  Parts 2a and 5b are α-helices which are split in two.  (b) shows 
the electrostatic properties of the channel.  Red represents a negative charge and is on the periplasmic 
side, whereas blue is positive and is the cytoplasmic side.  Figures taken from Waight et al (2010). 
 
The overall charges at the cytoplasmic and periplasmic ends of the pore are positive 
and negative, respectively.  The positive charge of the cytoplasmic side is considered 
to aid the collection of formate molecules and the negative periplasmic side to repel 
the positively charged formate (Figure 1.8).  The passage of the substrate is facilitated 
by hydrogen bonding through residues lining the pore, notably His 208 which is 
conserved between orthologues, hydrogen bonds are also formed from one formate 
molecule to another (Waight et al, 2010).  Waight et al (2010) hypothesised a role for 
the so called Ω loop (V. cholerae Phe 89 – Thr 134), a flexible and conserved amino 
acid sequence, in the gating of the protein.  Formate must compete with a weaker H 
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bond formed between the Asn 171 and Thr 90, the displacement of the bonding opens 
the channel.  This point is illustrated in Figure 1.9.  Waight et al (2010) revealed a 
water molecule bound to Thr 90 and postulated that water was also a substrate for the 
V. cholerae transporter.  Work on proteoliposomes with the E. coli FocA protein 
demonstrated that the transporter was impermeable to water, but allowed the passage 
of formate (Wang et al, 2009a). 
 
(A)          (B) 
 
Figure 1.9:  FocA selectivity filter. The images here demonstrate the selectivity filter in the central 
pore of the FocA monomer.  (A) shows the pore without formate and is in the closed state. The image in 
(B) includes a formate (FMT) molecule bound in the pore.  FMT2 is hydrogen bonded to His 208, and to a 
second formate molecule (not visible).  To open the pore, a hydrogen bond occurring between Asn 171 
and Thr 90 must be broken and replaced by a formate molecule.  Images have been reproduced from 
Waight et al (2010). 
 
More recently the structures of the Salmonella typhimurium (Lü et al, 2011) and 
Clostridium difficile FNT proteins have become available (Czyzewski, and Wang, 2012).  
Both structures are similar to the E. coli and V. cholerae structures.  The authors 
demonstrate that the S. typhimurium transporter acts in the uptake as well as the 
export of formate and that the process is dependent on pH.  The N-terminal amino 
acids in StFocA, which in VcFocA were disordered and in EcFocA were truncated, are 
flexible and allow conformational changes in the protein.  The suggested Ω loop gating 
mechanism was investigated, and Lü et al (2011) believe that an interaction between 
the N-terminal and the Ω loop is responsible for conformational changes.  The 2011 
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study results showed the protein crystallised in three conformational states, open, 
intermediate and closed (Lü et al, 2011).  Lü et al, (2012) show that the StFocA 
protein is permeable to anions but not cations, and this is suggestive of positively 
charged residues in the TMDs.  His 209 is a well conserved residue within FNT 
orthologues and is found in the so called selectivity filter (His 208 in V. cholerae).  The 
residue also forms part of an FNT motif (Section 3.2.2 and Saier et al, 1999).  This 
residue can become charged.  The amino acid was mutated to the non-polar 
phenylalanine (H208F) and the function of the permease was ablated showing His 208 
is required for StFocA function (Lü et al, 2012). 
 
The protein crystallised from C. difficile is thought to transport the hydrosulphide ion, a 
novel substrate for a FNT protein (Czyzewski and Wang, 2012).  The HSC was 
crystallised in buffers at three pH values (Table 1.1).  No structural differences were 
observed and in each crystal structure the protein was in a closed state.  A selection of 
mutant HSC proteins were also crystallised, these too were in the closed state.  
Mutations of residues in the so-called cytoplasmic slit or the periplasmic ring to less 
bulky residues caused an increase in the transport of formate due to an increase is the 
pore size of the protein.  The authors concluded that the opening of the CdHSC is 
tightly regulated. 
 
1.6 Antigenic Variation 
 
As noted in section 1.5, the malaria genome project (Gardner et al, 2002a) did not 
result in the annotation a large number of polytopic membrane proteins.  The study did 
however unearth a large number of monotopic membrane proteins postulated to be 
involved in antigenic variation.  This is not unexpected as there are multiple gene 
families involved (Scherf et al, 2008).  Moreover, antigenic variation is employed by 
parasites, including Giardia lamblia, Trypanosoma spp. and Plasmodium spp., and 
certain bacteria such as Neisseria and Borrelia (Faguy, 2000), as an immune evasion 
technique.  Antigenic variation acts to prolong the infection of a particular pathogen 
leading to further opportunities for its transmission to a new host.  If the pathogen 
killed the host in a short time period it could not be transmitted to other hosts.  
Conversely, if the host immune response killed the pathogen in a short time period it 
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similarly cannot be transmitted.  Figure 1.10 demonstrates an understanding of 
antigenic variation schematically. 
 
 
 
Figure 1.10: Antigenic variation.  The red line indicates a pathogen that causes great harm to the host 
and results in an early death.  Killing the host is not a useful attribute for the pathogen as it reduces the 
amount of time it can be transmitted to new hosts.  Conversely the green line represents a pathogen 
which does not undergo antigenic variation, and with time the immune system is able to overcome the 
pathogen and eliminate it form the host.  The blue line signifies a pathogen that undergoes antigenic 
variation.  The parasite is not eliminated from the host and is able to stay in a number above the 
transmission boundary, and can therefore be transmitted to many new hosts.  Source: A. Clarke. 
 
In Plasmodium parasites, antigenic variation is particularly complicated due to the 
number of variants available to switch between, as well as the fact that mechanisms 
for switching appear to be diverse.  Plasmodium has a range of proteins it exports to 
the surface of the erythrocyte.  Many of these proteins are thought to play a role in 
antigenic variation.  These variant surface antigens (VSA’s) help the parasite to elude 
detection by the host immune system.  Antigenic variation severely impedes the 
production of a successful vaccine against malaria as the parasites are capable of 
producing a multitude of different antigen types exposed to the host’s immune system 
at various levels.  These include the RBC surface targeted var gene products (PfEMP1 
proteins) and various other gene family products expressed at the erythrocytic and 
other stages of the life cycle.  The var genes vary between P. falciparum strains 3D7, 
HB3 and Dd2 and show very little overlap (Scherf et al, 2008), increasing the difficulty 
in finding target antigens for vaccine development.  However, there are other antigens 
that may be accessible to the immune system and it is important to identify key 
epitopes targeted by the immune response and those involved in the most severe 
forms of malaria. 
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The rodent malarias have been key to investigating parasite-host interactions from an 
immunologic point of view.  Given that (i) the understanding of how a protein interacts 
with the host immune system requires an accessible model, (ii) P. falciparum does not 
readily infect laboratory animals (the Aotus monkey and chimpanzees being exceptions 
(Herrera el al, 2002), (iii) experimental research on humans is unethical and (iv) it is 
difficult to find an in vivo experimental model, it is also important to study the 
molecular mechanisms involved in the gene switch in vivo as this may differ from 
laboratory cultured parasites.  Of note however, is the fact that P. falciparum seems to 
be relatively distinct with regard to parasite-host interactions and an ideal model for 
this parasite does not exist (Waters, 2002). 
 
1.6.1 Variant surface antigens 
The Plasmodium genome codes many different families of variant surface antigens 
(VSAs).  The importance of VSAs to Plasmodium is highlighted by the fact that many of 
the Plasmodium species employ antigenic variation, and the large proportion of the 
genome committed to it.  The most understood studied of the VSAs are the var genes, 
giving rise to the P. falciparum Erythrocyte Membrane Protein (PfEMP-1) group.  
PfEMP-1 surface protein plays a key role in sequestration of the parasite, most likely to 
avoid removal by purification processes in the spleen.  PfEMP-1 isoforms mediate 
cytoadherence to the endothelial lining in the capillaries through various ligands such 
as ICAM-1 and CD-36, in a process dependent on the PfEMP1 variant.  PfEMP-1 is the 
cause of cerebral malaria as the IEs adhere to endothelia causing clots to form in the 
brain and subsequently death (Pasternak and Dzikowski, 2009). 
 
The well-studied PfEMP proteins comprise a collection of variable and conserved 
domains.  It has been suggested that when the protein folds the conserved domains, 
e.g. the Duffy Binding Like (DBL) domain, adheres to the endothelial cells while it is 
the variable domains that are exposed to the immune system and therefore targeted.  
There are 59 var genes in the 3D7 strain, and many more pseudogenes the purpose of 
which is unknown, but may act to increase the gene repertoire (Frank and Deitsch, 
2006).  Further gene families thought to be involved in antigenic variation in 
Plasmodium include rifs, stevors, Pfmc-2TM, and, surfins (Scherf et al, 2008).  Janssen 
et al (2004) highlighted similarities between the stevor and rif families of P. falciparum, 
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the recently described vir genes from P. vivax (del Portillo et al, 2001) and bir/yir/cir 
gene families present in the three rodent malarias. 
 
1.6.1.1 rif  
The rif (relative interspersed family) genes or RIFIN proteins are a second gene family 
thought to play a role in antigenic variation.  The genes themselves have a close 
association with the var genes being situated sub-telomerically.  The proteins are 27 – 
45 kDa in size and there are approximately 200 genes per cell.   Using a ‘plotsimilarity’ 
program, the rif genes are thought to contain two TMDs which are fairly conserved, 
and have a polymorphic section in the middle of the protein.  The suggested 
orientation of a candidate rif gene has the polymorphic or hypervariable region outside 
the cell (Kyes et al, 1999).  The results in this 1999 paper also demonstrated that the 
rif genes are transcribed in the early and late trophozoite stages of the 
intraerythrocytic parasite, i.e. between 18 and 29 hours post invasion (hpi) as well as 
showing that expression levels differ between parasite strains.  Immunoprecipitation 
and immunofluorescence assays (IFA) revealed that the RIFIN proteins are located on 
the outside of the RBCs (Kyes et al, 1999). 
 
More recently it has been demonstrated that there are two subtypes of rif gene, 
dependent on the subcellular localisation.  A-type rifs contain a particular motif while 
B-type rifs do not.  The A-type is expressed on the erythrocyte surface and the B-type 
is not exported from the parasite cell (Petter et al, 2007).  Both RIFIN protein types 
are translated during the intraerythrocytic and merozoite stages illustrating that 
expression is not mutually exclusive (Petter et al, 2007).  At least one B-type RIFIN(s) 
is expressed in mature gametocyte stages and sporozoites (Wang et al, 2009b).  
Antibobies to RIFINs were present in patients infected with P. falciparum which is 
consistent with these proteins being exposed to the immune system at the surface of 
infected red cells (Schreiber et al, 2006).  IFA showed that RIFINs are present in all of 
the erythrocytic stages including merozoites.  It was demonstrated that A-type and B-
type RIFINs were localised to different areas in the merozoites, but not to the cell 
surface. 
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1.6.1.2 stevor  
stevor genes form a distinct gene family postulated to be involved in antigenic 
variation in P. falciparum.  They are structurally similar to rif genes, and are thought to 
contain two TMDs separating a hypervariable region with a conserved N-terminus 
containing a signal sequence.  stevor genes are temporally expressed after var and rif 
genes, and STEVOR proteins are displayed on late stage parasites.  It has been shown 
that STEVOR proteins are exported to the RBC surface through Maurer’s Clefts (Niang 
et al, 2009).  The conserved N-terminus of the STEVOR protein can be detected by 
antibodies on the surface of the RBC.  This observation may suggest one of two things, 
(i) the hypervariable region between the two TMDs is in fact intracellular, or (ii) the 
second TMD does not pass through the cell and acts as an anchor attaching the 
protein to the membrane.  Both possibilities allow the N-terminal to be exposed on the 
RBC surface (Niang et al, 2009). 
 
1.6.2 Plasmodium interspersed repeats 
The multi-gene family, known as pir (Plasmodium interspersed repeats) was the first 
gene family to be shown to be conserved between the human parasite P. vivax (vir), 
the simian/human parasite P. knowlesi (kir), and the rodent malarias P. berghei (bir), 
P. yoelii (yir) and P. chabaudi (cir).  The pir grouping represents the largest gene 
family revealed in Plasmodium spp. to date.  The cir genes of P. chabaudi were the 
first of a major gene family to be identified in rodent malaria.  This finding was later 
followed by the discovery of orthologues in P. berghei, and P. yoelii, which were 
revealed though database mining (Janssen et al, 2002).  These genes also show clear 
similarities to the vir genes described in P. vivax.  The vir gene family was described in 
the human malaria parasite P. vivax by del Portillo et al (2001), and is postulated to 
play a role in antigenic variation and is found at the erythrocyte membrane.  The 
bioinformatic studies by Janssen et al (2002 and 2004) demonstrates some similarity 
between members of the pir family and P. falciparum rif and stevor members, although 
various aspects of the structural arrangement of the P. falciparum gene members 
indicate they must have diverged earlier.  This observation, together with large 
differences in the amino acid sequence has left some uncertainty that the rif and pir 
genes are indeed evolutionarily linked (Cunningham et al, 2010).  The PIR proteins of 
Plasmodium species that infect rodents offer great potential to learn about the function 
of these proteins and will greatly aid malaria research. 
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1.6.2.1 pir gene structure and phylogeny 
The three exon/two intron structure of pirs from the rodent malarias (Janssen et al, 
2002) is relatively well conserved in P. vivax, although this is not true for all vir genes.  
The second exon is proposed to contain a TMD (only half of vir genes do so) and the 
3rd exon is highly conserved between sequences and has been postulated to be a 
cytosolic domain.  Data obtained by Janssen et al suggests the single rif intron was 
derived from the same common ancestor as the rodent and P. vivax genes due to the 
similarity with the second gene.  Other evidence pointing to a common ancestor is the 
similarity between the rif and pir sequences.  The variable and conserved sequences 
are in approximately the same positions, as are the positions of the hypervariable 
regions.  The copy number and sub-telomeric gene location are fairly conserved among 
the pir and rif genes.  There were also “four sequence motifs conserved between most 
of the cir homologues and rif introns” (Janssen et al, 2004), suggestive of a common 
ancestor. 
 
P. vivax contains 346 vir copies in its genome, including pseudogenes, and this high 
number is suggestive of variant proteins (Carlton et al, 2008).  These genes were 
grouped into twelve subfamilies, A – F and more recently families G – L were described 
(Fernandez-Becerra et al, 2008 and Carlton et al, 2008).  Subfamily C was most closely 
related to the yir/bir/cir genes, and two other families, A and D shared structural 
features with P. falciparum surfin’s and Pfmc-2tm genes the proteins of which are 
present in Mauer’s Clefts (del Portillo et al, 2004 and Merino et al, 2006).  
 
Fonager et al (2007) have grouped the yir genes of P. yoelii into five subfamilies, 
according to the chromosome location, alternative splicing events that take place in the 
gene transcript and presence of signalling or PEXEL motifs (Hiller et al, 2004, and Marti 
et al, 2004).  These five subfamilies do however only account for half of the yir 
repertoire.  Analysis of the P. berghei genome shows some shared pir groups with P. 
yoelii but also some unique to P. berghei (Cunningham et al, 2010).  The shared 
groups suggest a conserved evolutionary origin.  The presence of the unique groups 
suggests separate evolution of some pirs which could point to different functions in the 
different parasites.  The P. chabaudi cir gene multifamily was separated into two 
subfamilies, with many unassigned cir’s that showed sequence divergence (Ebbinghaus 
and Krücken, 2011, and Lawton et al, 2012).  Furthermore the cir subfamilies were 
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divided into subgroups, nine for subfamily 1 and seven for subfamily 2 (Ebbinghaus 
and Krücken, 2011).  
 
Comparatively little is known about the P. knowlesi kir genes and their proteins.  The 
genes have been grouped into 4 types dependent on gene structure and are 
distributed in the chromosome (not positioned sub-telomerically like other pirs) (Pain et 
al, 2008). 
 
1.6.2.2 Transcription and translation 
Studies on the asexual stages of P. vivax, P. yoelii, P. berghei and P. chabaudi indicate 
differences in the stages in which pir genes are expressed.  Transcription of cir and bir 
genes occurs during the late trophozoite stage, and transcription levels are reduced 
during the schizont stage (Janssen et al, 2002 and Girolamo et al, 2008).  
Interestingly, approximately 9 % of the BIR proteins of P. berghei are expressed 
exclusively in the mosquito stage (Hall et al, 2005).  Microarray analyses and RNA 
sequencing demonstrated that different cir genes are transcribed during different 
stages of the IDC, and different cirs were expressed in different parasitised cells.  
Some cirs were found to be expressed highly in various populations (Lawton et al, 
2012). 
 
The vir genes are transcribed in waves with transcription occurring in early ring stages 
and schizonts.  Approximately 59 % of virs are transcribed during the IDC (Fernandez-
Becerra et al, 2008).  The vir repertoire was examined in natural populations to find 
out how wide spread the genes are as they account for approximately 10 % of the 
genome (Merino et al, 2006).  This study showed that a wide range of vir genes are 
expressed, with the analyses being carried out on the genes present in each subfamily.  
The VIR proteins are not clonally expressed (Fernandez-Becerra et al, 2008).  In 
primary infections, there were IgG antibodies to many VIR proteins suggesting they 
are not in fact clonally expressed, pointing to a function other than that of (solely) 
antigenic variation. 
 
The profile for P. yoelii is very different as the transcription of yir genes is dependent 
on the host immune response.  In immunocompetent mice a different yir gene was 
transcribed upon re-infection, yet in immunocompromised mice yir transcription 
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remained constant (Cunningham et al, 2005).  In P. yoelii, many yir genes are 
transcribed at any one point, albeit at low levels, but not all are translated 
(Cunningham et al, 2005), suggestive of a post-transcriptional effect to modulate the 
particular gene being expressed.  However, in an individual cell only 1 – 3 yir genes 
are transcribed at any one time (Cunningham et al, 2009). 
 
 
 
Figure 1.11: PIR family amino acid conservation plot.  A scheme to illustrate the conservation of a 
set of sequences at the amino acid level.  The line of similarity drops close to the x-axis as the sequences 
are very divergent at this point and is where the hypervariable region is placed.  Image taken from 
Janssen et al (2004). 
 
Alternative splicing has been shown to take place in a subset of the yir genes.  It is 
thought that this alternative splicing may regulate the translation of YIR proteins.  A 
conserved promoter motif found in the 5’ untranslated region (UTR) has been 
identified in the P. yoelii genome upstream of the yir transcripts.  The motif was also 
found to be present in the P. chabaudi and P. berghei genomes.  The 5’ UTR motif 
could act as a ‘general recognition element’ for the transcription of these genes.  
However, as the domain is present in all pir genes this probably does not play a role in 
their regulation (Fonager et al, 2007). 
 
1.6.2.3 PIR proteins 
Given the presence of a TMD and the hypervariable region of the pir genes (Figure 
1.11), it is generally considered that these proteins play a role in antigenic variation. 
Therefore it is anticipated that these proteins would be displayed at the surface of the 
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RBC.  B-type RIFINS have been shown to be expressed in merozoites (Mwakalinga et 
al, 2012), therefore it is possible that the proteins would be expressed on the surface 
of merozoite too.  The amino acid sequences from approximately 46 % (160/346) of 
VIR proteins contain a PEXEL motif (Hiller et al, 2004, and Marti et al, 2004) and 
approximately 50 % (171/346) contain a putative TMD (Carlton et al, 2008).  
Consistent with these data, VIR proteins localise to the surface of reticulocytes 
(Fernandez-Becerra et al, 2008 and del Portillo et al, 2004).  The YIR protein from P. 
yoelii has been shown, using antibodies, to be antigenic and to be present at the 
surface of IEs (Cunningham et al, 2005).  The cellular location of the CIR protein family 
in P. chabaudi, a species thought to undergo both rosetting (Mackinnon et al, 2002) 
and antigenic variation has been experimentally determined using western blots.  The 
analysis was directed against the Triton X-100 insoluble fraction of parasites and 
erythrocyte ghosts.  Immunofluorescence analysis also demonstrated that the protein 
was present on the erythrocyte surface (Janssen et al, 2004).  The BIR proteins of P. 
berghei were associated with detergent resistant membrane lipid rafts and the PV 
(Girolamo et al, 2008) suggesting the BIR proteins may be molecular chaperones or 
are translocated outside the parasite by chaperones. 
 
The protein expression of YIR is thought to be predominantly in the schizont stage as 
the majority of cells observed when stained with YIR antisera were schizonts and less 
than 2 % were in ring or trophozoite stages (Cunningham et al, 2005).  YIR proteins 
were translated in all stages of the intraerythrocytic lifecycle.  The proteins translated 
are not always the same throughout the stages (Cunningham et al, 2009).  Contrary to 
the results in other species, a small number of CIR proteins are transcribed at any one 
time in an in vivo model over the 24 h period of investigation (Ebbinghaus and 
Krücken, 2011).  Akin to the other PIR proteins, the amino acid sequence of KIR 
contains a single predicted TMD at the C-terminal (Jemmely et al, 2010).  In some 
Plasmodium proteins a sequence motif, known as the PEXEL motif, is involved in 
carrying proteins beyond the vacuolar membrane, for example in protein targeted to 
red cell membranes (Hiller et al, 2004, and Marti et al, 2004).  No PEXEL motif is found 
within the KIR protein sequences.  However, another motif, the ZLPS motif, has been 
postulated to carry KIR proteins to the red cell surface (Pain et al, 2008). 
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The function of these PIR proteins has not yet been demonstrated.  However: 9 % of 
BIRS are expressed in ookinetes, VIR’s are non-clonally expressed, B-type RIFINS are 
expressed intracellularly and expressed in the gametocyte and sporozoite stages.  This 
is an indication that roles other than avoidance of mammalian immunity must be 
considered for at least a portion of these gene products. 
 
A study was undertaken to establish in which host tissues cir transcripts were present 
(Ebbinghaus and Krücken, 2011).  A broad range of tissues were analysed with 
products present in lung, liver, blood, spleen, kidney and brain tissues.  Interestingly 
for some subgroups, sequences were totally absent from some tissues.  For example, 
in subgroup 5 of subfamily 1, no sequences were observed in liver tissues, where 60 % 
of the total sequences (all subgroups) were present in the liver.  With respect to 
subgroup 1, no sequences were observed in the brain tissue (Ebbinghaus and Krücken, 
2011).  The differences in tissue type expression of the subgroups points towards 
multiple roles for this family of proteins.  Lawton et al (2012), and Janssen et al (2004) 
identified conserved amino acid motifs within the CIR and PIR sequences, respectively.  
Lawton et al (2012) suggest that the conservation of these motifs put constraints on 
the gene diversity, suggesting important biological functions for CIR’s.  The differences 
observed in cir transcripts between groups A and B, and the temporal expression of 
cirs suggests a different biological function for A and B CIRs and possibly stage specific 
roles (Lawton et al, 2012). 
 
1.6.3 Molecular mechanisms involved in switching 
The molecular mechanisms for gene switching are poorly understood, and most work 
has concentrated on the var genes of P. falciparum.  Each of the P. falciparum var 
genes has a dedicated promoter.  Therefore, one gene is switched on while another is 
inactivated to provide the organism with only one expressed surface antigen (of the 
var family) (Frank and Deitsch, 2006). 
 
The subtelomeric location of these var, rif, stevor and pir genes is important for gene 
diversity due to the increased possibility of multiple recombination events.  In the 
nucleus, var genes are clustered together at perinuclear positions.  This positioning has 
been inferred as being important for the generation of new genes due to the closeness 
of the various var genes (Frank and Deitsch, 2006).  The P. vivax genome encodes 
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many pseudogenes in the vir family (del Portillo et al, 2001) and these could be 
important for recombination and thereby increase the vir repertoire.  Another 
mechanism has been attributed to the A+T richness of the Plasmodium genome.  The 
A+T rich genome has been postulated to increase the recombination events which may 
increase the rate of generation of immunological diversity (Winzeler, 2008).  
 
The perinuclear position of the var genes is also thought to be important for the 
switching events.  Active genes are thought to be maintained in a specific region of the 
nucleus, and the relocation of chromosome ends switches the active gene with another 
(Dzikowski et al, 2006).  Each var gene has its own promoter, and these promoters 
have been grouped into three sub-types.  UpsA is found at the subtelomere, UpsC is 
found in internal clusters and UpsB a combination of the two locations.  These 
promoter types may have influence the gene expression (Frank and Deitsch, 2006).  
Sir2A and Sir2B are P. falciparum orthologues of a S. cerevisiae gene that plays a role 
in gene regulation.  The sir2 gene product binds to the chromosome ends and appears 
to prevent activation of the var gene.  As Sir2 binds to the chromosome ends, only the 
genes driven by the UpsA and UpsC promoter are affected (Frank and Deitsch, 2006).  
As the Sir2 protein binds to the end of the chromosome, the internal var genes do not 
appear to be affected (Tonkin et al, 2009).  The influence of PfSir2 on rif gene 
expression was also considered.  In this regard, it was demonstrated that in a pfsir2a 
knock-out strain the rif genes that were expressed often had close associations with 
var genes.  In a pfsir2a knock-out, the temporal rif expression was altered with rif’s 
being expressed at all stages of the intraerythrocytic lifecycle.  A pfsir2b knock-out 
mutant had little effect on rif gene expression (Tonkin et al, 2009). 
Introduction Chapter 1 
 
[43] 
 
1.7 Aims of this Study 
 
(i) The biochemical characterisation of P. falciparum NitA based on the development of a 
set of assays designed for the determination of substrate specificity.  This line of 
enquiry should a priori further our understanding of the role of the PfNitA transporter 
in Plasmodium. 
 
(ii) Determination of the importance of the PfNitA protein to asexual parasites and 
validation as a potential drug target by reverse genetics in P. falciparum.  In addition, 
the determination of the localisation of PfNitA within the asexual stage parasite. 
 
(iii) Recombinant expression of P. chabaudi Cir2 (17129530), a representative PIR protein 
in E. coli for structural and topological studies, towards determining a role for the 
protein family. 
 
The results of this study are provided in three chapters.  Chapters 3 and 4 contain 
research carried out into the functional and biochemical characterisation of PfNitA.  
Chapter 5 describes the production of rPcCir2 protein and its structural analyses.  The 
results presented in these three chapters will be discussed in Chapter 6.
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Consumables 
Reagents were of high grade and obtained from Sigma-Aldrich (Dorset, UK), Fluka 
(Gillingham, UK) and BDH (through VWR, Lutterworth, UK).  Enzymes were from 
Promega (Southampton, UK) or NEB (Hitchin, UK) unless stated otherwise. 
 
2.1.2 Bacterial cultures 
Bacterial overnight cultures were grown in 4.5 ml Luria Bertani (LB) broth (Appendix 1) 
with a plasmid selection antibiotic if required.  LB agar plates were used for bacterial 
transformations, and to streak out cultures to produce single colonies.  The agar plates 
were kept at 4 oC for short term storage.  For long term storage 0.5 ml overnight liquid 
culture was mixed with 0.5 ml fresh LB + glycerol (30 % v/v glycerol) and stored in 
cryovials at -85 oC.  Liquid cultures were grown in an orbital incubator with agitation at 
220 – 250 rpm, and solid cultures in a static incubator, both were grown at 37 oC 
unless stated otherwise. 
 
2.1.3 E. coli strains 
DH5α (supE44 Δ lacU169 (φ80lacZ Δ M15) hsdR17 recA1 gyrA96 thi-1 relA1) cells 
were routinely used in the transformation and amplification of plasmids, and the 
transformation of ligated products. 
BL21 (DE3) (hsdS gal (λcIts857 ind1 Sam7 nin5 lacUV5-T7 gene 1)) cells were used 
for protein expression, and are compatible with vectors using the T7 and tac promoters 
for recombinant expression of proteins. 
C43 (DE3) cells are a mutant strain of BL21 (DE3) cells that were found to be 
particularly useful for the expression of membrane proteins as they resulted in a lower 
toxicity to that observed with the BL21 (DE3) strain.  The strain has two 
uncharacterised mutations (Miroux and Walker, 1996). 
Arctic Express™ (DE3) (Stratagene, Stockport, UK) (B F– ompT hsdS(rB– mB–) dcm+ 
Tetr gal λ(DE3) endA Hte [cpn10cpn60 Gentr]) cells have been specially designed for 
the expression of proteins at lower temperatures.  Protein production at low 
temperatures is achieved by the co-expression of the two chaperones Cpn10 and 
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Cpn60 present on a pACYC-based plasmid that encodes a gentamycin resistance gene 
for selection. 
OneShot® (Invitrogen) (F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(araleu) 7697 galU galK rpsL (StrR) endA1 nupG) cells are resistant to killing 
by the ccdB gene product.  These were used for the propagation of the Gateway 
vectors. 
JCB4018 (RK4353 Δ napA-B ΔnarZ::Ω ΔnarK::tet narU::kan) and JCB4250 (RK4353 
ΔnapA-B ΔnarZ::Ω ΔnarK::tet narU::kan ΔnirC::cam ΔnrfA::chl) are kind gifts from 
Prof. J. Cole, University of Birmingham, UK, for the PfNitA functional complementation 
assay.  JCB4250 is a knock-out for the E. coli NirC nitrite transporter (Jia et al, 2009). 
MC4100 (F- araD139 Δ (aarfF-lac)U169 ptsF25 deoC1 relA1 flbB530 rpsL150λ-), 
REK701 (like MC4100 but ΔfocA) and RM201 (MC4100, Δ(pfl-25) 
Ω(pfl∷cat pACYC184)) are kind gifts from Prof. G. Sawers, Martin Luther University, 
Germany, for the PfNitA functional complementation assay.  REK 710 is a loss of 
function mutant for the E. coli Foc A formate transporter (Suppmann and Sawers, 
1994). 
CC118 (Δ(ara-leu), araD, ΔlacX74, galE, galK, phoA20, thi-1, rpsE, rpoB, argE(Am), 
recA,) cells were used in the alkaline phosphatase assay, and were a kind gift from Dr. 
D. Daley, Stockholm University, Stockholm, Sweden. 
 
2.1.4 Plasmids 
Gateway Vectors which were amplified in the specifically designed OneShot® Top 10 
competent cells. 
 
pTTQ18 and pTTQ10H are protein expression plasmids encoding 6 and 10 Histidine 
residues, respectively, as a tag for purification.  Both encode an ampicillin resistance 
gene as a selectable marker, tac promoter and are approximately 4500 bp in size.  
IPTG is used to induce protein expression (Stark, 1987). 
pEHISTEV and pEHISGFPTEV are protein expression plasmids encoding a N-terminal 
6 x His tag and a TEV protease site to cleave the tag from the expressed protein.  The 
plasmids were kind gifts from Dr. H. Lui, University of St Andrews.  The pEHISGFPTEV 
encoding a N-terminal green fluorescent protein (GFP) reporter gene.  These plasmids 
encode a kanamycin resistance gene as a selectable marker, and a T7 promoter, IPTG 
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is used to induce protein expression.  pEHISTEV is approximately 5500 bp and 
pEHISGFPTEV approximately 6500 bp in length (Lui and Naismith, 2009). 
pV5M and pV5MGPD are around 7700 bp in length and encode an ampicillin 
resistance gene as a selectable marker for selection in E. coli and the argB gene for 
selection in A. nidulans.  The V5M plasmid uses the NrtA promoter and V5MGPD the 
GPD promoter.  Both plasmids are used in fungal transformations.  At the 3’ end of the 
insert there is a sequence encoding a V5 viral protein epitope for detection in western 
blots using the horseradish peroxidase (HRP) conjugated anti-V5 antibody (Invitrogen). 
pCC1 and pCC4 were used to create Plasmodium falciparum knock out constructs.  
The plasmids were a kind gift from Dr. T.K. Smith, University of St Andrews. pCC1 
encodes the hdhfr (human dihydrofolate reductase) gene and confers resistance to 
Walter Reed Institute anti-DHFR antifolate 99210 (WR 99210), and pCC4 encodes the 
blasticidin S deaminase gene conferring resistance to blasticidin for positive selection.  
Both plasmids contain the cytosine deaminase gene as a negative selectable marker 
utilised during the transfection procedure.  There is an ampicillin resistance gene 
present for positive selection during cloning.  These plasmids create KO’s via double 
cross over recombination (Duraisingh et al, 2002 and Maier et al, 2006).  
pHA-1 has a C-terminal PhoA reporter gene.  pHA-1 was a kind gift from Dr. D. Daley 
(Stockholm University), and encodes a ‘stuffer’ gene, yedZ.  It encodes an ampicillin 
resistance gene and is approximately 8000 bp. (Whitley et al, 1994). 
pGFPe has a C-terminal GFP reporter gene and is a modified version of the pET28 
(a+) plasmid.  As it is made from the pET28 (a+) plasmid it encodes an 8x His tag, the 
kanamycin resistance gene and the T7 promoter.  The plasmid is approximately 7000 
bp in length.  pGFPe was also a kind gift from Dr. D. Daley, the original was created by 
Waldo et al (1999). 
 
2.1.4.1 Gateway® plasmids 
The Gateway® (Invitrogen) vectors are a set of plasmids designed for use in P. 
falciparum (Tonkin et al, 2004 and van Dooren et al, 2005).  They comprise a set of 
vectors in which a promoter is encoded, the gene of interest and a tag gene such as 
GFP. 
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(A)      (B) 
    
 
(C)        (D) 
    
 
   (E) 
 
 
Figure 2.1:  Gateway® vectors.  (A) the entry vector into which the gene is cloned highlighting the 5’ 
GGTG overhang for directional cloning. (B) the destination vector.  Between the att sites is a 
chloramphenicol resistance gene and a ccdB gene which are lost after correct recombination upon 
production of the final plasmid vectors. (C) Hsp-86 promoter. (D) GFP tag and (E) HA tag.  In each vector 
the att sites used for Gateway cloning are given, as well as the DSM’s used during bacterial cloning. 
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By using the Gateway® cloning method a gene of interest can have either an N-
terminal of C-terminal fusion tag.  The Gateway® vectors used in this thesis were a 
kind gift from Prof. S. Müller and are detailed in Figure 2.1. 
 
pENTR/D-TOPO is an entry vector used for the cloning of the gene of interest after 
PCR amplification. 
pCHD3/4 is the destination vector.  Plasmids encoding the genes of interest i.e. the 
above entry vectors are combined with the destination plasmid in a LR reaction 
(section 2.2.10) 
pDON-R GFP, pDON-R (HA)3 and pDON-R HSP-86 are entry vectors, these 
vectors encode 3’ or 5’ tags. 
 
2.1.5 Synthetic genes 
The P. falciparum nita gene was synthesised according to a codon bias required for 
expression in Aspergillus nidulans (pfnita_opt) and E. coli (pfnita_optEc). The P. 
chabaudi cir2 gene was synthesised according to the codon bias required for 
expression in E. coli (pccir2).  Both genes were purchased from GenScript (NJ, USA).  
Sequences of the synthetic genes are given in Appendix 6. 
 
2.1.6 Antibiotics 
Antibiotics were made up in 1 ml aliquots at 100 mg/ml and stored at -20 oC.  Table 
2.1 gives the antibiotics used in this thesis and working concentrations.  Carbenicillin 
(www.carbenicillindirect.com) was used instead of ampicillin (Melford, Suffolk, UK) in 
protein expression trials and for extended growth conditions as the ampicillin begins to 
decompose after 16 h.  All other antibiotics were obtained from Sigma. 
 
Antibiotic Working concentration 
Kanamycin 50 µg/ml 
Carbenicillin 100 µg/ml 
Ampicillin 100 µg/ml 
Gentamycin 20 µg/ml 
Table 2.1: Working concentrations of each of the antibiotics used in this thesis. 
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2.2 Molecular Biology 
 
2.2.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify gene products of interest for use 
in cloning and hybridisation.  Oligonucleotide primers were obtained from VH Bio 
(Gateshead, UK) and Eurogentec (Fawley, UK) and are given in Appendix 2.  PCR’s 
were carried out using the enzymes: Vent Thermo (NEB), Phusion (Finnzymes, Espoo, 
Finland) and Kapa HiFi (Kapa Biosystems, Woburn, MA, USA) polymerases and the 
buffers provided.  Each of these enzymes is a high-fidelity enzyme with proof reading 
activity.  When amplifying products from Plasmodium falciparum genomic DNA (gDNA), 
Kapa HiFi polymerase was used with the GC Buffer provided or Phusion polymerse.  
The reactions were carried out in a G-Storm GS1 thermocycler.  PCR products were 
sequenced after they had been cloned into their respective plasmids.  Sequencing was 
outsourced to the Dundee Sequencing Service (Dundee University, UK) or Macrogen 
(Seoul, South Korea), and carried out using specific PCR primers used in the PCR 
reaction or the T7 primer.  Sequences were analysed using Sequencher (Gene Codes 
Corporation, Ann Arbor, MI, USA). 
 
2.2.2 Mutagenesis PCR 
Mutagenesis PCR was carried out to generate a single amino acid mutation, the 
technique followed was that of splice overlap extension (Warrens et al, 1997).  Splice 
overlap extension involves two rounds of PCR. The so called hybrid primers are used to 
introduce the mutation of interest with a set of flanking primers, which are also used to 
create the full-length gene.  The process is illustrated schematically in Figure 2.2.  The 
first round of PCR was carried out using a hybrid antisense primer (3) and a flanking 
sense primer (1) to obtain the 5’ fragment of the gene (PCR 2).  The 3’ fragment of 
the gene was amplified using a hybrid sense primer (2) and a flanking antisense primer 
(4) (PCR 1).  The 5’ (Product 1) and 3’ (Product 2) gene fragments overlap by 22 base 
pairs and both include the mutation.  These two gene fragments were used to 
construct the full-length gene which was amplified using the two flanking primers (1 
and 4).  The final PCR (3) produces one full-length gene containing a single, desired 
mutation (Product 3). 
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Figure 2.2: Mutagenesis by splice overlap extension.  Two PCRs are carried out using the gene as 
the template and primer sets 1 + 3 (PCR 1) and 2 + 4 (PCR 2).  Hybrid primers 2 and 3 contain the 
desired mutation (X).  Both PCR products overlap by 22 bp where the mutation was created.  PCR 
products 1 and 2 containing the mutation are purified and serve as the template for the next round of PCR 
using the flanking primer set 1 + 4 (PCR 3).  The 22 bp overlap allows annealing of the two PCR products.  
The final PCR product 3 codes for the full-length protein, and contains the single mutation.  Source: A. 
Clarke. 
 
2.2.3 Agarose gel electrophoresis 
DNA products were run on a 1 % (w/v) agarose gel for visualisation and quantification, 
for smaller DNA fragments a higher percentage agarose gel (1.5 – 2 % w/v) was used.  
Agarose was made in 1 x TAE buffer (40 mM Tris acetate, 1 mM EDTA), and ethidium 
bromide was added to a final concentration of 0.5 µg/ml.  For large fragments xylene 
cyanol (30 % glycerol, 0.25 % xylene cyanol in distilled water (DW)) and for small 
fragments bromophenol blue (30 % glycerol, 0.25 % bromophenol blue in DW), were 
used as a loading and tracking dye.  A molecular weight marker was added, 
Hyperladder I (Bioline, London, UK) or Keyzyme 100 bp plus DNA ladder (Anachem, 
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Luton, UK).  Gels were viewed over a UV transilluminator and the image recorded 
using the Herolab E.A.S.Y Photographic Suite (Wiesloch, Germany).  
 
2.2.4 PCR product purification 
PCR products were either purified directly from the reaction, or if spurious bands were 
present extracted from agarose gel. 
 
Purification from PCR reactions was carried out using PCR purification kits from: 
Invisorb (Berlin, Germany), Marligen Biosciences (MD, USA), Omega Biotek (GA, USA), 
and GenScript.  The PCR product was purified using the instructions and solutions 
provided with each of the kits.  DNA was eluted in the elution buffer provided or TE 
buffer (10 mM Tris, 1 mM EDTA, pH 8.0). 
 
Fragments were extracted from an agarose gel using the manufacturer’s protocol in a 
Qiagen (Crawley, UK) Gel Extraction Kit.  Briefly, the DNA band was excised from the 
gel, incubated with buffer and silica beads at 50 oC, and washed to remove salts and 
other contaminants from the gel.  The DNA was eluted from the beads by incubation in 
TE buffer. 
 
A 1/10 elution volume of the purified PCR product was run on an agarose gel to 
confirm the correct size of the product, and for quantification a Nanodrop, ND-1000 
spectrophotometer (ThermoScientific, Northumberland, UK) was used. 
 
2.2.5 Plasmid isolation 
Plasmids were isolated from overnight culture following the instructions provided in a 
Qiagen miniprep kit.  The plasmids were eluted in 30 – 50 µl TE pH 8.0 and stored at  
-20 oC.  If large concentrations of plasmid were required, for example for malaria 
transfections, a Qiagen maxi prep was used.  1 µl of plasmid was retained for digestion 
to confirm the size and presence of insert by restriction analysis, if an insert was 
present.  Plasmids without insert were also cut to verify they were of the expected size 
(see section 2.2.7). 
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2.2.6 Ethanol precipitation of DNA 
Precipitation of DNA was carried out to concentrate a sample of DNA.  3 volumes of 
100 % ethanol was added to a purified DNA sample, followed by 1/10 volumes of 3 M 
sodium acetate (pH 5.2).  To facilitate DNA precipitation, 1 µl of 20 µg/µl glycogen 
(Invitrogen) was added.   The DNA suspension was incubated at -20 oC for 24 h.  The 
sample was centrifuged for 20 mins at maximum speed on a benchtop centrifuge, 4 oC 
washed with 200 µl of 70 % ethanol, and centrifuged as before, for 10 mins.  The 
sample was taken to a sterile tissue hood, the supernatant removed, and the 
precipitated DNA allowed to air dry to remove the ethanol.  The DNA was resuspended 
in 30 µl of filter sterilised MilliQ (MQ) water and stored at 4 oC for use in malaria 
transformations (see section 2.5.5). 
 
2.2.7 Restriction endonuclease digestion 
Up to 1 µg of DNA was digested with 10 – 20 units (U) of a specific Type II restriction 
endonuclease for 2 – 3 h, with the exception of SacII where 30 U were used per µg 
DNA.  When digesting with two enzymes using different buffer, the buffer was chosen 
as directed from the manufacturer, or a sequential digest was carried out using the 
lower salt containing buffer first followed by addition of salt to the required 
concentration of the second enzyme.  After digestion the reaction was treated with 5 
units Shrimp Alkaline Phosphatase (Promega) or Arctic Alkaline Phosphatase (NEB) in 
the buffer provided.  The DNA concentrations after digestion were checked by running 
1/10 volume on a gel to visualise the DNA and quantified using a Nanodrop 
spectrophotometer. 
 
2.2.8 Drop dialysis of DNA 
Drop dialysis was carried out on all purified PCR, digestion products and plasmid 
isolations to remove excess salts which may interfere with the subsequent reactions.  
Dialysis was carried out using HAWP mixed cellulose ester membranes from Millipore 
(Hertfordshire, UK) with a pore size of 0.025 µm.  The product to be dialysed was 
pipetted on the membrane floating on autoclaved DW.  The sample was left for 30 
minutes (mins) before being removed from the dialysis membrane. 
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2.2.9 DNA ligation 
Ligations were carried out using a Rapid DNA Ligation Kit (Fermentas, York, UK) 
according to the manufacturer’s instructions; digested plasmid and digested insert 
were mixed at a ratio of 1:3, and incubated with T4 ligase at room temperature for 1 
h.  2.5 U of ligase were used in a 10 µl reaction. 
 
2.2.10 Gateway® cloning 
The Gateway Cloning system was used to prepare knock-in constructs for Plasmodium 
transfections.  The cloning reactions were carried out as described in the Invitrogen 
manual and are described below.  Figure 2.3 displays the reaction schematically. 
 
The gene of interest was first amplified by PCR using primers specific to the gene with 
the forward primer containing a 5’ CACC sequence for the cloning into the pENTR™/D-
TOPO® vector.  The PCR (0.5 – 4 µl) product was combined with 1 µl pENTR™/D-
TOPO® at a 0.5:2 – 2:1 molar ratio, and 1 µl of a pre-defined salt solution, and made 
up to 6 µl with MQ water  and incubated at 22 oC for 5 mins.  If the PCR product was 1 
kb 1 – 5 ng was recommended and if 2 kb 5 – 10 ng recommended.  Two microlitres 
of the ligation reaction was transformed into chemically competent OneShot® Top 10 
DH5α  cells.  The remainder of the ligation reaction was stored at 4 oC. 
 
The Gateway® cloning reaction combines the desired PCR product (in the pENTR™/D-
TOPO® vector) with a promoter (5’ element) and an N- or C-terminal tag such as green 
fluorescent protein (GFP) or haemaggluntinin ((HA)3) (3’ element).  The reaction is 
illustrated schematically in Figure 2.4. 
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Figure 2.3: Topo cloning reaction.  An overview of the pENTR™/D-TOPO® vector cloning.  The PCR 
product contains a CACC sequence, which allows directional cloning to the GTCC overhang in the vector.  
Image is adapted from Invitrogen15. 
 
The three plasmids containing the tag, PCR product and promoter were diluted and 
used at 10 fmoles, the volume not exceeding 7 µl.  The destination vector was 
concentrated to 20 fmoles in 1 µl, the destination vector used is pCHD-3/4 (Figure 2.1) 
which has been specially designed for use in Plasmodium.  The total reaction volume 
was made up to 8 µl with TE buffer (pH 8.0), 2 µl of LR ClonaseTM II Plus (Invitrogen) 
added to the plasmid mixture, and the sample centrifuged briefly.  The reaction was 
incubated at 22 oC for 16 h.  After the 16 h incubation, 1 µl of 2 µg/µl proteinase K was 
added to stop the reaction.  The sample was transformed into chemically competent 
OneShot® DH5α cells. 
 
                                                 
15 http://products.invitrogen.com/ivgn/product/K240020 
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Figure 2.4: MultiSite Gateway® 3-Fragment reaction.  Overview of the Gateway® cloning reaction.  
The entry clones were pre-made using the BP reaction and contain the Hsp-86 promoter (5’ element) and 
GFP or (HA)3 tags (3’ element).  The gene specific entry clone was created by the TOPO reaction 
described above.  The LR reaction was carried out to bring each of the Entry Clones together with the 
Destination Vector to create the final construct.  Image is taken from the MultiSite Gateway® manual 
(Version H, 31 October 2010) (Invitrogen)16. 
 
2.2.11 Preparation of competent cells 
Competent cells were prepared according to the method by Inoue et al (1990).  E.coli 
were streaked on LB agar and grown overnight at 37 oC.  A single well defined colony 
was used to inoculate LB broth and grown overnight.  One millilitre of overnight culture 
was used to inoculate 100 ml of SOB medium (Appendix 1).  The freshly inoculated 
culture was grown at 18 – 20 oC with rotary shaking at 180 rpm until an OD680 of 
approximately 0.6 was reached.  The flask was left to stand on ice for 10 mins, and the 
cells harvested by centrifugation at 1000 x g for 15 mins at 4 oC.  The cell pellet was 
resuspended in 40 ml cold Transformation Buffer (10 mM PIPES, 15 mM calcium 
chloride, 250 mM potassium chloride, 55 mM manganese chloride, pH 6.7), and 
incubated on ice for 10 mins, before further centrifugation as before.  The resulting 
pellet was resuspended in 4 ml cold Transformation Buffer, 0.3 ml DMSO added, and 
                                                 
16 http://tools.invitrogen.com/content/sfs/manuals/multisite_gateway_man.pdf 
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the cells mixed gently and incubated on ice for a further 10 mins.  The cells were 
aliquoted into pre-chilled (to -85 oC) microfuge tubes and stored at -85 oC. 
 
2.2.12 Bacterial transformation 
Fifty microlitres of competent cells were added to 50 – 100 ng plasmid DNA or full 
ligation reaction, and incubated on ice for 20 mins.  The cells were ‘heat shocked’ at 42 
oC for 90 s (DH5α) or 45 s (all other strains), followed by 2 mins on ice.  Two hundred 
microlitres of prewarmed SOC medium (Appendix 1) was added and mixed gently, 
followed by a recovery period in a 37 oC incubator with agitation (220 rpm) for 1 h or 2 
h if  cells were to be plated on LB + kanamycin.  If a low number of transformants was 
expected the tubes were centrifuged briefly using a bench top centrifuge and the pellet 
resuspended in 100 µl (of the same medium) before being plated on LB agar 
containing the selection antibiotic, otherwise 100 µl of the transformation was plated. 
 
2.2.13 Colony cracking 
To check transformed bacterial colonies for the correct plasmid, colony cracking was 
used.  A single colony was resuspended in 10 µl DW, and 10 µl Cracking Buffer (200 
mM sodium hydroxide, 0.5 % SDS, 10 g sucrose, and a few crystals of bromocresol 
green) added.  The lysed colony was run on a 0.8 % agarose gel alongside a positive 
control plasmid of about the expected size, and a negative control of vector without an 
insert for comparison. 
 
2.2.14 Colony PCR 
Colony PCR’s were carried out to confirm the presence of an insert in a vector after a 
transformation.  The colony was suspended in the volume of PCR, generally 10 µl.  The 
PCR was carried out in the same way that it was amplified from plasmid or genomic 
DNA, or by using a taq polymerase; MyTaq™ HS DNA Polymerase (Bioline) and 2x 
Thermo-Start HP ReddyMix (Thermo Scientific). 
 
2.2.15 Southern blotting 
Two methods were used to do Southern blots.  The first was carried out in the 
University of Glasgow, the second at the University of St Andrews. 
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Method 1: Vacuum transfer with an alkaline phosphatase probe 
Genomic DNA (gDNA) (1 – 2 µg) was digested using 1 µl of the desired restriction 
enzyme/s.  The total digestion was loaded on an 0.8 % agarose gel and 
electrophoresed at 20 V overnight, the first and last lanes of the gel were left bank.  
The following day the gel was stained using Sybr Safe® (Invitrogen) and the gel 
photographed alongside a fluorescent ruler so that migration distances could be 
measured.  The gel was washed gently in MQ water and incubated with agitation, in 
300 ml of 0.25 M hydrochloric acid for 10 – 15 mins, the gel was washed twice in MQ 
water, followed by incubation in 300 ml denaturation buffer (1.5 M sodium chloride, 
0.5 M sodium hydroxide) for 30 mins.  Again the gel was washed twice in MQ water, 
incubated in neutralisation buffer (3 M sodium chloride, 0.5 M Tris, pH 7.0) for 30 
mins, and washed once in MQ water.  A vacuum blotting device (VacuGene XL, GE 
Healthcare, Chalfont St. Giles, UK) was set up to transfer the gDNA to a Hybond-N+  
membrane (GE Healthcare), 20 X SSC (3 M sodium chloride, 0.3 M sodium citrate, pH 
7.0) was poured over the gel, and was topped up as needed to ensure the gel was 
covered all the time.  The vacuum pressure was set between 50 – 60 mbar and applied 
1 h 30 mins.  The position of the lanes on the gel were marked onto the membrane, 
and the membrane air dried and crosslinked using a UV CX-2000 crosslinker (UVP, 
Cambridge, UK) at 700 x 100 µJ/cm2.  The membrane was placed in a very clean 
hybridisation bottle and incubated with 10 ml hybridisation buffer (5 x SSC, 0.1 % 
(w/v) dextran sulphate, 1:20 liquid block (GE Healthcare)) with rotation for 15 mins.  
The probe was added to the bottle and incubated with rotation at 55 oC overnight. 
 
The probe was made using the instructions found in the AlkPhos Direct Labelling and 
Detection System kit (GE Healthcare).  Briefly, The DNA for the probe was diluted to 
10 ng/µl and mixed with reaction buffer, labelling reagent, and cross linker.  The final 
DNA concentration was chosen so that there was 5 – 10 ng DNA probe per ml 
hybridisation buffer.  The reaction was incubated at 30 mins at 37 oC.  Half (16 µl) of 
probe was added to the hybridisation bottle, the other half was stored in 50 % (v/v) 
glycerol at -20 oC until required. 
 
The following day the membrane was washed 3 times for 15 mins with 50 ml primary 
wash buffer (2 M urea, 150 mM sodium chloride, 1 mM magnesium chloride, 50 mM 
sodium dihydrogen phosphate pH 7.0, 0.1% (w/v) SDS, 0.2 % (w/v) blocking reagent) 
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at 55 oC with rotation.  After which, the membrane was washed twice for 10 mins in 
100 ml secondary wash buffer (50 mM Tris, 100 mM sodium chloride, pH 10.0) at room 
temperature with shaking.  The buffer was drained and the blot covered in 2 – 3 ml 
CDP – star™ detection reagent (GE Healthcare) for 2 – 5 mins.  The detection solution 
was drained and the membrane sealed in plastic and taped in place in a film cassette.  
A piece of Hyperfilm™ ECL high performance chemiluminescence film (GE Healthcare) 
was placed on top of the membrane and the first film developed after 1 h.  Blots were 
stripped by incubation with 0.5 % SDS at 60 oC with agitation for 2 h. 
 
Method 2: Capillary transfer with a radiolabelled probe 
The initial steps of the second Southern blotting method are almost identical to the 
previous method, differences are stated below.  gDNA was digested overnight and size 
fractioned on an agarose gel, and stained with ethidium bromide (0.5 µg/ml).  The 
capillary transfer was set up by pouring 20 x SSC into a Pyrex dish and by creating a 
bridge using a perspex insert covered in two strips of 3MM (Whatman, Kent, UK) filter 
paper wetted in 20 x SSC acting as a wick.  The gel was placed onto the filter paper 
followed by a Hybond-N+ membrane placed over the gel with care taken to remove 
any bubbles.  On top of the membrane, 3 wet (in 20 x SSC) and 3 dry pieces of 3mm 
filter paper were added, followed by a large stack of paper towels and a weight.  The 
apparatus set up is illustrated in Figure 2.5.  The DNA was transferred overnight (8 – 
18 h).  The following morning the membrane was rinsed in 2 x SSC, dried and 
crosslinked as before in a Spectrolinker XL-1500 crosslinker (Spectronics Corporation). 
 
The membrane was incubated in approximately 50 ml hybridisation buffer (5x SSPE 
(175.3 g/L sodium chloride, 27.6 g/L sodium dihydrogen phosphate, 7.4 g/L EDTA, pH 
7.4 using sodium hydroxide), 9 % polyethylene glycol 6000, 0.5 % skimmed milk, 1% 
SDS, 0.1 % sodium pyrophosphate, 0.2 mg/ml herring sperm DNA) and prehybridised 
at 65 oC in a hybridisation oven with gentle agitation. 
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Figure 2.5:  Southern blotting by capillary transfer.  This figure demonstrates the set up a the 
Southern blot apparatus to transfer the DNA from agarose gel to the Hybond-N+ membrane.  Image was 
taken from the Thermo Scientific/Fermentas website17. 
 
The radiolabelled probe was made using a random primer labelling method.  DNA (50 
ng) was made up to 50 µl with DW and boiled for 2 mins, and placed on ice to cool.  5 
µl 10x dNTP's (minus dCTP) and 10 µl 5x labelling buffer (Promega) were added and 
mixed, after which 0.5 µl Klenow fragment (10 U/µl) was added and mixed gently.  2.5 
µCi of 32P dCTP (Perkin Elmer) 6000 Ci/mmol was added, and the whole reaction 
mixture incubated at 37 oC for 30 mins.  To the reaction mixture, approximately 5 µl 
dextran blue (in TE buffer) was added.  Labelled probe was separated from 
unincorporated nucleotides by running through a Sephadex G50 column.  The eluted 
probe was denatured by boiling for a further 10 mins followed by quenching to prevent 
re-annealing.  Once cool, the probe was added to the membrane and incubated 
overnight and 65 oC. 
 
The following day the buffer containing the probe was removed and the membrane 
washed in 5x wash buffer (5x SSC. 0.1 % SDS, 0.1% sodium pyrophosphate), washed 
twice in 3x wash buffer (3x SSC. 0.1 % SDS, 0.1% sodium pyrophosphate), followed 
by one wash in 1x wash buffer (1x SSC. 0.1 % SDS, 0.1% sodium pyrophosphate).  A 
final rinse on 1x SSC was carried out and the membrane was sealed in plastic bagging 
                                                 
17 http://www.fermentas.com/templates/files/tiny_mce/support_images/blotting.gif 
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which was placed into a cassette.  A phosphor storage screen (Imaging Screen K, 
BioRad, Hertfordshire, UK) was placed over the membrane and stored overnight at 
room temperature.  The phosphor screen was placed in a Molecular Imager FX 
(BioRad) and the Quantity One computer program (The Discovery Series, 1998, 
BioRad) used to visualise the blot. 
 
2.3 Biochemical Techniques 
 
2.3.1 Small scale protein expression 
Small scale expression trials were set up to optimise protein expression conditions.  For 
membrane proteins a 50 ml culture volume was grown in 250 ml conical flasks.  For 
expression of protein domains 10 ml culture volume was used in 25 ml glass 
Universals.  A 1:50 volume of overnight culture was used to inoculate the expression 
trial medium, and the appropriate antibiotic was added to maintain the expression 
plasmid.  Cells were grown at 37 oC, 250 rpm for around 2 h until an OD600 of between 
0.4 and 0.6, at which point inducer (IPTG or L-arabinose) was added at varying 
concentrations to induce protein expression.  Different temperatures (after the initial 
37 oC incubation), different medium (a list of the various media tested is given in 
Appendix 1) and expression/incubation times to optimise the expression conditions 
were all tested. 
 
For expression using Arctic Express™ cells the procedure was slightly different, and 
was carried out according to the manufacturers’ instructions.  Briefly, a single colony 
was grown overnight in LB broth containing the plasmid selection antibiotic and 
gentamycin to maintain the plasmids carried by the cells.  The overnight culture was 
used to inoculate LB without antibiotics, and the culture grown for 3 h at 30 oC.  The 
culture was induced with IPTG, the temperature reduced to between 10 and 13 oC, and 
expression allowed to continue for 24 h. 
 
To assess expression, either crude membrane extracts (see section 2.3.3) or cell lysate 
was applied to a denaturing Nu-PAGE gel (see section 2.3.5).  NuPage® loading buffer 
was added to the samples, cell lysate was heated to 70 oC before loading on a gel.  
Membrane preparations were incubated at room temperature for 30 mins, aggregation 
of hydrophobic proteins has been known to occur after boiling of samples (Thomas and 
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McNamee, 1990).  The protein concentration in the membrane was determined using a 
BCA protein assay (Pierce through Thermo Scientific), and a predetermined protein 
standard curve prepared with bovine serum albumin (BSA). 
 
2.3.2 Large scale protein expression 
Large scale expression was carried out in 6 x 5 L litre conical dimpled flasks filled with 
2 L of the desired medium.  Cells were grown to an OD600 of 0.4 – 0.5 and induced 
with the optimised concentration of IPTG, and supplemented with 20 ml 0.4 % 
histidine (filter sterilised) if a His-tag was fused to the desired protein.  The flasks were 
incubated for the optimised expression time and temperature.  Cells were harvested by 
centrifugation at 10 000 x g for 15 mins at 4 oC.  The weight of the cell pellet was 
recorded and the pellet stored at -85 oC after resupension in 20 mM Tris, 0.5 mM 
EDTA, 10 % glycerol pH 7.5 to a final volume of 100 ml and stored at -85 oC. 
 
2.3.3 Preparation of membranes 
 
2.3.3.1 E. coli membranes using homogenisation 
To prepare crude membranes, the Water Lysis Method was utilised.  Induced culture 
(50 ml) was centrifuged at 1400 x g.  The pellets were resuspended in 10 ml 0.2 M 
Tris-HCl pH 8.0, transferred to an Oakridge tube and placed on a Luckham 100 rotatest 
shaker for 20 mins at room temperature.  Cell lysis was achieved by adding 4.85 ml 
sucrose buffer (1 M sucrose, 0.2 M Tris-HCl, 1 mM EDTA) at T0.  At T1.5 mins 65 µl 10 
mg/ml lysozyme made fresh in sucrose buffer was added, at T2 mins 9.6 ml DW was 
added.  The tube was again placed on the rotatest shaker for 20 mins at room 
temperature followed by centrifugation at 38700 x g at 4 oC for 15 mins.  The 
periplasmic fraction in the supernatant was discarded.  The pellet was resuspended in 
30 ml DW using a dounce homogeniser, and left to stand at room temperature for 30 
mins before being centrifuged as before.  This supernatant fraction contains the 
cytoplasmic contents.  The pellet was washed in 30 ml phosphate buffer (0.1 M sodium 
phosphate pH 7.2, 1 mM β-mercaptoethanol), by homogenisation followed by 
centrifugation as before.  The wash was repeated, and the pellet containing the 
washed membranes resuspended in 150 – 300 µl phosphate buffer using a small 
dounce homogeniser.  Membranes were stored at -20 oC. 
 
Materials and Methods Chapter 2 
 
[62] 
 
2.3.3.2 E. coli large scale membrane preparation 
To prepare membranes from which protein was to be isolated, a second method was 
used (Hope, 2005).  The bacterial pellet from a large scale expression culture was 
passed twice through a cell disruptor (Constant Systems) at 25 Kpsi.  The cell lysate 
was centrifuged at 10 000 x g for 30 mins at 4 oC to remove cell debris.  The 
supernatant was aspirated and centrifuged at 131 000 x g for 2 h at 4 oC. The pellet 
containing the cell membranes was resuspended in the phosphate buffer (0.1 M 
sodium phosphate pH 7.2, 1 mM β-mercaptoethanol) using a small dounce 
homogeniser.  Membranes were aliquoted in 0.5 ml volumes to microfuge tubes and 
snap frozen using liquid nitrogen.  The tubes were strored at -85 oC. 
 
2.3.3.3 Aspergillus crude plasma membrane preparation 
A. nidulans ‘germlings’ (50 mg) (recently germinated conidia), previously prepared by 
SE Unkles, were thawed from -85 oC.  These were mixed with 300 µl cold extraction 
buffer (10 mM sodium phosphate, 200 mM sodium chloride, 10 % glycerol, pH 7.0) 
and 300 µl glass beads.  Cells were disrupted in a FastPrep-24 at 4.5 m/s for 20 s, and 
placed on ice.  The mixture was centrifuged at 12000 x g for 1 min to remove the 
beads, and the supernatant was transferred to a fresh microfuge tube and centrifuged 
at 38700 x g for 45 mins at 4 oC.  The pellet containing the Aspergillus plasma 
membrane was resuspended in 50 µl cold extraction buffer and stored at -85 oC. 
 
2.3.4 Separation of insoluble and soluble proteins from E. coli 
To determine if an expressed domain was soluble, the proteins were separated into the 
soluble and insoluble fractions.  Two methods were used: (i) sonication, and (ii) 
homogenisation, nevertheless, the protocol used throughout was the same.  10 ml of 
culture was harvested and resuspended in 1 ml 50 mM Tris-HCl, 2 mM EDTA.  
Lysozyme was added to a final concentration of 100 µg/ml and 100 µl 1% triton-X 100 
was added and mixed gently.  This was incubated at 30 oC for 15 mins and placed on 
ice.  For sonication the mixture was sonicated at a high output setting for a few 
seconds, and placed on ice.  For homogenisation the mixture was homogenised in a 
small dounce homogeniser until the mixture lost viscosity.  When the mixture was less 
viscous it was centrifuged at 12 000 x g for 15 mins.  The supernatant containing 
soluble proteins was transferred to a fresh microfuge tube and the pellet resuspended 
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in the total original volume.  Samples of these fractions were run on a NuPAGE (see 
Section 2.3.5.2) gel to determine which fraction contained the desired protein. 
 
2.3.5 Protein gels 
 
2.3.5.1 SDS PAGE 
Polyacrylamide gel electrophoresis is used to separate proteins dependant on 
molecular weight.  Gels consisted of a running gel and a stacking gel and were run in 
Tris-Glycine SDS running buffer (20 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS, pH 
8.3).  The percentages of running gels used in this thesis were 7.5 % and 12.5 % and 
are given in Table 2.2.  Running gel was mixed and poured into a 1 mm plastic 
cassette (Invitrogen), once set stacking gel was poured into the cassette and the 
appropriate comb was inserted.  The gels were electrophoresed at 200 V for 
approximately 40 mins.  Following electrophoresis, the gel was removed from the 
cassette and stained using Coomassie Brilliant Blue (CBB) (0.5 % coomassie blue in 
227 ml methanol, 227 ml DW, 46 ml acetic acid) for approximately 1 h and repeatedly 
washed in DW with gentle agitation. 
 
 7.5 % running gel 12.5 % running gel 5 % stacking gel 
Buffer 1 4.95 ml 3.85 ml  
Buffer 2   2.5 ml 
acrylamide 
A 
1.65 ml 2.75 ml 0.5 ml 
TEMED 8 µl 8 µl 8 µl 
APS (20 % (w/v)) 35 µl 35 µl 25 µl 
Table 2.2: Composition of SDS-PAGE gels.  Buffer 1: 375 mM Tris, 0.1 % (w/v) SDS, pH 8.9, Buffer 
2: 122 mM Tris, 0.1 % (w/v) SDS, pH 6.7.  TEMED – Tetramethylethylenediamine. 
 
2.3.5.2 NuPAGE® 
The NuPAGE (Invitrogen) gels have been formulated to work with InVision™ His-tag 
In-Gel Stain (Invitrogen) (hereto referred to as His-tag stain).  Gels were stained for 
the His-tag fused to the target protein without the need of western blotting.  After the 
gel had run, the proteins were fixed in destain solution (900 ml ethanol, 900 ml DW, 
200 ml acetic acid) for at least 1 h and washed twice in water before application of the 
His-stain.  The His-tag stain (20 ml) was applied to the gel and incubated at RT on a 
rotatest shaker for 1 h, and washed twice in 20 mM phosphate buffer (20 mM sodium 
phosphate, pH 7.8) for 10 mins to remove excess stain and minimise any background.  
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The stain was visualised under a UV transilluminator and an image recorded.  The gel 
was finally stained using SimplyBlue™ (Invitrogen) and latterly Instant Blue (Expedeon, 
Harston, UK) coomassie stains. 
 
2.3.6 Western blotting 
Protein samples of the same concentration were run on an SDS-PAGE gel, and soaked 
in transfer buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 20 % methanol, 0.1 % 
SDS) for 20 mins.  PVDF (GE Healthcare) or nitrocellulose membrane (Protran™, 
Whatman) and 3MM paper was cut to the same size as the gel.  The PVDF membrane 
was rinsed in methanol and soaked in transfer buffer along with the 3MM paper.  The 
blotting equipment (Mini Protean II System, BioRad) was assembled with the protein 
gel adjacent to the PVDF membrane.  The blotting equipment was placed in an ice 
bath, and voltage applied at 100 V for 50 mins to transfer the protein to the 
membrane.  The membrane was washed in TBST (0.9 % w/v sodium chloride, 10 mM 
Tris pH 7.4, 0.1 % v/v Tween 20) twice for 15 mins and incubated in TBS (0.9 % w/v 
sodium chloride, 10 mM Tris pH 7.4) with 5 % blocking agent (Amersham).  Incubation 
with the block was carried out for 1 – 4 h at RT or overnight at 4 oC.  The membrane 
was washed in TBST three times for 10 mins and incubated in TBS with 0.5 % blocking 
agent and appropriate antibody dilution.  The antibody was incubated with the 
membrane for 1 – 4 h at RT or overnight at 4 oC.  The membrane was washed four 
times in TBST, as a general rule twice for 5 mins and twice for 20 mins.  If a secondary 
antibody was required the process was repeated.  ECL Plus detection solution 
(Amersham) was prepared and 2 ml used to cover the membrane for 5 mins.  The 
membrane was placed in plastic ‘bagging’ and exposed using a LAS-3000 Imager 
(Fujifilm, Bedfordshire, UK); blots were recorded and saved as a computer file.  
Latterly, membranes were exposed on High Performance Chemiluminescence films (GE 
Healthcare).  The antibodies used and concentrations used at are given in Table 2.3. 
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Antibody Conjugate Raised in Dilution WB Dilution IFA Source 
Primary antibodies 
anti-V5 HRP  1:5000  Invitrogen 
anti-GFP HRP  1:5000  Santa Cruz 
anti-GFP  mouse 1:5000 1:500 BD Biosciences 
anti-PhoA HRP  1:10000  Abcam 
anti-His HRP  1:5000  Invitrogen 
anti-PfCRT  rabbit  1:600 Dr. P. Bray 
 
anti-PfHT  goat  1:500 Prof. S. Krishna 
anti-HA  mouse 1:2000 1:250 – 1:750 Roche 
anti-BCKDH  rabbit 1: 10000  Eurogentec 
Secondary antibodies 
anti-mouse HRP  1:10000  Promega 
anti-rabbit HRP  1:10000  Promega 
anti-mouse alexa 488   1:2000 Invitrogen 
anti-rabbit alexa 594   1:2000 Invitrogen 
anti-goat alexa 594   1: 2000 Invitrogen 
Table 2.3:  Working concentrations of each of the antibodies used in this thesis. 
 
2.3.7 Solubilisation of membrane proteins 
Small scale solubilisation trails were set up to find the best detergent to extract the 
protein from the membrane.  Detergents were trialled at 0.5, 1, 2 and 4 % (w/v) for 
their ability to extract protein from the E. coli membrane.  Total membrane protein was 
added to a buffer solution (20 mM Tris (pH 8.0 at 4 oC), 10 mM imidazole, 800 mM 
NaCl, 10 % glycerol) containing detergent so the final protein concentration was 10 
mg/ml.  This protein-detergent mixture was incubated for 1 hour or overnight in an ice 
bath and stored at 4 oC, followed by centrifugation at 47800 x g for 1 h at 4 oC.  The 
supernatant containing the solubilised proteins was transferred to a fresh microfuge 
tube and the pellet resuspended in the total original volume.  Samples were run on a 
NuPAGE gel to analysed the solubilised proteins. 
 
Large scale solubilisation involved incubating the membrane overnight in the desired 
detergent at the optimum concentration in solubilisation buffer (20 mM Tris (pH 8.0 at 
4 oC), 10 mM imidazole, 800 mM NaCl, 10 % glycerol).  Membrane extract was added 
to the solubilisation buffer to a final protein concentration of 10 mg/ml, the detergent 
was added to the mixture slowly and mixed well.  The mixture was placed in an ice 
bucket and stored overnight at 4 oC.  The following day the mixture was centrifuged at 
47800 x g for 30 mins at 4 oC.  The solubilised proteins were present in the 
supernatant and were purified. 
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2.3.8 Purification of solubilised membrane protein 
The BD Talon IMAC resin to be used in the purification process was washed.  0.5 ml 
was taken and washed in 50 ml DW and centrifuged at 335 x g for 3 mins at 4 oC 
twice, and once in wash buffer (20 mM Tris (pH 8.0 at 4 oC), 10 mM imidazole, 400 
mM NaCl, 5 % glycerol, [desired concentration of detergent]), and centrifuged at 
before.  Solubilised protein was applied to Co2+ metal affinity resin (BD Talon, 
Clontech).  A Co2+ column was chosen over Ni2+.  Co2+ binds less protein and the 
binding affinity is reduced compared to Ni2+.  However, the binding is more specific 
using Co2+ and the number of contaminating proteins eluted is reduced.  The cell 
lysate and resin was incubated on ice to allow binding of the protein to the beads for 4 
h.  The resin was washed twice in wash buffer and centrifuged as before.  The beads 
with protein bound were transferred to a 5 ml syringe blocked with 3mm paper and 
elution buffer (20 mM Tris (pH 8.0 at 4 oC), 200 mM imidazole, 400 mM NaCl, [desired 
concentration of detergent]) applied.  Fractions were collected in 1.5 ml microfuge 
tubes, 0.25 ml at a time.  After the elution buffer had run through the column, the 
syringe was blocked with a stopper and the fractions analysed for protein content 
using a Nanodrop spectrophotometer and OD280 for protein. 
 
Fractions containing the protein were combined and concentrated to 100 µl using 
Vivaspin (Sartorius, Surrey, UK) centrifugation devices with molecular weight cut-offs 
stated in each of the chapters.  Purified protein was stored at -85 oC.  An overview of 
the purification procedure is illustrated in Figure 2.6. 
 
 
Figure 2.6. Protein purification protocol. Following cell disruption and membrane preparation, the cell 
lysate was solubilised in detergent overnight (1).  The solubilised protein was bound to a Co2+ metal 
affinity column (2). The resin was washed and the protein was eluted from the column using imidazole 
(3). The resultant eluate was applied to a NuPAGE gel and concentrated (4).  Source: A. Clarke. 
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2.3.9 Purification of proteins from inclusion bodies 
Cells were harvested by centrifugation at 2000 x g for 5 mins.  The supernatant was 
removed and cells resuspended in an equal volume of lysis buffer (50 mM Tris-HCl pH 
8.0, 25 % sucrose (w/v), 1 mM EDTA) and 1/10 volume lysozyme (1 mg/ml in lysis 
buffer) added.  The cell suspension was incubated on ice for 30 mins and frozen at -20 
oC and thawed in water at room temperature.  One tenth volume DNase solution (100 
mg/ml in 100 mM MgCl2, 10 mM MnCl2) was mixed in and the cells incubated at room 
temperature until the suspension became less viscous.  An equal volume of detergent 
buffer (0.2 M sodium chloride, 1 % deoxycholic acid (w/v) 1 % nonidet P-40 (v/v)) was 
added to the cell solution.  The solution was centrifuged at 5000 x g for 10 mins.  The 
supernatant was removed carefully so as not to dislodge the white inclusion body 
pellet or membrane proteins which formed an upper jelly-like layer.  To remove the 
membrane proteins, the sample was washed in 1 % Triton X-100/1 mM EDTA until the 
jelly like phase was no longer be observed.  The remaining pellet was analysed by 
SDS-PAGE.  This method was adapted from a method available from 
‘www.molecularinfo.com’18. 
 
2.4 Structural and Functional Determinations 
 
2.4.1 Formate transport  
 
2.4.1.1 Radioactive tracer assay 
To measure the direct uptake of formate by cells a tracer assay was used with 14C 
formic acid (reference activity, 7.8 MBq).  Twenty millilitres of TGYEP medium was 
inoculated with 0.2 % overnight, aerobic LB culture from a single colony, and 
supplemented with 0.5 % glucose and the appropriate antibiotic.  Cultures were 
incubated in a static incubator at 37 oC for 22 h.  The OD600 of the culture was 
recorded, the cells pelleted and resuspended in 20 ml assay buffer (Section 3.4.2.2).  
To the resuspended culture, a specific concentration (Section 3.4.2.2) of a sodium 
formate and 14C formic acid mixture was added (450 µl 20 mM sodium formate and 10 
µl formic acid (reference activity, 7.8 MBq)), the cultures were placed in a water bath 
set at 37 oC.  At various time points a 1 ml sample volume was filtered through a 
                                                 
18 http://www.molecularinfo.com/MTM/G/G2/G2-2/G2-2-2.html.  Accessed on 10 August 2012. 
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vacuum filtration device with a 0.45 µm cellulose membrane filter (pre-wetted with 15 
ml assay buffer (without 14C formic acid).  The membrane filters were washed three 
times with 15 ml assay buffer (without 14C formic acid) to remove traces of 14C formic 
acid from the membrane and bacteria surfaces.  The washed membrane was placed in 
a scintillation vial and covered with 2.5 ml liquid scintillation cocktail (Optiphase HiSafe 
3, Perkin Elmer, MA, USA).  Two 5 µl and one 10 µl aliquot of the formate/fomic acid 
mixture were placed in scintillation vials and covered in 2.5 ml liquid scintillation 
cocktail to act as standards. 
 
2.4.1.2 Hypophosphite assay 
The method for characterising the uptake of formate, through its toxic analogue 
hypophosphite, was adapted from one described by Suppmann and Sawers (1994).  A 
single colony was picked and grown in 5 ml medium (Appendix 2) with and without 
100 mM hypophosphite in a static incubator to create an anaerobic environment, at 37 
oC for 22 h.  After the growth period a small aliquot was taken from each culture and 
the OD600 noted to monitor bacterial cell density. 
 
2.4.1.3 Indirect assay using a β-galactosidase reporter 
The indirect method for investigating formate uptake was an adaptation of the one 
used by Falke et al (2009). A β-galactosidase gene (lacZ) has been fused downstream 
of the fdhF promoter, the promoter is active only when formate is found in the cell. A 
single colony was grown aerobically in 5 ml LB + antibiotic overnight, 400 µl of 
overnight culture was used to inoculate 22 ml TGYEP medium pH 6.7 and 
supplemented with 50 mM formate.  Cells were grown for 4 h at 37 oC in a static 
incubator to provide anaerobic conditions, and IPTG added to induce protein 
expression.  500 µl samples were taken after 2, 3, and 4 h to carry out a β-
galactosidase assay.  The OD600 of the 500 µl culture sample was recorded using a 
nanodrop spectrophotometer.  The cells were centrifuged at top speed for 2 mins on a 
bench top centrifuge, and the supernatant discarded.  Cells were resuspended in 75 µl 
lysis buffer (250 mM Tris pH 7.5, 0.2 % Triton X-100, and 4 mg/ml sodium 
deoxycholate) and 225 µl buffer A (100 mM sodium dihydrogen phosphate, 10 mM 
potassium chloride, 1 mM magnesium sulphate, 50 mM ß -mercaptoethanol) was 
added.  The sample was incubated at 37 oC for 5 mins.   Seventy five microlitres of 
ONPG (ortho-Nitrophenyl-β-galactoside) (4 mg/ml in 100 mM sodium dihydrogen 
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phosphate, pH 7.5) was added to initiate the reaction.  The time for the reaction to 
occur was set to 5 mins to prevent any confusion in the time of the colour change.  
After 5 mins 150 µl of 1 M sodium carbonate was added to stop the reaction.  The cell 
debris was collected by centrifugation as before, and the OD420 of the supernatant 
recoded using a nanodrop spectrophotometer.  The β-galactosidase activity was 
calculated in Miller units using the following equation: 
 
Miller units = 
)(.(min)
1000
600
420
mlcellsvolODtime
OD
 
 
2.4.2 Nitrite transport 
A nitrite transport assay was carried out and measured the depletion of nitrite from the 
medium.  An overnight LB aerobic culture from a single colony was used to inoculate 
20 ml cultures of JC minimal salts medium (JC for Jeff Cole) and supplemented with 20 
mM potassium nitrate, 0.4 % glucose and appropriate antibiotic  (Cole et al, 1974 and 
Jia et al, 2009).  Cultures were transferred to a static 37 oC incubator.  Strains carrying 
plasmids were incubated for 4 h prior to induction with 1 mM IPTG, and incubated for 
a further 22 h. 
 
To prepare a nitrite standard curve 0 – 100 µM sodium nitrite solutions in 50 mM MOPS 
buffer (pH 8.5) were prepared and incubated at 37 oC for 30 mins.  40 µl of each 
solution was added to a 96 well plate in triplicate.  40 µl 1% sulphanilamide (in 25 % 
HCl) followed by 40 µl 0.2 5 N-1-naphthylethylenediamine dihydrochloride (NED) were 
added and mixed.  The reaction was incubated at RT for 10 mins.  The OD540 was read 
on a nanodrop spectrophotometer and values averaged to construct the standard 
curve. 
 
The OD600 of the anaerobic cultures was taken and the number of cells/ml medium was 
deduced (given that an OD600 of 1.000 is equal to 8 x 10
8 cells/ml).  1 x 109 cells were 
washed in 0.5 ml 50 mM MOPS buffer to remove any residual nitrate; heat killed cells 
placed on a heat block at 72 oC for 10 mins.  Washed cells were resuspended in 5 ml 
assay buffer (50 mM MOPS buffer pH 8.5, 10 mM glucose), and 100 µM sodium nitrite 
added at T0.  The cultures were placed in a 37 
oC static incubator and samples taken 
over a period of 2 h.  At T0, and at half hour intervals up to 2 h, 40 µl of culture was 
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placed, in triplicate, in a 96 well plate.  To each of the samples in the 96 well plate, 40 
µl of 1 % sulphanilamide and 40 µl of 0.2 % NED were added, and the reaction 
incubated for 5 mins.  The OD540 was recorded on a nanodrop spectrophotometer, and 
an average taken.  The standard curve was used to infer the concentration in µM of 
nitrite in the medium. 
 
2.4.3 PhoA assay 
The PhoA assay was performed as described by Manoil (1991), and the cell growth as 
described by Rapp et al (2004) although minor alterations have been made.  Cells from 
an overnight growth culture were diluted into fresh medium, grown until an OD600 
between 0.4 – 0.6, and induced with 0.1 % arabinose.  After induction cells were 
incubated for a further 4 h.  A 1 ml sample was harvested by centrifugation at 16000 x 
g for 1 min and washed once with cold 10 mM Tris pH 8.0, 10 mM magnesium 
sulphate.  The cell pellet was resuspended in 1 ml cold 10 mM Tris pH 8.0 and the 
OD600 recorded.  Cell suspension (0.1 ml) was added to 0.9 ml assay buffer (1 M Tris, 
pH 8.0, 0.1 mM zinc chloride) and 1 ml assay buffer was retained as a blank.  To each 
sample including the blank, 50 µl 0.1 % SDS and 50 µl chloroform was added, mixed 
by vortexing, incubated at 37 oC for 5 mins, and placed on ice for 5 mins.  0.1 ml of 
0.4 % p-nitrophenyl phosphate (pNPP) (in 1 M Tris) was added to the reaction and 
incubated at 30 oC for 90 mins (standardised for all reactions), until the mix had turned 
from colourless to a pale yellow.  To stop the reaction 120 µl 0.5 M EDTA, 1 M 
potassium dihydrogen phosphate in a 1:5 ratio was added.  The values for were 
recorded.  The activity of the phosphatase was calculated using the following equation:  
 
PhoA activity (units) = 
)(.(min)
1000
600
420
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2.4.4 GFP assay 
The GFP assay was described by Rapp et al (2004), however minor changes have been 
made.  The experiments were carried out in triplicate and repeated at least 5 times.  
Cells containing plasmid with a C-terminal GFP tag on the specific insert were grown 
overnight in LB containing the appropriate antibiotic.  They were subcultured 1:50 
dilution into 5 ml fresh LB medium containing the appropriate antibiotic, and grown at 
37 oC for 1.5 – 2 h until cells were in mid-exponential phase.  At this point, expression 
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of the GFP fused insert was initiated by the addition of 0.05 mM IPTG and cells allowed 
to grow for a further 3 h.  The OD600 was measured and recorded.  1 ml of the cell 
culture was harvested by centrifugation at 2800 x g for 1 – 2 mins and resuspended in 
1 ml GFP assay buffer (50 mM Tris pH 8.0, 200 mM sodium chloride, 15 mM EDTA).  
The cell suspension was incubated for 30 mins at room temperature.  Approximately 
300 µl of the cell suspension was transferred to a 3 x 3 mm microcuvette and read at 
excitation 490 nm and emission 520 nm, on a VersaFluor™ Fluorometer System (Bio-
Rad, Hemel Hempstead, UK). 
 
2.5 Plasmodium falciparum Culture 
 
The work detailed below was carried out in the laboratory of Professor S. Müller at the 
University of Glasgow. 
 
2.5.1 Maintenance of parasite cultures 
The in vitro culture of Plasmodium falciparum intraerythrocytic stages was first 
described by Trager and Jensen (1976), and the method was modified as described 
below.  P. falciparum, strains 3D7 (The Netherlands) and D10 (Papua New Guinea) 
were cultivated in complete RPMI medium (15.9 g/L RPMI 1640 (containing L-
glutamine and 25 mM HEPES) (Invitrogen), 0.5 % Albumax II (Invitrogen), 0.1 % 
(w/v) sodium bicarbonate, 20 µg/ml gentamycin, 200 µM hypoxanthine, pH 7.4).  The 
medium was filter sterilised using a 0.22 µm stericup filter unit (Millipore) and stored at 
4 oC.  The medium was prewarmed to 37 oC before use.  Cultures (10 ml) were 
propagated with a 5 % haematocrit (HCT) in a 50 ml TC (non-vented) culture flasks 
(Greiner, Stonehouse, UK) at 37 oC.  Parasites were maintained under reduced oxygen 
conditions (1 % oxygen, 3 % carbon dioxide and 96 % nitrogen). 
 
Parasitaemia was maintained between 0.5 – 2 %, cultures were diluted and supplied 
with fresh medium and red blood cells (RBC) accordingly.  Parasitaemia was 
determined by a thin blood smear stained with Giemsa stain solution (BDH).  Air dried 
slides were fixed with 100 % methanol for about 1 min, followed by staining in surplus 
Giemsa (diluted 1:10) for 5 – 10 mins.  The slide was rinsed with water to remove 
excess Giemsa, and air dried before analysis by light microscopy with an objective 
magnification of 100 fold.  The parasitaemia was recorded by counting the number of 
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infected and uninfected erythrocytes.  At least 1000 RBCs were counted.  Parasitaemia 
is expressed as a percentage of infected erythrocytes (IE). 
 
2.5.2 Blood 
Human blood was received weekly from the Blood Transfusion Service.  Briefly, packed 
erythrocytes were washed 3 – 4 times in blood wash medium (RPMI medium described 
above without the addition of Albumax II) and the white blood cells or ‘buffy coat’ and 
serum removed by centrifugation at 600 x g, 4 oC for 10 mins.  After washing, a small 
aliquot was taken, mixed with growth medium and incubated at 37 oC for two days to 
check for growth of any contaminants.  Blood was stored at 4 oC is v/v blood wash 
medium, and was stored for no longer than four weeks after the bleed date. 
 
2.5.3 Drug selectable markers 
Drug selectable markers (DSM’s) were used to select for parasites containing 
transfected plasmids.  5-fluorocytosine (5-FC) was made at 4 mM and was stored at 
room temperature.  While in use, WR99210 and blasticidin were stored at 4 oC, 
blasticidin is stable for 1 week at 4 oC and was refreshed accordingly.  WR99210 was 
dissolved in dimethyl sulphoxide (DMSO) to a concentration of 20 mM and stored at  
-80 oC.  Every four weeks a working solution was made in blood wash medium at a 
concentration of 20 µM.  Blasticidin powder was dissolved in HEPES buffer (pH 7.8) to 
a final concentration of 10 mg/ml and stored in 50 µl aliquots at -20 oC.  Table 2.4 
presents the working concentrations of each drug. 
 
Drug Working concentration 
WR99210 0.0125 nM 
Blasticidin 0.025 µg/ml 
5-FC 1 µM 
Table 2.4: Concentrations of DSM used in the culture of P. falciparum. 
 
2.5.4 Preparation of P. falciparum stabilates 
Stabilates were prepared using cultures of mixed stage parasites containing ≥ 2 % ring 
stages.  A culture was centrifuged at 380 x g for 5 mins at 4 °C with a low 
deceleration, and the supernatant aspirated.  The RBC pellet volume of fresh cold 
medium was added to the RBCs.  Twice the RBC pellet volume of freezing solution 
(PBS (phosphate buffered saline) + 30 % v/v glycerol) was added and mixed gently.  
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Aliquots of 600 µl were transferred to 1 ml cryovials and cooled to 4 °C before the vials 
were frozen in liquid nitrogen. 
 
2.5.5 Thawing of P. falciparum stabilates 
Stabilates were removed from liquid nitrogen and placed in a 37 oC incubator until 
thawed. One tenth the original volume of cells of thawing solution 1 (12 % w/v sodium 
chloride) was added slowly to the falcon tube and mixed, followed by incubation for 5 
mins at room temperature.  Ten times original volume of thawing solution 2 (1.8 % 
w/v sodium chloride) was added slowly and mixed, after which, the cell suspension 
was incubated at room temperature for 5 mins.  Finally, ten times original volume 
thawing solution 3 (0.9 % w/v sodium chloride, 0.2 % w/v glucose) was added slowly 
and mixed, followed by incubation at room temperature for 5 mins.  The samples were 
centrifuged at 1500 x g for 5 mins.  The supernatant containing the freezing and 
thawing solutions was discarded and the parasites transferred to a new flask 
containing 9.3 ml medium and 200 µl fresh blood. 
 
2.5.6 Synchronisation of P. falciparum RBC stages 
To synchronise the parasites to the same phase of growth, cultures were centrifuged 
at 380 x g at room temperature for 5 mins with a low deceleration.  The medium was 
aspirated and the parasitised RBCs resuspended in 5 volumes of 5 % sorbitol (w/v) in 
phosphate buffer (10 mM potassium phosphate, pH 7.2).  The parasite mixture was 
placed in a 37 oC incubator for 5 mins and centrifuged as previously described.  The 
supernatant was aspirated and the pellet resuspended in 10 ml RPMI complete 
medium, gassed and returned to the 37 oC incubator (Lambros and Vanderberg, 1979). 
 
2.5.7 P. falciparum transfection 
Prior to carrying out the transfection 50 – 100 µg of plasmid DNA was ethanol 
precipitated and subsequently resuspended in 30 µl of filter sterilised MQ water (see 
section 2.2.6).  The DNA was stored at -20 oC until use in the transfection.  A 
synchronised culture of early ring stage parasites was required for transfections, with a 
parasitaemia of no more than 5 %.  As the parasites required 4 – 6 weeks continuous 
growth to recover from the transfection, fresh human RBCs were used in the 
transfection.  Transfections were carried out in duplicate on separate days. 
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Transfections were carried out using the method of Wu et al (1995) and Crabb et al 
(2004).  A 10 ml parasite culture was centrifuged at 4 oC, 380 x g for 5 mins, the 
supernatant aspirated and the infected RBC (iRBC) pellet washed in 5 ml ice cold 
Cytomix (120 mM potassium chloride, 0.15 mM calcium chloride, 2 mM EGTA, 5 mM 
magnesium chloride, 10 mM potassium dihydrogen phosphate/dipotassium hydrogen 
phosphate, 25 mM HEPES, pH 7.6).  The washed iRBCs were stored on ice.  Three 
hundred and seventy microlitres ice cold Cytomix was added to 30 µl of plasmid DNA, 
and 200 µl infected RBCs added with gentle but thorough mixing.  The mixture was 
placed in a 2 mm electroporation cuvette (BioRad).  Electroporation carried out at 310 
V and 950 µF using a Gene Pulser Xcell (BioRad).  After electroporation, the mixture 
was immediately added to a culture flask, containing 300 µl fresh RBCs and 8 ml pre-
warmed RPMI 1640 complete medium.  Parasites were gassed and returned to the 37 
oC incubator.  After 6 h, the medium was aspirated and replaced with fresh medium.  
The following day, the medium was again removed and replaced and the selection 
drug either WR or Blasticidin (section 2.5.5.2) was added to the flask at the 
appropriate concentration, this was repeated daily for 10 days.  After 10 days medium 
was replaced every second day for up to 8 weeks.  One hundred microlitres fresh RBCs 
were added to cultures once a week.  To assess whether transfected parasites started 
to appear, Giemsa stained thin smears were prepared twice a week.  When parasites 
began to appear in thin blood smears, stabilates were made (section 2.5.3).  When 
parasitaemia was greater than 5 % in a 50 ml culture genomic DNA was extracted to 
analyse the genotype. 
 
2.5.7.1 Drug cycling 
To facilitate the selection of parasites where the transfected plasmid has integrated 
into the desired gene locus, a ‘drug cycling procedure’ was employed.  Transfected 
parasite lines were selected with the positive DSM until the parasitaemia reached ≥ 5 
%.  Following the production of stabilates and isolation of gDNA, the selection drug 
was removed to encourage loss of the transfected plasmid.  After 3 weeks the 
selection drug was re-applied until the parasite culture reached ≥ 5 % parasitaemia, at 
which point more stabilates and gDNA were made.  The drug cycling was repeated 
multiple times and is depicted in Figure 2.7.  In each of the sections where drug 
cycling has taken place, this diagram is used again. 
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The negative selectable marker 5-fluorocytosine (5-FC) was applied to those parasites 
lines that were previously transfected with either pCC1 or pCC4 knock-out plasmids.  
The presence of the cd chimera gene on the transfection plasmid leads to death of 
cells containing the plasmid when 5-FC is added to the medium.  The chimeric CD 
protein converts 5-FC to the toxic 5-fluorouracil and 5-fluorouridine monophosphate. 
which causes an inhibition of RNA synthesis and the enzyme thymidylate synthase 
(Duraisingh et al, 2002 and Maier et al, 2006). 
 
 
Figure 2.7: Overview of the drug cycling process.  Parasites after transfection, growing on selectable 
marker (either WR 99210 or Bla) are termed cycle 0 (black box).  Drug cycling of transfected parasites is 
carried out to select for integration of plasmids into the parasites’ genome.  Off/on drug cycling (either WR 
99210 or Bla) is indicated by blue boxes/arrows and treatment with 5-FC is indicated in orange.  At each 
stage gDNA is taken for analysis using PCR and/or Southern blot, and stabilates are made for the 
preservation of the parasite line.  This is indicated by a green box/arrow combination 
 
2.5.8 Saponin lysis of P. falciparum infected RBCs 
Parasites from a 25 or 50 ml culture were resuspended in complete medium.  For 
generation of gDNA 0.2 % saponin (v/v) was added to the culture and for isolation of 
parasite proteins 0.1 % saponin was added, followed by incubation at 4 oC for 10 mins.  
Subsequently the cells were centrifuged at 2000 x g for 5 mins at 4 oC with a low 
deceleration, followed by washes with PBS and transferred to a microfuge tube.  The 
centrifugation was repeated at 2300 x g for 3 mins at 4 oC.  The wash was repeated 
until the PBS was clear of any haemoglobin.  For protein extraction 0.1 % saponin 
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(w/v) was used.  The final pellets were stored at -80 oC until use (Umlas and Fallon, 
1971). 
 
2.5.9 gDNA extraction 
 
2.5.9.1 Kit 
Parasite gDNA was extracted using a Qiagen QIAamp DNA mini kit.  A 50 ml culture 
was lysed using saponin (section 2.5.6) and resuspended in 200 µl sterile PBS.  DNA 
extraction was carried out using the Blood or Body Fluid Spin Protocol with two minor 
changes.  Parasite extracts were incubated at 56 oC for 30 mins to fully lyse the 
parasites and elution of gDNA was carried out twice using 100 µl of MQ water, and 
stored at 4 oC. 
 
2.5.9.2 Phenol extraction 
Saponin lysis was carried out as described (Section 2.5.6) and the parasite pellet 
resuspended in resuspension buffer (1200 µl SDW, 200 µl 10xTN9 (500 mM Tris, 2 M 
sodium chloride, pH 9) 400 µl 0.5 M EDTA, 40 µl 50 mg/ml proteinase K), after which 
200 µl 10 % SDS (w/v) was added to prevent precipitation of solutions.  The cell 
suspension was mixed in a 50 ml falcon tube and incubated at 50 oC with agitation 
overnight.  The following day, 1 ml phenol was added and the sample mixed on a 
spinning wheel for 1 h at room temperature, after which the sample was centrifuged at 
3000 x g for 10 mins.  The upper phase was collected and transferred to a new 15 ml 
falcon tube, the phenol extraction was repeated.  The upper phase was again 
transferred to a new 15 ml falcon tube, and 66.7 µl (1/30 volume) 3 M sodium acetate 
and 1200 µl (0.6 volume) isopropanol added.  The tube was inverted vigorously until 
the DNA formed a white precipitate.  The precipitate was removed to a microfuge tube 
containing 200 µl TE buffer and incubated at 4 oC overnight. 
 
2.5.10 Protein extraction 
To separate the soluble and insoluble (containing membranes) fractions of the 
parasites, a culture was lysed with saponin (as above) and the pellet frozen at -80 oC.  
To the frozen pellet and equal volume of lysis buffer (1% Triton X-100, 5 µg/ml 
RNaseA, 1 mM PMSF, 1 mM benzamidine, 20 µM leupeptin, 10 µM E64, 4 µM pepstatin 
A, 2 µM 1, 10-phenanthroline, 250 µg/ml DNase in PBS) was added.  The pellet was 
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thawed at room temperature and the buffer mixed with cells.  The parasite cell 
suspension was frozen on dry ice and thawed at 37 oC.  The freeze/thaw process was 
repeated three times.  After the final thawing the resuspension was incubated on ice 
for 20 mins and centrifuged at full speed on a benchtop centrifuge for 20 mins.  The 
supernatant was transferred to a fresh microfuge tube and kept on ice.  The pellet 
containing the insoluble fraction was resuspended in lysis buffer and the pellet 
homogenised.  The homogenised pellet incubated on ice with gentle agitation for 30 
mins, and centrifuged as before.  This was repeated twice.  Proteins were quantified 
using the BCA assay. 
 
2.6.11 Microscopy 
 
2.6.11.1 Live cell imaging 
Parasite culture (500 µl) at a high parasitaemia (> 4 %) was placed in a microfuge 
tube, and 5 µl of 0.5 µg/ml Hoechst 33258 added.  Cells were incubated for 5 mins at 
37 oC.  Cells were centrifuged at 200 x g for 30 s and washed in 500 µl medium to 
remove any excess DNA stain and centrifugation repeated.  Five hundred microlitres 
fresh RPMI complete medium was added to the microfuge tube without disturbing the 
pellet.  A small volume of packed RBCs was mixed with a little of the medium and 
placed on a slide and a cover slip placed on top. 
 
Cells were visualised using an Axioskop (Zeiss) or Delta Vision (Applied Precision) 
microscope, at a 100x magnification.  To visualise the Hoechst 33258 nuclear stain a 
DAPI filter was used.  To visualise proteins tagged with GFP a GFP or FIT-C filter was 
used. 
 
2.6.11.2 Immunofluorescence assay 
Immunofluoresence assays were carried out using the method of Tonkin et al, (2004). 
Parasite culture (5 – 10 µl of ≥ 5% parasitaemia, 2.5 % HCT) was placed into a 
chamber slide pre-treated with poly-L-lysine, and allowed to air dry in a laminar flow 
hood.  One hundred microlitres of a 4 % para-formaldehyde + 0.0075 % 
gluteraldehyde premade solution was added to each chamber and left for 10 – 30 mins 
to fix the cells.  After washing three times with 250 µl PBS the cells were premeabilised 
with 100 µl 0.1% Triton X-100 for 10 mins.  Following another wash step (three times 
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with 250 µl PBS) 100 µl 0.1 mg/ml sodium borohydride in PBS was added and 
incubated for 10 mins.  Again the slide was washed three times with 250 µl PBS.  The 
samples were blocked overnight with 3% BSA in PBS at 4 oC with humidity.  The 
following day the slide was washed with 250 µl PBST (PBS + 0.05% Tween 20).  The 
primary antibody was diluted in 3% BSA in PBS and 200 µl added to each chamber for 
1 h at room temperature with agitation.  The slide was washed in PBST three times.  
The secondary antibody was diluted in 3 % (w/v) BSA in PBS, 200 µl added to each 
chamber and incubated for 1 hour at room temperature with agitation.  Prior to the 
final washes, 3 µl of a 1:10 dilution of Hoechst 33258 (0.5 µg/ml in 3 % (w/v) BSA) 
was added to each chamber and left for 1 min.  The samples were washed three times 
with PBS + 0.05 % Tween 20.  The plastic well divider was removed and the slide 
mounted with 500 µl 2.5% DABCO (1,4-diazabicyclo[2.2.2]octane), 50 % (v/v) glycerol 
in PBS.  A cover slip was added, ensuring no bubbles, and sealed with black nail polish. 
 
Cells were visualised using an Axioskop (Zeiss) or Delta Vision (Applied Precision) 
microscope, at a 100x magnification.  To visualise the Hoechst 33258 nuclear stain a 
DAPI filter was used.  To visualise proteins tagged with GFP or antibodies conjugated 
with AlexaFluor488 a GFP or FIT-C filter was used, and a TRIT-C or Alexa594 filter for 
antibodies conjugated with AlexaFluor594. 
 
2.6 Biocomputational Analyses 
 
2.6.1 Alignments and homology searches 
There is a single annotated formate-nitrite transporter putative gene predicted in 
PlasmoDB.  In PlasmoDB, the genomic structures of protein coding genes were 
predicted using computer based programs and manual curation (Gardner et al, 2002a).  
Protein coding genes were annotated using electronic means, many have a putative 
function and some no function at all (Kissinger et al, 2002).  More information on the 
sequencing and annotation of genes in P. falciparum can be found in Hall et al (2002), 
Hyman et al (2002) and Gardner et al (2002b).  Protein sequences from P. falciparum 
and E. coli were used as queries in order to identify genes in other organisms 
(bacteria, parasites, etc) that encode potential orthologues to the FNT proteins.  
Protein sequences retrieved from the PlasmoDB database (Plasmodium) and NBCI 
database (E. coli) were submitted to BLASTP searches of the online PlasmoDB 
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database for Plasmodium orthologues and through the NCBI database non-redundant 
protein sequences (nr) for other organisms.  The top-scoring sequence for a particular 
organism was selected as the putative FNT orthologue, unless the protein had been 
annotated as a FNT protein or putative FNT protein (including FocA, NirC, FDHC and 
transporter annotations).  Information on the various BLASTP searches performed in 
this thesis can be found in Appendix 5. 
Alignments of multiple amino acid sequences were created using MAFFT (Katoh et al, 
2002) version 6, the L-INS-i mode was used unless stated otherwise, for the 
phylogenetic analysis.  For the alignments in the thesis an online MAFFT19 program was 
used and the ClustalW output mode was selected.  The MAFFT program, as found on 
the EBI website, implements a selection of multiple alignment methods as described on 
the MAFFT website (http://mafft.cbrc.jp/alignment/software/). 
 
2.6.2 Membrane topology analyses 
Hydropathy plots were used to estimate the number of transmembrane domains 
(TMDs) in a given amino acid sequence, and to identify the likely locations for the 
TMDs.  The computer programs used for membrane topology analysis are listed below 
and their URLs are given in Table 2.5. 
 
Program URL 
TMHMM Server v 2.0 http://www.cbs.dtu.dk/services/TMHMM-2.0/ 
HMMTOP version. 2.0 http://www.enzim.hu/hmmtop/ 
SOSUI engine ver. 1.11 http://bp.nuap.nagoya-u.ac.jp/sosui/ 
TMpred http://www.ch.embnet.org/software/TMPRED_form.html 
TopPred 0.01 http://mobyle.pasteur.fr/cgi-bin/portal.py?form=toppred 
Table 2.5:  Membrane protein topology prediction programs. 
 
TMHMM predicts the number of transmembrane helices in a protein sequence given 
the amino acid properties, and gives the likelihood of these being true TMDs using 
other properties such as length of predicted TMD.  The overall structure is used to 
determine the probability of the N-terminus being on the cytoplasmic side (Möller et al, 
2001).  HMMTOP (hidden markov model for topology prediction) is software used for 
the prediction of transmembrane helices and the topology of proteins given the protein 
sequence (Tusnády and Simon, 1998).  TMpred predicts membrane-spanning regions 
                                                 
19 http://www.ebi.ac.uk/Tools/msa/mafft/.  Accessed on 10 August 2012. 
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and the overall orientation of a given amino acid sequence using statistical analyses of 
known transmembrane proteins present in the TMbase database (Hofmann and Stoffel, 
1993).  SOSUI (Mitaku et al, 2002) and TopPred (von Heijne, 1992) are also 
membrane topology and transmembrane domain prediction programs. 
 
2.6.3 Protein modelling 
Data gained from hydropathy plots and visual analysis were used to generate the data 
that was combined to produce a 2D model of the proteins. 
 
The 3D protein model in this thesis was created using I-TASSER v1.120 from the Zhang 
Lab (University of Michigan, MI, USA).  The program is based on multiple-threading 
alignments by LOMETS and iterative TASSER assembly situations (Zhang, 2008).  
Models retrieved with the highest confidence score (indicating the significance of 
alignment) were selected as the best models. 
 
Conserved residues were identified through multiple alignments and those deemed to 
be important from two of the FocA structure papers (Wang et al, 2009 and Waight et 
al, 2010) were mapped onto the corresponding 3D structure for visualisation of 
possible binding interactions using PyMol v. 1.3 (Schrodinger, Camberley, UK). 
 
2.6.4 Phylogenetic tree reconstruction 
Sequences to be used in the phylogenetic tree were downloaded from NCBI and 
PlasmoDB, and aligned using MAFFT as detailed in section 2.6.1.  The alignment was 
submitted to ModelGenerator (Keane et al, 2006) and the Bayesian information 
criterion (BIC) selected to choose a phylogenetic substitution model for the data.  The 
number or Gamma categories selected in ModelGenerator was set as four.  Each gene 
ID entry was edited give a less than 9 letter sequence identifier in order to make them 
suitable for input into the PhyML application.  The maximum likelihood phylogeny was 
created by inputting the alignment file to PhyML 3.021 (Guindon et al, 2010), the 
substitution model was set to LG as chosen by ModelGenerator and type of tree 
improvement was set to SPR & NNI.  The data were bootstrapped and set to 250 
replicates.  Output from PhyML was visualised using TreeView v 1.6.6 (Page, 1996). 
                                                 
20 http://zhanglab.ccmb.med.umich.edu/I-TASSER/.  Accessed on 25 November 2011. 
21 http://atgc.lirmm.fr/phyml/.  Accessed on 10 August 2012. 
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2.6.5 Statistical analyses 
Statistical analyses were carried out using SPSS (PASW Statistics, now IBM, 
Portsmouth, UK).  To compare the means of data sets the one-way ANOVA (analysis of 
variance) was used.  A one-way ANOVA makes the assumption that the variances of 
the groups being tested is similar.  Therefore a homogeneity of variance’ test was 
chosen.  This tests for similar variences in the groups being tested, if the test returns a 
significant value, there is variation in the variences of the groups and a one-way 
ANOVA is not the correct test to use.  If the result is not significant, the homogeneity 
of variences has been met, and the one-way ANOVA can be carried out.  Post hoc tests 
were selected to compare each of the data sets by ANOVA, this was set to Bonferroni 
comparisons, the most stringent method in SPSS to correct for problems that could 
arise when comparing many data sets.  If data did not conform to parametric 
assumptions a Kruskal-Wallis test was used instead of an ANOVA.  
 
2.6.6 Subcellular localisation prediction 
To investigate the possible cellular location for a specific protein, a selection of 
computer programs were used.  The subcellular prediction computer programs used 
and their URLs are given in Table 2.6. 
 
The PlasmoAP prediction program uses an algorithm to identify protein sequences 
containing an N-terminal amino acid sequence predicted to contain a signal and transit 
peptide consistent with apicoplast targeted sequences from P. falciparum.  The transit 
peptides contain more basic (histidine, lysine and arginine) than acidic (aspartate and 
glutamate) residues (Foth et al, 2003).  The PATS predication software uses neural 
network analysis to predict the transit sequence from an amino acid sequence (Zuegge 
et al, 2001), it is suggested by the authors that a secondary analysis is carried out on 
sequences predicted to be targeted to the apicoplast.  PlasMit is used to predict 
mitochondrial transit peptides in P. falciparum.  PlasMit consists of four neural 
networks, and output is based on all four.  The networks consider amino acid 
composition and the physicochemical properties of the residue sequence (Bender et al, 
2003).  iPSORT is used to predict signal peptides, mitochondrial targeting peptides and 
chloroplast transit peptides in the N-termini of protein sequences.  The iPSORT 
program uses an ‘amino acid index rule’ analysing the biochemical properties of each 
of the first 30 amino acids and ‘alphabet indexing’ which detects patterns in the 
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residue sequence (Bannai et al, 2002).  Signal P predicts the presence and location of 
any cleavage peptides and signal peptides in eukaryote organisms, and is based in a 
combination of artificial neural networks (Petersen et al, 2011). 
Program URL 
PlasmoAP http://v4-4.plasmodb.org/restricted/PlasmoAPcgi.shtml  
PATS v 1.2.1N http://gecco.org.chemie.uni-frankfurt.de/pats/pats-index.php 
PlasMit http://gecco.org.chemie.uni-frankfurt.de/plasmit/ 
iPSORT http://ipsort.hgc.jp/ 
SignalP 4.0 Server http://www.cbs.dtu.dk/services/SignalP/ 
Table 2.6: Subcellular localisation programs for Plasmodium spp. 
Substrate Specificity of Plasmodium falciparum NitA Chapter 3 
 
[83] 
 
3 Substrate Specificity of Plasmodium falciparum NitA 
 
3.1 Introduction 
 
The pfnita gene was annotated as a formate-nitrite transporter.  In this chapter, the 
investigation of the possible substrate/s of the Plasmodium protein was pursued.  
Protein orthologues in other organisms are known to transport formate, nitrite or the 
hydrosulphide ion.  However, there are organisms with orthologues that have unknown 
functions and no other possible substrates have been proposed.  For example, the 
substrates of the E. gracilis (Deloménie et al, 2007) and the S. cerevisiae (Macuk et al, 
2001) orthologues are unknown.  The green algae C. reinhardtii contains six 
homologous proteins annotated as FNTs, one of which has been shown to transport 
bicarbonate (Mariscal et al, 2006).  In Clostridia spp. and other bacteria the 
orthologues are known to transport the hydrosulphide ion (Czyzewski and Wang, 
2012).  Orthologues are found in protozoan parasites such as Trichomonas vaginalis, 
and the Apicomplexans Plasmodium, Babesia and Theileria.  No orthologue has been 
found in Cryptosporidium, the only Apicomplexan not to contain an apicoplast (Zhu et 
al, 2000). 
 
In this chapter the results of functional complementation assays are described.  The 
assays were designed to aid in the identification of the substrate of PfNitA.  Given the 
annotation of PfNitA as a formate-nitrite transporter, two possible substrates provided 
the basis for investigation: formate and nitrite.  The first model organism chosen was 
Aspergillus nidulans.  A. nidulans is a useful organism as it can be genetically 
manipulated with ease when compared to other organisms.  This is due to a deletion in 
the nkua gene which allows an integration efficiency at the target locus of greater than 
90 % (Dr. J.R. Kinghorn, personal communication).  This organism has also been 
extensively researched with regard to nitrate and nitrite uptake (Wang et al, 2008 and 
Symington, 2009 and references therein) in this laboratory making it an ideal place to 
initiate this line of enquiry with regard to Plasmodium.  A second model organism used 
for functional complementation was Escherichia coli.  E. coli is easily propagated in the 
laboratory, and work has been carried out on the PfNitA orthologues EcFocA a formate 
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transporter (Suppmann and Sawers, 1994) and EcNirC a nitrite transporter (Clegg et 
al, 2002). 
 
3.1.1 Possible roles for formate in Plasmodium 
Formate is a by-product of fermentation in anaerobic bacteria such as E. coli, 
Salmonella and Clostridium species.  Formate is formed in the production of acetyl CoA 
from pyruvate by pyruvate:formate lyase, an enzyme only expressed in anaerobic 
conditions (Sawers, 2005).  The formate can be toxic to the bacteria, and needs to be 
exported from the cell to prevent acidification of the cytosol (Suppmann and Sawers, 
1994).  Experimental results characterising carbon metabolism in P. knowlesi have 
demonstrated formate and acetate to be end-products of pyruvate metabolism 
(Scheibel and Pflaum, 1970) and in P. berghei (Fulton and Spooner, 1956).  This 
formate produced as a by product of cellular processes could be toxic to Plasmodium 
parasites.  If so, the formate would require removal from the parasite and RBC, and 
the PfNitA transporter could efflux unwanted the formate. 
 
Formate is produced as a by-product in the conversion of guanosine triphosphate to 
dihydroneopterin by GTP cyclohydrolase (GCH) I, this is the first step of the folate 
biosynthetic pathway (Krungkrai et al, 1985).  In P. falciparum the GCH I enzyme 
shows variation in the copy number between parasites (Nair et al, 2008) most likely 
due to antifolate drug pressure which affects enzymes involved in folate biosynthesis.  
The formate produced is likely to be detrimental to the parasites and, as before, a 
transporter to eliminate the toxic product would be of benefit. 
 
3.1.2 Possible roles for nitrite in Plasmodium 
It is known that there are nanomolar concentrations of nitrite present in human red 
blood cells (RBCs), and that nitrate is found in the RPMI used in malaria culture 
medium (Ostera et al, 2011 and Invitrogen22).  The removal of nitrate from RPMI leads 
to a decrease in parasite growth suggesting nitrate and/or nitrite are used for growth, 
and that parasites are able to utilise intraerythrocytic nitrite (Ostera et al, 2011).  Nitric 
oxide (NO) and reactive nitrogen species (RNS) derived from NO are found in the 
parasites’ digestive vacuole, and play a role in the formation of soluble and crystallised 
                                                 
22
 http://www.invitrogen.com/site/us/en/home/support/Product-Technical-
Resources/media_formulation.117.html.  Accessed on 17 September 2012. 
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haem.  However, there is no obvious nitric oxide synthase gene in the malaria genome.  
There are however three possible functionally similar molecules, namely a putative 
flavodoxin-like protein (PFI1140w), a putative cytochrome b5 (PFL1555w) and putative 
NADH-cytochrome b5 reductase (PF13_0353) that have partial similarity to inducible 
nitric oxide synthase (iNOS) and plant nitrate reductases, respectively.  It has been 
shown that two of these proteins, PF13_0353 and PFL1555w, also localise to the 
parasites DV in the trophozoite stage (Ostera et al, 2008 and Ostera et al, 2011).  
These data imply that (i) nitrite and nitrate from the erythrocyte and in vitro growth 
media, respectively, are used in the production of nitric oxide for use in the 
haemoglobin detoxification process (Ostera et al, 2011) and (ii) that nitrite could be 
produced as a by product of NO generation which is exported from the parasite and 
incorporated into the existing RBC nitrite pool (Ostera et al, 2008).  The transport of 
nitrite and/or nitrate into or out of the parasite cell, or into the parasites’ DV may 
require a permease.  This engenders a role for the pfnita gene as a transporter for 
nitrite. 
 
The role of nitric oxide in the pathogenesis and immune response to malaria is not yet 
fully understood.  NO has been proposed, however, to have a protective effect against 
severe disease (Gramaglia et al, 2006 and Weinberg et al, 2008).  For instance, 
inhibition of NO has also been demonstrated to reduce the parasitaemia of P. 
falciparum in vitro (Ostera et al, 2008) and in the P. berghei rodent model (Koka et al, 
2008).  A protective role for NO could be related to decreased cytokine production that 
may help avert the related immunopathologies, and reduce endothelial adhesion 
molecules.  Such events would prevent rolling adhesion and sequestration of 
parasitised RBCs (Serirom et al, 2003).  The supplementation of exogenous NO donors 
has been demonstrated to protect mice infected with P. berghei from the development 
of cerebral malaria thus limiting the disease symptoms but not parasitaemia 
(Gramaglia et al, 2006).  During the infection, the levels of NO and arginine (a 
precursor of NO) are seen to be diminished, the reason for this observation is unclear.  
It has been considered that malarial arginase uses arginine from the hosts blood to 
produce ornithine thus diverting the arginine from being converted to NO or that haem 
released by the RBC rupture binds to NO rendering it inactive (Weinberg et al, 2008).  
Another possible explanation could be, that as in S. typhimurium infection (Section 
1.5.3.1) (Das et al, 2009), the Plasmodium parasites use the formate-nitrite transporter 
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to prevent nitrosative stress.  The exact role that the Salmonella transporter plays is, 
however, yet to be defined. 
 
mRNA expression data from PlasmoDB23 indicates the PfNitA transporter is active 
throughout intraerythrocytic and gametocyte stages.  There is no current data on the 
gene expression in the mosquito stages available (at time of writing).  The mosquito 
elicits an immune response which includes NO production leading to the expression of 
anti-microbial peptides which have anti-parasitic effects (Herrera-Ortiz et al, 2010).  A 
mechanism to limit the amount of NO produced, such as the pfnita gene function, 
could be beneficial to the parasites’ development and transmission.  The justification is 
similar for the exo-erythrocytic stage of infection as NO is produced by the hepatocytes 
as a response to infection (Klotz el al, 1995). 
 
Glutamine synthetase uses ammonia as a substrate in the synthesis of glutamine from 
glutamate.  Glutamine is thought to be a carbon source for the parasites unusual TCA 
cycle and therefore an essential nutrient (Olszewski et al, 2011).  A source of ammonia 
may be from the reduction of nitrite, a molecule, as noted above, to be freely available 
in the host erythrocyte. 
 
3.2 Sequence Considerations 
 
The pfnita gene from P. falciparum has been so given this designation due to its 
similarity to formate-nitrite sequences and has been so designated in accord to the 
FNT gene of A. nidulans known as annita, which has been much researched in the 
Unkles laboratory.  The gene is not found in higher organisms making it an ideal choice 
for research studies as a selective drug target.  Orthologues of this protein have been 
crystallised from various bacteria (Wang et al, 2009a, Waight et al, 2010, Lü et al, 
2011 and Czyzewski and Wang, 2012 and Chapter 1).  The crystal data has led to the 
identification of key residues involved in substrate binding and maintenance of the 
protein structure. 
 
 
                                                 
23 www.plasmodb.org.  Accessed on 01 January 2012. 
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3.2.1 Gene structure 
The pfnita genomic sequence is predicted to contain four exons and three introns 
(PlasmoDB) (Figure 3.1), the UTR’s are unknown.  However, caution must be exerted 
in these regards as, to my knowledge, no cDNA copy has been sequenced and 
compared to the genomic copy, indeed the A+T rich genome makes cDNA sequence 
analysis difficult in Plasmodium species (López-Barragán et al, 2011).  To obtain the 5’ 
and 3’ untranslated regions, 5’ and 3’ rapid amplification of cDNA ends (RACE) could be 
carried out.  Each of the putative introns contains the canonical GU AG dinucleotide 
sites at its periphery for 5’ and 3’ splicing.  The A+T content of the three introns 
averages at 86.67%, typical of P. falciparum (Zhang et al, 2011).  The two nucleotides 
adjacent to the 5’ splice site in P. falciparum are most often AG, this is observed in the 
first and third putative exons.  In exon two however, the nucleotides are AC.  The AC 
in this position is not well represented in P. falciparum with approximately 3 % of 
introns having an ACgt boundary (Zhang et al, 2011) (uppercase representing exons 
and lower case introns).  The final exon is only 25 nucleotides long, with the final 3 
making up the stop codon. 
 
 
 
Figure 3.1: Putative genomic structure of pfnita.  A schematic to illustrate the putative intron and 
exon structure of the pfnita gene (PFC0725c).  Exon 4 is distorted due to its small size.  The UTR’s are 
unknown and have not been included.  The diagram was created using Vector NTI. 
 
3.2.2 Protein secondary structure predictions 
Membrane topology analysis using online computer software was used to investigate 
the number of predicted transmembrane domains (TMDs) in the protein (Section 2.6.2 
and Table 2.5).  FNTs are thought to have 6 – 7 transmembrane domains.  The PfNitA 
amino acid sequence was subjected to five common topological prediction programs 
(Table 3.1).  These hydropathy plots consistently demonstrated the likely presence of 
Pf NitA int/ex
5000 bp
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Intron 3
Exon 1 Exon 2
Exon 3
Exon 4
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six TMDs in the amino acid sequence, this is in agreement with other FNTs.  The plots 
only estimate the likely position of TMDs in amino acid sequences using a 
hydrophobicity index.  To confirm the output data the sequence was analysed for 
hydrophobic residues known to be found in transmembrane domains and charged 
residues not regularly found in TMDs.  The putative transmembrane domain positions 
from each program are given in Table 3.1.  A representative hydropathy plot has been 
reproduced in Figure 3.2. 
 
TMD TMHMM HMMTOP SOSUI TMpred TopPred 
1 48-70 41-64 43-65 49-68 47-67 
2 83-105 77-101 84-105 76-98 80-100 
3 129-151 132-155 130-152 132-156 138-158 
4 184-206 186-203 182-204 186-206 186-206 
5 216-238 210-227 219-241 209-228 209-229 
6 258-280 258-281 266-282 262-281 261-281 
Table 3.1:  Hydropathy plot output data for PfNitA.  The amino acid positions of each of the 
transmembrane domains of PfNitA, as predicted by each TM predictor program. 
 
 
 
Figure 3.2:  Hydropathy plot to indicate the predicted transmembrane domains of PfNitA.  An 
upper and lower hydrophobicity value was set automatically and can be seen as a red and green line 
running across the images, respectively.  Peaks above the red line are taken as transmembrane domains, 
and those above the green line are putative transmembrane domains.  ‘start position of window in 
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sequence’ denotes the sliding window of 21 amino acids, which can be found in the 309 amino acid PfNitA 
sequence.  Image taken from Mobyl@Pasteur v1.0 24. 
 
A 2D structure model of the PfNitA protein was created using data generated from the 
combination of hydropathy plots (Table 3.1 and Figure 3.2) and visual analysis of the 
sequence as well as known important residues (Figure 3.3).  The model does not 
however indicate the precise locations of the transmembrane domains.  The TMDs of 
PfNitA are predicted to form α-helices and therefore, hydrophilic faces of such TMDs 
may form the lining of an aqueous accessible region through which the substrate is 
transported. 
 
 
Figure 3.3: 2D structure model of the PfNitA protein.  Structural model for PfNitA based on the 
outputs from the hydropathy plot programs (Table 3.1 and Figure 3.2) and sequence data.  The known 
FNT motifs 1, 2 and 3 are shown in orange, green and pink, respectively.  The novel formate motif is 
indicated in blue.  N and C denote the termini.  Diagram is not to scale. 
 
There are three conserved motifs conserved in FNT proteins (Saier et al, 1999).  The 
first motif [LIVMA]-[LIVMY]-X-G-[GSTA]-[DES]-L-[FI]-[TN]-[GS], is present in the 
                                                 
24 http://mobyle.pasteur.fr.  Accessed on 28 January 2012. 
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PfNitA amino acid sequence as ICTGSDLFTG.  This motif is found in the second TMD 
and covers amino acids 98 – 107. 
 
Residues D103, L104 and T106 are proposed to play a role in the transporters activity 
and structural fold.  D103 and T106 correspond to E. coli and V. cholerae residues that 
are involved in hydrogen bonding, while L104 corresponds to a channel lining 
constriction residue in E. coli (Wang et al, 2009a) or in V. cholera a residue forming 
part of the selectivity filter (Waight et al, 2010).  In Figures 3.3 and 3.4 this motif is 
illustrated in orange. 
 
The second motif [GA]-X(2)-[CA]-N-[LIVMFYW](2)-V-C-[LV]-A, is present as 
AVGCNIFVCLA.  This second motif is found in the fourth TMD and spans residues 189 – 
199.  Residues N193 and V196 are proposed to be in the selectivity filter of V. cholerae 
(Waight et al, 2010) and V196 a channel lining residue of E. coli, implying they might 
play a role in the translocation of the substrate.  Residue N193 corresponds to a 
residue involved in bonding to T91 in E. coli, which is T106 in the P. falciparum 
orthologue and found in the first FNT motif (Wang et al, 2009a).  This data points to a 
structural role for these latter residues.  In Figures 3.3 and 3.4 this motif is presented 
in green. 
 
The third motif F-[IVFA]-X-[LIS]-G-[LEYT]-[EQ]-H-[SVCY]-[VI]-[AG]-[ND]-[MLQ] is 
present in The P. falciparum protein as FAIAGYEHIIANI.  This motif is found in TMD 5 
and spans residues 223 – 234.  F223, H230 and A233 are found as channel lining 
residues and as part of the selectivity filter.  E229 and N234 correspond to residues 
that form hydrogen bonds with each other in E. coli (E208 and N213) (Wang et al, 
2009a), and residue H230 was shown to be in the selectivity filter and form hydrogen 
bonds in V. cholerae (Waight et al, 2010).  In Figures 3.3 and 3.4 this motif is 
indicated the by pink colouring. 
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PfNitA MPPNNSKYVLDPVSIKSVCGGEESYIRCV----EYGKKKAHYSNLNLLAKAILAGMFVGL 
PkFNT MSKGKSKYVIDPISVKTACTSEESYIRCV----EYGKGKAHYPNLSLLAKAILAGVFVGV 
PvFNT MTKG-SKYTIDPISVKTACTSEESYIRCV----EYGKGKAHYPNLSLLAKAILAGVFVGV 
PbFNT MGKSGKQYIIDPASVKTTCSSEESYIRCV----EYGKAKATYSNFNLFLKAILAGIFVGL 
PcFNT MGKIGKQYILDPTSVKTTCSSEESYIRCV----EYGKAKAAYSNFNLFLKAILAGIFVGL 
PyFNT MGKTGKQYILDPPCVKTTCSSEESYIRCV----EYGKAKATYSNFNLFLKAIMAGIFVGL 
BbFNT M---------EVGTVSQIRKAGDAYKVAI----DTGIYKKSCPIYILLVKAMMGGYFAAL 
TaFNT M----------FEYTRQLASAKDNYERIA----KEAGDKVNGNILTLFVKSLLGGWFVAI 
TgFNT M---------------VVTASPDTYLHVI----DYGLKKVRLRFDRLLLQAFMAGVYIGM 
EcFocA M---------KADNPFDLLLPAAMAKVAE----EAGVYKATKHPLKTFYLAITAGVFISI 
StFocA M---------KADNPFDLLLPAAMAKVAE----EAGVYKATKHPLKTFYLAITAGVFISI 
VcFocA M---------E-HNQFDSLLPPQMAERAA----ITGEGKAKKAAYKSFLLAISAGIQIGI 
StNirC M--------------FT-----DSINKCAAKLRASAPVSANNPL-GFWVSSAMAGAYVGL 
EcNirC M--------------FT-----DTINKCAANAARIARLSANNPL-GFWVSSAMAGAYVGL 
CdHSC M---------G--RAHK-----ETLDKLTNAAINSINLLNTSKV-KYLVSSAFAGLYVGI 
MtFDHC M---------G--SSFK--SPADTAKACS----AIAELKEKAPLGKVIVLSFLAGAYIAF 
MfFDHC M---------A--SSFK--SPADTAKACV----GVAALKEKAPLSNLIVLSFVAGAYIAF 
AnNitA M---------P--PSIDAYTPLEVVEFVS----RAGSVKGHMRLDKIFLSSLSAGCLLAL 
EgFTH M--------------PNHVKAVDVLEGAI----NAGVMKAHMPFMDMAIRGLYAGFFLGV 
CaYHA8 M------------DDNLYLTTYEAALAVV----ATAMKKARLRIDVLVINSLMGGMLFTT 
ScYHL M-----------VDDSNYLTPHETALAVV----ATAMKKARLQLDTLLINSILGGVLFSS 
 
PfNitA CAHAS-GIAGGLFYYHKLREIVGASMSVFVYGFTFPIAFMCIICTGSDLFTGNTLAVTMA 
PkFNT CAHAS-GIAGGHFYYHKLREYVGISMSAFVYGFTFPIAFLCIIATGSDLFTGNTLAVTTA 
PvFNT CAHAS-GIAGGHFYYHKLREHVGISMSAFVYGFTFPIAFLCIIATGSDLFTGNTLAVTTA 
PbFNT CAHAS-GIAGGLFYYHKLRAYVGPSFSSFVYGFTFPIAFLCIICTGSDLFTGNTLAVTVA 
PcFNT CAHAS-GIAGGLFYYHKLRAHVGASFSSFVYGFTFPIAFLCIICTGSDLFTGNTLAVTIA 
PyFNT CAHAS-GIAGGLFYYHKLRAYVGASFSSFVYGFTFPIAFLCIICTGSDLFTGNTLAVTVA 
BbFNT GGHAA-MVLASYYY-MD--GHHGGAKLAF--GVIFSGALLCIVFTGTDLVTSNCMNFAFL 
TaFNT GGYAA-SVIASLFYEQD--ASNGAARAAF--SLIFPGALCAILFTGSDLYTGNTMSFTFA 
TgFNT AGNACISLAGGFSTDPADPKAITAGVQKFIYASIFPVAFIAIIMTGAELFTGNTMTMLIC 
EcFocA AFVFYITATTGTGT-----M--PFGMAKLVGGICFSLGLILCVVCGADLFTSTVLIV-VA 
StFocA AFVFYITATTGTGA-----M--PYGMAKLIGGICFSLGLILCVICGADLFTSTVLIV-VA 
VcFocA AFVFYTVVTTGAHD-----M--PYGVTKLLGGLAFSLGLILVVITGGELFTSSVLIL-VA 
StNirC GIILIFTLGNLLDP-----SVRP--L---VMGATFGIALTLVIIAGSELFTGHTMFLTLG 
EcNirC GIILIFTLGNLLDP-----SVRP--L---VMGATFGIALTLVIIAGSELFTGHTMFLTFG 
CdHSC GILLIFTIGGLLTD-----AGSP--MTKIVMGLSFAIALSLVIMTGTELFTGNNMVMSAG 
MtFDHC GGLLAEVVTGGMAK-----AGYPAGLVKLVFGAVFPVGLMLVVIAGSELFTGNCMYMPLG 
MfFDHC GGLLAEVATGGMAA-----AGWPTGLVKLVFGGVFPVGLMLVVIAGSELFTGNCMYMPMG 
AnNitA ACGTTLSTNASPWF-----TENAPGLIRTISALVFPYGLVLIILTGADLCTGSFMFTTVA 
EgFTH TASFNFQLTALYGN-------------AMIGGLLFFAGFMMIIFYGFELVTGNMLVLPLA 
CaYHA8 GGMLYDLIRAGFSG----INETNPGVISLLQGICYPIGLFYVVILGVDLFNSNILFFSTA 
ScYHL GSFLLVAVYSEDPD----IVARNPGIVNLITGVNFAMGLFYVVMMGADLFNSNILFFSVG 
 
PfNitA LYEKKVKLLDYLRVMTISLFGNYVGAVSFAFFVSYLSGAFT-NVHAVEKN-HFFQFLNDI 
PkFNT LLQRKVSLLQYLRVMSISLFGNYLGAVSFAFFVSHLSGAYE-KHTDVTKN-HIFQFLNDI 
PvFNT LLQRKVTLLEYLRVMSISLFGNYVGAVSFAFFVSHLSGAFK-KHEEIGKN-HIFQFLNDI 
PbFNT LLQKKVKLLSYIRVMSISLLGNYIGAVSFAFIVSYGSGAFH-QHSDIEKN-HIYEFLNAI 
PcFNT LLQKKIKLLSYIRVMSISLLGNYIGAVSFAFIVSYGSGAFH-QQASIEKN-HIYEFLNAI 
PyFNT LLQKKVKLLSYIRVMLISLLGNYIGAVSFAFIVSYGSGAFH-QHSDIEKN-HIYEFLNAI 
BbFNT AYSRQVTLFQYLTRMGTSLLGNYCGAILGAALLTAGTGYFS-L--D-KRP-E--AYLKAI 
TaFNT LCKKHITFLNYFLKLGISIMGNYIGAVIGALILSGGTTYFL-K--DVGKG-A--PYLLDM 
TgFNT WFERRITIWQLLQNWAGSFLGNWLGTMFSAYFLTYLCCPFD-H------D-PYLSYLNYT 
EcFocA KASGRITWGQLAKNWLNVYFGNLVGALLFVLLMWLSGEYMT-A------NGQWGLNVLQT 
StFocA KASGRITWGQLAKNWLNVYFGNLIGALLFVLLMWLSGEYMT-A------NGQWGLNVLQT 
VcFocA KASGKISWKELVRNWTVVYFGNLCGSIILVFIMLATRQFME-D------GGQLGLNAMAI 
StNirC VKAGTISHGQMWAILPQTWLGNLVGSVFVALLYSWGGGS-L-L------P-VDTSIVHSV 
EcNirC VKAGSISHGQMWAILPQTWLGNLVGSVFVAMLYSWGGGS-L-L------P-VDTSIVHSV 
CdHSC MLNKGVSIKDTSKIWAYSWVGNLIGALVLGIIFVGTGLV-D-K------G-PVAEFFANT 
MtFDHC ILDKRASIMGLIRNWVTSWVFNLVGAVFVAYFLAVATGILT-A------D-PWQAGALTV 
MfFDHC ILQGEASVMGTIKNWVGSWVFNLVGALFVAYVLAYLTGILT-A------E-PWAATAVTI 
AnNitA ALHRRLSWPKMLLHWFITFWGNLCGSLFVVAIIFGYGEVFS-A------D-PFRSAVISF 
EgFTH LMARRAPWLGCPKNLLTVYTGNFLGCALYLAFFYGSSLILDCGWTAIKVAQLYCSWKTKT 
CaYHA8 LCRGAVSFLDLFISWFVSWWFNLVGNIFVCYIFCYYSDVVR--------TQLMVVGSVEV 
ScYHL VLRKAVTIYDLMISWVVSWLGNIAGSLFVSYLFGHLSGISS--------QKLWIIGSRQI 
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PfNitA AEKKV--------------HHTFVECVSLAVGCNIFVCLAVYFVLTLKDGAGYVFSVFFA 
PkFNT AEKKI--------------SHTFIQCICLAIGCNIFVCLAVYFVLTIKDGSGMVFSVFFA 
PvFNT AEKKV--------------SHTFVQCVCLAIGCNIFVCLAVYFVLTIKDGSGMVFSVFFA 
PbFNT AIKKV--------------HHSFSECISLAIGCNIFVCLAVYFVLSIKDGSGVVFSVFFA 
PcFNT AMKKV--------------HHTFSECIALAIGCNIFVCLAVYFVLSIKDGSGVVFSVFFA 
PyFNT ATKKV--------------HHSFFECISLAIGCNIFVCLAVYFVLSIKDGSGVVFSVFFA 
BbFNT YDAKT--------------ALPFWRTMLSAIGCNSYVCMAVWCCYVAMDSAGCVLAVMIL 
TaFNT AIAKT--------------NKPFWKTMFSAIGCNCFVCLAVWSFYACYDSAGAVLIVFAH 
TgFNT AASKV--------------SYGWGSCFLRGVGCNTWVCLAVWFVVACDDAAGKILALWFP 
EcFocA ADHKV--------------HHTFIEAVCLGILANLMVCLAVWMSYSGRSLMDKAFIMVLP 
StFocA ADHKM--------------HHTFIEAVCLGILANLMVCLAVWMSYSGRSLMDKAFIMVLP 
VcFocA SQHKL--------------HHTFLQAFALGLMCNILVCLAVWMTFSARSLTDKVMVLILP 
StNirC ALAKT--------------TAPATVLFFKGALCNWLVCLAIWMAIRTEG-TAKFLAIWWC 
EcNirC ALAKT--------------TAPAMVLFFKGALCNWLVCLAIWMALRTEG-AAKFIAIWWC 
CdHSC AASKA--------------SMPFTALFFRGILCNILVCVSVLCSFRTNSDTAKIIMIFLC 
MtFDHC AKTKALGGASFIAAGKVTKSLTWAQAFWRAVGCNWLVCLAVYLAIASDDIIGKIWGIWFP 
MfFDHC AKTKALGGAQFIAAGKTVTSLSWMQVFWRAIGCNWLVCLAVYLAVASDDVIGKSFGIWFP 
AnNitA ATKKQV-------------TPEFHSIFLRGIGCNWLVCLACFLGLQGRDMASKIIGIWLP 
EgFTH ADYYM--------------MWTGWPPAFQGCHVQLLVSFAVLGSLASTSTTGKVIACWFP 
CaYHA8 AVQKA--------------ESTFVETLLKATAGNFYVCLAIFLQLMAKPLHVKFLMMLLP 
ScYHL IEQKV--------------SYSFVQTFLKGIACNFFVCLAIYLQLMAKPIHVKFILMSFP 
 
PfNitA VYAFAIAGYEHIIANIYTLNIAL----MVNT--------------KITVYQAYIKNLLPT 
PkFNT VYAFAIAGYEHIIANMYTLNLAL----MVEA--------------KVTWSKVYFHNLLPT 
PvFNT VYAFAIAGYEHIIANMYTLNLAL----MIEA--------------NVDWTKAYVDNLLPT 
PbFNT VYAFAIAGYEHIIANIYTLNIAL----MVKT--------------NVTFFDVYFKNLIPT 
PcFNT VYAFAIAGYEHIIANIYTLNIAL----MVKA--------------DVTFMEVYFNNLIPT 
PyFNT VYAFAIAGYEHIIANIYTLNIAL----MVKT--------------DVTFFDVYFKNLIPT 
BbFNT ITSFAVAGFEHIVANFYTLHAAL----FSCE--------------GTSVGVVYGRNLAPT 
TaFNT IGAFAAGGLEHTIANFYLLNAAL----ISQS--------------GVSFLDVYYRNLIPV 
TgFNT IVAFVLSSYEHIIANLYTLQLCA----MLGV--------------DTSLADMIAFNLLPT 
EcFocA VAMFVASGFEHSIANMFMIPMGIVIRDFASPEFWTAVGSAPENFSHLTVMNFITDNLIPV 
StFocA VAMFVASGFEHSIANMFMIPMGIVIRDFATPEFWTAVGSSPESFSHLTVMSFITDNLIPV 
VcFocA VAMFVSSGFEHCIANMFQVPMAIGIKYFAPESFWAMTGANIAQYADLNFVNFIVNNLIPV 
StNirC LLAFIASGYEHSVANMTLFALSW----FGHHSDAYTLA-------GIG------HNLLWV 
EcNirC LLAFIASGYEHSIANMTLFALSW----FGNHSEAYTLA-------GIG------HNLLWV 
CdHSC LFAFITSGFEHSVANMTIYSVSL----FSPTISTVTIG-------GAI------YNLVAV 
MtFDHC IFAFVAIGFEHSVANMFFIPVGI----F--------LG-------GVTWSQFFMNNLIPV 
MfFDHC IMAFVCIGFEHVVANMFFIPVGI----F--------IG-------GVTWSQFFINNMIPA 
AnNitA IYAFVSLGFDHVVANMTFIPLAI----W--------LDA-----PGISVGLYIWKGIIPT 
EgFTH VALFAVMRYEHVVVNMYTVPCSM----ALGS--------------GVSWGLFWGWSIAPS 
CaYHA8 VFTFVAMGFTHSVADMFLVTMGL----INGA--------------PISVGKAAWKVFLPG 
ScYHL IIDFIGIGFTHVVGDMSASFIAM----LNGA--------------NVSVGKYIWKLLIPA 
Figure 3.4:  Partial multiple alignment of FNT orthologue amino acid sequences.  The three 
highly conserved FNT sequence motifs 1 2 and 3 (as described above) are indicated by orange, green and 
pink bars, respectively.  Residues within these sequences are postulated to play a role in the selectivity 
and activity of the group of permeases and are coloured appropriately.  StNirC, EcNirC, and AnNitA are 
known to transport nitrite. EcFocA, VcFocA and StFocA are known to transport formate.  CdHSC is known 
to transport the hydrosulphide ion. MtFDHC and MfFDHC are known to transport formate.  Ca YHA8 and 
ScYHL are yeast orthologues.  PfNitA, PkFNT, PvFNT, PbFNT, PcFNT, PyFNT TaFNT, BbFNT, TgFNT, and 
EgFTH are protist orthologues with unknown substrates.  Pf – P. falciparum, Pk – P. knowlesi Pv – P. 
vivax, Pb – P. berghei, Pc – P. chabaudi, Py – P. yoelii , Bb – Babesia bovis,  Ta – Theileria annulata, Tg – 
T. gondii, Ec – Escherichia coli, St – Salmonella typhimurium, Vc – Vibrio cholerae, Cd – Clostridium 
difficile, Mt – Methanothermobacter thermautotrophicus, Mf – Methanobacterium formicicum, Eg – 
Euglena gracilis, Ca – Candida albicans an Sc – Saccharomyces cerevisiae.  The alignment was made using 
MAFFT and sequences were truncated at the C-terminals.  Accession numbers can be found in Appendix 3. 
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A fourth putative motif HKXHHTF, found to be conserved between putative formate 
transporters (Dr. J.L. Cecile, personal communication) is also present in Plasmodium 
orthologues, and is found in an extracellular loop.  Interestingly this novel motif is not 
found in other Apicomplexan organisms such as Theileria and Babesia, or formate 
transporting archaea.  An alignment of select Plasmodium and bacterial orthologues 
highlighting the presence of this novel motif can be found in Figure 3.5.  From the 
alignment, the HKXHHTF motif (KKVHHTF in P. falciparum) is observed only in putative 
bacterial formate transport proteins and Plasmodium proteins.  In Figures 3.3 and 3.5 
this motif is shown in blue. 
 
PfNitA 103 SLFGNYVGAVSFAFFVSYLSGAFTNVHAVEKNHFFQFLNDIAEKKVHHTFVECVSLAVGCNIF 166 
PkFNT  103 SLFGNYLGAVSFAFFVSHLSGAYEKHTDVTKNHIFQFLNDIAEKKISHTFIQCICLAIGCNIF 166 
PcFNT  103 SLLGNYIGAVSFAFIVSYGSGAFHQQASIEKNHIYEFLNAIAMKKVHHTFSECIALAIGCNIF 166 
EcFocA 87  VYFGNLVGALLFVLLM-WLSGEYMTANGQWGLNVLQ----TADHKVHHTFIEAVCLGILANLM 145 
StFocA 87  VYFGNLIGALLFVLLM-WLSGEYMTANGQWGLNVLQ----TADHKMHHTFIEAVCLGILALMV 145 
VcFocA 86  VYFGNLCGSIILVFIM-LATRQFMEDGGQLGLNAMA----ISQHKLHHTFLQAFALGLMCNIL 144 
Figure 3.5:  Partial multiple alignment of Plasmodium orthologues and known formate 
transporters.  The novel formate transporter sequence motif (HKXHHTF) is indicated by the blue bar. 
EcFocA, VcFocA and StFocA are known to transport formate.  PfNitA, PkFNT, and PcFNT are example 
Plasmodium orthologues with unknown substrates.  Pf – P. falciparum, Pk – P. knowlesi, Pc – P. chabaudi, 
Ec – Escherichia coli, St – Salmonella typhimurium, Vc – Vibrio cholerae.  Accession numbers can be found 
in Appendix 3. 
 
3.2.3 Protein tertiary structure predictions 
Four crystal structures have been produced for formate-nitrite transporters, namely 
FocA, of E. coli, V. cholerae, and Salmonella typhimurium and FNT3/CdHSC of 
Clostridium difficile.  These four structures make it relatively simple to create a 
prediction of the PfNitA tertiary structure.  The PfNitA amino acid sequence was 
aligned to the sequences with known crustal structures.  The FocA proteins from E. coli 
and S. typhimurium demonstrate the greatest sequence similarity to PfNitA (Table 3.2). 
 
The PfNitA amino acid sequence was uploaded onto the I-TASSER25 (Zhang, 2008) 
sever, and this approach yielded five predicted 3D models.  This program computes 
the likely structure and returns a model based on the template.  These 5 models were 
studied with regard the predicted TMDs, structural motifs crystal data, and from the 
                                                 
25http://zhanglab.ccmb.med.umich.edu/I-TASSER/.  Accessed on 4 September 2012. 
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outcomes the most suitable chosen.  The model, however, is a prediction and does not 
show the true structure of the PfNitA protein.  So caution must be exerted since to 
obtain the precise information the crystal structure of the protein must be solved. 
 
PfNitA amino acid sequence comparison with crystallised orthologues 
Organism Identity (%) Similarity (%) 
V. cholerae 23.4 38.7 
E. coli 24.7 41.5 
C. difficile 22.3 36.2 
S. typhimurium 24.6 41.4 
Table 3.2:  Comparison of the amino acid sequence from PfNitA and homologous transporters 
with known crystal structures. Identity is an identical match between two amino acids, similarity is 
where two amino acids share similar properties.  Alignments were carried out using EMBOSS Needle – 
Alignment26. 
 
 (A)      (B) 
  
 
Figure 3.6:  Predicted tertiary structure for the PfNitA monomer.  (A) The protein as viewed from 
the planar angle, both termini are at the bottom of the diagram as they are predicted to be intracellular.  
From this angle, the split helices of domains 2 (yellow/green) and 5 (pale orange) can be seen.  (B) The 
four motifs discussed in the text are displayed with respect to the crystal structure while the other 
residues are shaded in grey. 
 
                                                 
26 http://www.ebi.ac.uk/Tools/psa/emboss_needle/.  Accessed on 15 August 2012. 
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Secondary structure programs predict the N and C termini of the PfNitA protein to be 
intracellular.  The image in Figure 3.6, A illustrates a 3D structural model of the PfNitA 
protein with the termini coloured red and blue.  With respect to B, the important 
residues from each motif have been highlighted, the colours corresponding to previous 
figures.  The structures illustrate possible interactions of the important residues with 
each other and where they are likely to be found within the 3D structure. 
 
3.2.4 Construction of a phylogenetic tree  
A phylogenetic tree was constructed to explore which of the 4 known clusters, I – IV, 
(Saier et al, 1999) of FNT proteins the PfNitA protein most closely related to.  It was 
anticipated that a phylogenetic study might give further clues to the possible 
substrate/s of the transporter.  Initially a large tree was constructed using 28 of the 
FNT protein sequences from prokaryotes, archaea and eukaryotes.  The longer 
sequences (T. gondii, E. gracilis and the yeast orthologues) created too many gaps in 
the alignment to be processed by PhyML.  To eliminate these gaps, the putative FNT 
domains from the four sequences were chosen and the N- and C-termini truncated.  
The truncation left an approximately 250 amino acid fragment for each sequence.  This 
inspection was carried out manually though an alignment made using MAFFT.  The T. 
gondii FNT domain was created between amino acids 81 – 332, E. gracilis domain 9 – 
257, S. cerevisiae 1 – 261 and C. albicans 1 – 260.  The data presented in Figure 3.7 
shows a bootstrapped (250 replications) unrooted phylogenetic tree.  The phylogenetic 
tree remained unrooted because no outlier could be chosen from the known 
orthologues and another factor taken into consideration is that the evolutionary history 
of the FNT family is as yet unknown.  Bootstrap support numbers are indicated on 
branches. 
 
The large unrooted tree clusters the Plasmodium orthologues into their own group 
which have the closest evolutionary history the apicomplexan orthologues, and further 
with the eukaryote orthologues, as might have been expected (Figure 3.7).  The 
protozoan parasite orthologues show the closest history with the other eukaryotic 
organisms, however, given the low bootstrap values extending from this part of the 
tree, it is difficult to draw any meaningful conclusions about function.  The very low 
bootstrap support values (i.e. those less than 50 %) implied that there either was not 
enough, or was too much variation between the sequences to find a useable 
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phylogenetic 'signal' (Dr. D. Barker, personal communication).  It is possible that 
repeating the analysis using the nucleotide sequences from each of the orthologues 
could assist the creation of a more meaningful tree. 
 
 
Figure 3.7:  Unrooted large phylogenetic tree.  A phylogenetic tree made from a MAFFT alignment of 
28 FNT orthologues from each of the four known FNT clusters and protozoan organisms.  Gaps found in 
the sequences were eliminated (see text) for submission to PhyML.  Numbers indicate the percentage 
support for each branch from a total of 250 replicates.  The branch lengths are arbritary as they are 
generated by the software. 
 
A second unrooted tree was created (Figure 3.8) using two organisms from each of the 
reported clusters, the Clostridium orthologue and the single P. falciparum sequence.  
In this tree the Plasmodium orthologue shows the closest evolutionary history with the 
formate transporters of E. coli and V. cholerae. 
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Figure 3.8: Smaller unrooted phylogenetic tree.  A phylogenetic tree made from a MAFFT alignment 
of two orthologues from each of the four reported FNT clusters (yeast transporters, bacterial formate 
transporters, bacterial nitrite transporters and archeae formate transporters), the Clostridium HSC, and the 
P. falciparum FNT orthologue.  Numbers indicate the support for each branch in percentages from a total 
of 250 replicates.  The branch lengths are arbritary as they are generated by the software. 
 
The bootstrap support numbers on each branch are fairly high from the smaller tree 
indicating that the data is significant.  Given that the bootstrap values are much higher 
on the second smaller tree than on the initial larger tree, indicating that the data and 
analysis strongly support most of the groupings.  Thus the data from the phylogenetic 
analyses points towards a role in the transport of formate for the P. falciparum 
transporter.  However, care must be taken in the assessment of the smaller tree as it 
contains a smaller number (eleven) of protein sequences.  Long branch attraction 
(LBA) is a phenomenon where sequences are grouped together in a cluster even 
though they have disparate sequences (Bergsten, 2005).  Due to the limited number of 
sequences in this analysis, it is possible that some of the sequences have been placed 
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together due to LBA.  In this example, the P. falciparum protein sequence may have 
been wrongly placed in the tree due to its potentially divergent sequence and the long 
branch length observed in Figure 3.8. 
 
3.3 Complementation in A. nidulans 
 
To facilitate expression in A. nidulans, the pfnita gene was redesigned to reduce the 
A+T richness from 70 % to 45 %.  The codon-optimised synthetic pfnita_opt gene was 
cloned into two Aspergillus expression vectors upstream of a V5 tag (Figure 3.9, A and 
B) by Dr. S.E. Unkles. 
 
 (A)           (B)          
     
Figure 3.9:  Cloning pfnita_opt for expression in A. nidulans.  Plasmid constructs showing the 
pfnita_opt gene downstream from a V5 tag, and the two different promoters (A) gpda a strong promoter 
and (B) nrta a nitrite/nitrate inducible promoter.  The restriction sites used to clone in the pfnita_opt gene, 
PstI and ClaI are shown as well as the ampicillin resistance (AmpR) gene which acted as a selectable 
marker during cloning.  Images are not to scale. 
 
As this was the first work carried out on this protein, coupled with the difficulty in 
expressing and purifying membrane proteins, the V5 tag was fused to the C-terminus 
of the protein to allow detection using a V5-antibody (Table 2.3).  The pfnita_opt 
optimised gene was cloned into the Aspergillus-V5 vectors using the restriction 
endonuclease site EcoRI.  The orientation of the insert was checked using two single 
restriction enzymes digests using the restriction enzymes PvuII and SfuI, inserts in the 
correct orientation were sequenced.  The Aspergillus-V5 vectors contain either a strong 
gpda promoter or a nitrite/nitrate inducible nrta promoter, and a V5 tag for detection.  
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Both constructs pgpda-pfnita_opt and pnrta-pfnita_opt (Figure 3.9, A and B) were 
transformed into a mutant strain of A. nidulans (deleted for the two nitrate transporter 
genes, annrta and annrtb, and the single nitrite transporter annita gene, as well as the 
anargb2 gene, a system which allowed for selection for arginine prototrophs) by Dr. 
S.E. Unkles.  Integration of the plasmid into the A. nidulans genome was confirmed by 
Southern blot analyses of DNA isolated from transformants. 
 
(A)      (B) 
                            
 
(C)      (D) 
       
 
Figure 3.10:  Expression of PfNitA_opt in A. nidulans.  (A) Aspergillus minimal medium with 2 mM 
nitrite as sole nitrogen source was point inoculated with a small number of fungal spores and the growth 
phenotype assessed after three days incubation at 37 oC. 1. pgpda-pfnita_opt 2. pgpda-pfnita_opt -intron-
Y212K 3. Triple mutant lacking annrta, annrtb and annita 4. WT A. nidulans.  (photograph courtesy of Dr 
J.R. Kinghorn)  (B) Western blot directed against the V5 tag on PfNitA_opt with PF11 a single copy (lane 
2) and PF12 a multicopy (lane 3), a control sample of another protein containing the V5 tag is shown in 
lane 1.  (C) A western blot using an anti-V5 antibody directed against the 3’ V5 tag.  Lane 1 contains 
membranes from PF104, lane 2 PF105, and lane 3 PF106.  All samples are ‘intron’ mutated and expressed 
with the nrta promoter.  Lane 4 contains membrane from PF124, lane 5 PF125, and lane 6 PF128, again 
all are ‘intron’ mutated however under the control of the gpda promoter.  (D) CBB stained gel of the same 
samples shown in the western blot in (C) to confirm protein is present in each of the samples. 
 
1
2
3
4
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From the first transformation experiment using pgpda-pfnita_opt, two transformed 
strains were chosen for further analysis, PF11 a single copy and PF12 a multi copy of 
the transformed plasmid containing pfnita_opt.  Fungal cells were inoculated onto 
minimal agar medium supplemented with nitrite as the sole source of nitrogen, to 
assess any change in growth phenotype.  The strains containing the codon-optimised 
synthetic pfnita_opt gene did not grow on nitrite as sole nitrogen source and therefore 
did not complement the mutant.  The growth responses presented in Figure 3.10, A 
shows that there is no growth of the transformed strain containing the Plasmodium 
based gene pgpda-pfnita_opt (lane 1) which is similar to the triple mutant defective 
control (lane 3).  A WT with respect to all three transport proteins is also present as a 
comparison where typical growth is observed (lane 4).  To determine if the pgpda-
pfnita_opt was expressed, western analyses were carried out using a HRP conjugated 
anti-V5 antibody (Figure 3.10, B and C). 
 
Membranes were prepared from A. nidulans transformants as the expressed PfNitA_opt 
protein required to be present in the plasma membrane to complement the mutant.  
After an exposure time of 30 mins the blot showed the PfNitA_opt protein had not 
been expressed in the membranes of PF11 and PF12, (Figure 3.10, B).  A strain known 
to express a fungal protein with a V5 fusion in the membrane was included as a 
positive control, A, lane 1) is approximately 45 kDa in size and was present as 
expected.  It was noted that the expected size of the PfNitA_opt protein is 36 kDa 
(ExPASy27). 
 
Although there could be several reasons for the lack of expression, two more plausible 
possibilities were chosen for further consideration.  The first was the presence a 
potential Aspergillus 5’ intron boundary that was formed during the cloning procedure 
at the codon-optimised gene stop codon and plasmid junction. (Dr. S.E. Unkles, 
personal communication).  The second possible problem was the presence of a highly 
conserved amino acid residue (a lysine) among PfNitA orthologues that was absent 
from the Plasmodium residue sequence.  The potential intron boundary was altered by 
PCR, using the oligonucleotide primers NitAoptF and NitAoptR producing pfnita_opt-
intron.  Secondly, using mutagenesis primers Y212KF and Y212KR (Appendix 2) a 
mutation was created by means of spliced overlap extension (Figure 2.2). 
                                                 
27 http://web.expasy.org/compute_pi/.  Accessed on 28 January 2012. 
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Between the TAG stop codon of the cloned pfnita_opt gene sequence and the EcoRI 
site used for cloning there is an additional SnaBI for cloning and/or mutagenesis.  After 
the initial problems with expression of PfNitA_opt in A. nidulans the sequence was re-
visited by Dr. S. E. Unkles.  This revealed another potential drawback.  The sequence 
read TAGTACGTAGAATTC, the underlined nucleotides could make a 5' intron 
boundary in Aspergillus, and the SnaBI site is in bold.  If the adjacent 'intron' were to 
be spliced out, the stop codon would be lost and the following sequence nonsensical 
until the next stop codon was reached. To circumvent this problem, the SnaBI 
restriction site was mutated.  The resulting insert was termed producing pfnita_opt-
intron.  This gene/plasmid is referred to as ‘intron’ mutated in Figure 3.10.  This 
section of the experimental work was carried out by Dr. S. E. Unkles. 
 
 (A)            (B) 
    
 
Figure 3.11:  Mutagenesis and cloning of pfnita_opt for expression in A. nidulans.  (A)  
Mutagenesis PCR products lane 1 contains the 3’ PCR (400 bp) product and lane 2 the 5’ PCR product (800 
bp).  Lane 3 contains the final 1200 bp product of the splice overlap mutagenesis PCR.  The final product 
was cloned into the pV5M and pV5GPD vectors. (B)  Plasmid construct showing the pfnita_opt gene 
downstream from a V5 tag, and the gpda promoter.  The site of the Y212K mutation has been indicated.  
The restriction sites used to clone in pfnita_opt are shown as well as the ampicillin resistance (AmpR) 
gene which acted as a selectable marker during cloning.  Diagram is not to scale. 
 
The P. falciparum amino acid, tyrosine was mutated using spice overlap extension 
mutagenesis (for description see Section 2.2.2 and Figure 2.2) to the less bulky and 
hydrophilic lysine.  The PCR products generated in this process are given in Figure 
3.11, A. This produced a second mutant pfnita_opt-intron-Y212K.  These two PCR 
products were cloned into the previously mentioned expression vectors creating three 
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new constructs: pgpda-pfnita_opt-intron, pnrta-pfnita_opt-intron and pgpda-
pfnita_opt-intron-Y212K (Figure 3.11, B).  The expression results from the new 
constructs were no more encouraging as none grew on nitrite as the sole nitrogen 
source.  In these respects, the results in Figure 3.10, A part 3 show that no growth of 
the doubly mutated pgpda-pfnita_opt-intron-Y212K transformants was obtained. 
 
Given the large number of arginine prototrophic strains generated from 
transformations with the three new constructs that lacked growth on nitrite, it was 
decided not to perform Southern blots (Dr. S.E. Unkles, personal communication).  The 
transformants from pnrta-pfnita_opt-intron-Y212K (designated PFT 100 – 108) and 
pgpda-pfnita_opt-intron (designated PFT 120 – 128) were analysed by western blot 
and a selection are shown in Figure 3.10, C.  Each of these shows no expression of the 
protein, except certain spurious bands (lane 3) around 25 kDa and 45 kDa, most likely 
revealed by the lengthy exposure time.  The data in D shows a CBB stained gel to 
confirm that there is protein in the membrane preparations.  It was decided that as the 
Y212K/intron mutants did not grow on nitrite, it was not worthwhile carrying out 
Southern or western analyses. The continuation of this general approach, i.e. the 
characterisation of the P. falciparum transporter in A. nidulans, would most likely not 
be of any benefit and was consequently abandoned. 
 
3.4 Complementation in E. coli 
 
As E. coli contains at least two individual transporters for formate or nitrite, it was 
decided this bacterium should be used as a model for functional complementation of 
both the formate and nitrite transporter genes.  A second codon-optimised gene was 
purchased (Invitrogen) and is designated pfnita_optEc.  Both of the optimised genes, 
pfnita_opt and pfnita_optEc, were used in the functional complementation assays, as 
fungal genes without introns are usually expressed in E. coli.  The nitrite assay was 
performed in two E. coli strains, (i) the ecnirc gene, and the nitrate/nitrite antiporters 
(i.e. ecnaru and ecnark) have been knocked out and (ii) contains the ecnirc gene but 
lacks the nitrate/nitrite antiporters.  The formate assay was performed using three 
methods with each method requiring strains in which a mutation had been generated 
in the ecfoca gene resulting in the mutants being unable to transport hypophosphite 
and by extension formate (Suppmann and Sawers, 1994), and a WT foca strain. 
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The pfnita_opt gene was amplified from a plasmid using the primers NitAopt TTQ F 
and NitAopt V5 TTQ R (Appendix 2) which amplified the pfnita gene with V5 tag, with 
the addition of the restriction sites for EcoRI and HindIII. The pfnita_optEc gene was 
excised from its plasmid using EcoRI and PstI cleavage.  One or other of the two 
products were cloned into the TTQ18 plasmid (Figure 3.12).  The pfnita_opt gene was 
not cloned in frame with the hexahistidine tag as it contained a C-terminal V5 tag, 
while pfnita_optEc was cloned with a C-terminal hexahistidine tag.  Proteins were 
expressed from the TTQ18 plasmid under tac promoter gene regulation, resulting in 
plasmid constructs pTTQ18_pfnita_opt and pTTQ18_pfnita_optEc. 
 
(A)      (B)          (C) 
      
 
Figure 3.12:  Cloning vectors for expression of the synthetic codon-optimised pfnita genes in 
E. coli.  (A) Plasmid construct showing pfnita_opt upstream from a V5 tag. (B) Plasmid construct showing 
pfnita_optEc upstream from a His-tag.  The restriction sites used to clone in pfnita are shown as well as 
the ampicillin resistance (AmpR) gene which acted as a selectable marker during cloning.  Diagrams are 
not to scale.  (C) Restriction digest of pTTQ18_pfnita_opt (lane 1) with HindIII and EcoRI.  Digest of 
pTTQ18_pfnita_optEc (lane 2) with PstI and EcoRI. 
 
To act as a second positive control, the deleted/mutated genes, ecnirc and ecfoca were 
also expressed from the TTQ18 plasmid.  The ecfoca gene was amplified from E. coli 
genomic DNA using the primers FocA F and FocA R, and ecnirc amplified from a 
plasmid using the primers NirC F and NirC R (Appendix 2).  These two products were 
inserted into the TTQ18 vectors upstream from the hexahistidine tag, to produce re-
expressor constructs pTTQ18ecfoca and pTTQ18ecnirc. 
 
 
Substrate Specificity of Plasmodium falciparum NitA Chapter 3 
 
[104] 
 
3.4.1 Nitrite as a possible substrate 
Six strains were used in the nitrite complementation assays, these are given in Table 
3.3. 
E. coli Strain Strain Designation 
Wild Type 4018 
Knock out 4520-/- 
ecnirc complementing 4520-/+ 
ecfoca complementing 4520
-/ecfoca 
pfnita_opt complementing (A. nidulans) 4520-/pfnita_opt 
pfnita_optEc complementing (E. coli) 4520-/pfnita_optEc 
Table 3.3: E. coli strains used for the nitrite assays.  Each of the strains used in the nitrite assay are 
given in this table, the ‘Strain Designation’ column gives the names of each strain as referred to in the 
text. 
 
3.4.1.1 Expression of complementing proteins in cells grown under 
anaerobic conditions 
Cells lacking EcNirC, 4520-/- were transformed with plasmids pTTQ18ecnirc, 
pTTQ18ecfoca, pTTQ18pfnita_optEc, and pTTQ18pfnita_opt (Figure 3.12) to give 
strains 4520-/+, 4520-/ecfoca, 4520-/pfnita_opt and 4520-/pfnita_optEc, respectively (Table 3.3).  
Initially 4520-/pfnita_opt cells were grown in JC minimal salts media under anaerobic 
conditions to investigate the expression levels of the PfNitA_opt protein.  Trials were 
established and bacterial cells containing the pTTQ18pfnita_opt plasmid were grown 
initially for 4 h at 37 oC, induced with one of two different IPTG concentrations and 
were grown for 16 or 20 h after induction.  All experiments were carried out in JC 
media at 37 oC again under anaerobic conditions.  E. coli crude membrane preparations 
were analysed for PfNitA_opt expression using NuPAGE® protein electrophoresis and 
western blotting against the V5 protein fused to PfNitA_opt (Figure 3.12, A).  Two 
bacterial colonies were examined to investigate possible variation in expression 
between colonies.  A total of 15 µg protein from a crude membrane preparation of 
induced bacterial cultures was applied to each gel lane.  It was observed that a 
combination of (i) induction with 1 mM IPTG after an initial growth period of 4 h, and 
(ii) cells grown for a further 22 h showed best expression of PfNitA_opt (Figure 3.13, A 
lane 4). 
 
The experimental blot for the 16 h time point is not presented as there was little to no 
protein expression in each of the samples.  It is noteworthy that there was observable 
variation in expression levels between the colonies (data not shown).  In addition the 
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V5 antibody has detected a much lower band on the gel, most likely this is due to 
proteolysis of the expressed protein. 
 
(A)     (B) 
     
 
Figure 3.13: Expression of complementing proteins in E. coli in JC minimal salts medium.  (A) 
A western blot to show expression of PfNitA_opt, after detection with an anti-V5 antibody, directed against 
the C-terminal tag on the expressed protein.  Lane 1 contains a negative control with no IPTG.  IPTG 
concentrations used were 0.1 mM (lane 2), 0.5 mM (lane 3), and, 1 mM (lane 4).  The protein is running 
slightly lower than its expected molecular weight.  Certain lower molecular weight products can be 
observed in each of the induced samples, probably degradation products.  (B) Western blot of 
PfNitA_optEc (lane 1), EcFocA (lane 2) and EcNirC (lane 3) membrane proteins, using an anti-His antibody 
directed against the C-terminal tag.  The blot confirms expression of all constructs. 
 
The expression trials were repeated for the re-expresser strains containing the ecnirc 
and ecfoca sequences in cells grown for 22 h with 0.1 mM IPTG concentration of 
inducer.  As before, all trials were carried out in JC media at 37 oC.  The ecnirc, ecfoca 
and pfnita_optEc constructs did not contain a V5 tag, and therefore was replaced using 
an anti-His antibody against the C-terminal His-tag.  The pfnita_optEc gene was cloned 
into the TTQ18 expression vector upstream of a His-tag.  Expression trials for this 
protein were carried out using the 22 h regime with 0.1 mM, 0.5 mM and 1 mM IPTG 
inducer concentration.  All trials were carried out in JC media at 37 oC.  The data 
presented in lane 1 of Figure 3.13, B) shows the expression of pfnita_optEc using 1 
mM IPTG, the lower concentrations did not induce protein expression. 
 
The ecnirc and ecfoca constructs were expressed using different conditions to the ones 
for the pfnita_opt gene.  These changes were 0.1 mM IPTG and 22 h growth after 
induction at 37 oC.  The results presented in Figure 3.13, B includes a western blot for 
FocA (lane 2) and NirC (lane 3) using optimised conditions.  It was found that EcNirC 
and EcFocA were expressed at relatively high levels. 
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3.4.1.2 Nitrite transport assays 
A nitrite transport assay was used to determine if the pfnita optimised genes would 
complement an E. coli strain lacking the endogenous nitrite transporter, ecnirc.  
Initially two control strains were selected: (i) JCB 4018 containing the WT ecnirc gene 
and lacking the nitrite/nitrate transporters ecnaru and ecnark as the positive control, 
and (ii) JCB 4520, mutant in all three genes to act as the negative control.  MOPS 
buffer at pH 8.5 was used as the assay buffer, it was essential to have a high pH.  This 
ensures that no nitrite could diffuse into the cells to give false positive readings.  It has 
been shown that in A. nidulans, nitrite diffusion does not occur readily until pHs lower 
than pH 6.5 (Unkles et al, 2011). 
 
To detect the levels of nitrite present in the medium, the Griess Assay was used.  NED 
and sulphanilamide were combined with an aliquot of each of the samples in triplicate 
and the results read on a spectrophotometer.  The production of a pink/purple azo dye 
(from colourless) confirmed the presence of nitrite in the media. This meant that it was 
known, early on, if the controls were working as expected and we had proof of correct 
experimental design.  Bacterial cells were resuspended in MOPS buffer and 100 µM 
sodium nitrite added to the assay medium to induce and therefore initiate the nitrite 
transport.  The nitrite uptake assay was carried out over 4 h, and samples were taken 
at 4 time points to check for the disappearance of nitrite from the medium (and 
therefore uptake into cells).  The assay was repeated 4 times, and samples from the 
two strains were taken in duplicate.  An average value for each sample at each time 
point was taken and used to construct a graph (Figure 3.14).  There was some 
variation observed in the levels of uptake between colonies and between experiments, 
but, the trend was similar and is reflected in the chart (Figure 3.14, A).  For a second 
negative control, assay buffer with 100 µM sodium nitrite and no cells was included 
(designated No Cells).  The chart in Figure 3.14, A shows the depletion of nitrite from 
the assay medium over the 240 mins of the assay.  Strain 4018 showed a reduction in 
the concentration of nitrite from the medium to approximately 10 µM which is 
indicative of nitrite uptake into the WT cells expressing EcNirC.  The negative controls 
4520-/- and No Cells did not show the same reduction in assay medium nitrite 
concentration.  After approximately 120 mins, strain 4520-/- shows a reduction in nitrite 
concentration to approximately 60 µM thus exhibiting intermediate levels of nitrite 
uptake.  The pH of the assay medium was sampled after 240 mins to determine if the 
Substrate Specificity of Plasmodium falciparum NitA Chapter 3 
 
[107] 
 
pH had dropped which might explain the apparent uptake of nitrite in 4520-/-.  The pH 
was still above pH 8.0 after 240 mins confirming nitrite entry to the cell through means 
other than passive diffusion.  It was decided that in future assays that the reaction 
should be halted after 120 mins.  It is of interest, that even though 100 µM of nitrite 
(final concentration) was added to the assay medium none of the samples show this 
concentration at T0. 
 
The results presented in Figure 3.14, B shows a box and whisker plot for the 120 mins 
time points.  The box represents the high quartile (top line), median (middle line) and 
low quartile (bottom line).  The mean is represented by a +, and the upper and lower 
whiskers represent the range.  The data revealed in B shows the levels of nitrite 
remaining in the medium after 120 mins.  At this time the levels of nitrite transport by 
the two negative controls, 4520-/- and No Cells, are similar with a mean value of 
approximately 70 µM.  The range is greater for the 4520-/- sample than the No Cells 
control which is not surprising as variation is more likely to be observed in samples 
with cells than without cells. 
 
The nitrite assay results showed clear differences between the positive and negative 
controls and therefore the two test strains, 4520-/pfnita_opt and 4520-/pfnita_optEc, were next 
investigated.  As a further positive control, the endogenous ecnirc gene was expressed 
on a plasmid (see above) to ensure that complementation could take place (sample 
4520-/+).  Two additional negative controls were used, (i) heat killed JCB 4018 and 
therefore non-viable cells (the WT positive control strain was chosen to ensure the 
heat treatment had fully killed the cells) (ii) No Cells.  An ecfoca complementing strain 
was also included in the experiments. 
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Figure 3.14: Graph of nitrite depletion from the medium in control samples.  (A) The control 
strains were investigated for the uptake of nitrite from the medium by sampling the concentration of 
nitrite that remained in the medium at various time points over 240 mins.  Depletion of nitrite from the 
medium equates to transport of nitrite into the cell.  Error bars indicate the standard error of the mean, 
4018 and 4520-/- are from 8 replictates and No Cells is from 3.  (B)  The results at 120 mins were made 
into a box and whisker plot to demonstrate the difference in the uptake patterns with regard to the 
positive and negative controls.  The box represents the high quartile (top line), median (middle line) and 
low quartile (bottom line).  The mean is represented by + and is from 8 (4018 and 4520-/-) or 4 (No Cells) 
replicates, the upper and lower whiskers represent the range.  Raw data can be found in Appendix 7.1.1. 
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The information presented in Table 3.4 highlights the results of nitrite concentration as 
evaluated from the Griess assay, with the average shown and the range in brackets for 
each time point as well as for each of the strains.  Charts were created for the sample 
results in which the depletion of nitrite from the assay medium was recorded over the 
120 mins assay incubation time.  The charts are displayed in Figure 3.15.  As before, 
the results shown in one chart (A) shows the depletion of nitrite from the medium and 
a second box and whisker plot data (B) for 120 min time point displays the variation in 
nitrite transport levels between the strains. 
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µM nitrite 
E. coli strain 0 mins 30 mins 60 mins 90 mins 120 mins 
4018 89.90 (75.24-100.95) 80.57 (59.05-87.62) 56.19 (14.29-76.19) 34.8572 (8.57-59.05) 22.03 (9.52-50.48) 
4520-/- 94.48 (77.14-116.19) 93.90 (81.91-106.67) 91.81 (81.91-101.91) 88.38 (80.95-100.11) 83.43 (76.19-95.24) 
4520-/+ 86.48 (72.38-109.52) 76.76 (69.52-83.81) 64.76 (54.29-75.24) 54.86 (40.95-64.76) 48.00 (31.43-60.95) 
4520-/ecfoca 85.72 (72.38-92.38) 85.91 (70.48-100.00) 75.43 (62.86-85.71) 72.29 (52.38-90.95) 68.76 (44.73-86.67) 
4520-/pfnita_opt 93.33 (78.10-107.62) 93.14 (86.67-104.76) 93.33 (86.67-104.76) 86.48 (81.91-90.47) 85.33 (77.14-102.86) 
4520-/ pfnita_optEc        * 79.55 (75.20-83.16) 81.87 (77.89-86.84) 80.39 (78.71-84.21) 80.75 (77.08-85.96) 78.46 (69.44-87.90) 
Heat Killed 4018 88.38 (80.00-100.95) 94.10 (86.67-113.33) 94.48 (80.95-107.62) 93.52 (83.81-110.48) 94.29 (82.86-112.38) 
No Cells 85.90 (69.52-105.71) 89.52 (80.95-105.71) 89.33(81.91-103.81) 86.48 (76.19-100.95) 88.38(81.91-102.86) 
 
Table 3.4: The rate of nitrite depletion from the medium.  This table contains the average concentration of nitrite that remains in the media at each time point, 
followed by the range in brackets.  The average is from 5 replicates.  * The data for strain 4520-/ pfnita_optEc  was collected by Dr. S. E. Unkles.  Raw data can be found in 
Appendix 7.1.1. 
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Figure 3.15: Graph of nitrite depletion from the medium.  (A) All strains were examined for the 
disappearance of nitrite from the medium by sampling the concentration of nitrite that remained in the 
medium over 120 mins.  Depletion of nitrite from the medium equates to transport of nitrite into the cell.  
Values are the mean of 5 replicates, error bars show the standard error of the mean (SEM).  (B)  The 
results at 120 mins were presented as a box and whisker plot to demonstrate the difference in the uptake 
between the positive and negative controls.  The box represents the high quartile (top line), median 
(middle line) and low quartile (bottom line).  The mean is represented by + and is from 5 replicates, the 
upper and lower whiskers represent the range.  Raw data can be found in Appendix 7.1.1. 
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It can be seen from the data in Figure 3.15, strain 4520-/+ (48.00 µM at T120) does not 
restore the average uptake value of nitrite to that of WT value where 22.03 µM 
remained in the medium after 120 mins.  The pfnita_opt test strains 4520-/pfnita_opt and 
4520-/pfnita_optEc show very little alteration in the levels of nitrite in the media illustrating 
that little to no nitrite uptake took place over the time period.  The average nitrite 
concentration remaining in the medium for strain 4520-/pfnita_opt was found to be 85.33 
µM (from 93.33 µM at T0) and for strain 4520
-/pfnita_optEc is 78.46 µM (from 79.55 µM at 
T0).  These results are consistent with the data obtained for the three negative 
controls, 4520-/- (at T120 83.43 µM), heat killed strain 4018 (at T120 94.29 µM) and 
sample No Cells (at T120 88.38 µM).  The 4520
-/ecfoca strain shows a slight increase in 
nitrite transport compared to the negative controls (at T120 68.67 µM compared to 
83.43 µM for strain 4520-/-), but does not reach the levels of nitrite transport attained 
by the ecnirc complementing strain (4520-/+). 
 
3.4.1.3 Statistical analysis 
A one-way ANOVA (analysis of variance) was carried out to examine if there is any 
significant differences between the levels of nitrite in the media from each of the 
samples at the 120 min time point.  Bonferroni post-hoc tests were used to compare 
each of the means from the sample results. 
 
The positive control strain 4018 shows significant differences (p < 0.001) between all 
samples except strain 4520-/+ where the KO has been complemented with a plasmid 
containing ecnirc where p = 0.059, and thus loses significance (Figure 3.15 and Table 
3.5).  Strain 4520-/+ the re-expresser positive control, shows significant differences 
when compared with the negative control strains, and no significant differences to 
4018 and the EcFocA complementing strain 4520-/ecfoca.  The negative control strains, 
Heat Killed 4018 and No Cells controls show significant differences with strains 4018 
and 4520-/+, p < 0.001 and p = 0.002, respectively.  These data confirm that the 
positive and negative controls are significantly different from each other. 
 
The two test strains 4520-/pfnita_opt and 4520-/pfnita_optEc show a p value of 1.000 when 
compared to each other, the three negative controls and 4520-/ecfoca.  These values are 
p < 0.001 when compared to 4018 the WT positive control, p = 0.001 (4520-/pfnita_opt) 
and p = 0.012 (4520-/pfnita_optEc) when compared to the re-expresser positive control 
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4520-/+.  Overall, these data imply that the pfnita synthetic codon-optimised genes are 
unable to complement the loss of function nitrite transport defective mutant of E. coli 
and therefore is incapable of transporting nitrite at least in this bacterium.  A table 
containing the relevant statistical data is provided below (Table 3.5). 
 
Strain 
 
Compared to Significance 
4018 4520-/- 0.000* 
4520-/+ 0.059 
4520-/ecfoca 0.000* 
4520-/pfnita_opt 0.000* 
4520-/ pfnita_optEc 0.000* 
Heat Killed 4018 0.000* 
No Cells 0.000* 
4520-/- 4018 0.000* 
4520-/+ 0.002* 
4520-/ecfoca 1.000 
4520-/pfnita_opt 1.000 
4520-/ pfnita_optEc 1.000 
Heat Killed 4018 1.000 
No Cells 1.000 
4520-/+ 4018 0.059 
4520-/- 0.002* 
4520-/ecfoca 0.326 
4520-/pfnita_opt 0.001* 
4520-/ pfnita_optEc 0.012* 
Heat Killed 4018 0.000* 
No Cells 0.000* 
4520-
/ecfoca 
4018 0.000* 
4520-/- 1.000 
4520-/+ 0.326 
4520-/pfnita_opt 1.000 
4520-/ pfnita_optEc 1.000 
Heat Killed 4018 0.068 
No Cells 0.462 
 
Strain Compared to Significance 
4520-
/pfnita_opt 
4018 0.000* 
4520-/- 1.000 
4520-/+ 0.001* 
4520-/ecfoca 1.000 
4520-/ pfnita_optEc 1.000 
Heat Killed 4018 1.000 
No Cells 1.000 
4520-/ 
pfnita_optEc 
4018 0.000* 
4520-/- 1.000 
4520-/+ 0.012* 
4520-/ecfoca 1.000 
4520-/pfnita_opt 1.000 
Heat Killed 4018 1.000 
No Cells 1.000 
Heat 
Killed 
4018 
4018 0.000* 
4520-/- 1.000 
4520-/+ 0.000* 
4520-/ecfoca 0.068 
4520-/pfnita_opt 1.000 
4520-/ pfnita_optEc 1.000 
No Cells 1.000 
No Cells 4018 0.000* 
4520-/- 1.000 
4520-/+ 0.000* 
4520-/ecfoca 0.462 
4520-/pfnita_opt 1.000 
4520-/ pfnita_optEc 1.000 
Heat Killed 4018 1.000 
Table 3.5:  Statistical analyses for nitrite uptake by E. coli cells.  This table displays the 
significance as determined by a one-way ANOVA and Bonferroni comparisons.  Where the significance is 
0.000, p < 0.001.    An * designates significance.  Raw data can be found in Appendix 7.1.2. 
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3.4.2 Formate as a possible substrate 
Three strategies were adopted to investigate the prospect of formate being a substrate 
for the PfNitA permease.  E. coli cells containing a loss-of-function mutation in the 
ecfoca gene were transformed with plasmids pTTQ18ecnirc, pTTQ18ecfoca, 
pTTQ18pfnita_optEc, pTTQ18pfnita_opt and pTTQ18pccir2 (refer to Chapter 6).  A list 
of strains used is provided in Table 3.6. 
 
E. coli Strain Strain Designation 
Wild Type MC4100 
Mutant 1 REK701-/-  
ecfoca complementing REK701 -/+ 
ecnirc complementing REK701
-/ecnirc 
pfnita_opt complementing REK701-/pfnita_opt 
pfnita_optEc complementing REK701-/pfnita_optEc 
Mutant 2 RM 201-/- 
ecfoca complementing RM 201-/+ 
ecnirc complementing RM 201
-/ecnirc 
pfnita_opt complementing RM 201-/pfnita_opt 
pfnita_optEc complementing RM 201-/pfnita_optEc 
pccir2 plasmid RM 201-/pccir2 
Table 3.6:  E. coli strains used for formate assays.  Each strain in which the formate assays were 
performed are included in this table, the ‘Strain Designation’ column gives the names of each strain as 
referred to in the text. 
 
3.4.2.1 Hypophosphite inhibition assay 
Initially a hypophosphite inhibition assay, as demonstrated by Suppmann and Sawers 
(1994) was used to assay formate transport capability.  Hypophosphite (HP) has been 
reported as a toxic analogue of formate, and thus cells capable of transporting formate 
and ergo HP, would be killed.  The structures of formate and hypophosphite are 
provided in Figure 3.16 for reference.  In the 1994 article (Suppmann and Sawers), the 
OD420 of the cells were measured and the WT strain MC4100 showed a 53 % reduction 
in growth compared to the FocA mutant REK701-/- in the presence of HP 
concentrations of 100 mM.  This approach was repeated using the WT and null mutant 
strains.  However, as cell death was being investigated additionally an optical density 
of OD600 was measured.  The test strains, MC4100, REK701
-/-, REK701-/+ and REK701-
/pfnita_opt were initially analysed for their ability to grow in WM minimal salts media 
(Appendix 1) under aerobic conditions.  It was found that after an overnight growth 
period (without IPTG induction) cells containing plasmids, REK701-/+ and REK701-
/pfnita_opt did not grow to sufficient densities to permit inoculation the test liquid culture 
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medium.  The removal of ampicillin from the growth media allowed the strains to 
increase in cell density but unfortunately the cells had lost their plasmid.  This infers 
that the complementing plasmids were unable to replicate in WM media.  A second 
minimal medium, M9 minimal salts, was investigated for growth of plasmid containing 
strains.  As before, the levels of growth were poor for all strains when glycerol or 
glucose was the sole carbon source.  In contrast a third medium, namely TGYEP 
allowed sufficient growth and consequently the bacteria were able to be propagated 
anaerobically as required for the assay conditions. 
 
The two control strains MC4100 and REK701-/- were studied for inhibition of growth by 
hypophosphite using various media.  WM minimal medium experiments resulted in 
growth inhibition values of 41 % for strain REK701-/- and 87.5 % for MC4100.  The 
results were obtained from two assays only, but show the WT growth is severely 
reduced by the addition of hypophosphite compared to the null mutant.  Using M9 
medium supplemented with glucose the growth inhibition values are as follows:  30.5 
% for REK701-/-, 68.0 % for MC4100, 37 % for REK701-/+ and, 35.5 % for REK701-
/pfnita_opt.  Overall, the growth inhibition responses suggest that the two complementing 
strains are similar to the negative control and do not appear to transport HP and ergo 
formate.  The inhibitory effect of hypophosphite could not be repeated using TGYEP in 
our laboratory as inhibition values of only 84 to 93 % compared to the null mutant 
strain (if growth of null mutant with hypophosphite is 100 %) were observed. 
 
A second null mutant strain RM201 was obtained, and the experiment repeated using 
TGYEP media.  Using the WT strain, the reductions in growth observed were between 
77 % and 85 % compared to the RM201 null mutant.  Given the very low growth 
inhibition between the WT and two FocA null mutants, REK701-/- and RM201-/- it was 
decided not to pursue this assay. 
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  (A)        (B) 
    
Figure 3.16:  Chemical structure comparison.  (A) The chemical structure of formate and (B) 
hypophosphite demonstrating similarities. 
 
3.4.2.2 Radioactive tracer assay 
A more direct way of characterising the uptake of formate, using tracer C14 formic acid, 
was used.  From this it was believed that data on the transporters kinetics could also 
be acquired. 
 
The two control strains MC4100 and REK701-/- were tested for differences in the 
uptake of C14 formic acid.  Initially MOPS buffer (containing 10 mM glucose) was used 
at pH 8.5 in an attempt to prevent possible diffusion of formic acid across the cell 
membranes.  Bacterial cells representing each strain were grown anaerobically in 
TGYEP liquid media for 22 h at 37 oC in static culture.  Cells were pelleted and 
resuspended in a sodium formate/C14 formic acid mixture, and incubated in a 37 oC 
water bath for the duration of the assay.  A 50 mM sodium formate concentration was 
chosen as standard.  At different time points between 1 and 40 mins, a 1 ml sample 
was taken.  Samples were rapidly filtered and washed three times in 50 mM sodium 
formate.  The filter membranes were tested for radioactivity using a scintillation 
counter.  An aliquot of the sodium formate/C14 formic acid mixture was also taken at 
the end of each experiment and used as a control.  Five microlitres of the control 
sample gave scintillation readings between 9014.50 and 11972.80 units whilst none of 
the control samples gave readings as high as this (Table 3.7) although slight 
differences were observed between the MC4100 and REK701-/- strains with the WT 
having slightly higher values, indicating higher levels uptake into these bacterial cells.   
As noted previously, the diffusion of nitrite in the fungus A. nidulans only occurs at pHs 
below 6.5, the assay was repeated in MES buffer at pH 6.5 (Table 3.8).  A minor 
difference is observed in the uptake of formate between the two cell lines, unlike the 
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experiment carried out using MOPS buffer, the uptake is greater into the ecfoca 
mutant.  Each experiment was carried out in duplicate.  The values for uptake of C14 
formic acid into the control strains imply the uptake was very low and a different 
approach was undertaken. 
 
Mins 1 5 10 20 40 
MC4100 66.8 49.5 88.0 153.9 265.1 
REK701 35.1 47.8 102.0 103.1 169.8 
Table 3.7:  Formate uptake over time using 
MOPS buffer pH 8.5. 
 
Mins 1 5 10 20 40 
MC4100 33.8 40.0 122.9 84.6 203.3 
REK701 37.1 55.3 97.1 124.3 176.8 
Table 3.8:  Formate uptake over time using 
MES buffer pH 6.5. 
The experiment was repeated using a single time point of 20 mins, and the 
concentration of sodium formate was varied between 50 and 400 mM to circumvent 
problems due to formate concentration being insufficient to produce any measurable 
uptake.  As before, the two buffers MOPS pH 8.5 and MES pH 6.5 were tested.  Only 
one experiment was carried out for each buffer as the levels of uptake were again 
poor.  The data is presented in tables 3.9 and 3.10. 
[Formate] 50 100 200 400 
MC4100 18.8 23.3 20.3 27.0 
REK701 25.8 24.3 19.8 26.0 
Table 3.9:  Formate uptake using MOPS 
buffer pH 8.5. 
 
[Formate] 50 100 200 400 
MC4100 24.0 25.0 27.0 64.8 
REK701 45.5 42.3 113.3 75.0 
Table 3.10:  Formate uptake using MES 
buffer pH 6.5. 
 
3.4.2.3 β-galactosidase assay 
An indirect assay using β-galactosidase fused to the fdhF promoter was employed by 
Falke et al (2009) to examine the uptake of formate into bacterial cells.  The fdhF 
promoter is induced by formate.  The bacterial strain RM201-/- contains a fusion and is 
a ecfoca null mutant.  Plasmid constructs of interest were transformed into the null 
mutant strain, RM201-/-, to generate strains RM201-/+, RM201-/ecnirc, RM201-/pfnita_opt and 
RM201-/pfnita_optEC.  Strain RM201-/- was used as a negative control.  As strain RM201-/- 
has been shown to have residual β-galactosidase activity (Falke et al, 2009) when 
grown with and without additional formate, a second protein expressing negative 
control was created.  Since residual β-galactosidase activity was found in cells grown 
without formate it was deemed unnecessary to include a control of cells grown without 
formate.  Heat Killed cells were considered, but as these should lack β-galactosidase 
activity, they were not included in this series of experiments as the negative control 
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strain does have residual β-galactosidase activity.  The second negative control is the 
loss-of-function mutant strain expressing the Cir2 protein from the pTTQ18 plasmid 
(Chapter 6), RM201-/PcCir2.  Expression of the PcCir2 protein should not facilitate the 
uptake of formate from the media.  There was no positive control of a strain containing 
both the β-galactosidase fusion and a chromosomal foca gene available. 
 
3.4.2.3.1 Study of the control strains 
Initial trials were set up using the RM201-/- strain as the negative control and RM201-/+ 
as the positive control re-expressing the EcFocA protein.  The objective was to 
determine if expression of formate carriers in the RM201-/- cell line could restore 
formate uptake into the cells.  These tests were carried out using IPTG concentrations 
between 0.1 and 2 mM with 1 – 4, 20 and 24 h growth time after induction.  The 2, 3 
and 4 h assays were repeated in triplicate. 
 
From the results presented in Figure 3.17 it can be observed that for cells grown for 20 
and 24 h, the levels of β-galactosidase activity had substantially dropped compared to 
the 1 – 4 h samples.  Moreover the activities at 20 and 24 h were not greatly different 
to the null mutant.  β-galactosidase activity at 1 h after induction was again not 
particularly different between the induced and mutant strains, and the activity was 
quite high.  Therefore only times of 2, 3 and 4 h were investigated in future assays.  
The concentration of IPTG which gave the best β-galactosidase activity was found to 
be 0.1 mM.  The uninduced sample yielded a β-galactosidase activity somewhat higher 
than the RM201-/- strain indicating the expression of ecfoca from the TTQ18 plasmid 
may be leaky allowing expression of the formate permease. 
 
Statistical analyses using one-way ANOVA with Bonferroni post-hoc comparisons show 
no significant differences between any of the treatments or between the time points.   
The lowest p value was p = 0.696 for the 4 h time point for strain RM201 and 0.1 mM 
IPTG. 
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Figure 3.17: β-galactosidase activity of controls. (A)  Bar chart showing the β-galactosidase activity 
in Miller Units on the y-axis against incubation time (h) on the x-axis.  The expression of FocA was induced 
using different IPTG concentrations and the cells incubated for varying times to determine the optimal 
conditions for this study.  Mean values are plotted where possible, the error bars indicate the standard 
error of the mean.  The 1 and 24 h experiments were carried out once only, the 20 h experiment in 
duplicate and the 2, 3, and 4 h experiment in triplicate.  (B)  This graph shows the fold difference in the 
average ß-galactosidase activity of the induced samples when compared to the RM201-/- control (= 0) over 
each of the time points.  β-galactosidase activity is an indicator of formate import into the bacterial cell 
cytoplasm.  Raw data can be found in Appendix 7.2.1. 
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Therefore 0.1 mM IPTG inducer concentration was chosen for further experiments as it 
gave the most striking differences compared to RM201-/- and the no IPTG control when 
presented in the chart in Figure 3.17, A.  The lack of significance is most likely due to 
the large standard deviations observed for each of the samples (Figure 3.17).  The 
results exhibited in Figure 3.17, B shows the fold difference of each of the samples 
compared to the RM201-/- control strain.  The RM201-/- control strain therefore equalled 
0.  From this chart, the marked difference of the induced samples is clearly observed. 
 
3.4.2.3.2 Expression of complementing proteins in cells grown under 
anaerobic conditions 
Null mutant ecfoca cells, RM201-/- were transformed with plasmid constructs 
pTTQ18ecnirc, pTTQ18ecfoca, pTTQ18pfnita_opt, pTTQ18pfnita_optEc (Figure 3.12) 
pTTQ18pccir2 to give strains RM201-/+, RM201-/ecnirc, RM201-/pfnita_opt, RM201-/pfnita_optEc, 
and RM201-/pccir2 respectively (Table 3.6). 
 
Initially strain RM201-/pfnita_optEc cells were grown in TGYEP liquid medium under 
anaerobic conditions to test the expression levels of the PfNitA_optEc protein.  Trials 
were established and bacterial cells containing construct pTTQ18pfnita_optEc were 
grown initially for 4 hours at 37 oC, induced with one of three different IPTG 
concentrations and were grown for a further 22 h after induction with IPTG.  All trials 
were carried out in TGYEP liquid medium at 37 oC in a static incubator.  E. coli crude 
membrane preparations were analysed for PfNitA_optEc expression using NuPAGE® 
protein electrophoresis and western blotted against the His-tag fused to the C-terminus 
(Figure 3.18).  A total of 15 µg protein from a crude membrane preparation of induced 
bacterial cultures was applied to each gel.  It was found that induction with 1 mM IPTG 
after an initial growth period of 4 h with cells grown for a further 22 h showed best 
expression of PfNitA_optEc (Figure 3.18, A).  The band at the expected molecular 
weight from 0.5 mM IPTG induction (lane 3) is darker than the others, however the gel 
contains many other products in the lane implying more protein had been applied to 
the lane.  This observation made the results difficult to interpret.  Experiments were 
repeated using 0.1 mM IPTG inducer concentration for strains RM201-/+ and RM201-
/ecnirc as this concentration had given best results for the functional complementation of 
the null mutant harbouring the ecfoca plasmid (Figure 3.18).  The expression trials for 
strain RM201-/pfnita_opt were probed with an anti-V5 antibody against the C-terminal V5 
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tag contained on the expressed protein.  These western blots failed to produce bands 
on a gel, even when control strains were included.  Therefore strain RM201-/pfnita_opt 
was not used for the formate assays. 
 
    (A)                                 (B) 
         
 
Figure 3.18: Expression of complementing proteins in E. coli in TGYEP medium.  (A) Western 
blot to show expression of PfNitA_optEc, after detection with an anti-His antibody, directed against the C-
terminal tag on the expressed protein.  Lane 1 contains a negative control with no IPTG.  IPTG 
concentrations used were 0.1 mM (lane 2), 0.5 mM (lane 3), and, 1 mM (lane 4).  (B) Western blot of 
EcFocA (lane 1) and EcNirC (lane 2) membrane proteins, using an anti-His antibody directed against the C-
terminal tag.  The blots confirm expression of all constructs under the assay conditions. 
 
3.4.2.3.3 Formate uptake assay 
A formate uptake assay was used to determine whether the synthetic pfnita genes, 
optimised in accord with E. coli or A. nidulans codon usage, would permit uptake in an 
E. coli strain mutated in ecfoca and thus lacking its own formate transport ability.  
There is no positive control strain for this assay, therefore the null mutant strain, 
RM201-/- transformed with a plasmid containing the foca gene acted as the only 
positive control.  The negative control was the untransformed bacterial strain.  As a 
further negative control, strain RM201-/- was transformed with a plasmid containing 
pccir2 which is not a transporter (See Chapter 5).  The assay was carried out in cells 
grown in liquid TGYEP media with a pH value of 6.7.  This pH value switches the 
activity of the transporter from the efflux of formate to importing formate (Sawers, 
2005).  The fdhF promoter possesses a downstream lacZ fusion (fdhF::lacZ (Falke et 
al, 2009)), thus if formate enters the cells there should be a concomitant increase in β-
galactosidase activity.  β-galactosidase activity is recorded using the Miller assay and 
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thus is presented in Miller Units.  Cells were grown as described in the methods section 
2.4.1.3.  After 2, 3 and 4 h, 1 ml aliquots were taken and the β-galactosidase assay 
carried out.  The assay was repeated at least 5 times on each sample. 
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β-galactosidase activity (Miller units) 
E.coli strain 2 h 3 h 4 h 
RM201-/- 1759.169 (1146.667-2206.061) 1380.612 (117.391-1731.915) 1209.104 (1043.165-1407.273) 
RM201-/+ 3167.754 (1146.667-4082.353) 3684.167 (3126.829-5670.588) 3810.153 (2793.750-5326.316) 
RM201-/ecnirc 3045.330 (2328.571-3666.667) 
3045.330 (2328.571-3666.667) 
3196.273 (2700.000-3936.842) 3147.887 (2608.333-3894.737) 
RM201-/pfnita_optEc 2175.971 (1731.034-2482.759) 1969.726 (1720.000-2311.765) 2034.421 (1626.667-3166.667) 
RM201-/pccir2 1724.224 (1140.909-2561.905) 1641.829 (904.000-2535.714) 1629.220 (677.143-266.667) 
 
β-galactosidase activity as an indirect measure of formate uptake.  This table contains the average β-galactosidase activity values for the different 
strains at each time point, followed by the range in brackets.  The average of from 5 samples.  Raw data can be found in Appendix 7.2.1. 
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(A)
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Figure 3.19: β-galactosidase activity.  (A) Box and whisker plot showing β-galactosidase activity in 
each of the strains.  The box represents the high quartile (top line), median (middle line) and low quartile 
(bottom line).  The mean is represented by a + and is from 5 replicates, the upper and lower whiskers 
represent the range.  (B) Graph showing the fold difference in average β-galactosidase activity of the test 
samples (from the five replicates) when compared to the RM201-/- control (= 0) over each of the time 
points.  β-galactosidase activity is an indicator of formate import to the cell cytoplasm. Raw data can be 
found in Appendix 7.2.1. 
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An average for each of the samples at the given time points have been used to create 
the graph presented in Figure 3.19.  There was variation observed between the activity 
levels of the colonies tested.  In this regard, Table 3.11 provides the average activity 
value for each sample with the range in brackets. 
 
3.4.2.3.4 Statistical analysis 
A one-way ANOVA (analysis of variance) was carried out to examine if there is any 
significant differences between the levels of β-galactosidase activity from each of the 
samples at the 2, 3 and 4 h.  Bonferroni post-hoc tests were used to compare each of 
the means from the samples.  As an ANOVA could not be used for the 2 h samples, a 
Kruskal-Wallis test was.  This test showed there were no significant differences (p = 
0.18) between β-galactosidase activity values in the strains tested.  A one-way ANOVA 
was used for the 3 and 4 h samples and the data is presented in Table 3.12 below. 
  
 
3 h Time point 
Strain Compared to Significance 
 
RM201-/- RM 201-/+ 0.000* 
RM 201-/pfnita_optEc 1.000 
RM 201-/pccir2 1.000 
RM 201-/ecnirc 0.002* 
RM201-/+ RM 201-/- 0.000* 
RM 201-/pfnita_optEc 0.004* 
RM 201-/pccir2 0.001* 
RM 201-/ecnirc 1.000 
RM201- 
/pfnita_optEc 
RM 201-/- 1.000 
RM201-/+ 0.004* 
RM 201-/pccir2 1.000 
RM 201-/ecnirc 0.060 
RM201- 
/pccir2 
RM 201-/- 1.000 
RM201-/+ 0.001* 
RM 201-/pfnita_optEc 1.000 
RM 201-/ecnirc 0.009* 
RM201- 
/ecnirc 
RM201-/- 0.002* 
RM201-/+ 1.000 
RM 201-/pfnita_optEc 0.060 
RM 201-/pccir2 0.009* 
 
4 h Time point 
Strain Compared to Significance 
 
RM201-/- RM 201-/+ 0.000* 
RM 201-/pfnita_optEc 0.520 
RM 201-/pccir2 1.000 
RM 201-/ecnirc 0.001* 
RM201-/+ RM 201-/- 0.000* 
RM 201-/pfnita_optEc 0.002* 
RM 201-/pccir2 0.000* 
RM 201-/ecnirc 1.000 
RM201- 
/pfnita_optEc 
RM 201-/- 0.520 
RM201-/+ 0.002* 
RM 201-/pccir2 1.000 
RM 201-/ecnirc 0.114 
RM201- 
/pccir2 
RM 201-/- 1.000 
RM201-/+ 0.000* 
RM 201-/pfnita_optEc 1.000 
RM 201-/ecnirc 0.011* 
RM201- 
/ecnirc 
RM201-/- 0.001* 
RM201-/+ 1.000 
RM 201-/pfnita_optEc 0.114 
RM 201-/pccir2 0.011* 
 
Table 3.12:  Statistical analyses of β-galactosidase activity in strains.  This table displays the 
significance as determined by a one-way ANOVA and Bonferroni comparisons.  Where the significance is 
0.000, p < 0.001.    An * designates significance.  β-galactosidase activity is an indicator of formate import 
to the cell cytoplasm.  Raw data can be found in Appendix 7.2.2. 
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At the 3 and 4 h time points, the negative control RM201-/- shows significant 
differences to strain RM201-/+ (p = 0.000 at both times) and strain RM201-/ecnirc (p = 
0.002 at 3 h, and, p = 0.001 at 4 h).  This result shows that the ecfoca and ecnirc 
genes encoded on the complementing plasmids produce proteins that import formate 
from the extracellular medium and/or bacterial cell periplasm.  There are no significant 
differences to the strains containing the PfNitA gene construct (p = 1.000 at 3 h, and, 
p = 0.520 at 4 h) or PcCir2 complementary plasmids (p = 1.000).  The graphs 
presented in Figure 3.19 show that the RM201-/pfnita_optEc strain has appreciably more ß-
galactosidase activity than either of the negative control strains.  The additional 
negative control strain, RM201-/pccir2, shows significant differences to strain RM201-/+ (p 
= 0.009 at 3 h, and, p = 0.011 at 4 h) and RM201-/ecnirc (p = 0.002 at 3 h, and, p = 
0.001 at 4 h), the same as the RM201-/- negative control.  Interestingly, there is no 
significant differences between strains RM201-/ecnirc and RM201-/pfnita_optEc (p = 0.060 at 
3 h, and, p = 0.114 at 4 h).  This suggests the uptake levels between the two strains 
are fairly similar. 
 
From the results shown in Figure 3.18 it is clear that EcFocA and EcNirC proteins are 
expressed to higher levels than PfNita_optEc.  It is possible that this comparably low 
level of protein expression is the reason the ß-galactosidase activity observed is so low 
in cells expressing PfNita_optEc.  Densitometry analysis was unable to be carried out 
as the PfNita_optEc western blot was separate to the blot for EcFocA and EcNirC as 
further optimisation of expression from the initial studies was required.  Taken 
together, these data imply that formate may be transported by the PfNitA permease.  
However further study is required before interpretation of this can be confirmed. 
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3.5 Summary 
 
 The several possible functions for a formate-nitrite transporter in P. falciparum were 
discussed.  Nitrite and nitrate have a putative role in the digestive vacuole, possibly in 
the degradation of haemoglobin to produce amino acids and haem.  Formate may be 
produced as a by product of cellular processes such as glucose catabolism or folate 
biosynthesis. 
 
 Structural predictions for the P. falciparum formate-nitrite transporter suggest an 
overall topology that is consistent with published crystal structures.  The protein 
contains six transmembrane domains and the C- and N-termini are intracellular.  The P. 
falciparum NitA protein sequence contains three amino acid motifs found in all FNT 
orthologues.  The conserved residues in these motifs are proposed to play a role in the 
selectivity of the transport protein.  In addition to this, PfNitA contains a novel 
sequence motif shared by bacterial formate transporters. 
 
 Phylogenetics places the Plasmodium FNT transporters in their own phylogenetic 
group.  This group displays the most recent evolutionary history with other 
apicomplexan organisms (Toxoplasma, Theileria and Babesia).  A streamlined tree 
showed PfNitA to have the closest evolutionary history with the bacterial formate 
transporters. 
 
 The codon-optimised synthetic pfnita_opt gene was unable to be expressed in terms of 
activity and protein production in the lower eukaryote fungus Aspergillus nidulans.  
Attempts were made to alter the pfnita/plasmid sequences to facilitate expression.  
Western blotting indicated the mutated PfNitA was not expressed in the fungi.  
Therefore it remains unknown if the transporter would have been able to complement 
an A. nidulans mutant strain. 
 
 Attempts to express the Plasmodium FNT transporter in the bacterium Escherichia coli 
were carried out.  Two codon-optimised synthetic pfnita genes were chosen for 
expression in E. coli based on bacterial or fungal codon usage rules.  Western blots 
confirmed expression of both the PfNitA_opt and PfNitA_optEc in E. coli membranes.  
The uptake of nitrite by a null mutant (Δnirc) was not significantly different to the 
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uptake levels by the null mutant overexpressing the synthetic codon-optimised pfnita 
genes.  The lack of nitrite uptake from the assay medium could be due to one of two 
things (i) the expressed protein was not active in the uptake of nitrite from medium or 
(ii) the protein was not functionally expressed. 
 
 Three methods were pursued to study formate transport in bacterial cells.  From these 
an indirect assay proved to be the most useful.  This assay procedure measures β-
galactosidase activity as a marker for formate uptake.  β-galactosidase activity 
observed in a null mutant overexpressing the PfNitA_optEc protein was markedly 
higher than the activity in the null mutant (Δfoca).  However statistical analysis using a 
one-way ANOVA confirmed such differences not to be significant.  The PfNitA_optEc 
was poorly expressed under assay conditions and the standard deviations of the 
samples were quite large.  Potentially, if PfNitA_optEc was expressed to higher levels a 
significant difference may have been observed.  The lack of a meaningful outcome 
strongly indicates that further research into the possibility that PfNitA functions as a 
formate transporter needs to be carried out (e.g. characterisation in Xenopus oocytes). 
 
 The addition of a His or V5 tag to the C-terminal of the protein was deemed not to 
have a detrimrntal effect on the oloigomerisation and activity of the recombinant 
PfNitA_opt and PfNitA_optEc proteins as the addition of a C-terminal His-tag to the 
endogenous EcFocA and EcNirC proteins did not prevent the proteins from functioning 
in the uptake of formate and/or nitrite.  A V5 tag added to the C-terminal of the 
endogenous AnNitA protein does not affect the function and activity of the protein (Dr. 
S.E. Unkles, personal communication). 
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4 Genetic Manipulation of Plasmodium falciparum nita 
 
4.1 Introduction 
 
The overall objective of the line of study into the characterisation of the PfNitA protein 
was to assess whether the PfNitA transporter is suitable as a novel chemotherapeutic 
target.  Drug targets are required to be genetically and chemically validated.  In the 
research described in this chapter the subcellular localisation of PfNitA was established 
using episomal expression of a tagged synthetic codon-optimised (for A. nidulans) 
PfNitA protein in Plasmodium falciparum.  Research efforts were made to (i) generate a 
genetically modified cell line deficient in the pfnita gene using double cross-over 
recombination, and (ii) to investigate its essentiality using reverse genetics.  In 
addition, we wanted to demonstrate that the gene locus was targetable using a knock-
in approach to tag the native gene. 
 
4.2 Subcellular Localisation of PfNitA 
 
4.2.1 Subcellular localisation predictions 
Orthologues of the PfNitA permease are found in all apicomplexan parasites excluding 
Cryptosporidium which does not contain an apicoplast (Zhu et al, 2000).  Therefore it 
is possible that the PfNitA protein might be present in the apicoplast membrane.  The 
apicoplast is bound by four membranes, and therefore has a requirement for 
permeases to transport molecules into and out of the organelle.  To investigate a 
possible apicoplast location two apicoplast targeting motif predictors, PlasmoAP (Foth 
et al, 2003) and PATS (prediction of apicoplast targeted sequences) (Zuegge et al, 
2001), were used.  Further localisation predictors were employed, that determined (i) a 
possible mitochondrial location using PlasMit (Bender et al, 2003) and iPSORT (Bannai 
et al, 2002), and (ii) the presence of signal peptides using iPSORT and SignalP 
(Petersen et al, 2011).  A list and overview of the prediction programs utilised are 
provided in Section 2.6.6.  The full-length amino acid sequences of all known PfNitA 
orthologues from Plasmodium species were studied.  Each program employed returned 
a negative result for a signal peptide and for localisation to the mitochondrion or 
apicoplast (Table 4.1).  The amino acid sequence does not encode a known signal 
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sequence to direct it outside the parasite and to the RBC such as the PEXEL/VTS motif 
(Hiller et al, 2004, and Marti et al, 2004).  Proteins are known to be transported to the 
RBC using other routes (Girolamo et al, 2008).  It has been predicted that the cellular 
location for PfNitA is the parasite plasma membrane (PPM), due to the hydrophobic 
nature of the protein and annotation as a transporter.  A PPM location has already 
been inferred in Figure 1 of Martin et al, (2009a). 
 
 
  
PATS PlasmoAP MitoProt PlasMit iPSORT SignalP 
P. falciparum No No No No No No 
P. chabaudi No No No No No No 
P. berghei No No No No No No 
P. yoelii No No No No No No 
P. knowlesi No No No No No No 
P. vivax No No No No No No 
Table 4.1: Subcellular localisation predictions.  PATS and PlasmoAP predict targeting to the 
apicoplast, MitoProt, PlasMit to the mitochondrion and SignalP, iPSORT predict targeting sequences.  The 
full-length PfNitA amino acid sequence and orthologue from other Plasmodium spp. were analysed using 
prediction software programs.  An output from the program that suggests positive location is indicated by 
Yes and a negative result by No. 
 
4.2.2 Biochemical subcellular localisation 
To determine the subcellular localisation of the PfNitA protein, the synthetic codon-
optimised pfnita gene (pfnita_opt) was episomally expressed in P. falciparum.  The 927 
bp pfnita_opt gene was amplified using the primers NitAopt GW F and NitAopt GW R 
(Appendix 2), and cloned upstream of a 3xHaemagglutinin ((HA)3) epitope tag or green 
fluorescent protein (GFP) tag using the MultiSite Gateway® technology (Invitrogen) 
(Tonkin et al, 2004, and van Dooren  et al, 2005).  Expression of the cloned gene was 
placed under the control of the Hsp86 promoter in both plasmids.  The final 
transfection plasmids were termed pCHD-Hsp86-pfnita_opt-GFP and pCHD-Hsp86-
pfnita_opt-(HA)3, and are displayed in Figure 4.1, A and B, respectively.  An overview 
of the MultiSite Gateway® cloning procedure is provided in Figure 2.4. 
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(A)            (B) 
   
 
Figure 4.1:  Subcellular localisation transfection plasmids.  The final plasmids (A) pCHD-Hsp86-
pfnita_opt-GFP and (B) pCHD-Hsp86-pfnita_opt-(HA)3 encode the codon-optimised pfnita gene and a GFP 
or (HA)3 tag, respectively.  These plasmids were transfected into 3D7 and D10 parasites.  The att sites 
that bring the constructs together during the gateway cloning LR reaction are indicated.  The ampicillin 
and hDHFR selectable markers used in bacterial cloning and parasite transfection/selection procedures, 
respectively, are also given. 
 
Given that the codon-optimised pfnita gene was under transcriptional control of the 
Hsp86 promoter, its mRNA expression profile was analysed for an Hsp86 family protein 
(PF07_0030) and for pfnita using the PlasmoDB website28 and information therein (Le 
Roch et al, 2003).  The only obvious differences in the mRNA expression profiles of the 
two genes are during the merozoite and gametocyte stages where the pfhsp86 family 
gene is expressed at slightly elevated levels than pfnita (Figure 4.2).  During the 
sporozoite stage the pfnita transcript is expressed at higher levels than that of 
pfhsp86.  Therefore, the substitution of the native promoter with the Hsp86 promoter 
would not be expected to cause marked overexpression of the PfNitA protein.  
Interestingly, analysis of the P. falciparum proteome found PfNitA protein to be present 
in the gametocytes but not in gametes (Supplementary Table B, Lasonder et al, 2002). 
 
Two strains of P. falciparum were transfected, namely 3D7 and D10.  The main 
differences between these strains are that D10 cells can grow to a higher parasitaemia 
in vitro than 3D7 and do not produce gametocytes.  Parasites were thus transfected 
with the plasmids pCHD-Hsp86-pfnita_opt-GFP or pCHD-Hsp86-pfnita_opt-(HA)3 on two 
separate occasions (1 and 2).   
                                                 
28 www.plasmodb.org.  Accessed on 01 January 2012. 
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(A)            PFC0275c 
 
 
 
(B)            PF07_0030 
 
 
 
Figure 4.2: Expression profiles of PFC0725c (pfnita) and PF07_0030. Relative mRNA expression 
level of the genes intensity is compared relative to all other genes for a given experiment. Green bars 
represent stage synchronization using sorbitol, purple bars represent stage synchronization by 
temperature.  (A) PFC0725c, (B) PF07_0030.  S = sporozoites, ER = early rings, LR =late rings, ET = early 
trophozoites, LT = late trophozoites, ES = early schizonts, LS = late schizonts, M = merozoites, G = 
gametocytes.  Images taken from PlasmoDB29. 
 
These plasmids encode the human dihydrofolate reductase (hdhfr) gene conferring 
resistance to Walter Reed Institute anti-DHFR antifolate 99210 (WR 99210).  
Transfected parasites resistant to WR 99210 were observed in thin blood smears 
approximately four weeks after transfection, giving rise to strains D10pfnita_opt-GFP-1 and -
2, 3D7pfnita_opt-GFP, and, D10pfnita_opt-HA-1 and -2, 3D7pfnita_opt-HA-1 and -2. 
 
4.2.2.1 Expression and localisation of GFP tagged PfNitA 
To confirm that the correct sized protein had been expressed, protein was extracted 
from transfected parasites for western blot analysis.  The extracted protein was 
separated into insoluble and soluble fractions, with the insoluble fraction being washed 
well to remove the majority of remaining cytoplasmic proteins (Section 2.5.10).  These 
fractions were separated by a 7.5 % SDS-PAGE gel, blotted onto nitrocellulose and the 
GFP tagged PfNitA visualised using anti-GFP and HRP conjugated secondary antibodies 
                                                 
29 www.plasmodb.org.  Accessed on 01 January 2012. 
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(antibody details are provided in Table 2.3).  The expected size of the fusion protein is 
approximately 64.8 kDa (ExPASy Compute pI/Mw tool).  The results presented in 
Figure 4.3 confirm the protein was expressed well, and that it was found in the soluble 
fraction as well as the insoluble pellet.  The band size of the blot is smaller than 
expected, however this is not unusual for hydrophobic proteins and the reason for 
discrepancy may be related to the large GFP tag (Rath et al, 2008).  No dissociated 
GFP (approximately 30 kDa) was detected by the anti-GFP antibody in the western 
blots (data not shown).  The blot was reprobed with an anti-BCKDH (branched chain α-
keto acid dehydrogenase) antibody and HRP conjugated secondary antibody (Table 
2.3) as a loading control. 
 
 
Figure 4.3:  Expression of GFP tagged PfNitA_opt.  Western blot of the insoluble and soluble 
parasite protein fractions using an anti-GFP antibody directed against the C-terminal tag confirms the full-
length protein expression.  Lanes 1, 3, and 5 contain the soluble parasite protein fraction and lanes 2, 4, 
and 6 the insoluble.  Lanes 1 and 2 are D10pfnita_opt-GFP-1, lanes 3 and 4 are D10pfnita_opt-GFP -2, and lanes 5 
and 6 are 3D7pfnita_opt-GFP.  The blot was stripped and re-probed with an anti-BCKDH antibody as a loading 
control.  20 µg total protein was loaded in each lane, the arrow indicates the position of PfNitA-GFP. 
 
BCKDH shows equal expression throughout the intraerythrocytic developmental cycle 
(IDC) and is a soluble mitochondrial protein (Günther et al, 2007).  This showed that 
there was no contamination of the insoluble fractions with the soluble fraction, though 
the insoluble fraction may still be found in the soluble fraction.  The fact that the 
PfNitA_opt-GFP protein was found in the soluble fraction as well as insoluble suggests 
the protein may not have folded correctly and may be found in the cell cytoplasm.  All 
GFP transfected cell lines were subject to fluorescent live microscopy to determine the 
subcellular localisation of PfNitA-GFP.  Cell lines were analysed by light microscopy 
using an AxioSkop-2 fluorescence microscope (Zeiss, Herts., UK). 
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Figure 4.4: Localisation of epitope tagged PfNitA using live cell microscopy.   To investigate the 
subcellular localisation of PfNitA the synthetic codon-optimised pfnita_opt gene was C-terminally tagged 
with GFP using Multi site Gateway® technology, and expressed episomally in D10 and 3D7 parasites.  The 
images are from D10 parasites only.  The images show the synthetic codon-optimised PfNitA protein 
tagged with GFP under the control of the Hsp86 promoter (PfNitA-GFP).  Overlays of the images are 
provided to establish potential co-localisation (Merge).  The merge ‘Trophozoite’ image has been 
duplicated to highlight the important components of the image: RBC, parasite, nucleus and haemozoin 
pigment (digestive vacuole).  Hoechst 33258 was used as a nuclear stain.  Images were obtained by DIC 
microscopy, or in the FITC (GFP) and the DAPI (Hoechst) fluorescent channels.  DIC: differential 
interference contrast microscopy. 
 
All lines exhibited GFP fluorescence at the periphery of the parasite cells indicative of a 
plasma membrane or parasitophorus vacuole membrane location of PfNitA-GFP.  A low 
number of images showed good resolution of the brightfield (differential interference 
contrast microscopy (DIC)) parasites such as presented in Figure 4.4.  Data obtained 
from the two parasites in Figure 4.4 suggest the PfNitA_opt protein is located in the 
parasite plasma membrane (PPM) as the individual merozoites show GFP fluorescence 
in the schizont image, although the individual merozoites cannot be discerned in the 
DIC image.  Further means of microscopy were investigated to gain better overall 
images.  D10pfnita_opt-GFP-1 showed a stronger fluorescent signal when cells were viewed 
using the AxioSkop-2 microscope and were therefore selected for analysis by Delta 
Vision microscopy (Figure 4.5). 
 
The merged images presented in Figure 4.5 clearly show the PfNitA_opt-GFP fusion 
protein localises to the PPM or parasitophorus vacuole membrane (PVM) of all parasite 
IDC stages.  Evident from 12.9% (n = 31) of trophozoite and 31.6 % (n = 19) of 
schizont images was GFP fluorescence surrounding the haemozoin pigment and 
therefore digestive vacuole (DV). 
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Figure 4.5: Localisation of PfNitA using Delta Vision microscopy.  To investigate the subcellular 
localisation of PfNitA the synthetic codon-optimised PfNitA_opt was C-terminally tagged with GFP using 
Multi site Gateway® technology and expressed episomally in D10 parasites.  The images show PfNitA_opt 
tagged with GFP under the control of the Hsp86 promoter.  Images were taken at indicated stages of the 
intraerythrocytic developmental cycle.  In the ‘Trophozoite’ image, two parasites are present in a single 
RBC.  Overlays of the images are provided to show potential co-localisation (Merge).  Hoechst 33258 was 
used as a nuclear stain.  Images of infected RBCs were obtained by DIC microscopy, and by using the 
DAPI (Hoechst) and GFP (GFP) channels. 
 
Furthermore, 41.4 % (n = 29) of ring stage parasites showed staining associated with 
two membranes (as presented in Figure 4.5 ‘Ring’) compared to 31.0 % (n = 29) with 
a single (outer) membrane fluorescence (data not shown).  Two images were captured 
showing merozoites recently released from the RBC, these showed PfNitA_opt-GFP 
localisation to the plasma membrane of free merozoites.  The peri-nuclear stain 
recorded in the ‘Early Trophozoite’ stage was observed in 19.4 % (n = 31) of 
trophozoite images.  This staining may be the endoplasmic reticulum (ER) and is 
possibly indicative of the transport of the fusion protein.  A single bright fluorescent 
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area was recorded in certain images from both trophozoite and schizont stages (Figure 
4.5 ‘Trophozoite’).  It is thought that the punctate fluorescence could be due to vesicle 
transportation of the fusion protein to the cell membrane, or perhaps an artefact due 
to overexpression of the synthetic fusion protein. 
 
4.2.2.2 Confirmation of subcellular localisation using immunofluorescence 
analysis of (HA)3 tagged PfNitA 
To confirm that the PfNitA-(HA)3 fusion protein was being expressed, total protein was 
extracted from transfected parasites for western blot analysis.  The total parasite 
protein was separated into insoluble and soluble fractions with the insoluble fraction 
being washed thoroughly to remove soluble proteins.  Western blot analysis of these 
fractions using an anti-HA antibody and HRP conjugated secondary antibody revealed a 
band of approximately 37 kDa which is in line with the predicted size of the fusion 
protein at 41.7 kDa (ExPASy Compute pI/Mw tool) (Figure 4.6).  The results in Figure 
4.6, A illustrate the full-length protein with (HA)3 tag is expressed well in all cell lines. 
 
P. falciparum 3D7 transfected cell lines possess a protein band present in both the 
soluble and insoluble fractions. This implies there may be (HA)3 tagged fusion protein 
present in the cytoplasm possibly due to the overexpression of the fusion protein.  As 
the 3D7 cell lines display expressed (HA)3 tagged protein in the soluble fractions, we 
decided to use only the Plasmodium D10 cell lines for further analysis.  The western 
blot was reprobed with the anti-BCKDH antibody as a loading control.  This experiment 
confirmed that there was a reasonable separation of soluble and insoluble fractions for 
D10.  However, a certain level of contamination of the fractions was observed in the 
3D7 samples.  Therefore D10pfnita_opt-HA-1 was chosen for further analysis by 
fluorescence microscopy. 
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(A) 
 
 
(B) 
 
 
Figure 4.6: Localisation of epitope tagged PfNitA using immunofluorescence analysis (IFA). 
(A) Western blot of the insoluble pellet and soluble parasite extract using an anti-HA antibody directed 
against the C-terminal tag confirms the full-length protein expression.  Lanes 1, 3, 5, and 7 contain the 
soluble parasite extract and lanes 2, 4, 6, and 8 the insoluble pellet.  Lanes 1 and 2 are D10pfnita_opt-HA-1, 
lanes 3 and 4 are D10 D10pfnita_opt-HA-2.  Lanes 5 and 6 are 3D7 D10pfnita_opt-HA-1 and lanes 7 and 8 are 3D7 
D10pfnita_opt-HA-2.  The blot was stripped and re-probed with an anti-BCKDH antibody as a loading control 
which ensured the fractions had been separated well.  20 µg total protein was loaded in each lane, the 
arrow indicates the position of PfNitA_opt-HA.  (B) To investigate the subcellular localisation of PfNitA the 
synthetic codon-optimised PfNitA_opt protein was C-terminally tagged with (HA)3 and expressed in D10 
and 3D7 parasites.  The above images are taken from D10 parasites.  The images show the synthetic gene 
tagged with (HA)3 under the control of the Hsp86 promoter (anti-HA) when probed with anti-HA and 
secondary Alexa594 antibodies.  Overlays of the images are provided to establish potential co-localisation 
(Merge).  Hoechst 33258 was used as a nuclear stain.    Images were obtained by DIC microscopy, or in 
the TRITC (PfNitA-(HA)3/Alexa594) and the DAPI (Hoechst) fluorescent channels. 
 
The cell line D10pfnita_opt-HA was exploited for immunofluorescence analyses (IFA) with a 
mouse anti-HA antibody and an anti-mouse-Alexa594 antibody (Table 2.3).  DNA was 
stained with Hoechst 33258.  The images presented in Figure 4.6, (B) are typical of 
those for the IFA of strain D10pfnita_opt-HA.  In the ‘Schizont’ image, the staining of the 
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individual merozoite plasma membranes was clear.  In the trophozoite stages the 
staining of the parasite plasma membrane was less apparent, but the DV staining was 
pronounced in some parasites. 
 
The fluorescent live microscopy and IFA results suggests that PfNitA_opt is found in 
the PPM as fluorescence is observed encircling the parasites of ring, trophozoite, and 
merozoite stages.  If the fluorescence had appeared around the schizont stage parasite 
and not the merozoites a PVM location would have been proposed.  In the trophozoite 
and schizont stages where a clear DV is indicated by the haemozoin pigment, 
approximately 50 % of the parasites displayed fluorescence indicative of the DV 
membrane (DVM).  Overall these results suggest a dual localisation for PfNitA to the 
parasite plasma membrane and digestive vacuole membrane. 
 
4.2.2.3 Co-localisation studies of PfNitA with PfHT or PfCRT 
Given the potential PPM and DVM location of PfNitA_opt described in Sections 4.2.2.1 
and 4.2.2.2, co-localisation studies were carried out using antibodies raised to a PPM 
protein and a DVM protein.  In this regard, the PPM antibody was directed against the 
P. falciparum hexose transporter (HT) (Woodrow et al, 1999) and was a kind gift from 
Prof. S. Krishna (University of London).  The primary anti-PfHT antibody was used at a 
1:500 dilution, and the secondary was an anti-goat-Alexa594.  The DVM antibody was 
directed against the chloroquine resistance transporter (CRT) (Fidock et al, 2000) and 
was a kind gift from Dr. P. Bray (Liverpool School of Tropical Medicine).  The anti-
PfCRT antibody was used at a 1:400 dilution, and the secondary was an anti-rabbit-
Alexa594 (antibodies and dilutions are given in Table 2.3). 
 
Strain D10 pfnita_opt-GFP was employed for the co-localisation experiments.  The GFP signal 
was enhanced using an anti-GFP antibody to cross-react with the GFP fusion protein 
and secondary antibody conjugated to Alexa488 (Table 2.3).  As in previous 
experiments (Sections 4.2.2.1 and 4.2.2.2) DNA was stained using Hoechst 33258.  
Synchronised late stage parasites were used for these experiments and not ring 
stages.  The images presented in Figure 4.7 are of trophozoite parasites, no schizont 
stages were pictured during the analyses.  Initially studies using only the anti-PfCRT or 
the anti-PfHT antibodies and their conjugates were carried out.  The images from the 
anti-PfHT labelled experiments provided well defined images with clear fluorescence 
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observed around the parasites demonstrating the PPM location of PfHT.  The anti-
PfCRT antibody labelled the DV well, but unfortunately yielded non-specific binding to 
the RBC and parasite (data not shown). 
 
(A) 
 
 
(B) 
 
 
Figure 4.7: Co-localisation studies using immunofluorescence analysis.  The subcellular 
localisation of PfNitA was investigated using antibodies to a known parasites plasma membrane protein, 
and a known digestive vacuole protein, both of which are transporters.  (A)  Immunofluorescence analysis 
using anti-HT (hexose transporter located in the parasite plasma membrane) denoted in red.  The GFP 
tagged synthetic PfNitA is in green and fluorescence was boosted using an anti-GFP antibody. (B)  
Immunofluorescence analysis using anti-CRT (chloroquine resistance transporter found on parasite 
digestive vacuole membrane) is indicated in red.  The GFP tagged synthetic PfNitA is presented in green.  
All images were taken from trophozoites.  Overlays of the images are provided to establish potential co-
localisation (Merge).  Hoechst 33258 was used as a nuclear stain.  IFA slides were viewed using DIC 
microscopy, and the DAPI (Hoechst), GFP (GFP and Alex488) and Alexa594 (Alexa594) channels. 
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The merged images presented in Figure 4.7, (A) show a co-localisation of PfHT (red) 
with PfNitA_opt (green) both of which surround the parasite.  The results confirm the 
PPM location of PfNitA_opt.  The merged images in Figure 4.7, (B) fail to demonstrate 
co-localisation between the PfCRT antibody (red) and the PfNitA_opt fusion protein 
(green).  The results therefore do not support the DVM location of PfNitA_opt.  The 
IFA experiments were limited in the parasite life cycle stage that was examined, e.g. 
trophozoite stage and not ring or schizont stages.  The anti-PfCRT antibody did not 
provide a clear localisation to the DV only and was perhaps not the optimum for use in 
IFA as previous use in the Müller lab had been for western analyses only.  The shape 
of the parasites and lack of clear RBC outline as observed in the DIC images of (B) 
suggests that the RBC and parasites are distorted perhaps relating to the anti-PfCRT 
antibody as all IFA experiments were treated the same.  Taken together, although the 
IFA experiment does not support a DVM location for PfNitA_opt this possibility must 
not be excluded.  To confirm the DVM localisation, additional IFA experiments including 
all the life cycle stages would be of practical value.  Further to this, the parasite line 
encoding the GFP tagged PfNitA_opt could be transfected with a second plasmid 
encoding, for example, a PfCRT-mCherry fusion protein.  Fluorescent live microscopy 
experiments should be carried out with the new cell line to analyse any co-localisation. 
 
4.3 Knock-out of pfnita by Gene Replacement 
 
As noted previously, many of the integral membrane proteins of P. falciparum have 
been demonstrated to be indispensable to the organism (e.g. Slavic et al, 2010, el 
Bissati et al, 2008, and, Waller et al, 2003).  To genetically assess the pfnita gene 
product as a potential drug target, knock-out (KO) studies of the pfnita gene were 
attempted using the pCC1 and pCC4 plasmid constructs (Duraisingh et al, 2002 and 
Maier et al, 2006).  Given the essentiality of other Plasmodium permeases an approach 
was taken to maximise the likelihood of obtaining KO cell lines after transfection.  pCC1 
and pCC4 vectors each encode a different drug selectable marker (DSM), namely 
human dihydrofolate reductase (hdhfr) and blasticidin-S-deaminase (bsd) conferring 
resistance to the drugs Walter Reed Institute anti-DHFR antifolate 99210 (WR 99210) 
and blasticidin-S-HCl (Bla), respectively (Table 2.4) (Fidock and Wellems 1997, and 
Ben Mamoun  et al, 1999, respectively).  In addition to a positive selection marker, the 
two pCC plasmids also encode a negative selectable marker.  The negative selectable 
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marker is cytosine deaminase/uracil phosphoribosyl transferase (cd), a chimeric gene 
made from two genes of S. cerevisiae (Table 2.4) (Maier et al, 2006).  The chimera is 
expressed by cells containing the plasmid and converts 5-fluorocytosine (5-FC) to the 
toxic 5-fluorouracil and 5-fluorouridine monophosphate. 5-fluorouracil elicits its toxic 
effects by causing an inhibition of RNA synthesis and 5-fluorouridine monophosphate 
inhibits thymidylate synthase (Maier et al, 2006).  For this system to be successful for a 
gene KO, a double cross-over is required and the gene is replaced by the DSM and not 
merely disrupted, while the negative selectable marker is lost.  A double cross-over is 
preferable to a single cross-over as in some instances the plasmid can ‘loop out’ which 
would leave a functional gene.  The double cross-over event is rare in Plasmodium 
parasites, and this negative marker selects for parasites in which the rare event has 
taken place (Maier et al, 2006).  The DSMs and their use during drug cycling are 
described in sections 2.5.3 and 2.5.7.1, respectively. 
 
Fragment 
Amplified 
Forward Primer  Reverse Primer  Construct Name 
724 bp NitA 5’ NitA_KO_750_5_F 1 NitA_KO_750_5_R 2 pfnita750 
756 bp NitA 3’ NitA_KO_750_3_F 3 NitA_KO_750_3_R 4 
508 bp NitA 5’ NitA_KO_500_5_F 5 NitA_KO_500_5_R 6 pfnita500 
542 bp NitA 3’ NitA_KO_500_3_F 7 NitA_KO_500_3_R 8 
Table 4.2: Oligonucleotide primers used for amplification of pfnita inserts for KO constructs.  
Oligonucleotide sequences are given in Appendix 2.  The numbers following each oligonucleotide primer 
correspond to the numbers in Figure 4.8, (A). 
 
For cross-over locations, a 542 bp fragment homologous to a stretch of the pfnita 3’ 
open reading frame (ORF), and a 508 bp fragment homologous to the 5’ ORF were 
amplified from 3D7 gDNA.  These PCR products were cloned into the pCC1 and pCC4 
vectors.  Additionally, a 756 bp fragment homologous to part of the pfnita 3’ ORF and 
upstream non-coding region and a 724 bp fragment homologous to the 5’ ORF and 
downstream non-coding region were amplified and likewise cloned into the pCC1 and 
pCC4.  The oligonucleotide primer sets used for these amplifications are provided in 
Table 4.2 and Appendix 2. 
 
The approximately 500 bp DNA stretches covered more of the gene itself, while the 
approximately 750 bp inserts covered more of the 5’ and 3’ non-coding regions.  This is 
illustrated in Figure 4.8, (A) and (B).  Cloning yielded the plasmids pCC1-pfnita500, 
pCC1-pfnita750, pCC4-pfnita500 and pCC4-pfnita750 (Figure 4.8, (C)). 
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3D7 and D10 parasites were transfected with the four KO constructs.  After five to six 
weeks, parasites of both strains resistant to Bla or WR 99210 were detected in Giemsa 
stained thin blood smears. 
 
(A)
 
 
(B)                 (C) 
            
 
Figure 4.8:  Knock-out by gene replacement strategy. (A) Schematic illustrating the PCR fragments 
generated from pfnita and non-coding regions targeted by the knock-out constructs.  Red arrows show the 
722 and 756 bp fragments and the blue arrows the 508 and 542 bp fragments.  Image is not to scale.  (B) 
Digest showing the approximately 500 bp (lanes 3, 4, 7, and 8) and appromimately 750 bp (lanes 1, 2, 5, 
and 6) 5’ and 3’ knock-out fragments were amplified from 3D7 gDNA and cloned into the pCC1 (lanes 1 - 
4) and pCC4 (5 - 8) vectors encoding the drug selectable markers hdhfr and bsd, respectively. (C) 
Example plasmid construct showing the 750 bp 5’ and 3’ pfnita gene fragments cloned into the pCC4 
vector and the drug selectable marker blasticidin-S-deaminase (bsd).  The restriction sites used to clone in 
the pfnita gene fragments are shown, NcoI and AvrII for the 5’ fragment and SacII and AflII for the 3’ 
fragment.   The ampicillin resistance (AmpR) cassette is a selectable marker for cloning and selection in 
bacteria.  CD acted as a negative selectable marker during the transfection and integration process.  
Diagrams are not to scale. 
 
Ring and late stage parasites were observed at a very low parasitaemia (0.1 – 0.2 %) 
for approximately two weeks after the first parasites were observed, but the 
parasitaemia never reached higher levels.  The parasites maintained abnormal 
morphology and were always surrounded by a large quantity of debris suggesting 
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continuous parasite death.  The reason most of the transfected cell lines did not form 
stable cultures is unknown, though it could be speculated that the pfnita gene was was 
being targeted by the KO construct leading to eventual cell death.  Only one of these 
lines, transfected with pCC1-pfnita500 (designated pCC1-pfnita), was able to establish 
a WR 99219 resistant culture named D10pCC1-pfnita.  Stabilates were made and gDNA 
generated for Southern blot analysis of the genotype of transfected parasites. 
 
The D10 pCC1-pfnita cell line was taken through drug cycling to promote integration of the 
plasmid (summarised in Figure 4.9).  The parasite culture was divided into two and 
drug treatments carried were out as described in Section 2.5.7.1 and illustrated in 
Figure 2.6.  Removing WR 99210 from the culture should result in the loss of the 
episome and thus the hdhfr gene.  After three weeks in the absence of drug pressure, 
the culture was subjected to renewed drug pressure, ensuring that only those parasites 
that still contained plasmid DNA where the selectable marker had integrated into their 
genome would survive.  It is believed that this drug cycling procedure enriches the 
culture for parasites where a recombination event has taken place. 
 
 
 
Figure 4.9: Overview of the drug cycling process for parasites transfected with pCC1-pfnita.  
Parasites after transfection, growing on WR 99210 were termed cycle 0 (black box).  Drug cycling of 
transfected parasites was carried out to select for integration of plasmids into the parasite genome.  
Off/on WR 99210 cycling is displayed by blue boxes/arrows and treatment with 5-FC is indicated in 
orange.  At each stage gDNA was taken for analysis using PCR and/or Southern blot, and stabilates were 
made for the preservation of the parasite line, as indicated by a green box/arrow combination. 
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The second subculture was treated with 5-FC.  5-FC is metabolised to the toxic product 
5-fluorouracil by the negative selectable marker cytosine deaminase/uracil 
phosphoribosyl transferase (CD).  The product inhibits RNA synthesis and thymidylate 
synthase (Maier et al, 2006).  Using the negative selection drives double homologous 
recombination which leads to replacement of the gene of interest (GOI) by the positive 
selectable marker and the loss of the negative selectable marker.  If a double cross-
over event has taken place parasites should be resistant to both WR 99210 and 5-FC. 
 
The D10pCC1-pfnita parasites that were cycled off WR 99210 for three weeks and 
subjected to WR 99210 again underwent a slight growth defect for 3-4 days after the 
drug was added, but were able to establish a typical culture.  As soon as normal 
growth was resumed gDNA was recovered for a diagnostic Southern blot.  An overview 
of the expected banding pattern from a Southern blot when gDNA is digested with 
NdeI is provided in Figure 4.10, (A).  The culture was divided into two again for further 
on/off WR 99210 cycles and 5-FC treatment. 
 
The on/off drug cycling was carried out twice.  The parasites recovered from each 
cycle were termed D10 pCC1-pfnita-cyc0, D10 pCC1-pfnita-cyc1and D10 pCC1-pfnita-cyc2.  It took 
approximately seven weeks for the WR 99210 and 5-FC resistant D10pCC1-pfnita-cyc0 
parasites to appear in a Giemsa stained thin blood smear.  This is a relatively long time 
of exposure to 5-FC as resistance to 5-FC can occur after prolonged exposure to the 
drug.  Subsequently, if parasites did not establish a culture after four weeks they were 
terminated.  Parasites D10pCC1-pfnita from drug cycles zero, one and two were treated 
with 5-FC.  After four weeks no parasites could be detected in a thin blood smear.  An 
overview of the drug cycling process that was carried out for this parasite line is given 
in Figure 4.9. 
 
A Southern blot of gDNA isolated from a WT D10 strain and D10pCC1-pfnita at each cycle 
was carried out after digestion with the restriction enzyme NdeI.  The blot was 
hybridised using a probe homologous to the 3’ 542 bp pfnita insert, and a second 
probe was generated against hdhfr.  The restriction sites and areas covered by the 
probe are shown in Figure 4.10, (A).  The results of Southern blotting are presented in 
Figure 4.10 (B) shows a 4.46 kb fragment is revealed and confirms the presence of the 
endogenous gene in all cell lines.  A fragment of 2.5 kb would have been present if the 
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plasmid had integrated at the correct locus.  The 0.68 kb fragment shows that the 
transfected line in cycle 0 does contain the knock-out plasmid.  The presence of the 
additional fragment, approximately 700 bp, on the blot could be due to incomplete 
digestion of the plasmid or may suggest a random integration event has taken place if 
pCC1-pfnita has integrated into the P. falciparum genome at an unknown locus.  The 
Southern blotting experiments revealed that by cycle 2 the plasmid appeared to have 
been lost when using the gene specific probe, but may still have been present as an 
approximately 8 kb fragment is present when using the hdhfr specific probe 
corresponding to the plasmid. 
 
Interestingly, the results from the Southern blot containing gDNA from the 5-FC 
treated culture D10pCC1-pfnita-cyc0 indicated that no genotypic change had occurred when 
compared to the pre-5-FC cultures suggesting parasites were resistant via some other 
means than loss of the KO plasmid (Figure 4.10, (B), lane 3).  If integration had 
occurred, a band of 3 kb would have been present with the hDHFR probe.  Using the 
gene specific probe, a band of 2.5 kb would be expected. 
 
A PCR experiment using primers CD F and CD R (Appendix 2) against the negative 
selectable marker did not amplify a product in any of the parasites treated with 5-FC 
(Figure 4.10, (C)) suggesting loss of the negative selectable marker.  An overview of 
the results is given in Table 4.3.  A PCR experiment was carried out using primer sets 
that would amplify a correct sized gene product only if integration had taken place at 
the intended locus.  The 5’ forward primer (F 5’) (5’ KO check int F) is present in the 
downstream non-coding region of the gene and the 5’ reverse primer (R 5’) (5’ KO 
check int R) is present on the KO plasmid between the 5’ gene fragment and DSM.  
Conversely, the 3’ forward primer (F 3’) (3’ KO check int F) is present on the KO 
plasmid between the DSM and 3’ gene fragment and the 3’ reverse primer (R 3’) (3’ KO 
check int R) is present in the upstream non-coding region.   
 
The primers are indicated by red arrows in the data presented in Figure 4.10, A.   
Oligonucleotide primers are provided in Appendix 2.  The expected product sizes of 
1555 bp for the 5’ product and 1505 bp for the 3’ product would have been amplified 
only if integration had taken place.  No products were amplified from a gradient PCR 
(data not shown). 
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 (A) 
 
 
(B)
 
   Probe: pfnita specific          Probe hdhfr specific 
 
 
 
 
 
(C) 
 
Figure 4.10:  Knock-out by double cross-over recombination.   (A)  A schematic diagram of the 
pfnita wild-type locus (I), the pCC1-pfnita plasmid (II) and the pfnita gene locus following a double cross-
over recombination event (III).  NdeI restriction sites are indicated by black arrows.  The lengths of the 
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expected fragments detectable with pfnita specific probe homologous to the 5’ insertion of the plasmid are 
indicated by blue arrows, and those homologous to the drug selectable marker hdhfr are shown in green.  
The oligonucleotide primers used to test for integration using PCR are indicated by small red arrows in 
part III.  The expected sizes are 1555 bp for the 5’ product (F 5’ + R 5’) and 1505 bp for the 3’ product (F 
3’ + R 3’).  (B)  Southern blot analysis after digestion of gDNA with NdeI, of cell lines transfected with 
pCC1-pfnita, probed with gene specific and hdhfr probes.  Lane 1 contains D10 WT gDNA, lanes 2 and 3 
contain gDNA from D10pCC1-pfnita in WR 99210 selection cycle 0, lane 3 after 5-FC treatment, and lane 4 
contains gDNA in WR 99210 selection cycle 2.  (C) PCR using primers against the negative selectable 
marker CD was carried out to check for loss of the negative selectable marker.  Lane 1 contains D10 WT 
gDNA, lanes 2 and 3 contain gDNA from D10pCC1-pfnita in WR 99210 selection cycle 0 Lane 3 after 5-FC 
treatment, lane 4 contains gDNA in WR 99210 selection cycle 2. 
 
Parasite line PCR Southern Blot 
 cd pfnita hdhfr 
Cycle 0 positive endogenous gene, KO plasmid     positive 
Cycle 0 + 5-FC (seven weeks) negative endogenous gene, KO plasmid     positive 
Cycle 0 + 5-FC (four weeks) -------------------------no parasites----------------------------------- 
Cycle 1 positive endogenous gene, KO plasmid     positive 
Cycle 1 + 5-FC (four weeks) -------------------------no parasites----------------------------------- 
Cycle 2 positive endogenous gene only     negative 
Table 4.3:  Overview of Southern blot and PCR results from cell line D10pCC1-pfnita.  PCRs are 
either positive or negative for the amplification product from cd.  Southern blots using the hdhfr probe are 
either negative or positive for the presence of hdhfr on the pCC1-pfnita plasmid. 
 
A second set of transfections of vectors pCC4-pfnita500 and pCC4-pfnita750 into 3D7 
wild-type parasites was performed in duplicate, no parasites were observed after two 
months of selection on Bla.  Thus, from 20 transfections with four different plasmids 
and two different parasite strains, a single parasite line containing the KO plasmid was 
generated.  This single parasite line, denoted D10pCC1-pfnita, was taken through drug 
cycling to promote integration of the plasmid.  However, drug cycling resulted in the 
loss of the plasmid and no integration was achieved. 
 
As lack of integration was observed, it can be inferred that either the gene is refractory 
to recombination events, or that it is essential to the intraerythrocytic stage of the 
parasite.  An approach where a complementary copy of the gene was co-transfected 
with the KO plasmid was therefore attempted (Section 4.5). 
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4.4 “Conditional” Knock-out of pfnita 
 
As the previous strategy to produce a knock-out of pfnita in P. falciparum did not give 
rise to a viable line lacking the pfnita gene, another plan was developed and pursued.  
In this strategy the codon-optimised synthetic A. nidulans pfnita_opt gene was used to 
complement the knock-out of the endogenous GOI (for example, Slavic et al, 2010).  It 
was anticipated that by using the synthetic gene to restore the function of pfnita, the 
endogenous gene should be targetable by a knock-out construct.  The A. nidulans 
synthetic codon-optimised pfnita gene was chosen as both organisms are eukaryotes.  
The pCHD-Hsp86-pfnita_opt-(HA)3 plasmid was used as this vector encodes a C-
terminal tag smaller than GFP and may thus circumvent possible problems of 
interference with the activity or oligomerisation of the transporter protein.  The 
outcome of this approach relies on the synthetic codon-optimised pfnita_opt gene 
being processed into the active protein.  The results presented in Section 4.2 show that 
the codon-optimised synthetic pfnita gene is processed into the full-length protein 
when expressed in strains D10 and 3D7 P. falciparum (Figure 4.6, (A)), and is 
transported to the PPM (Figure 4.6, (B)). 
 
The pCHD-Hsp86-pfnita_opt-(HA)3 plasmid was used for the complementary copy of 
pfnita which encodes a hdhfr gene as a DSM.  For the KO plasmid pCC4-based 
constructs were chosen as pCC4 encodes a different DSM, bsd.  The transfected 
parasites were therefore selected for using Bla and WR 99210. 
 
Two procedures were tested.  (i) the KO plasmid was transfected into cells already 
harbouring pCHD-Hsp86-pfnita_opt-(HA)3.  Thus D10
 pfnita_opt-HA parasites were 
transfected with pCC4-pfnita500 or pCC4-pfnita750, on two separate occasions.  No 
parasites were detected in any of the four transfections after eight weeks incubation.  
(ii) D10 and 3D7 parasite strains were transfected with the two plasmids pCHD-Hsp86-
pfnita_opt-(HA)3 and pCC4-pfnita500 or pCC4-pfnita750 simultaneously, and in 
duplicate.  The transfected parasites were selected using Bla and WR 99210.  After six 
weeks, parasites were detected in a single culture from a total of eight co-transfections 
which had been transfected with the pCC4-pfnita500 KO plasmid (referred to as pCC4-
pfnita) and pCHD-Hsp86-pfnita_opt-(HA)3 (designated pCHD-pfnita_opt-HA).  The 
single transfected line was designated D10 pfnita_opt-HA/pCC4-pfnita. 
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Figure 4.11: Overview of the drug cycling process for parasites transfected with pCHD-
pfnita_opt-HA and pCC4-pfnita.  Parasites after transfection, growing both WR 99210 and Bla are 
termed cycle 0 (black box).  Drug cycling of transfected parasites was carried out to select for integration 
of plasmids into the parasite genome.  Off/on Bla cycling is indicated by blue boxes/arrows and treatment 
with 5-FC is indicated in orange.  At each stage gDNA was taken for analysis using PCR and/or Southern 
blot, and stabilates were made for the preservation of the parasite line.  This is indicated by a green 
box/arrow combination. 
 
Transfected parasites, D10 pfnita_opt-HA/pCC4-pfnita, were taken through drug selection cycles 
as described previously (Sections 2.5.7.1 and 4.3) and an overview is provided in 
Figure 4.11.  The parasites were taken through two drug selection cycles where Bla 
drug pressure was removed and WR 99210 drug pressure was maintained to preserve 
the episomal copy of the gene.  When parasites were growing as normal under drug 
pressure, gDNA was generated for a diagnostic Southern blot. 
 
The band sizes expected after gDNA restriction with NdeI are given in Figure 4.12, (A).  
In addition a western blot was carried out on soluble and insoluble protein extracted 
from D10 pfnita_opt-HA/pCC4-pfnita at cycle 0 (B).  The result showed that the synthetic codon-
optimised PfNitA protein was expressed well and was present in the membrane 
containing insoluble fraction as anticipated. 
 
D10 pfnita_opt-HA/pCC4-pfnita parasites in cycles 0 and 1 were treated with 5-FC to promote 
the integration of the KO plasmids.  After two weeks of continuous culture under the 
selective pressure of Bla, WR 99210 and 5-FC parasites were observed to be growing 
normally.  Therefore gDNA was generated and stabilates were prepared.  In 
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comparison to the results presented in Section 4.3, the recovery of parasites treated 
with 5-FC was rapid, two weeks compared to seven weeks.  This finding suggested the 
cd gene had been lost and the KO plasmid may have integrated by double cross-over 
recombination. 
 
A PCR amplification was carried out to amplify the cd gene from each of the parasite 
cycles with and without 5-FC treatment.  The results displayed in Figure 4.12, (C) show 
the cd gene is still present during cycles 0, 1, and 2.  A very faint product is observed 
for cycle 0 + 5-FC (lane 4) with no band in cycle 1 + 5-FC (lane 5) illustrating the loss 
of the cd gene from cycle 1 + 5FC parasites.  Furthermore, a PCR experiment to check 
for 5’ integration and 3’ integration was carried out on the 5-FC treated samples only.  
The primers were placed up and downstream of the native gene, and up and 
downstream of the drug selectable marker (Section 4.3 and Appendix 2).  These PCR’s 
did not give any products when applied to an agarose gel (data not shown).  Without a 
positive control it is impossible to establish if (i) the PCR is simply not working or if (ii) 
integration has not occurred.  However, at low PCR primer annealing temperatures (40 
oC) it might be anticipated that some products would have amplified due to non-
specific binding of the primers to the plasmid construct. 
 
A diagnostic Southern blot was consequently carried out using the restriction enzyme 
NdeI (Figure 4.12).  The DNA fragments detected by the pfnita gene specific probe are 
indicated by blue arrows, while fragments expected with a probe specific for the hdhfr 
selectable marker are specified by green arrows Figure 4.12, (A).  The pfnita probe 
detected the WT fragment of around 4.5 kb in each of the D10 pfnita_opt-HA/pCC4-pfnita cell 
lines, and plasmid of approximately 0.7 kb in the transfected cell lines Figure 4.12, (D).  
In the event of a double cross-over having occurred, a 2.5 kb fragment would have 
been expected, but this was not observed in any of the samples.  Two high molecular 
weight fragments (around 6 and 10 kb) were observed in the 5-FC treated samples 
only.  This pattern may indicate recombination between the two plasmids. 
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 (A)
 
(B) 
 
 
     
(C) 
 
 
 
     (D)              (E) 
                 Probe: pfnita specific               Probe hdhfr specific   
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Figure 4.12: Knock-out in the presence of an episomal copy of pfnita.   (A)  Knock-out of pfnita 
by gene replacement.  A schematic diagram (not to scale) of the pfnita wild-type locus (I), the pCC4-pfnita 
plasmid (II), the pfnita gene locus following a double cross-over recombination event (III), and the pCHD-
pfnita_opt-HA plasmid (IV).  Diagnostic digests to analyse the genotype of transfected parasites were 
performed with NdeI.  Restriction sites are indicated by black arrows.  The lengths of the expected DNA 
fragments detectable with pfnita specific probe homologous to the 5’ insertion of the plasmid are indicated 
by blue arrows, and those homologous to the drug selectable marker of the synthetic gene plasmid, 
hDHFR, are indicated in green.  (B) A western blot using an anti-HA antibody directed against the 3’ HA 
tag.  The soluble (lane 1) and insoluble pellet (lane 2) are shown.  The blot was stripped and re-probed 
with an anti-BCKDH antibody as a loading control.  20 µg total protein was loaded in each lane, the arrow 
indicates the position of PfNitA_opt-HA.  (C) A PCR amplification was carried out to check for the loss of 
the cytosine deaminase/uracil phosphoribosyl transferase chimera at cycles 0 (lane 1) 1 (lane 2) and 2 
(lane 3) and after treatment with 5FC at cycles WR 99210 cycles 0 (lane 4) and 1 (lane 5).  (D)  Southern 
blot using a gene specific probe after restriction of gDNA with NdeI, of cell lines co-transfected with pCC4-
pfnita and pCHD-pfnita_opt-HA.  The blue arrows in (A) indicate the expected sizes with a gene specific 
probe and the green arrow the hdhfr specific probe.  Lane 1 contains D10 WT genomic DNA, lanes 2 and 
3 contained gDNA from D10 pfnita_opt-HA/p
CC4-pfnita in WR 99210 selection cycle 0, lane 3 was after 5-FC 
treatment, and lane 4 contained gDNA in WR 99210 selection cycle 1 after 5-FC treatment.  (E) Is as (D) 
using a hdhfr specific probe. 
 
The hdhfr probe should detect only the plasmid containing the synthetic gene and 
produce a single 7.6 kb DNA fragment on the Southern blot.  The 7.6 kb fragment was 
indeed present in the blot, as well as two lower molecular weight fragment bands of 
around 3 and 4.5 kb were also detected (lane 4) corresponding to parasites in WR 
99210 selection cycle 1 after treatment with 5-FC.  The two lower molecular weight 
fragments may suggest recombination between the KO and complementing plasmids. 
To extend these data, probes were generated to the bsd and cd genes contained in the 
KO plasmid.  The bsd DNA probe detects a 7.3 kb fragment in the KO plasmid and a 3 
kb fragment after an integration event.  The cd gene is only present on the plasmid 
and is lost during double cross-over recombination.  Figure 4.13 displays Southern 
blots carried out using bsd (A) and cd (B) probes.  The bsd probe hybridises to a band 
diagnostic to the presence of the pCC4 knock-out plasmid in each of the D10 pfnita_opt-
HA/pCC4-pfnita cell lines, and as expected no signals were detected in the WT sample.  In 
addition to the 7.3 kb DNA fragment, a low molecular weight DNA fragment of around 
500 bp was observed.  The size expected by the cd probe is 7.3 kb present on the KO 
plasmid.   The cd probe detected a very faint band in each of the lanes containing the 
transformed parasites.  The PCR analysis presented in Figure 4.12, (C) lane 1 confirms 
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the presence of the cd gene in the non- 5-FC treated cycle 0.  Thus an obvious band 
should have been present in the Southern blot (Figure 4.13, (A) lane 2).  In the event 
of a single cross-over either at the 5’ or 3’ insert only (i.e. a single cross-over), the cd 
gene should remain.  If a 3’ only integration had occurred, the bsd and cd probes 
should hybridise to a 7.3 kb DNA fragment, the equivalent to the plasmid.  The pfnita 
gene specific probe would detect two fragments of similar molecular weight, 2.5 and 
2.6 kb.  However, a band or bands corresponding to these sizes was not observed in 
Figure 4.12, (D) ruling out a 3’ only integration.  On the other hand, a 5’ only 
integration may also have taken place.  The fragment sizes detected by the bsd and cd 
probes should be 3 and 8.8 kb, respectively.  There was no 3 kb fragment detected by 
the bsd probe in Figure 4.13, (A), and the fragment in Figure 4.13, (B) is too small to 
correspond to the 8.8 kb fragment detected by the cd probe. 
 
 (A)       (B) 
 
        Probe: bsd specific              Probe cd specific 
 
Figure 4.13:  Southern analysis of D10 pfnita_opt-HA/pCC4-pfnita using bsd and cd probes.  Southern 
blots after digestion of gDNA with NdeI, from cell lines transfected with pCC4-pfnita and pCHD-pfnita_opt-
HA, probed with (A) bsd and (B) cd probes.  The bsd probe detects a 7.3 kb fragment for the plasmid and 
a 3kb fragment after integration, the cd probe detects a 7.3 kb fragment on the plasmid only.  Lane 1 
contains D10 WT genomic DNA, lanes 2 and 3 contain gDNA from D10 pfnita_opt-HA/pCC4-pfnita in WR 99210 
selection cycle 0, lane 3 is after 5-FC treatment, and lane 4 contains gDNA in WR 99210 selection cycle 1 
after 5-FC treatment. 
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As the additional bands cannot be explained by plasmid recombination with the 
parasite genome it is possible the two plasmids have recombined leading to the 
resistance of parasites to both Bla and 5-FC without integration of the pCC4-pfnita KO 
plasmid.  This is somewhat speculative and in order for this idea to be verified the 
parasite lines would have to be analysed in greater detail in further experiments.  
Thus, the attempt to knock-out PfNitA whilst in the presence of a supplementary copy 
of the gene was not successful.  This failure indicates that the gene may be essential 
to asexual stage P. falciparum parasites.  The information in Table 4.4 provides an 
overview of the results from this section. 
 
Parasite PCR Southern Blot 
 cd pfnita hdhfr bla cd 
Cycle 0 positive  WT, KO plasmid positive positive positive 
Cycle 0+ 5-FC negative WT, KO plasmid positive positive positive 
Cycle 1 positive WT, KO plasmid positive positive positive 
Cycle 1+ 5-FC  negative WT, KO plasmid positive positive positive 
Cycle 2 positive WT, KO plasmid positive positive positive 
Table 4.4: Overview of Southern blot and PCR results from cell line D10 pfnita_opt-HA/pCC4-pfnita 
after drug cycling.  PCR reactions are either positive or negative for the amplification product from cd.  
Southern blots using the hdhfr probe are either negative or positive for the presence of hdhfr on the 
pCHD-pfnita_opt-HA plasmid and blots using the bla or cd probes are either positive or negative for the 
corresponding genes from the pCC4-pfnita plasmid. 
 
4.5 Tagging the Native Gene by Allelic Exchange 
 
In order to assess the susceptibility of the pfnita locus to recombination following the 
failure to obtain null mutants using double homologous crossover recombination a 
tagged functional copy of the C-terminal pfnita region was created using the MultiSite 
Gateway® system.  To attempt to reconstitute the gene function of pfnita, a single 
homologous crossover reaction should yield a functional, tagged copy of the pfnita 
gene, while demonstrating that the region can be targeted by exogenous DNA through 
the integration of the plasmid backbone.  To target the locus of pfnita an 859 bp C-
terminal region of the gene (710-1569 bp) was amplified from 3D7 gDNA using the 
primers PfNitACtml GW F and PfNitA GW R (Appendix 2).  The forward primer contains 
a CACC overhang for directional cloning into the TOPO ENTR/D vector.  The C-terminal 
pfnita (ctml) gene fragment was cloned in frame with 3xHaemagglutinin ((ha)3) or 
green fluorescent protein (gfp) genes using the MultiSite Gateway® technology (Figure 
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4.14).  The final plasmid contains the C-terminal pfnita gene fragment controlled by 
the Hsp86 promoter.  Since only the C-terminus is present on the plasmid, no 
expression should occur from this construct. 
  
Both constructs pCHD-Hsp86-ctml-GFP and pCHD-Hsp86-ctml-(HA)3 were transfected 
on two independent occasions into P. falciparum D10 strains.  Parasites containing the 
plasmid were selected by applying WR 99210 since the plasmid contains the hdhfr 
resistance gene.  Parasites were observed four to five weeks after transfection.  
Transfected lines were termed D10ctml-GFP-1, D10ctml-GFP-2, D10ctml-HA-1 and D10ctml-HA-2.  
To obtain expression of the full-length gene with a GFP or (HA)3 tag, a single cross-
over must take place.  The single cross-over forms one full-length copy of the gene 
with the GFP or (HA)3 tag and a non-functional truncated copy further downstream (A 
of 4.17 and 4.18, respectively).  After a single cross-over the endogenous gene would 
therefore be tagged with GFP or (HA)3. 
 
(A)      (B) 
            
 
Figure 4.14: C-terminal pfnita integration transfection plasmids.  The final plasmids (A) pCHD-
Hsp86-ctml-GFP and (B) pCHD-Hsp86-ctml-(HA)3 encode the codon-optimised pfnita gene and a GFP or 
(HA)3 tag, respectively.  These plasmids were transfected into 3D7 and D10 parasites.  The attB sites that 
bring the constructs together during the Gateway cloning LR reaction are indicated.  The ampicillin and 
hDHFR selectable markers used in bacterial cloning and parasite transfection/selection, respectively, are 
also shown. 
 
gDNA was isolated from WR 99210 resistant parasites, analysed by diagnostic 
Southern blot and diagnostic PCR for integration events.  Parasites from both GFP and 
(HA)3 cell lines were taken through two on/off drug cycles, (see Section 2.5.7.1 and 
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Figure 2.6 for an explanation).  The data shown in Figure 4.15 provides an overview of 
the drug cycling process for GFP tagged parasites and Figure 4.17 for (HA)3 tagged 
parasites.  The GFP and (HA)3 tagged cell lines will be described separately. 
 
4.5.1 GFP tagged PfNitA 
After each drug selection cycle for D10ctml-GFP-1, gDNA was isolated from parasites for a 
diagnostic Southern blot.  The expected fragment sizes using a pfnita gene specific and 
hdhfr probes is presented in Figure 4.16, (A).  gDNA was digested with NdeI and ClaI 
and probed with the pfnita gene specific probe and hdhfr specific probe against the 
DSM of the plasmid.  After integration of the plasmid by single cross-over, the DSM will 
remain.  Parasites transfected with D10ctml-GFP-1 appeared to have lost the plasmid after 
two off/on drug cycles, as demonstrated by lack of the diagnostic fragment of 4.55 kb 
in the Southern blot using the gene specific probe and the absence of the hdhfr 
fragment at 3.65 kb using the hdhfr probe (Figure 4.16 (B) lane 3).  The Southern blot 
also demonstrated that no integration of pCHD-Hsp86-ctml-GFP had occurred. 
 
 
 
Figure 4.15: Overview of the drug cycling process for parasites transfected with pCHD-Hsp86-
ctml-GFP.  Parasites after transfection, growing on WR 99210 were termed cycle 0-1 and cycle 0-2 (black 
boxes).  Drug cycling of transfected parasites was carried out to select for integration of plasmids into the 
parasites genome.  Off/on drug WR 99210 cycling is indicated by blue boxes/arrows.  At each stage gDNA 
was taken for analysis using PCR and/or Southern blot, and stabilates were made for the preservation of 
the parasite line.  This is indicated by a green box/arrow combination. 
 
DNA fragment sizes of 1.3 and 6.2 kb were expected using the gene specific probe if 
construct integration had taken place.  The hdhfr probe should detect a fragment of 
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3.65 kb which is identical to the plasmid fragment after integration.  The results 
presented in Figure 4.16 (B) lanes 2 and 3 shows that the endogenous gene has not 
been affected by drug cycling as it is present in cycle 0 and cycle 2. 
 
Consequently, a second parasite line, D10ctml-GFP-2, was thawed since it had not been 
taken through any drug selection cycles (cycle 0).  This parasite line was maintained in 
culture in the presence of selectable drug pressure and no drug cycling was carried 
out. 
 
At four week intervals gDNA was isolated and analysed by a diagnostic PCR using three 
forward primers and a single reverse primer from the gfp gene (Table 4.5 and 
Appendix 2) to test for the presence of an integration event.  The three forward 
primers were made from different areas of the 5’ pfnita gene to maximise the chances 
of obtaining a product from the PCR as no positive control for integration was 
available.  The oligonucleotide primer locations are indicated by red arrows in Figure 
4.16 (A).  The expected sizes of the PCR products using the integration primers are as 
given in Table 4.5.  PCR amplification was also carried out to detect the presence of an 
approximately 500 bp hdhfr fragment using primers hDHFR F and hDHFR R (Appendix 
2).  The results from the integration PCR are included in Figure 4.16 (C).   
 
Primer Name  Product size 
PfNitA KO 750 5 F A 2445 bp 
PfNitA KO 500 5 F B 1787 bp 
PfNitA F1 C 1314 bp 
GFP mut2 R R n/a 
Table 4.5: Primers used to check for integration of pCHD-Hsp86-ctml-GFP.  The primer name 
denotes the designation of the primer as in Appendix 2.  The single letter after the primer corresponds to 
Figure 4.16.  The product size is the size of the product amplified if integration has taken place when PCR 
was carried out using each of the forwards primers in combination of the single reverse primer. 
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(A) 
 
(B)
 
Probe: pfnita specific                                             Probe: hdhfr specific 
 
       
       
    (C)            
 
Figure 4.16: Tagging the native gene with GFP using allelic exchange.  (A)  A schematic diagram 
(not to scale) of the pfnita wild-type locus (I), the pCHD-Hsp86-ctml-GFP plasmid (II) and the pfnita gene 
locus following a single cross-over recombination event (III).  Diagnostic digests to analyse the genotype 
of transfected parasites were performed with NdeI and ClaI.  Restriction sites are indicated by black 
arrows.  The lengths of the expected fragments detectable with pfnita specific probe homologous to the 5’ 
insertion of the plasmid are indicated by blue arrows, and those homologous to the drug selectable marker 
hDHFR are shown in green.  Primers used to detect integration are shown by small red arrows.  (B)  
Southern blots of cell lines transfected with pCHD-Hsp86- ctml-GFP after digestion of gDNA with NdeI and 
ClaI, and probed with a gene specific probe and hdhfr probe.  The blue arrows in (A) indicate the 
expected sizes with a gene specific probe and the green arrows the hDHFR specific probe.  Lane 1 
contains D10 WT genomic DNA, Lanes 2 and 3 contain gDNA from D10pCHD-Hsp86-ctml-GFP in WR 99210 
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selection cycles 0 and 2, respectively.  (C) A PCR amplification using primers to detect integration was 
carried out after 12 weeks growth.  Forward primer A is specific to the downstream non-coding region and 
primers B and C are specific to the 5’ pfnita sequence, and the reverse primer is found in the GFP 
sequence.  The expected sizes were as follows: A + R 2445 bp, B + R 1787 bp and C + R 1314 bp. 
 
None of the primer sets amplified a product from D10ctml-GFP-2 gDNA after 12 weeks of 
continuous growth in culture subject to WR 99210 selection pressure.  The hDHFR 
primers amplified an approximately 500 bp product indicating the hdhfr gene was still 
present (data not shown).  No Southern analysis was carried out on this cell line.  
When I left the laboratory no integration event was detectable for this plasmid after 12 
weeks. 
 
4.5.2 (HA)3 tagged PfNitA 
An overview of the drug cycling process for strain D10ctml-HA-1 is presented in Figure 
4.17.  After each off/on drug selection cycle for D10ctml-HA-1, gDNA was isolated from 
parasites for a diagnostic Southern blot.  The expected fragment sizes using gene 
specific and hdhfr probes is presented in Figure 4.18, (A).  gDNA was digested with 
NdeI and ClaI and probed with a gene specific probe and hdhfr specific probe against 
the DSM of the plasmid.  After integration of the plasmid by single cross-over 
recombination, the DSM should remain in the parasite genome.  In the Southern blot 
results of D10ctml-HA-1 a dark smear was repeatedly observed at cycles 0, 1 and 2, 
suggesting potential non-specific degradation of gDNA.  The plasmid construct (7.5 kb) 
and endogenous gene (3 kb) were also detected in each of the cycles (Figure 4.18 (B) 
lane 2).  After cycle 2 parasites were maintained in culture under drug pressure.  gDNA 
was generated from these parasites and the possibility of integration was investigated 
using a diagnostic PCR amplification using the same forwards primers as described 
above (Section 4.5.1, Table 4.5 and Table 4.6) and a reverse primer (R2) found 
between the (ha)3 sequence and the hdhfr gene (GW int R1, Table 4.6 and Appendix 
2).  The expected product sizes are outlined in Table 4.6.  Each of the primer sets 
returned a positive result implying integration had taken place in at least a subset of 
the parasite population and the results are presented in Figure 4.18 (C).  A second 
Southern blot was carried out and the results are presented in Figure 4.18 (B) lane 3. 
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Primer Name  Product size 
PfNitA KO 750 5 F A 2081 bp 
PfNitA KO 500 5 F B 1743 bp 
PfNitA F1 C 1270 bp 
GW int R1 R2 n/a 
Table 4.6: Primers used to check for integration of pCHD-Hsp86-ctml-(HA)3.  The primer name 
denotes the name of the primer from Appendix 2.  The single letter after the primer corresponds to Figure 
4.16.  The product size is the size of the product amplified if integration has taken place when the PCR 
reaction was carried out using each of the forwards primers in combination of the single reverse primer. 
 
The results of the Southern blot using the gene specific probe showed that the 
endogenous gene (3 kb) was still present as was the plasmid pCHD-Hsp86-ctml-(HA)3 
of 7.5 kb.  The dark smear was still present but additional bands at approximately 10 
kb, 6 kb, 5 kb and 4 kb were distinguishable (Figure 4.18 (B) lane 3).  Following an 
integration event hybridising DNA fragments would be expected at 4.3 kb and 6.2 kb, 
possibly corresponding to some of the detected fragments.  When the blot was 
reprobed with a hdhfr specific probe a fragment was observed at 7.5 kb which is 
consistent with the plasmid, however, additional fragments were visible at 1.75 kb and 
4 kb. 
 
Figure 4.17: Overview of the drug cycling process for parasites transfected with pCHD-Hsp86-
ctml-(HA)3.  Parasites after transfection, growing on WR 99210 were termed cycle 0 (black box).  Drug 
cycling of transfected parasites was carried out in order to select for integration of plasmid constructs into 
the parasite genome.  Off/on drug WR 99210 cycling is indicated by blue boxes/arrows.  At each stage 
gDNA was taken for analysis using PCR and/or Southern blot, and stabilates were made for the 
preservation of the parasite line.  This is indicated by a green box/arrow combination. 
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After an integration event a DNA fragment would be expected at 4.3 kb when using 
the hdhfr probe.  The fact that the additional bands observed with both the gene 
specific and hdhfr probes were faint indicated only a small population of parasites 
contained the integrated plasmid at the correct locus, and that integration elsewhere in 
the genome may also have taken place.  Further to this, a western blot of the insoluble 
and soluble protein from D10ctml-HA-1 was carried out using an anti-HA antibody (as 
described previously).  Insoluble protein from D10pfnita_opt-HA was used as a positive 
control for size reference. 
 
The results presented in Figure 4.18, (D), lane 1 shows the presence of the insoluble 
protein and no protein cross-reacted with the antibody. However, three distinct bands 
were observed in the insoluble fraction (lane 2), one of which corresponded to the 
positive control (lane 3) at approximately 35 kDa.  This result implied a full-length 
tagged PfNitA protein was expressed by the parasites.  Moreover, the other band on 
the blot is perhaps related to non-specific integration of the plasmid and subsequent 
protein expression.  The blot was stripped and re-probed with an anti-BCKDH antibody 
to verify separation of the soluble and insoluble fractions. 
 
Both protein fractions from D10ctml-HA-1 parasites were positive for BCKDH at different 
intensities (Figure 4.18, (D)).  Visualisation of a band on the western blot may be due 
to the large concentration of protein applied to the SDS-PAGE gel, approximately 1 mg.  
If only a relatively small number of parasites contained the correctly integrated pCHD-
Hsp86-ctml-(HA)3 plasmid then by extension, only a small number of parasites would 
contain the full-length (HA)3 tagged PfNitA protein, thus the volumes of insoluble and 
soluble proteins that were electrophoresed was titrated between 20 µg and 2.5 mg.  At 
1.2 mg, the anti-HA antibody gave the banding pattern present in lane 3 of Figure 
4.18, (D).  At concentrations lower than 1.2 mg no bands were detected using the 
anti-HA antibody, though bands were detected in all soluble protein lanes when probed 
with anti-BCKDH as well as insoluble protein in lanes with 160 µg plus of total protein. 
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               Probe: pfnita specific          Probe hdhfr specific 
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(C)                    (D) 
             
 
Figure 4.18: Tagging the native gene with (HA)3 using allelic exchange.  (A)  A schematic 
diagram (not to scale) of the pfnita wild-type locus (I), the pCHD-Hsp86-ctml-(HA)3 plasmid (II) and the 
pfnita gene locus following a single cross-over recombination event (III).  Diagnostic digests to analyse 
the genotype of transfected parasites were performed with NdeI and ClaI.  Restriction sites are indicated 
by black arrows.  The lengths of the expected fragments detectable with pfnita specific probe homologous 
to the 5’ insertion of the plasmid are indicated by blue arrows, and those homologous to the drug 
selectable marker hDHFR are shown in green.  Primers used to detect integration are shown by small red 
arrows.  (B)  Southern blots after digestion of gDNA with NdeI and ClaI, of cell lines transfected with 
pCHD-Hsp86-ctml-(HA)3, and probed with a gene specific probe and hdhfr probe.  The blue arrows in (A) 
indicate the expected sizes with a gene specific probe and the green arrows the hDHFR specific probe.  
Lane 1 contains D10 WT genomic DNA, Lanes 2 and 3 contain gDNA from D10ctml-HA in WR 99210 selection 
cycles 0 and 2, respectively.  (C) A PCR using primers to detect integration was carried out.  Forward 
primer A is specific to the downstream non-coding region and primers B and C are specific to the 5’ pfnita 
sequence, and the reverse primer, R, is found in the plasmid only.  The expected sizes are as follows: A 
2081 bp, B 1743 bp and C 1270 bp.  (D) A western blot was carried out against insoluble and soluble 
parasite extract using an anti-HA antibody directed against the C-terminal tag.  Lane 1 contains the 
soluble parasite extract and lane 2 the insoluble pellet.  Lane 3 provides a control sample for size (the 
synthetic PfNitA insoluble pellet). The blot was stripped and re-probed with an anti-BCKDH antibody as a 
loading control which examined whether or not the fractions had been separated efficiently.  The black 
arrow indicates the position of PfNitA-HA and the grey arrows the additional bands. 
 
Cells of D10ctml-HA-1 should therefore be cloned by limiting dilution to select for a clonal 
cell line which has undergone the integration event at the intended locus.  However, 
due to technical reasons this work is yet to be completed. 
 
4.6 Knock-out by Gene Disruption and Knock-out Control by Allelic Exchange 
 
An alternative method to achieve loss of function of a gene product is to generate a 
gene disruption by single homologous recombination into the gene locus of interest.  
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pHH1 based plasmid constructs are employed successfully in knock-out and knock-out 
control studies to prove that the gene locus is targetable without the addition of any 
tags as described in Section 4.5.  The approach is depicted in Figure 4.19. 
 
The pHH1 plasmid contains the hdhfr gene for selection of transfected parasites with 
WR 99210, and an ampicillin resistance cassette for selection during bacterial cloning 
(Reed et al, 2000) (Figure 4.19, A and B I).  The gene of interest (GOI)fragments are 
cloned between BglII and XhoI restriction sites, and these must be incorporated into 
the primers. 
 
The GOI is truncated at the N-terminus and is missing the ATG start codon.  The GOI 
is also truncated at the C-terminus and contains an artificial stop codon (A) II.  For 
knock-out control constructs the GOI fragment to be cloned into the vector is truncated 
at the N-terminus as in the knock-out, but contains the full C-terminal sequence (B) II.  
A single cross-over recombination event between a knock-out construct and the GOI 
leads to two truncated and non-functional copies of the gene (A) III.  Recombination 
between a knock-out control construct and the GOI leads to the formation of one full-
length copy and one truncated copy of the gene (B) III.  The knock-out control does 
not contain any N-terminal or C-terminal tag that may disrupt the function of the 
protein making this a viable option as previous attempts altered the C-terminal of the 
protein with a tag. 
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 (A) 
 
 
 (B) 
 
 
Figure 4.19:  Future Strategy; knock-out and knock-out control by allelic exchange.  (A) A 
schematic diagram of the pfnita WT locus (I).  The knock-out fragment is truncated at the 5’ and 3’ of the 
gene, leaving approximately 1000 bp available for recombination (II).  A single cross-over at the correct 
locus should result in an interruption of the locus producing two non-functional copies of the gene (III).  
(B) A control integration event. The knock-out control fragment is, as with the knock-out construct 
truncated at the 5’, but is in contrast full-length at the 3’ retaining the endogenous stop codon (II).  
Integration of the knock-out control construct, by single cross-over, into the gene locus should thus result 
in the disruption of the locus generating a single functional copy of the gene and a truncated copy (III).  
Diagrams are not to scale. 
 
Therefore, as a knock-out control, a 1375 bp insert homologous to the pfnita C-
terminal region and containing the endogenous stop codon was amplified using the 
primers PfNitA pHH1 KOcon F  and PfNitA pHH1 KOcon R (Appendix 2) from 3D7 gDNA 
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and cloned into the intermediate cloning vector pSCB (StrataCloneBlunt, Agilent 
Technologies, Cheshire, UK) for sequencing.   A knock-out construct was also prepared 
truncated at the 5’ and 3’ ends containing a TAA stop codon.  The construct was 
amplified using the primers PfNitA pHH1 KO F and PfNitA pHH1 KO R (Appendix 2) 
from 3D7 gDNA, and cloned into pSCB for sequencing.  The sequences of the two 
products were confirmed.  However, due to time constraints, the KO and KO control 
inserts have not yet been cloned into the final pHH1 vectors and sequenced, and the 
transfections with these new plasmids await further experimental work. 
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4.7 Summary 
 
 Subcellular prediction programs do not predict a localisation for Plasmodium falciparum 
NitA, or any Plasmodium orthologues.  Therefore the synthetic codon-optimised pfnita 
gene was cloned into an expression plasmid containing sequences encoding GFP or 
(HA)3 tag to allow biochemical analysis.  The synthetic pfnita gene was expressed 
episomally, and the fusion protein expression was confirmed by western blot exploiting 
antibodies made to the C-terminal epitope tag.  Using fluorescence light microscopy, 
the GFP or (HA)3 tagged PfNitA protein was located to the parasite plasma membrane 
but was also observed in the digestive vacuole membrane. 
 
 Co-localisation studies of PfNitA were carried out using immunofluorescence analysis 
comparison with two known transporters.  One of these transporters is known to be 
located in the parasite plasma membrane (hexose transporter) whilst the second in the 
digestive vacuole membrane (chloroquine resistance transporter).  In IFA’s co-
localisation of PfNitA was observed exclusively with the hexose transporter in the 
plasma membrane.  However, the location in the digestive vacuole membrane 
localisation was not confirmed. 
 
 Attempts to knock-out the pfnita gene were unsuccessful using a double cross-over 
recombination approach.  Out of 20 individual transfections into two different parasite 
strains only one parasite line was generated in which the KO plasmid was maintained 
episomally.  This suggests that pfnita is either essential for parasite survival or that the 
locus is unable to be genetically targeted. 
 
 A synthetic codon-optimised pfnita expression plasmid (pCHD-pfnita_opt-HA) was co-
transfected with a pCC4-pfnita knock-out vector to complement for the potential loss of 
the pfnita gene.  Both plasmids were maintained episomally as shown by Southern 
blot.  Western blot analysis confirmed expression of the complementing PfNitA-(HA)3 
protein.  Treatment with 5-FC caused loss of the negative selectable marker and 
potentially led to the recombination between the two constructs as suggested by 
Southern blot analysis. 
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 A C-terminal portion of the pfnita gene was cloned into a plasmid harbouring a GFP or 
(HA)3 tag.  The purpose was to tag the endogenous gene and to express the tagged 
gene under control of its native promoter to show whether the gene locus is 
targetable, per se.  Recombination was not achieved using the GFP tagged gene 
construct.  In contrast, the (HA)3 tagged gene construct, on the other hand, underwent 
recombination at the correct gene locus as confirmed by diagnostic Southern blot and 
PCR.  The cloning of this parasite line has not yet been achieved due to technical 
difficulties. 
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5 Plasmodium chabaudi Cir2 Expression and Structural 
Analyses 
 
5.1 Introduction 
 
The PcCir2 protein is one of a large family of proteins encoded by rodent, simian and 
human malarias.  The proteins of the family have been postulated to play a role in 
antigenic variation due to the presence of a hypervariable region (HVR) (Figure 1.6), 
but no evidence of such a role has been determined.  The objectives of this chapter 
were (i) to overexpress PcCir2 in a bacterial expression system, (ii) to produce purified 
protein for crystallography trials, (iii) develop a 2D structural model, and, (iv) 
determine the 3D crystal structure of the protein.  It was hoped that with structural 
models, progress could be made in the determination of a role. 
 
5.1.1 Membrane protein expression 
Membrane proteins (MP’s) are particularly difficult to work with and special 
considerations need to be taken when it comes to overexpression and purification.  
However, the production of proteins, and in particular membrane proteins, is important 
to enable the study of membrane proteins as they comprise the largest class of drug 
targets (Arinaminpathy et al, 2009).  The overexpression of membrane proteins can be 
toxic to the cells they are produced in.  There is a finite surface area that can be 
utilised by membrane proteins, too high an expression may prevent the hosts’ 
endogenous, and in some cases essential, membrane proteins from reaching their 
destination.  Nonetheless, membrane proteins must be produced at high levels to 
reach a sufficient concentration to be purified for further study.  In this regard, purified 
protein for crystallography is required in milligram amounts.  The large hydrophobic 
domains contained within membrane proteins can result in instable proteins that have 
a tendency to aggregate when removed from the phospholipid bi-layer (Junge et al, 
2008).  Such aggregation may lead to the packaging of proteins into inclusion bodies 
(IBs).  Protein can be extracted from IBs.  To guarantee a protein has been correctly 
re-folded, an activity assay is normally required to test the proteins’ activity is as 
expected. 
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During the purification of a membrane protein, a detergent is used to replace the lipid 
bi-layer and maintain the structural conformation of the protein.  Choosing the correct 
detergent is fundamental for membrane protein stabilisation and for retaining the 
protein in its native state.  The removal of a protein from its membrane may cause 
unfolding and other structural changes.  Likewise, the detergent must be compatible 
with purification and related procedures such as crystallographic approaches 
(Newstead et al, 2007).  Detergents are amphiphilic compounds with polar and 
nonpolar domains.  Solubility is provided by the hydrophilic domain of a detergent.  
The hydrophobic domain allows access to the lipid bi-layer.  Detergents are able to 
disrupt the hydrophobic associations that hold membrane proteins in place (Newstead 
et al, 2007).  The small amphipathic molecules bind to the hydrophobic regions of the 
membrane proteins and dislodge the lipid molecules.  The side chains of detergents 
come in a variety of lengths and can be ionic, anionic and zwitterionic.  Using strong 
ionic detergents, such as SDS, causes the protein to become denatured and are 
therefore unsuitable to the purification of membrane proteins which need to be 
functionally active when purified.  Milder anionic detergents such as DDM have been 
proven to be useful (e.g. Beckham et al, 2010).    The “membrane proteins of known 
structure database” 30 contains a list of all membrane proteins crystallised and the 
detergents used. 
 
E. coli was chosen as the expression host for the pccir2 gene rather than more 
complicated and expensive systems such as yeast, insect or mammalian cells (Junge et 
al, 2008).  E. coli has many advantages over other expression systems, despite the fact 
that it has drawbacks when used in the production of a eukaryotic protein, especially 
one from Plasmodium due to the high AT content of its genome.  Yeasts such as Pichia 
pastoris (e.g. Beckham et al, 2009) are used in the expression of membrane proteins.  
Yeasts are eukaryotic organisms and therefore carry out a range of posttranslational 
modifications (PTM), though these are not always suited to the protein of interest 
(Junge et al, 2008).  The cost of culturing yeasts is low, and the processes are 
reasonably easy to carry out.  The culture and transfection of insect cells is more 
difficult, due to the complexity in creating protein expression vectors and more 
complex media.  However, PTMs are possibly more similar to those in Plasmodium and 
                                                 
30 http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html.  Accessed on 16 January 2010. 
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the larger size of cells provides more membrane for the overexpressed proteins (Junge 
et al, 2008).  Mammalian cells carry out PTMs typical of human cells, though 
potentially not Plasmodium cells.  The culture of mammalian cells, such as human 
embryonic kidney cells and human epitheloid cells, is the most complicated of the 
eukaryotic cell types and transfection/expression can take many days to occur (Junge 
et al, 2008).  For each of the expression hosts, the protein expression must be 
optimised to maximise the protein production with minimal cost to the host. 
 
E. coli was chosen as the host for this project due to the low cost of culturing and 
relative ease of use.  Most of the structural information known about membrane 
proteins has come from those expressed in bacterial expression systems, 85 % 
compared to 7.2 % (yeast, insect and mammalian cells combined) (Junge et al, 2008).   
There are many plasmid vectors for E. coli and each of these can be used to fine tune 
the production of a given membrane protein.  These vectors can also add tags such as 
GFP to act as a reporter protein or a polyhistidine tag to aid in purification.  The 
downside of using a prokaryote system to express a eukaryotic protein is the absence 
of post-translational modifications such as palmitoylation and proteolytic cleavage 
(Junge et al, 2008) which may prove to be essential for the correct folding and 
therefore protein function. 
 
5.1.2 P. chabaudi as a model 
P. falciparum, the causative agent of most human malarial deaths, can be propagated 
in the laboratory.  However, as it infects only humans and a small number of monkeys, 
which raises ethical issues, no in vivo model is readily available.  To study Plasmodium 
in vivo researchers turn to rodent malarias as these share a conservation of their 
genetic and biochemical processes with the human malarias (Waters, 2002).  The 
whole of the rodent malaria life cycle can be studied in vivo under laboratory 
conditions, and the parasites are able to be genetically manipulated in vitro (Reece and 
Thompson, 2008).  In this respect P. chabaudi is recognised as a useful model for the 
investigation of aspects such as drug resistance (Afonso et al, 2010), testing of drugs, 
and research on antigenic variation (Cunningham et al, 2005) as rodent models allow 
in vivo investigations of host-parasite relationships.  Rodent malaria models are not 
without their disadvantages such as validity of extrapolating host-parasite interactions 
from the rodent model to the human.  However the study of a process such as 
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antigenic variation requires in vivo investigation and we are thus concentrating on a 
protein from the rodent malaria P. chabaudi, the only rodent malaria known to undergo 
antigenic variation under laboratory conditions (Fischer et al, 2003). 
 
5.2 Sequence Considerations 
 
We chose to study the Cir2 protein of P. chabaudi as a representative PIR protein.  
This protein was known to be expressed in the parasites at the time of selection (Dr. C. 
Janssen, personal communication).  An an antigenically variable protein, the PcCir2 
protein is expected to be present at the surface of the RBC, as has been shown for 
other members of the CIR and PIR family (Janssen et al 2004, and Cunningham et al, 
2005). 
 
 
Figure 5.1:  Hydropathy plot of the PcCir2 protein.  The y-axis is the hydrophobicity value, the 
higher the value the more hydrophobic a set of amino acids is deemed to be.  The x-axis displays the 
amino acid residue number.  A single predicted TMD for Cir2 is observed approximately at residues 260 – 
280.  Default settings for upper and lower hydrophobicity value were used and can be seen as a red and 
green line running across the images, respectively.  Peaks above the red line are taken as TMDs, and 
those above the green line are putative TMDs.  ‘start position of window in sequence’ denotes the sliding 
window of 21 amino acids, which can be found in the 312 amino acid PfNitA sequence.  Diagram taken 
from Mobyl@Pasteur v1.0. 
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The SignalP and IPSORT (Section 2.6.6 and Table 2.6) computer programs were used 
to identify any signal peptides the PcCir2 protein sequence may contain.  Both 
programs returned a negative result, indicating they do not predict a signal sequence 
in PcCir2.  The PIR protein family have been postulated to have 1 or 2 transmembrane 
domains (TMDs).  To investigate the number of TMDs present within the PcCir2 
protein, the amino acid residue sequence was subject to in silico analyses using 
membrane protein topology predictions, summarised in Table 5.1.  The hydropathy 
plots obtained from these analyses indicated that the protein contains one TMD (Figure 
5.1) between residues Leu 263 and Tyr 281.  The amino acid sequence 
(LIPGLLIFAAIPVFLGIAY) is flanked by two lysine residues Lys 262 and Lys 282.  These 
positively charged side chains are unlikely to be located within the putative TMD. 
However this possibility cannot be ruled out. 
 
TMD Predictor TMDs Orientation 
TMHMM 1 N-out 
HMMTOP 1 N-out 
SOSUI 1 N-out 
TMpred 1 N-out 
TopPred 1 N-out 
Consensus 1 N-out 
Table 5.1: Membrane topology predictions.  Multiple membrane protein topology predictions were 
used to predict the number of transmembrane segments in PcCir2 and the orientation through the 
membrane.  Computer program URLs are given in Section 2.6.2. 
 
The hypervariable region (HVR) was established using a Plotcon (EMBOSS) program as 
reported by Janssen et al (2004).  The program positions the HVR before the predicted 
TMD and covers around 41 residues given as: 213 
NKKKGESCDFPSLPQISPKKSFAQNSLESPGHTSGHNSEDI 253.  The study also established 
5 sequence motifs conserved between members of the pir and rif gene families 
(Janssen et al, 2004).  Two of these conserved motifs are present in PcCir2.  The first 
motif (Motif 3) [KV]-L-C-I-[YF]-[LA]-[YI]-[LIY]-W-L, is present in PcCir2 with the 
residue sequence as 85 KLAQYAILWL 94 and the second (Motif 4) [CF]-D-K-[ED]-I-Q-
K-[IQ]-[IY]-L-[KR]-[DE] is present as 287 FDKQRHRQYLRE 298.  The schematic PcCir2 
protein presented in Figure 5.2, A highlights the positioning of these key features.  The 
predicted 2D model is presented with the key features (Figure 5.2, B). 
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(A) 
 
 
 
(B) 
 
 
Figure 5.2:  PcCir2 predicted 2D membrane topology.  (A) A schematic of the PcCir2 residue 
sequence and (B) predicted 2D topology, illustrating the key features in different colours.  The HVR is 
green, the TMD in blue, the grey bar represents the lipid bi-layer.  The two pir family motifs observed in 
the PcCir2 residue sequence are presented in pink and orange.  N and C denote the termini.  Diagram is 
not to scale. 
 
5.3 Recombinant Expression of Full-length PcCir2 in E. coli 
 
To facilitate expression in E. coli, the pccir2 coding sequenced was codon-optimised to 
reduce the A+T richness from 71 % to 56 %.  Whilst redesigning the gene sequence, 
Plasmodium chabaudi Cir2 Expression and Structural Analyses Chapter 5 
 
[175] 
 
it was important to ensure (i) the removal any Shine-Dalgarno motifs (AGGAGG) which 
could be misread as ribosomal binding sites, and (ii) to omit repeats of A’s that could 
be mistaken for polyA tails and degraded.  The synthetic codon-optimised P. chabaudi 
cir2 gene and protein are herein referred to as pccir2 and PcCir2, respectively. 
 
5.3.1 Optimisation of PcCir2 expression in pTTQ18 and pTTQ10H 
The synthetic codon-optimised pccir2 gene was inserted into the IPTG inducible 
vectors pTTQ18 and pTTQ10H to give the PcCir2 protein expression plasmids 
pTTQ18_pccir2 and pTTQ1OH_pccir2 (Figure 5.3, A and B).  These plasmids encode a 
hexa-histidine and deca-histidine His-tag, respectively, and the linking sequence RGS 
(Stark, 1987).  Expression of the pccir2 coding region results in a protein with a C-
terminal His-tag fusion. 
 
(A)        (B) 
    
 
Figure 5.3:  Cloning of pccir2 into the TTQ vectors for expression in E. coli.  (A) Plasmid construct 
of pccir2 upstream from a His-tag.  pTTQ10H encodes 10 histidine residues, and pTTQ18 encodes 6.  The 
restriction sites used to insert the pccir2 gene are indicated as well as the ampicillin resistance (AmpR) 
gene which acted as a selectable marker during cloning.  The tac promoter is upstream of the inserted 
gene for inducible expression using IPTG.  Diagram is not to scale.  (B) The 938 bp pccir2 gene was 
cloned into the 4500 bp TTQ vectors using the restriction sites EcoRI and PstI. 
 
Small scale expression trials using two E. coli strains, BL21 (DE3) and C43 (DE3), 
transformed with either plasmid were carried out with a number of conditions tested.  
The C43 (DE3) strain was demonstrated to be particularly effective in the production of 
membrane proteins through two uncharacterised mutations (Miroux and Walker, 
1996).  Bacterial cells were grown in two types of media, LB or 2xTY (Appendix 1), 
with the inducer IPTG used at 0.1 mM, 0.5 mM or 1 mM.   The temperatures tested 
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after induction were 37 oC or 22 oC, the amount of time after induction varied with cells 
grown for 3 or 6 h.  Bacterial samples were harvested and crude membranes prepared.  
The preparations were analysed by SDS-PAGE and staining with a His-tag stain. 
 
 
 
Figure 5.4: Small scale expression trials of PcCir2 from pTTQ18 and pTTQ10H.  Crude 
membrane preparations were run on 4–12% NuPAGE gels and stained with CBB (lanes 1 – 13).  Lane 1 is 
an uninduced control.  Protein was expressed in C43 (DE3) (lanes 2–3) and BL21 (DE3) (lanes 4 – 13) E. 
coli host strains transformed with pTTQ18-pccir2 (lanes 2, 4, 6, 8, 10 and 12) and pTTQ1OH-pccir2 (lanes 
3, 5, 7, 9, 11 and 13).  The bacterial cells were cultured in different growth media: LB (lanes 2 – 7, 10 and 
11) and 2xTY medium (lanes 8, 9, 12 and 13), and were induced with 1 mM (lanes 2 – 5) and 0.1 mM 
(lanes 6 – 13).  All samples were obtained from a growth time of 3 h after induction with IPTG, cells were 
incubated at 37 oC (lanes 2 – 9) and 22 oC (10 – 13).  Lanes 14 and 15 display the His-tag stained gel, 
lane 14 corresponding to lane 1 and lane 15 corresponding to lane 6.  15 μg of total protein extract was 
loaded in each lane.  An arrow indicates the position of PcCir2.  Molecular weight markers are indicated on 
the left hand side. 
 
The data presented in Figure 5.4 displays proteins from crude membrane preparations 
of cells grown under the various conditions following electrophoresis in NuPAGE gels 
and staining using Coomassie brilliant blue (CBB) (lanes 1 – 13) or the His-tag stain 
(lanes 14 and 15).  The PcCir2 protein is indicated with an arrow and conforms to the 
expected molecular weight of 37.4 kDa (hexahistidine tag) and 38.0 kDa (decahistidine 
tag) (ExPASy Compute pI/Mw tool31).  Lane 1 is an uninduced control with pTTQ18-
pccir2 in which the 37.4 kDa protein is not observed. 
                                                 
31 http://www.expasy.ch/tools/pi_tool.html.  Accessed on 26 March 2009. 
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Figure 5.5:  Large scale membrane preparations.  Lane 1 contains the PcCir2 protein expressed in a 
crude membrane preparation from the large scale expression.  This was prepared to verify that PcCir2 
protein is well expressed and confirm the expected size.  Lane 2 displays the E. coli membranes from the 
small scale expression trial, and confirms protein expression in each preparation.  15 µg of total protein 
was loaded in each lane.  An arrow indicates the position of PcCir2.  Molecular weight markers are 
indicated on the left hand side. 
 
Several conditions produced good expression and the conditions chosen for further 
studies were the BL21 (DE3) strain transformed with pTTQ18-pccir2 and grown in LB 
media, cells induced with 0.1 mM IPTG and grown for a further 3 h at 37 oC (Lane 6).  
The expression trials incubated for 6 h produced less protein than the 3 h samples and 
are not presented.  The decrease in observed protein after 6 h was possibly due to 
degradation of the protein as there were a number of smaller bands present on the gel 
when stained with the His-tag stain. These low molecular weight products imply 
degradation of the protein, premature termination of protein translation or non-
specificity of the His-tag stain. 
 
Large scale attempts to obtain the PcCir2 protein in milligram quantities were carried 
out using the optimised conditions (detailed above) and 12 L LB broth.  The reason for 
such a large culture volume is that membrane proteins are expressed at relatively low 
quantities as they must be expressed in bacterial membranes without toxicity to the 
cell.  Recombinantly expressed membrane proteins may result in adverse effects to the 
host bacteria for a number of reasons including the formation of perforations in the 
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membrane causing an osmotic disparity and interfering with targeting of native 
membrane proteins. 
  
A small aliquot equivalent to 15 µg of protein from the membrane preparation was 
analysed for presence of PcCir2.  The results presented in Figure 5.5 demonstrate that 
the PcCir2 protein was expressed in the membrane.  The membrane preparation 
provided 2.25 g of total protein, from 24.6 g of cells. 
 
5.3.2 Purification of PcCir2 
PcCir2 is a transmembrane protein, therefore detergents are required to release the 
protein from the lipid bi-layer. 
 
 
Figure 5.6:  Solubilisation of PcCir2 using DDM and OG.  A CBB stained gel with PcCir2 in lane 1, 
the DDM (n-Dodecyl-ß-D-maltopyranoside) soluble and insoluble fractions are in lanes 2 and 3, 
respectively.  The soluble and insoluble fractions from incubation with OG (n-Octyl-ß-D-glucopyranoside) 
are in lanes 4 and 5, respectively.  Equal volumes of the soluble and insoluble fractions were loaded in 
each lane.  An arrow indicates the position of PcCir2.  Molecular weight markers are indicated on the left 
hand side. 
 
The PcCir2 protein is thought to be monotopic.  Thus, the detergents used for the 
crystallisation of monotopic proteins32 were taken into account.  Only a few monotopic 
                                                 
32 http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html.  Accessed on 16 January 2010. 
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proteins have been crystallised, consequently no consensus detergent was discovered.  
For this reason, two detergents DDM and OG available in our laboratory were trialled 
first.  Total protein extract were solubilised in 1 % or 2 % of the detergents for 1 h or 
overnight, and incubated at 4 oC on ice. 
 
Soluble and insoluble fractions were separated by high speed centrifugation and 
separated on a Nu-PAGE gel.  The results obtained were not encouraging as most of 
the protein remained in the insoluble fractions (Figure 5.6, lanes 3 and 5).  Further 
detergents of short or long chain length and of non-ionic, ionic or zwitterionic nature 
were obtained and tested at different percentages (Table 5.2). 
 
Abbreviation Chemical % Tested CMC mM (%) Properties 
CH CHAPS* 2, 4 8.0 (0.49) zwitterionic 
DA Deoxycholic Acid 2, 4 6.0 (0.24) anionic 
DDM n-Dodecyl-ß-D-maltopyranoside 1, 2 0.17 (0.0087) long, non-ionic 
DM n-Decyl-ß-D-maltopyranoside n/a 1.8 (0.087) non-ionic 
FC-12 Fos Choline-12 0.5, 1 1.5 (0.047) harsh, zwitterionic, short 
FC-14 Fos-Choline-14 0.5, 1, 2, 4 0.12 (0.0046) harsh, zwitterionic, long 
OG n-Octyl-ß-D-glucopyranoside 1, 2 18 (0.53) short, non-ionic 
OT n-Octyl-ß-D-thioglucopyranoside 2, 4 9 (0.28) non-ionic 
TX Triton X -100 2 ,4  0.23 (0.015) mild, anionic 
ZG Zwittergent 3-14 2, 4 0.01 - 0.06 zwitterionic 
Table 5.2:  Detergent properties.   Details the various detergents tested in the solubilisation of PcCir2 
and the various percentages they were tested at.  The CMC and associated chemical properties are also 
given.  *3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). 
 
Detergent 1 Detergent 2 
FC-14 DDM 
FC-14 ZG 
FC-14 TX 
DDM DA 
DDM TX 
DDM ZG 
TX ZG  
TX DA 
ZG DA 
Table 5.3: Detergent combinations.  The combination of detergents that were tested, each detergent 
was used at 1 %. 
 
To increase the chances of obtaining soluble protein after incubation with the 
detergents combinations were also used (Table 5.3).  Each of the solubilisation trials 
was incubated on ice at 4 oC overnight.  The critical micelle concentration (CMC) is 
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given in Table 5.2 which is the minimum concentration at which micelles will be 
spontaneously formed in a liquid.  It is important not to use a concentration of 
detergent that falls below its CMC. 
 
The soluble and insoluble membrane protein fractions of the detergent tests were 
separated as before and samples applied to a NuPAGE gel.  The solubilised proteins 
from a selection of the detergents tested are presented in Figure 5.7, A.  The 
combination of DA and DDM gave the most solubility.  However, it was determined 
that FC-14 and FC-12 were the most effective at releasing protein from the E. coli 
plasma membrane.  Purification trials were continued using FC-14 as this has the lower 
CMC, and latterly FC-12. 
 
(A)         (B) 
     
Figure 5.7:  Solubilisation of PcCir2 using further detergents.  (A)  Lane 1 contains the optimised 
PcCir2 protein from a small scale expression trial.  Proteins solubilised from incubation with the detergents 
ZG, CH, DA, ZG + DA and DDM + DA are given in lanes 2 – 6, respectively.  (B)  NuPage gel stained with 
CBB (lanes 1 – 3) and the His-tag stain (lanes 4 – 6).  Lanes 1 and 4 are optimised PcCir2 from a small 
scale expression trial.  The other lanes contain protein solubilised using 0.5 % FC-14 in an overnight 
incubation experiment.  Detergent solubilised membrane protein is observed in lanes 2 and 5, and 
insoluble in lanes 3 and 6.  Equal volumes of the soluble and insoluble fractions were loaded in each lane.  
The arrows indicate the position of PcCir2.  Molecular weight markers are indicated on the left hand side. 
 
One drawback of these detergents is that they solubilise most of the proteins in the 
membrane, and many of proteins are present when stained with the His-tag stain as 
can be seen in Figure 5.7, B.  As the recombinant protein was insoluble in most of the 
detergents trialled, it is possible the protein was packaged into inclusion bodies (IB’s) 
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and that is the reason for the lack of solubility, this possibility was not examined.  
However it should be noted that in section 5.5.3 and Figure 5.31, the PcCir2 protein is 
expressed (albeit from a different vector) and shown not to be present in IB’s. 
 
Despite the possible contaminating protein bands, the PcCir2 protein was purified using 
a cobalt IMAC column to bind the His-tag after solubilisation overnight using FC-14.  
Protein was eluted in fractions 1 – 13 and a total of 20 x 0.25 ml fractions were 
collected for analysis.  During elution, the concentration of imidazole was increased 
incrementally when the OD280 of samples began to decrease.  After 8 eluted fractions 
the imidazole was increased from 200 mM to 300 mM, after elution fraction 12 the 
imidazole was increased to 400 mM and for elutions 17, 18, and 19 the concentration 
was increased to 500 mM, this can be seen by the peaks and troughs on the chart 
displayed in Figure 5.8, A .  Protein content in the fractions was assessed by reading 
the OD280 on a nanodrop as Bradford’s reagent reacted with the FC-14 and gave a false 
positive result.  The chart in Figure 5.8, A was generated by measuring the OD280 of 
each of the eluted samples.  The extinction coefficient was calculated as an OD280 of 
0.850 = 1 mg/ml protein (Pepstats, EMBOSS33). 
 
To verify the correct protein had been eluted, a small volume was analysed on a 
NuPAGE gel.  The preparation was not particularly clean as numerous extra bands of 
could be detected on the gel one of these particularly close to the PcCir2 band Figure 
5.8, B.  Once the protein sequence had been confirmed by mass spectrometry (MS) 
analysis, the fractions were applied to Vivaspin columns with molecular weight cut-offs 
(MWCO) of 50 and 30 kDa for concentration by diafiltration.  However, many of the 
smaller protein bands could still be observed and a few larger bands were also present 
when the concentrated proteins were applied to a NuPAGE gel.  In addition, the 50 
kDa MWCO device allowed some of the protein to be eluted in the flow through.  The 
larger fragments gave a ladder-like appearance, inferring the protein may have 
aggregated during concentration. 
 
Since the detergent can play a role in the stability of the protein and its 
monodispersity, FC-12 was also tested.  As before, during elution the concentration of 
                                                 
33 http://emboss.bioinformatics.nl/cgi-bin/emboss/pepstats.  Acessed on 20 August 2012. 
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imidazole was increased incrementally.  After 8 eluted fractions the imidazole was 
increased from 200 mM to 300 mM, after elution 12 increased to 400 mM and for 
elutions 17 and 18 the concentration was increased to 500 mM, this can be seen by 
the peaks and troughs on the chart present in Figure 5.8, C (protein concentration was  
calculated as before). 
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Figure 5.8:  Purification of PcCir2.  (A)  Line chart showing the concentration of protein eluted in each 
fraction, after solubilisation and purification of PcCir2 using FC-14.  (B) A CBB stained gel, lanes 1 – 3 are 
eluted fractions 2, 5 and 7.  (C) The chart illustrates the concentration of protein eluted in each fraction, 
after solubilisation and purification of PcCir2 using FC-12.  (D) A CBB stained gel, lanes 1, 2 and 3 display 
the elution fractions 2, 5 and 7.  The same volumes of elutate were loaded on the gel.  An arrow indicates 
the position of PcCir2.  Molecular weight markers are indicated on the left hand side. 
 
The results are presented in Figure 5.8, D and many additional bands were still present 
in the samples when proteins were separated using a Nu-PAGE gel.  The major lower 
contaminating bands appear to be the same sizes in the gels from FC-12 and FC-14 
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solubilisation.  From each preparation three - four higher molecular weight protein 
bands are also observed.  In particular, the protein band closest to the PcCir2 protein 
is present in both purifications. 
 
Approaches to evaluate the quality of a protein and to characterise a membrane 
protein require a highly pure protein.  As expression in this vector did not yield a pure 
protein it was decided not to pursue this line of investigation further. 
 
5.3.3 Optimisation of PcCir2 expression using pGFPe 
Given the problems in purifying the protein from the TTQ18 vector, another vector was 
chosen.  This vector, pGFPe, encodes a GFP reporter gene, TEV protease site and His-
tag.  The pccir2 gene was amplified with the oligonucleotide primers PcCir GFPe F and 
PcCir GFPe R (Appendix 2).  The PCR product was cloned into the vector upstream of 
these coding regions so as to give a fusion protein with a C-terminal cleavable GFP and 
His-tag, the resulting plasmid was termed pGFPe_pccir2 (Figure 5.9, A and B).   
 
  (A)     (B)    
     
Figure 5.9:  Cloning of pccir2 into the pGFPe vector for expression in E. coli.  (A) Plasmid 
construct showing the pccir2 gene upstream from a 8xHis-tag, gfp gene, and TEV protease site.  The 
restriction sites used to clone in the pccir2 gene, XhoI and KpnI are given as well as the kanamycin 
resistance (KanR) gene which acted as a selectable marker during cloning.  The T7 promoter is present 
upstream from the gene.  Diagrams are not to scale.  (B) The 938 bp pccir2 gene was cloned into the 
7000 bp pGFPe vector using the restriction sites XhoI and KpnI. 
 
The gfp reporter gene is useful in protein expression research since its addition as a 
fusion to other genes leads to production of proteins where the protein expression can 
be monitored by measuring GFP fluoresence.  This implies that the fluorescent tag and 
Plasmodium chabaudi Cir2 Expression and Structural Analyses Chapter 5 
 
[184] 
 
its fused protein both fold correctly and that the targeting of the fusion protein is 
similar to that of the native protein without the fluorescent tag.  A second benefit of 
this plasmid is that a two-step purification process can take place.  The expressed 
fusion protein is initially purified and eluted using a metal affinity column.  The eluted 
protein is then applied to a metal affinity column and bound using the His-tag, a TEV 
protease is added to the column and the desired protein cleaved from the His-tag and 
is eluted. 
 
Two colonies were tested for each condition to check for variability of expression 
between colonies.  The results from one colony are present as protein production was 
similar in both.  In all trials the media used was LB broth containing 50 µg/ml 
kanamycin.  Figure 5.10 displays samples from cell lysate (lanes 2 – 10) and 
membrane preparations (lanes 11 – 14) with good expression observed in each of the 
conditions tested. 
 
 
Figure 5.10: Small scale expression trials of PcCir2-GFP. Samples run on 4–12% NuPAGE gels 
stained with CBB.  Lanes 1 – 10 contain cell lysate and lanes 11 – 14 are membrane preparations.  Lane 1 
is an uninduced control.  The cells were induced with 0.05 mM (lanes 3, 5, 7, 9, 12 and 14) and 0.1 mM 
(lanes 2, 4, 6, 8, 10, 11 and 13).  All samples were grown in LB, and after induction with IPTG, cells were 
grown at 37 oC (lanes 5, 6, 9, 10, 11 and 12) and 22 oC (lanes 2, 3, 4, 7, 8, 13 and 14).  Growth time after 
induction was 3 h (lane 2), 6 h (lanes 3 – 6 and 11 – 14) and 8 h (lanes 7 – 10).  Lanes 15 and 16 contain 
an uninduced and expressing (same as lane 5) culture which has been stained against the C-terminal His 
tag.  The same volumes of cell lysate or 15 μg membrane protein was loaded on the gel.  An arrow 
indicates the position of PcCir2.  Molecular weight markers are indicated on the left hand side. 
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The expected molecular weight of the protein is 66.3 kDa.  After MS analysis, the lower 
of the two prominent bands was confirmed to be PcCir2-GFP, the protein running at a 
lower molecular weight than expected, approximately 45 kDa.  This is not unknown for 
membrane proteins, possibly though the reduced binding of SDS to hydrophobic areas 
(Rath et al, 2008).   MS analysis indicated the approximately 66 kDa molecular weight 
band to be an E. coli protein, namely mannose-1-phosphate guanyltransferase.  
Protein production was deemed to be better at 6 h, and thus the experiments were 
repeated and crude membranes prepared (Figure 5.10 lanes 11 – 14).  It was hoped 
that the larger MW weight band would be removed in the cytoplasmic or periplasmic 
fractions, but it was not.  Large scale expression of PcCir2-GFP was carried out in 12 L 
LB broth using the following conditions, 0.05 mM IPTG and a growth time following 
induction of 6 h at 22 oC.  The cells from this were harvested and produced a total wet 
weight of 46.2 g.  Cells were used to prepare cell membranes.  The large scale 
membrane preparations produced 446 mg of total protein. 
 
5.3.4 Purification of PcCir2-GFP 
Solubilisation trials were carried out for PcCir2-GFP using a single concentration (2.5 
%) of each detergent.  The detergents tested were DDM, ZG, OG, OT, FC-12, TX, DA 
and DM (Table 5.2). 
 
 
Figure 5.11: Solubilisation of PcCir2-GFP using different detergents at 2.5 %.  Soluble fractions 
are in lanes 1, 3, 5, 7, 9, 11, 13 and 15.  Insoluble fractions are in lanes 2, 4, 6, 8, 10, 12, 14 and 16.  
Membranes were solubilised with DDM (1 and 2), ZG (3 and 4), OG (5 and 6), OT (7 and 8), FC-12 (9 and 
10), TX (11 and 12), DA (13 and 14) and DM (15 and 16).  The same volumes of soluble and insoluble 
fractions were loaded on the gel.  The arrow indicates the position of PcCir2-GFP.  Molecular weight 
markers are indicated on the left hand side. 
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Solubilised and insoluble proteins from membranes solubilised with detergents were 
electrophoresed using a NuPAGE gel to separate the proteins by weight.  The results in 
Figure 5.11 display the gel after staining with CBB. 
 
Again, FC-12 provided the best solubilisation of the protein (Figure 5.11, lanes 9 and 
10).  However, unlike the solubilisation of PcCir2 expressed from the pTTQ18 plasmid, 
the solubilised fraction contains merely around 50 % of the PcCir2 protein.  It could be 
that the GFP moiety increasing the size of the protein is making it less accessible to the 
detergents. 
 
(A)       (B)
       
 
Figure 5.12:  Purification of PcCir2-GFP.  (A) The chart illustrates the concentration of protein eluted 
in each fraction, after solubilisation and purification of PcCir2-GFP in FC-12.  (B) A CBB stained gel with 
eluted fractions 5, 8 and 11 (in lanes 1, 2 and 3 respectively).  The same volumes (5 µl) of eluted fractions 
were loaded on the gel.  The arrow indicates the position of PcCir2-GFP.  Molecular weight markers are 
indicated on the left hand side. 
 
The PcCir2-GFP protein was purified using an IMAC column.  The detergent-
membrane/protein mixed was loaded into the coloum, and protein eluted by adding 
200 mM imidazole, the imidazole concentration was not increased during the elution.  
The purification of PcCir2-GFP was monitored visually, by the colour of the elutate.  
After elution fraction 14, the column was stopped to determine if more protein would 
elute after a short static incubation of the beads in buffer containing imidazole.  The 
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chart in Figure 5.12, A was generated by measuring the OD280 of each of the eluted 
samples. The extinction coefficient was calculated as an OD280 of 0.800 = 1 mg/ml 
protein (Pepstats, EMBOSS).  Samples of eluted fractions 5, 8, and 11 were separated 
on a NuPAGE gel to ensure the correct protein had been eluted (Figure 5.12, B). 
Eluted fractions 5 through 16 were combined and concentrated using a Vivaspin 
centrifugation device with a 30 kDa MWCO.  After the first centrifugation step, the flow 
through and 100 µl concentrate were both a bright green colour suggesting some of 
the protein had passed through the column, or that the GFP had somehow detached 
from the PcCir2 fusion.  The centrifugation step was repeated by adding 6 ml of elution 
buffer (without imidazole) to reduce the imidazole concentration by diafiltration.  This 
had the effect of eluting and diluting the previously concentrated protein.  When eluted 
fractions were applied to a gel the dilution of the protein with elution buffer made the 
bands very faint and thus it is difficult to state if the GFP had dissociated or if the 
protein had passed through the concentration column.  Some protein was concentrated 
as observed on the CBB stained gel, however, after repeated attempts at concentration 
the protein was lost in the flow through (data not shown).  Other means of protein 
concentration were not investigated. 
 
5.3.5 Optimisation of PcCir2 expression in pTTQ18-TEV 
The TTQ18 vector was engineered by Dr. S.E Unkles to contain a TEV protease site 
between the cloned gene and His-tag to allow a two step purification process to be 
applied.  The pccir2 gene was cloned into the TTQ18-TEV plasmid using the PstI and 
EcoRI sites as described previously (Section 5.3.1) to produce TTQ18-TEV_pccir2.  The 
construct was transformed into BL21 (DE3) cells for analysis of protein expression.  
Two colonies were chosen for small scale expression trials of PcCir2 in the TTQ18-TEV 
vector.  Conditions tested were temperature after induction of 37 oC and 22 oC, and a 
growth time of 3 and 6 h.  Concentrations of IPTG used were 0.1 mM, 0.5 mM and 1 
mM.  An HRP conjugated anti-His tag antibody was used to demonstrate the 
expression of PcCir2 (Figure 5.13).  Approximately three mins after detection solution 
had been added to the membrane, the membrane began to develop yellow-brown 
bands where the PcCir2 protein would be expected.  This was most likely due to using 
a concentration of antibody that was too high.  At these areas, a white band is 
observed on the film after exposure using the X-ray processor.  The western blot 
shows a great deal of background staining, however the blot was not repeated at a 
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higher antibody dilution.  Both colonies reacted similarly in the western blot and the 
results from one colony are displayed.  Cells grown at 22 oC and 37 oC induced with 1 
mM IPTG for 6 h contain a two proteins at a similar size (38 kDa) on the western blot, 
one of which may correspond to PcCir2 (Figure 5.13).  Therefore these conditions were 
not chosen for large scale expression of the PcCir2 protein.  The greatest expression 
was thus observed in Lane 1 using the conditions 0.1 mM IPTG, 3 h incubation after 
induction at 37 oC, the same as the expression conditions using the TTQ18 vector. 
 
The large scale production of PcCir2 from the pTTQ18-TEV was carried out in 12 L LB 
broth, using the optimum conditions determined from the small scale expression trials: 
0.1 mM IPTG was added after initial growth at 37 oC, and cells continued to incubate 
for 3 h at 37 oC (Figure 5.13).  The cells from the large scale growth were harvested 
and produced a total wet weight of 39.0g. 
 
 
Figure 5.13: Small scale expression trials of PcCir2 from TTQ18-TEV.  A western blot to illustrate 
the expression of PcCir2, using an antibody against the C-terminal hexahistadine tag.  The cells were 
induced with 0.1 mM (lanes 1, 2, and 5), 0.5 mM (lane 7) and 1 mM (lanes 3, 4, and 6).  All samples were 
grown in LB, and after induction with IPTG, cells were grown at 37 oC (lanes 1– 4) and 22 oC (5 – 7).  
Growth time after induction was 3 h (lanes 1 and 3) and 6 h (2, 4 – 7).  1 μg protein was loaded in each 
lane.  The arrow indicates the expected position of PcCir2.  Molecular weight markers are indicated on the 
left hand side. 
 
5.3.6 Purification of PcCir2 with TEV cleavage site 
Six detergents DDM, ZG, FC-12, TX, DA, and DM, (Table 5.2) with mixed properties 
were used to test for the solubilisation of PcCir2 when expressed in the pTTQ18-TEV 
vector.  Cells were grown in 200 ml LB and expressed using the conditions optimised 
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above followed by crude membrane preparation.  Each of the detergents was used at a 
concentration of 2.5 %, and incubated with the membranes overnight at 4 oC on ice.  
The solubilised fractions were separated from the insoluble fractions by centrifugation. 
 
 
 
Figure 5.14: Solubilisation using different detergents at 2.5 %.  Soluble fractions are in lanes 1, 3, 
5, 7, 9, and 11.  Insoluble fractions are in lanes 2, 4, 6, 8, 10, and 12.  Membranes were solubilised with 
DDM (1 and 2), ZG (3 and 4), FC-12 (5 and 6), TX (7 and 8), DA (9 and 10) and DM (11 and 12).  The 
same volumes of soluble and insoluble fractions were loaded on the gel.  An arrow indicates the position 
of PcCir2.  Molecular weight markers are indicated on the left hand side. 
 
Samples were run on a NuPAGE gel to determine in which fraction the PcCir2 protein 
was present in (Figure 5.14) and therefore the best detergent for solubilisation of 
PcCir2 from membranes.  A sample was extracted from the gel and sent for MS 
analysis which confirmed the presence of the PcCir2 protein.  FC-12 was the best at 
solubilising PcCir2 (lanes 5 and 6) with slightly more protein detected in the soluble 
fraction. 
 
Cells from the large scale culture were used to prepare membranes.  The large scale 
membrane preparations produced a total of 572 mg protein.  Protein was solubilised 
overnight in 0.5 % FC-12 at 4 oC on ice.  The following morning the soluble fraction 
was separated by centrifugation and protein purified using a cobalt IMAC column to 
bind the hexahistidine tag.  Protein was eluted in 0.5 ml fractions and the OD280 
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measured.  The column was stopped after the elution of fraction 6 to allow the 
imidazole to elute more protein.  After elution fraction 14, the imidazole concentration 
was increased to 300 mM and allowed equilibrate.  No more protein was eluted at this 
stage. 
 (A)
 
(B) 
 
 
 
 
Figure 5.15:  Purification of PcCir2 with TEV cleavage site.  (A) The chart presents the 
concentration of protein eluted in each fraction, after solubilisation and purification of PcCir2 in FC-12.  (B)  
Eluted fractions have been separated on a NuPAGE gel, lane 1 displays the protein and detergent 
suspension; lanes 2 and 3 contain the soluble and insoluble fractions after overnight incubation in FC-12, 
respectively; lanes 4 and 5 show the flow through and wash of the metal affinity beads, respectively.  The 
eluted fractions 4, 6, 8 and 10 are in lanes 6 – 9, respectively.  The same volumes of each of the samples 
(2.5 µl) were applied to the gel.  The arrow indicates expected position of PcCir2 as no MS analysis was 
carried out.  Molecular weight markers are indicated on the left hand side. 
 
The extinction coefficient was calculated as an OD280 of 0.860 = 1 mg/ml protein 
(Pepstats, EMBOSS) and the information used to prepare the chart in Figure 5.15, A.  
Figure 5.15, B displays proteins separated on a NuPAGE gel.  The PcCir2 protein can be 
seen in the first 5 lanes but not 6 – 9 which are eluted fractions 4, 6, 8 and 10.  Protein 
from a large scale culture is provided as a comparison in lane 1.  In previous 
experiments (Sections 5.3.1 and 5.3.3) and the western blot in Figure 5.13, the PcCir2 
protein was found to be well expressed and it was therefore surprising that in this 
instance the quantity of PcCir2 was less than anticipated.  The soluble and insoluble 
fractions after the high speed centrifugation step are presented in lanes 2 and 3, 
respectively.  As was expected from the small scale trials, the protein is present in both 
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fractions.  What was not expected was for the protein to be contained in the flow 
through after incubation with the IMAC beads and in the wash fraction.  This implies 
the protein was unable to bind to the metal affinity column.  The eluted fractions 
(lanes 6 – 9) demonstrate the presence of some proteins, but none corresponding to 
that of PcCir2. 
 
Time permitting, experiments using different metal affinity columns such as Ni2+ or 
Zn2+ to find out if these ions would provide a purer PcCir2 protein.   Further to this, gel 
filtration (size exclusion chromatography) would take place to separate the eluted 
proteins on size.  Gel filtration should elute the protein with fewer contaminants and 
remove any large aggregates which may have formed.  The gel filtration method can 
be monitored to analyse the monodispersity of the protein especially as a 
monodisperse protein is required for crystallography for example flouresence size 
exclusion chromatography (FSEC). 
 
Given the problems with expression and purification of PcCir2 using each of the 
expression plasmids, it was decided to concentrate on expressing domains of PcCir2 
which lacked the TMD and should be soluble. 
 
5.4 Recombinant Expression of PcCir2 Domains in E. coli 
 
A putative ordered domain, ending just before the HVR and not including the TMD, 
was identified by Dr. R. Russell (University of St Andrews), where he studied the 
secondary predictions for the PcCir2 protein, looking for ordered regions 
(sheets/helices) and disordered regions.  As this domain is lacking the TMD and HVR it 
should be soluble and therefore would not require optimisation of detergent 
solubilisation, and purification might be easier.  It was thought that any structural data 
acquired from the domain would corroborate any structural data gained from the full-
length protein.  A schematic illustrating the placement of the domain with regards the 
full-length gene is given in Figure 5.16. 
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Figure 5.16: PcCir2 protein domain 1.  A schematic of the protein and protein domain, full-length 
PcCir2 (Cir2) and PcCir2Domain (Cir2Dom).  Indicated by the blue block is the TMD, the green block 
shows the position of the HVR.  Diagrams are not to scale. 
 
5.4.1 Optimisation of PcCir2 Domain expression in pEHISGFPTEV and 
pEHISTEV 
DNA encoding the putative soluble domain, pccir2domain (pccir2dom) was amplified, 
using primers PcCir2Dom F and PcCir2Dom R (Appendix 2), from the synthetic codon-
optimised pccir2 gene.  The 630 bp domain was inserted into plasmid vectors 
pEHISGFPTEV and pEHISTEV producing pEHISGFPTEV_ pccir2dom and pEHISTEV_ 
pccir2dom, respectively (Figure 5.17 A and B). 
 
(A)     (B)    (C) 
            
 
Figure 5.17:  Cloning of pccir2dom. (A) Plasmid constructs displaying the pccir2dom downstream from 
a His-tag and TEV protease site. (B) Plasmid constructs showing pccir2dom downstream from a His-tag, 
GFP gene and TEV protease site.  The restriction sites used to clone in the pccir2dom gene are given as 
well as the kanamycin resistance (KanR) gene which acted as a selectable marker during cloning.  The T7 
promoter is upstream from the gene. (C) The 630 bp pccir2dom (lane 1) was cloned into the 6500 bp 
pEHISGFPTEV vector (lane 2) using the restriction sites XhoI and NcoI. 
 
The pEHISGFPTEV plasmid contains a gfp gene situated N-terminally to the cloned 
gene and a TEV protease site to allow cleavage of the GFP protein.  In addition both 
plasmids contain a His-tag situated at the N-terminus of the cloned gene to allow 
purification of the expressed protein.  The gfp reporter gene is useful in protein 
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expression research as fluorescence is observed only when the GFP polypeptide has 
been folded correctly and implies the downstream protein will also be correctly folded. 
 
The GFP containing vector has the added bonus that only a small (100 µl) sample of 
bacterial cell suspension is required to observe fluorescence using a standard UV 
transilluminator.  This meant that a large number of conditions could be screened in a 
relatively short time without the need of protein gels and western blotting.  Samples 
with GFP fluorescence were applied to a NuPAGE gel and all provided good expression 
of the expected 54.6 kDa band (ExPASy).  Induced cells grown at a lower temperature 
(22 oC, lanes 1 – 4) and for longer time periods (6 – 8 h, Lanes 2 and 3) showed better 
expression (Figure 5.18) possibly due to the longer growth time additional protein was 
produced.  For each condition giving rise to GFP fluorescence, the whole cell soluble 
and insoluble fractions were separated and analysed by exposure of the fraction to UV 
light source.  GFP fluorescence of the samples was assessed by comparison with a 
strain expressing GFP alone (the empty vector pEHISGFPTEV). 
 
 
Figure 5.18:  Expression of PcCir2Dom-GFP.  CBB stained Nu-PAGE showing the expression of 
pEHISGFPTEV-pccir2dom under different conditions.  The cells from lanes 1 – 4 were incubated at room 
temperature with rotary shaking of 180 rpm for 3, 6, 8 and 16 h respectively, and lanes 5 – 6 were grown 
at 37 oC with 250 rpm and 3 and 6 h expression time, respectively.  All were grown in LB broth and 
induced with 0.5 mM IPTG.  The same volume of cell lysate was loaded in each lane.  The arrow indicates 
the position of the PcCir2Dom-GFP fusion protein.  Molecular weight markers are indicated on the left 
hand side. 
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Figure 5.19, A displays the separated soluble and insoluble fractions from cells 
expressing the vector pEHISGFPTEV alone and cells expressing 
pEHISGFPTEV_pccir2dom.  GFP is observed in the soluble fraction in the sample from 
pEHISGFPTEV alone (Figure 5.19, A) but not in the soluble fraction of cells expressing 
pEHISGFPTEV_pccir2dom as shown in B. 
 
In each of the conditions trialled no soluble PcCir2 protein was obtained (Figure 5.19, 
C).  In all conditions trialled the GFP tagged PcCir2 domain was well expressed.  As the 
expression levels were high (as judged by the band size on CBB stained gel) it was 
questioned that if too much protein was produced, was it packaged into IBs.  Attempts 
were therefore made to slow down the growth of the expressing bacteria by limiting 
the concentration of IPTG to 0.05 mM and by growing the cells in a M9 minimal salts 
medium (Appendix 1).  Figure 5.20 (lanes 1 – 4) demonstrates that M9 media had little 
to no effect on the solubility of the PcCir2Dom protein. 
 
(A)   (B)         (C) 
    
        
 Figure 5.19:  Solubility of PcCir2Dom-GFP.  (A) The tubes represent the vector alone where the GFP 
is soluble (B) the tubes are from cells expressing pEHISGFPTEV-pccir2dom.  The tube on the left hand side 
of each image is the soluble fraction, and the right hand side tubes are the insoluble fractions.  (C) a CBB 
stained Nu-PAGE gel containing the soluble (lanes 1, 3 and 5) and insoluble (lanes 2, 4 and 6) fractions of 
cells expressing pEHISGFPTEV-pccir2dom, grown in LB media and induced with 0.5 mM IPTG.  Cells were 
induced for 16 h (lanes 1 and 2) and 8 h (lanes 3 and 4) at 22 oC and for 8 h at 37 oC (lanes 5 and 6).  
The arrow shows the PcCir2Dom-GFP fusion protein.  Equal volumes of the soluble and insoluble fractions 
were applied to the gel.  Molecular weight markers are indicated on the left hand side. 
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Arginine and urea have been used to aid in the solubilisation and re-folding of proteins 
from IBs.  As it would be impossible to ensure the PcCir2 domain would be in the 
correct conformation, it was decided against attempting to re-fold it, however, in the 
future it might be useful to attempt this in the efforts to obtain a pure protein sample.  
Arginine was added to M9 minimal media at a concentration of 1 M to analyse if it 
might improve the solubility of protein produced from either pEHISGFPTEV-pccir2dom 
or pEHISTEV-pccir2dom.  Again no soluble protein was detected after separation of 
soluble and insoluble proteins on a NuPAGE gel (Figure 5.20 lanes 5 – 8). 
 
 
 
Figure 5.20:  Solubility of PcCir2Dom-GFP after addition of arginine to the growth medium.  
CBB stained NuPAGE showing the soluble (lanes 1, 3, 5 and 7) and insoluble (lanes 2, 4, 6 and 8) fractions 
of cells expressing pEHISGFPTEV-pccir2dom and grown in M9 minimal salts media (all lanes) with 
supplemented 1 M arginine (lanes 5 – 8).  Cells were induced for 6 h (lanes 1, 2, 5 and 6) and 16 h (lanes 
3, 4, 6 and 7) at 22 oC.  The arrow shows the PcCir2Dom protein.  Molecular weight markers are indicated 
on the left hand side. 
 
The same expression vector lacking the GFP gene, pEHISTEV-pccir2dom, was also 
used as it was thought that the N-terminal GFP extension could have been causing 
problems with the solubility of the protein.  The pEHISTEV-pccir2dom vector was 
transformed into BL21 (DE3) cells.  Protein expression was induced using 0.1 and 0.05 
mM IPTG.  Cells were grown for a further 3, 6 and 8 h at either 22 oC or 37 oC.  Cell 
lysate from each of the growth conditions was applied to a NuPAGE gel, and protein 
separated by electrophoresis.  In each of the conditions tested protein corresponding 
to the correct molecular weight (24.6 kDa) was observed (Figure 5.21, A).  Total 
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soluble and insoluble protein was extracted from each of the conditions tested and was 
separated on a NuPAGE gel and stained with CBB.  The image in Figure 5.21, B 
demonstrates that PcCir2Dom is observed in the insoluble fractions (lanes 2, 4, and 6).  
In Figure 5.21 B, there is a well expressed band towards the top of the gel in the 
insoluble fractions, the identity of this protein was never analysed as it was thought to 
be an E. coli protein or an aggregate of the PcCir2 protein. 
 
  (A)       (B) 
              
 
Figure 5.21: Expression and solubility of PcCir2Dom in pEHISTEV.  (A)  Cell lysate from BL21 
(DE3) cells applied to a NuPAGE gel and stained with CBB.  Cells in lane 1 and 5 were grown at 22 oC, 
cells in lanes 2 – 4 were grown at 37 oC after induction with 0.1 mM (lanes 1 and 4) and 0.05 mM (lanes 
2, 3 and 5) IPTG.  Cells were grown for 16 h (lane 1), 3 h (lane 2), 6 h (lane 3) and 8 h (lanes 4 and 5) 
after induction.  (B)  Soluble (lanes 1, 3 and 5) and insoluble (lanes 2, 4 and 6) fractions separated from 
cells expressing the PcCir2Dom protein.  Lanes 1 and 2 were grown for 16 h at 22 oC after induction with 
0.1 mM IPTG.  Lanes 3 – 6 were grown for 8 h at 37 oC after induction with 0.05 mM (lanes 3 and 4) and 
0.1 mM (lanes 5 and 6) IPTG.  The arrows indicate the PcCir2Dom protein.  Molecular weight markers are 
indicated on the left hand side. 
 
5.4.2 Optimisation of PcCir2 Domain expression in pGFPe 
DNA encoding the putative soluble domain, pccir2domain (pccir2dom) was amplified 
from the pccir gene using the primers PcCir GFPe F and PcCir2 210 R (Appendix 2). 
The 630 bp domain was cloned into the KpnI and XhoI restriction endonuclease sites 
of the plasmid vector pGFPe.  This gave rise to a third domain expression construct, 
pGFPe_ pccir2dom.  The pGFPe plasmid contains a gfp gene situated C-terminally to 
the cloned gene and a TEV protease site to allow cleavage of the GFP fusion protein.  
In addition, a His-tag is encoded by the plasmid vector thus the expressed protein will 
possess a C-terminal 6xHis-tag.  Expression of recombinant protein is driven by the 
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IPTG-inducible T7 promoter.  As in Sections 5.3.3 and 5.4.1 above, GFP fluorescence 
was used as an indicator of correct folding. 
 
Small scale trials were carried out using LB broth as the expression medium at 22 oC. 
Cultures were induced with 0.05 mM IPTG as has been described previously and 0.4 
mM IPTG as described by Rapp et al (2004).  Samples were taken at various time 
points (3, 6, and 8 h) and pelleted to assess the samples for GFP fluorescence a proxy 
for protein expression.  Figure 5.22, A displays a CBB stained gel containing lysate 
from cells after induction of protein expression with 0.05 mM IPTG for 3, 6 and 8 h.  
The gel shows expression of the 54.6 kDa fusion protein, as well as two smaller 
proteins around 40 kDa.  Not much difference is observed in the levels of expression 
over the different incubation times.  Cells from the 3 h and 8 h cultures were separated 
into the soluble and insoluble fractions applied to a NuPAGE gel.  The overexpressed 
PcCir2Dom was present in the insoluble fraction only (Figure 5.22, B) with no visible 
proteins in the soluble fraction. 
 
(A)      (B) 
               
 
Figure 5.22:  Expression and solubility of PcCir2Dom in pGFPe.  (A)  CBB stained gel of 
PcCir2Dom-GFPe fusion protein.  Cells were grown at 22 oC in LB broth and induced with 0.05 mM IPTG.  
Samples were taken at 3 h (lane 1), 6 h (lane 2) and 8 h (lane 3). (B) Soluble (lanes 1 and 3) and 
insoluble (lanes 2 and 4) protein fractions separated on a NuPAGE gel.  Cells were grown as before, lanes 
1 and 2 for 3 h after induction and lanes 3 and 4 for 8 h.  The arrows indicate the PcCir2Dom protein.  
Molecular weight markers are indicated on the left hand side. 
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A potential reason for PcCir2Dom being insoluble would be the presence of additional 
stretches of hydrophobic amino-acids, for example as in a second trans-membrane 
domain within PcCir2.  However, hydropathy plots failed to identify a second trans-
membrane domain in PcCir2 hence the reason for PCir2Dom’s insolubility remains 
uncertain.  Also, the RIFIN proteins, related to CIR proteins, are thought to possess 
two TMDs.  Lowering the default cut-off in TMHMM revealed a second potential TMD 
between residues 50 – 70.  Further scrutiny of the hydropathy plot shows a second 
peak at the N-terminus of the amino acid sequence (circled in Figure 5.23, A), the peak 
does not reach the lower cut-off value and covers amino acids 50 – 70.  It is possible 
that this hydrophobic region could be an addition TMD or may interact with the 
membrane. 
 
5.4.3 Optimisation of PcCir2Dom2 expression in pEHISGFPTEV 
To examine the possibility of a second hydrophobic domain, a second nucleotide 
domain encoding residues 73 – 210 was amplified using primers PcCir2Dom2 F and 
PcCir2Dom R from the pccir2 gene sequence and termed PcCir2Dom2 (Appendix 2).    
A schematic shows the position of PcCir2Dom2 compared to the full-length protein and 
original PcCir2 domain (Figure 5.23, B). 
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(A) 
 
 
 (B)
 
 
Figure 5.23: PcCir2 protein domain 2.  (A) showing the hydropathy plot from Figure 5.1 with 
hydrophobic domain circled.  (B) gives a schematic of the protein and protein domains, full-length PcCir2 
(Cir2), PcCir2Dom (Cir2 Dom) and PcCir2Dom2 (Cir2 Dom2).  Indicated by the blue block is the TMD, the 
green block shows the position of the HVR.  Diagrams are not to scale. 
 
This putative new domain was amplified from pccir2.  The sequence encoding 
PcCir2Dom2 was inserted into pEHISGFPTEV yielding pEHISGFPTEV-pccir2dom2.  
Expression trials were carried out as before using the GFP fluorescence as an indicator 
of protein expression.  Strong fluorescence was observed when the protein was 
expressed in BL21 (DE3) cells and induced with 0.05 mM IPTG, and grown for different 
times at 37 oC and at 22 oC. Cell lysate was separated by a NuPage gel, to check that 
the correctly sized protein was expressed (Figure 5.24, A).  The size of the 
PcCir2Dom2-GFP fusion protein was predicted to be 47.4 kDa.  From this it can be 
seen that PcCir2Dom2-GFP was expressed well, however when cell lysate was 
separated into the soluble and insoluble fractions, the majority of expressed protein 
was still present in the insoluble fraction (Figure 5.24, B). 
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(A)          (B) 
   
 
Figure 5.24:  Expression of PcCir2Dom2 in BL21 (DE3) cells.  (A) CBB stained NuPAGE gel showing 
the expression of PcCir2Dom2 in BL21 (DE3) cells in cell lysate after induction with 0.05 mM IPTG.  Lane 1 
shows protein from an uninduced culture.  Lane 2 contains protein from a culture induced for 3 h at 37 oC.  
Lanes 3 and 4 were induced at 22 oC for 6 and 8 h, respectively.  (B)  Cells expressing the PcCir2Dom2 
protein, using the same conditions as (A), were separated into the soluble (lanes 1, 3, and 5) and 
insoluble (lanes 2, 4, and 6) fractions.  Lanes 1 and 2 are from a culture h at 37 oC.  Lanes 3 and 4 were 
induced at 22 oC for 6, and, lanes 5 and 6 induced at 22 oC for 8 h.  The arrows show the PcCir2Dom2 
protein.  Molecular weight markers are indicated on the left hand side. 
 
The addition of arginine as described in Section 5.4.1 was tested.  Cells were grown in 
M9 minimal salts media for 16 and 20 h with the addition of arginine.  A bacterial 
expression strain known as Arctic Express™ was also tested as this strain can be grown 
at temperatures as low as 10 oC.  Arctic Express™ cells co-express two cold-adapted 
chaperonins from the extremophillic bacterium Oleispira antarctica that can process 
proteins at lower temperature.  Cells were thus grown in LB medium at 10 oC for 20 h 
as stated in the Arctic Express™ manual and induced with either 0.1 mM or 0.05 mM 
IPTG.  Arctic Express™ expression trials were carried out in LB medium.  The 
PcCir2Dom2-GFP fusion protein was expressed well but remained, for the most part, 
insoluble.  Figure 5.25 shows the results for BL21 (DE3) cells (A) and Arctic Express™ 
(B) grown with and without arginine, separated into the insoluble and soluble fractions.  
Two additional well expressed bands can be seen in the soluble fractions, these are the 
chaperone proteins present in the Arctic Express™ cells, Cpn60 is 57 kDa, and Cpn10 is 
10 kDa. 
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(A)         (B) 
            
 
Figure 5.25:  Solubility of PcCir2Dom2 with supplemented arginine. (A) CBB stained NuPAGE gel 
showing the expression of PcCir2Dom2 in BL21 (DE3) cells induced with 0.05 mM IPTG.  Cells have been 
separated into soluble (lanes 2, 4, 6, and 8) and insoluble fractions (lanes 3, 5, 7 and 9), and 
supplemented with (lanes 2, 3, 6, and 7) and without (lanes 4, 5, 8, and 9) arginine.  Lane 1 contains an 
uninduced control.  Lanes 2 – 5 have been grown for 20 h after induction and lanes 6 – 9 grown for 16 h 
after induction.  (B) CBB stained NuPAGE gel showing the expression of PcCir2Dom2 in Arctic Express™ 
cells. The cells have been separated into the soluble (lanes 2, 4, 6, and 8) and insoluble (lanes 1, 3, 5 and 
7) fractions and have been treated with (lanes 1, 2, 5, and 6) and without (lanes 3, 4, 7, and 8) arginine.  
Lane 1 – 4 show protein induced with 0.1 mM IPTG and lanes 5 – 8 induced with 0.05 mM IPTG.  The 
black arrows show the PcCir2Dom2 protein.  The upper and lower bands (grey arrows) in the soluble 
fractions indicate the Cpn60 and Cpn10 proteins which are co-expressed in the Arctic ExpressTM cells.  
Molecular weight markers are indicated on the left hand side. 
 
Possibly the protein domain is not a particularly soluble protein.  As the protein was 
missing the N-terminus it could be that it was unable to fold correctly, and requires the 
N-terminus as a guide to its native state.  If this is correct, the protein would not have 
been produced in the proper state and as a result may have been deposited in IBs.  
There is nothing known about the protein and its possible function, thus purification 
from IBs was not of practical value as there is no way on ensuring the protein would 
be re-folded in the correct orientation.  Therefore it was decided not to pursue the 
strategy of producing PcCir2 protein domains for structural studies including 
crystallography. 
 
 
 
Plasmodium chabaudi Cir2 Expression and Structural Analyses Chapter 5 
 
[202] 
 
5.4.4 Data collected by collaborators 
The following work was carried by Prof. A. Hawkins and collaborators at Newcastle 
University.  The results are presented here to complete the data set on the analysis of 
the expression of the PcCir2 domain. 
 
The pccir2dom DNA sequence was cloned onto the plasmid pMUT279, and the protein 
expressed in E. coli BL21 AI cells.  The cells were grown at 25 oC for 9 ½ h, the 
temperature reduced to 15 oC.  The culture was induced with 0.2 % arabinose and the 
cells incubated for a further 17 h.  Cells were harvested (50 g wet weight) and the 
protein purified using a Proband IMAC column using imidazole.  The eluted protein was 
dialysed using 50 mM potassium phosphate (pH 7.2), 1 mM dithiothreitol (DTT) and 
further purified by MONO Q FPLC ion exchange chromatography using a sodium 
chloride gradient.  Fractions from the ion exchange chromatography were pooled and a 
sample applied to a 12 % SDS-PAGE gel to analyse purity.  The sample was 
concentrated to 0.27 mg/ml in 0.5 ml using a 10 kDa MWCO Vivaspin centrifugation 
device. 
 
Dynamic light scattering (DLS) was carried out using the concentrated protein solution.  
DLS showed the protein preparation was monodisperse.  Further to this, the secondary 
structure was analysed by far ultra violet circular dichroism (UV-CD).  The conclusions 
are that the protein has a mixed structure of α-helix and ß-sheet components, and the 
overall spectrum is consistent with that of a folder protein.  A more detailed analysis of 
secondary structure could not be carried out due to salts in the buffer. 
 
This work shows the small percentage of soluble PcCir2Dom protein present could be 
extracted and used for structural analysis.  However, the concentration of protein 
produced was too low for further investigation. 
 
5.5 PcCir2 Membrane Topology 
 
In the investigation of membrane protein topology it is insufficient to employ in silico 
prediction methods alone, other approaches including biochemical, should also be 
taken.  The results presented previously, suggested that the first PcCir2 domain could 
be associated with the membrane.  This raises the possibility of a membrane 
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associated domain or second TMD present in the PcCir2 protein.  This section reports 
the biochemical characterisation of the secondary structure of PcCir2. 
 
The membrane topology of PcCir2 is important as it contains a HVR which has been 
proposed as the domain exposed to the immune system and hence the hypervariability 
means expression of different variants allows immune avoidance.  An understanding of 
PcCir2 membrane topology, especially the positioning of HVRs, is important to the 
elucidation and understanding of the function/s of this gene family. 
 
5.5.1 PhoA and GFP protein fusions as a basis for topology modelling  
PcCir2  fusions to GFP or PhoA were made at various points along the amino acid chain 
of PcCir2, using  standard vectors which fuse the reporter gene to the C-terminus of 
the protein domain under study, according to the method described by von Heijne and 
colleagues (Rapp et al, 2004, Daley et al, 2005).  The use of C-terminal fusions has 
proven more accurate in the determination of protein topology using E. coli (Rapp et 
al, 2004).  Six gene truncations were prepared for the membrane topology analysis, 
shown schematically in Figure 5.26, A.  The full-length PcCir2 protein schematic 
indicates the locations of the TMD, hydrophobic region and the position of the HVR.  
Each of these truncations was cloned into the pHA-1 vector encoding a C-terminal 
phoa gene, and a pGFPe vector encoding a C-terminal gfp gene.  An example plasmid 
from each is shown in Figure 5.26, B and C containing the full-length pccir2 gene.  
Figure 5.26, D shows the cut vectors and five of the gene fragments (the full-length 
pccir2312 has been omitted as it is shown in Figure 5.9). 
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(A) 
 
 
  
(B)      (C) 
   
 
    
(D) 
 
 
Figure 5.26: Cloning of truncated proteins.  (A) Schematic of the truncated proteins, PcCir2, full-
length PcCir2 with blue and green boxes denoting the TMD and HVR, respectively.  Fusions of GFP (green 
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fluorescent protein) or PhoA (alkaline phosphatase) were made to the C-terminal of each truncation.  This 
produced one set of proteins with a GFP fusion, and one set with a PhoA fusion protein.  PcCir240 4.1 kDa, 
PcCir2106 12.2 kDa, PcCir2210 24.6 kDa, PcCir2254 59.3 kDa, PcCir2312 66.3 kDa, PcCir2Δ73 58.2 kDa.  (B) 
Example plasmid showing the cir2 gene upstream of the PhoA reporter.  (C) Example plasmid showing the 
cir2 gene upstream of the gfp reporter gene, TEV protease site and 8xHis tag.  Diagrams are not to scale.  
(D) The 630 bp (pccir2210 lane 3), 708 bp (pccir2 Δ73 lane 4), 120 bp (pccir240 lane 5), 318 bp (pccir2106 lane 
6) and 762 bp (pccir2254 lane 7) pccir2 gene truncations were cloned into the 7000 bp GFPe (lane 1) and 
pHA-1 (lane 2) vectors using the restriction sites XhoI and KpnI.  Arrows point to the plasmids and inserts. 
 
The strategy behind PhoA/GFP method is the comparison between the activities of two 
reporter proteins.  Each of the fusion proteins is active on a different side of the E. coli 
inner membrane: GFP in the cytoplasm and PhoA in the periplasm.  In this regard, the 
GFP protein is not exported to the periplasm correctly and thus little to no fluorescence 
should be observed if the fusion is located on the periplasmic side.  If the C-terminus 
of the hybrid protein locates on the cytoplasmic side, high levels of fluorescence should 
be observed.  Conversely, PhoA is not active on the cytoplasmic surface but is 
activated in the periplasm.  PhoA is active only as a dimer.  The reducing environment 
of the E. coli cytosol prevents this dimerisation and thus the activity of the protein.  
Consequently, if high PhoA activity is observed the C-terminus of the hybrid protein is 
located on the periplasmic surface.  This is demonstrated schematically in Figure 5.27. 
 
 
Figure 5.27:  Location of fusion protein fluorescence or activity.  Schematic of a membrane 
showing the areas of activity for GFP and PhoA.  GFP fluorescence is observed only if the C-terminus of 
the protein is found in the cytoplasm as the protein is not exported in the correct orientation.  PhoA 
activity is only detected in the periplasm, and thus the C-terminus of the protein must be located in the 
periplasm. 
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It is essential to have similar expression levels of fused proteins under examination to 
obtain meaningful results, since the assay depends on quantifying differing levels of 
GFP fluorescence and PhoA activity.  Thus, expression trials were carried out for each 
of the six fusions to ensure that (i) each bacterial colony expresses the same fusion 
protein and at a similar level, and (ii) expression levels between fusions are 
comparable. 
 
5.5.1.1 Expression of GFP constructs 
The full-length gene and sequences encoding the six protein fragments were inserted  
into the pGFPe plasmid upstream from a gfp gene creating six constructs with a C-
terminal GFP fusion Figure 5.26, B.  Experimental trials were carried out using E. coli 
BL21 (DE3) cells and induced with IPTG as the gene is under the control of the T7 
promoter.  IPTG concentrations of 0.1 and 0.05 mM were tested, as well as two 
temperature conditions (22 oC or 37 oC) and incubation time after IPTG induction (3 h, 
6 h, 8 h and 16 h).  Crude membranes were prepared from each culture and 1 μg 
protein ran on a NuPage gel, and western blotted using an HRP conjugated anti-GFP 
antibody.  Figure 5.28, A shows the resulting western blot containing all 6 fusion 
proteins.  Lane 1 contains PcCir240-GFP which has an estimated molecular weight of 
34.1 kDa, lane 2 PcCir2106-GFP with estimated MW 42.2 kDa, lane 3 PcCir2210-GFP with 
estimated MW 54.6 kDa, lane 4 PcCir2254-GFP with estimated MW 59.3 kDa, lane 5 
PcCir2312-GFP with estimated MW 66.3 kDa and lane 6 PcCir2Δ73-GFP with estimated 
MW 58.2 kDa.  The protein domains not containing the TMD, PcCir240-GFP, PcCir2106-
GFP and PcCir2210-GFP, all show a protein band size corresponding to the expected 
molecular weight.  The two domains containing the TMD, PcCir2312-GFP and PcCir2Δ73-
GFP and fusion PcCir2254-GFP not containing the TMD ran further on the gel than 
expected, however this observation is sometimes noted with membrane proteins.  Two 
gene fusion constructs PcCir2312-GFP and PcCir2 -GFP gave a multiple banding 
pattern and protein sequencing confirmed that the lower band of PcCir2312-GFP was 
the correct protein.  It should be noted that the amount of protein detected (by way of 
band size) in sample PcCir2254-GFP was slightly less than the five others.  Figure 5.28 B 
shows streaked out colonies from a single colony for each fusion.  The gfp gene 
product fluoresces green under UV light.  After storage at 4 oC for approximately one 
week the bacteria cells exhibited a bright green fluorescence for construct PcCir2210-
GFP with a paler green for constructs PcCir240-GFP and PcCir2254-GFP.  The paler green 
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observed for the PcCir2254-GFP colony could be due to the lack of expression as 
observed in Figure 5.28, however, the sample still shows green fluorescence and was 
not further optimised.  PcCir2106-GFP, PcCir2312-GFP and PcCir2Δ73-GFP constructs 
remained non-fluorescent.  This result implies that whereas PcCir2312-GFP and 
PcCir2Δ73-GFP fusions are periplasmic due to the lack of GFP fluorescence, the C-
termini of fusions PcCir240-GFP, PcCir2210-GFP, and, PcCir2254-GFP are cytoplasmic. 
 
 (A)       (B) 
        
 
Figure 5.28: Expression and analysis of PcCir2 truncated proteins fused to GFP.  (A)  Bacterial 
cells were grown under assay conditions and induced with IPTG.  Cell lysate was prepared and applied to 
a gel and western blotted using an anti-GFP antibody.  Lane 1 PcCir240, lane 2 PcCir2106, lane 3 PcCir2210, 
lane 4 PcCir2254, lane 5 PcCir2312, and lane 6 PcCir2Δ73.   (B) Furthermore, live bacteria were analysed for 
reporter gene fluorescence.  LB agar was supplemented with IPTG and exposed to UV trans-illumination to 
reveal GFP fluorescence. 
 
The optimal protein expression conditions selected were found to be 0.05 mM IPTG 
inducer coupled with bacterial incubation for 3 h at 22 oC with agitation.  Darker bands 
were observed on the gels for longer induction periods such as 8 and 16 h suggesting 
a greater concentration of protein had been produced, however variation in expression 
levels were observed.  In this respect, bacterial cells did not display bright GFP 
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fluorescence when grown at 37 oC, but the fusion protein was expressed well when 
analysed using PAGE.  Despite that the conditions employed did not, per se, give the 
highest concentration of protein expression, GFP production was sufficient to carry out 
the GFP assays. 
 
5.5.1.2 Expression of PhoA constructs 
To optimise the production of PhoA containing chimeric constructs expression trials 
were carried out.  The phoa gene fusion constructs are driven by the araB promoter 
and thus the inducer L-arabinose was used to induce expression of the fusion proteins.  
The bacterial strain used for the PhoA assay, and expression trials are E. coli CC118, 
which lacked the endogenous phoa gene.  To ensure that cells were producing the 
PhoA fusion gene, bacteria were plated on LB-agar containing 1 % L-arabinose and 40 
µg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP).  Figure 5.29, A shows a western 
blot containing the 6 fusion proteins.  Lane 1 contains PcCir240-PhoA which has an 
estimated molecular weight of 53.2 kDa, lane 2 PcCir2106-PhoA with estimated MW 
60.8 kDa, lane 3 PcCir2210-PhoA with estimated MW 73.3 kDa, lane 4 PcCir2254-PhoA 
with estimated MW 77.9 kDa, lane 5 PcCir2312-PhoA with estimated MW 84.9 kDa and 
lane 6 PcCir2Δ73-PhoA with estimated MW 76.9 kDa.  The anti-PhoA antibody was 
tested at several dilutions and the six fusions gave a rapid reaction in the presence of 
the detection reagents and produced unspecific bands on the western blot.  Aliquots 
were unable to be sent for MS protein sequencing as after staining with CBB the bands 
were not sufficiently distinguishable to cut from the gel.   Samples containing PcCir40-
PhoA and PcCir210-PhoA showed very faint bands. 
 
Figure 5.29, B contains streaked-out colonies originating from a single colony for each 
fusion.  The phoa gene product, alkaline phosphatase converts BCIP to a compound 
which has a dark blue colour.  After storage at 4 oC for approximately one week, 
bacterial cells demonstrated a dark blue colour change for constructs PcCir2312-PhoA 
and PcCir2Δ73-PhoA.  The PcCir2106-PhoA construct indicates a very slight change but 
remained pale blue. Constructs PcCir240-PhoA, PcCir2210-PhoA and PcCir2254-PhoA did 
not give rise to a noticeable colour change.  This result suggests that the PcCir2312-
PhoA, PcCir2Δ73-PhoA and possibly PcCir2106-PhoA fusions are periplasmic due to the 
phosphatase activity and that PcCir240-PhoA, PcCir2210-PhoA and PcCir2254-PhoA are 
cytoplasmic. 
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(A)           (B)
         
Figure 5.29:  Expression and analysis of PcCir2 proteins fused to PhoA.  (A)  Bacterial cells were 
grown under assay conditions and induced with L-arabinose.  Cell lysate was prepared and applied to a gel 
and western blotted using an anti-PhoA antibody.  Lane 1 PcCir240, lane 2 PcCir2106, lane 3 PcCir2210, lane 
4 PcCir2254, lane 5 PcCir2312, and lane 6 PcCir2Δ73.   (B) Furthermore, live bacteria were analysed for 
reporter gene activity.  Bacterial cells growing on LB agar plate supplemented with L-arabinose and BCIP 
to monitor PhoA production.  The BCIP turns blue due to PhoA activity. 
 
CC118 cells were grown at 37 oC until the exponential stage of growth, which took 
approximately 2.5 – 3 h.  Following this growth phase, the cells were induced with L-
arabinose to final concentrations of 0.1 % and 0.2 %.  Cells transformed harbouring 
the PcCir2210 fusion were allowed to incubate for a further 2 h and 4 h before 
harvesting.  Protein from induced cultures was electrophoresed on a NuPAGE gel.  The 
gel containing the separated proteins was western blotted using an anti-PhoA antibody 
directed against bacterial PhoA (Abcam, Cambridge, UK).  Very little or no protein was 
observed in the 2 h culture time, yet the 4 h samples showed good expression of the 
fusion protein.  There was no observable difference on protein expression when 
comparing the 0.1 % and 0.2 % the concentrations of L-arabinose inducer for the 
PcCir2210-PhoA fusion protein.  Consequently, bacterial cells harbouring each of the six 
fusion constructs were grown to log phase, and incubated for 4 h after induction with 
0.1 % L-arabinose.  From the data presented in Figure 5.29, it can be seen that four of 
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the six fusions proteins were produced at similar levels, while the PcCir240 and PcCir2210 
fusions which are less well expressed.  The conditions for the assay were selected as a 
4 h growth period after induction with 0.1 % L-arabinose.  Cells were grown 
throughout at 37 oC. 
 
5.5.2 PhoA activity and GFP fluorescence assays 
 
5.5.2.1 GFP fluorescence assay 
E. coli cells containing plasmids with each of the GFP fusions were grown in triplicate 
to the exponential phase which took approximately 90 mins.  The hybrid genes were 
induced with 0.05 mM IPTG, and incubated with agitation (180 rpm) for a further 3 h.  
After 3 h incubation, the OD600 were taken, and 1 ml culture was pelleted for GFP 
assays.  Fluorescence of each cell suspension was measured in terms of fluorescence 
units (FU) and normalised to the OD600 of the culture.  The normalised value for each 
sample in the assay was divided by the total mean. The resulting figure was combined 
with the PhoA data presented in the next section, and entered into the chart below.  
An average value was taken for each of the three repeats of the five experiments, and 
entered in Table 5.4. The average value for each of these is also tabulated. 
 
                                                    Experimental Repeats 
Construct 1 2 3 4 5 Average 
PcCir240-GFP 1.62 2.02 1.63 1.56 1.62 1.69 
PcCir2106-GFP 0.75 0.56 0.48 0.54 0.53 0.57 
PcCir2210-GFP 1.31 1.14 1.23 1.17 1.01 1.17 
PcCir2254-GFP 1.48 1.92 1.76 1.85 1.91 1.78 
PcCir2312-GFP 0.46 0.42 0.38 0.33 0.35 0.39 
PcCir2Δ73-GFP 0.48 0.43 0.40 0.29 0.39 0.40 
Table 5.4:  The normalised and mean divided values for each of the 5 replicates of the GFP 
fusion proteins.  The final columns show the average for each sample.  1 – 5 are the repeats for each 
experiment, with the average value from the 3 expreiments.  Raw data can be found in Appendix 7.3. 
 
5.5.2.2 PhoA activity assay 
Bacterial cells containing one of each of the plasmids from PhoA fusions were grown, 
in triplicate, until the exponential phase.  Cells were induced with 0.1 % L-arabinose, 
and incubated for a further 4 h, before the assay was carried out.  The calculation 
given in Section 2.4.3 was used to determine the PhoA activity for each of the samples 
(15 in total).  The value for each of the 15 samples was divided by the total mean to 
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give the ‘normalised data’, this was entered into the chart below.  An average value 
was taken for each of the three repeats in the five experiments, and is entered in table 
5.5, the average for each of these is also given. 
 
                                                    Experimental Repeats 
Construct 1 2 3 4 5 Average 
PcCir240-PhoA 0.45 0.54 0.59 0.45 0.36 0.48 
PcCir2106-PhoA 0.60 0.24 0.55 0.60 0.82 0.56 
PcCir2210-PhoA 0.70 0.41 0.68 0.34 0.42 0.51 
PcCir2254-PhoA 0.53 0.32 0.52 0.58 0.70 0.53 
PcCir2312-PhoA 2.36 2.64 2.71 2.65 2.77 2.63 
PcCir2Δ73-PhoA 1.13 0.94 1.37 1.31 1.94 1.34 
Table 5.5:  The normalised and mean divided values for each of the 5 replicates of the PhoA 
fusion proteins.  The final columns show the average for each sample.  1 – 5 are the repeats for each 
experiment, with the average value from the 3 expreiments.  Raw data can be found in Appendix 7.4. 
 
The average PhoA activity in cells with the PcCir2312 construct, 2.63 units, is higher 
than that of the PcCir2Δ73 construct, 1.34 units.  The values should be fairly similar as 
the fusion is in the same position.  Possibly the truncation of the protein has affected 
the folding and insertion of the PcCir2Δ73 fusion protein. 
 
5.5.3 Combining the data 
The data were normalised by taking the mean of the total data set for GFP or PhoA 
and dividing each data point by the overall mean.  This provided values for each set of 
experiments that were easily comparable.  The values for each of the five replicates of 
the GFP and PhoA assays were plotted against each other and the chart is presented in 
Figure 5.30.  Where the values for each truncated protein cluster towards the y-axis, 
the samples had a high GFP fluorescence and low PhoA activity, this suggests the C-
terminus of the truncated protein is cytoplasmic.  Where the values cluster towards the 
x-axis, the samples had a low GFP fluorescence and high PhoA activity, this suggests 
the C-terminus of the truncated protein is periplasmic. 
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Figure 5.30: PhoA activity vs. GFP fluorescence in truncated fusion proteins.  The GFP fluorescent units (calculated from the means) have been plotted 
against the normalised PhoA activity units (calculated from the means) and entered into the chart.  The sway to the left hand side illustrates high PhoA activity and low 
GFP activity and implying a cytoplasmic C-terminal.  The sway to the right hand side shows high GFP activity and low PhoA activity and suggests a periplasmic C-
terminal.  The PcCir240, PcCir2210 and PcCir2254 domains are present on the left hand side.  This suggests their C-termini are cytoplasmic.  Raw data can be found in 
Appendix 7.3 and 7.4. 
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From Figure 5.30, the PcCir2210 data is present on the left hand side of the chart 
demonstrating low PhoA activity and high GFP activity.  Conversely, PcCir2312 and 
PcCir2Δ73 display high-moderate PhoA activity and low GFP activity.  The results of 
PcCir2106 do not show a sway to any particular side of the chart.  Given that the 
PcCir2106 constructs gave low activities for both GFP and PhoA but was protein 
detectable by western analysis, subcellular localisation was investigated.  Inclusion 
bodies were therefore isolated and washed to remove any residual membranes.  The 
resultant pellets from the PhoA and GFP constructs were resuspended in buffer and 
applied to a NuPAGE gel and western blotted (Figure 5.31).  The PhoA and GFP 
constructs from PcCir2312 were included as controls as they are present in the 
membrane, this was to ensure that the membranes had been thoroughly separated 
from the IBs. 
 
 
Figure 5.31:  Inclusion body separation.  Western blot to confirming the presence of the PcCir2106 
fusion proteins in the IBs, and the absence of PcCir2312 from the IBs.  Lanes 1, 3, 5 and 7 are the PcCir2312 
constructs and lanes 3, 4, 6 and 8 are the PcCir2106 constructs.  Lanes 1,2, 5 and 6 are cell lysate, and, 
lanes 3, 4, 7 and 8 are IB preparations.  In lanes 1 – 4 the blot has been carried out with the anti-PhoA 
antibody and in lanes 5 – 8 the anti-GFP antibody. 
 
The combined results of the GFP and PhoA fusion protein assays provide a novel model 
for the topology of PcCir2, one that places the HVR and the C-terminus outside the 
cell, with the N-terminus on the inside.  The in silico prediction methods have flaws in 
predicting the orientation of single TMD proteins (Dr. D. Daley, personal 
communication).  Thus, TMHMM fix34 (Melén et al, 2003) was used to constrict the C-
terminus to the outside, and residue 210 (where the fusion was made) to the inside.  
                                                 
34 http://www.sbc.su.se/~melen/TMHMMfix/ 
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This produced a model of the protein that fitted to the experimental data and gave a 
good Reliability score of 0.72 (a score of 0.00 suggests there may be other topologies 
as likely as the suggested model35 (Melén et al, 2003)) and an expected accuracy score 
of 80 %.  The Expected Accuracy Score is proportional to the Reliability score and 
estimates how probable it is that the suggested topology is correct (taken from35). 
 
The experimentally determined topology reverses the predicted topology.  The N-
terminus, and therefore the hypervariable region, is intracellular.  There are many 
possible reasons for this.  One is the heterologous expression system.  Another may be 
the trafficking of the protein, perhaps the E. coli membrane is treated as a transport 
vesicle by the protein or the ER.  It could also be that this particular protein has an 
intracellular location.  These possibilities will be discussed fully in Chapter 6. 
 
  
                                                 
35 http://www.sbc.su.se/~melen/TMHMMfix/ 
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5.6 Summary 
 
 The PcCir2 protein belongs to the PIR protein family, possibly also including the RIFIN 
and STEVOR proteins of P. falciparum.  PcCir2 contains two conserved sequence motifs 
shared by the PIR family.  PcCir2 is predicted to contain a single transmembrane 
domain towards the C-terminus of the protein.  The N-terminus of the protein is 
predicted to be extracellular.  The protein family are thought to be variant surface 
antigens.  PcCir2 contains an area thought to be hypervariable. 
 
 The pccir2 coding sequence was redesigned to an E. coli codon bias to facilitate 
expression of the protein in the bacteria.   The synthetic codon-optimised gene was 
cloned into four vectors for protein expression trials, pTTQ18, pTTQ18-TEV, pTTQ10H 
and pGFPe.  In each of the vectors and under each of the conditions tested good 
protein expression was observed on Coomassie Brilliant Blue stained NuPAGE gels.  All 
vectors encode a C-terminal His-tag, and, pTTQ18-TEV and pGFPe also encode TEV 
protease sites. 
 
 The PcCir2 protein was only solubilised using the harsh zwitterionic detergents Fos 
Choline-12 and Fos Choline-14.  From expression using the plasmid pTTQ18 all the 
PcCir2 protein produced was solubilised, for expression from pTTQ18-TEV and pGFPe 
approximately 50 % of the protein was solubilised.  Protein solubilised by Fos Choline-
12 was taken forwards for purification.  Purification was carried out using a cobalt 
metal affinity column to bind the protein via the His-tag.  When the purified product 
was tested on a NuPAGE gel various contaminants were observed. 
 
 A putative ordered domain of PcCir2 was found.  This domain, PcCir2Dom was 
expressed from three vectors, pEHISGFPTEV, pEHISTEV and pGFPe.  Two contain N-
terminal His-tags (pEHISGFPTEV and pEHISTEV) and pGFPe a C-terminal His-tag.  All 
vectors encode TEV protease sites.  In each of the vectors and under each of the 
conditions tested good protein expression was observed on Coomassie Brilliant Blue 
stained NuPAGE gels.  However, when separated into soluble and insoluble fractions, 
most of the PcCir2Dom protein was present in the insoluble fractions.  A second 
domain missing the first 72 N-terminal amino acids was then created.  This second 
domain, PcCir2Dom2, is lacking a hydrophobic area that may have prevented the 
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solubilisation of the overexpressed PcCir2Dom protein.  This new domain was 
expressed from the pEHISGFPTEV vector only.  The PcCir2Dom protein was present in 
the insoluble E. coli protein fractions. 
 
 The membrane topology of the PcCir2 protein was assessed in E. coli using C-terminal 
GFP and PhoA fusions.  The full-length protein was split into six truncations, and GFP 
or PhoA fused to each on the C-termini.  An assay system was used to assess the GFP 
fluorescence and PhoA activity from each of the truncations.  The results suggested a 
topology where the N-terminus of PcCir2 is intracellular and the C-terminus 
extracellular.
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6 Discussion 
 
The overall aim of the research presented in this thesis was to functionally, 
biochemically and structurally characterise two Plasmodium membrane proteins to gain 
insights to the mechanisms involved and in so doing develop armaments against 
malaria.  The discussion is split conveniently into two parts, (i) to describe PfNitA 
(Section 6.1) and (ii) to cover PcCir2 (Section 6.2). 
 
6.1 PfNitA 
 
All Plasmodium parasites for which the genome has been sequenced encode a putative 
formate-nitrite transporter gene, that we have termed pfnita.  Orthologues are found 
in other apicomplexan parasites, prokaryotes, fungi and algae (Jia et al, 2009, Wang et 
al, 2008, and, Fernandez and Galvan, 2007).  In contrast, there are no orthologues in 
higher organisms such as plants and mammals.  Therefore this transporter should a 
priori make a selective drug target. 
 
Transport proteins serve many functions including the facilitation of signals and the 
passage of nutrients across biological membranes.  Transport may be between cellular 
organelles or from the extracellular medium into cells and vice versa.  Negatively 
charged ions are unable to cross the phospholipid bilayer.  However, even certain 
molecules such as water and urea, that are able to diffuse across the bilayer, require 
transport proteins to assist the process (Darnell et al, 2000).  Transport proteins make 
attractive drug targets and there are many currently used chemotherapies that 
interfere with transporter mediated mechanisms of uptake (Kell, 2012).  It was our 
intention to characterise the PfNitA transporter and thereby lay down the foundations 
for future research work to be carried out on this potential drug target. 
 
Therefore the questions raised in this thesis were: 
 
(i) What is the function of the formate-nitrite transport protein in P. falciparum and 
what is its subcellular localisation? 
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(ii) Is the pfnita gene and its protein product essential to IDC parasite survival? 
 
6.1.1 Substrate specificity of PfNitA. 
The NitA protein of Plasmodium falciparum belongs to the formate-nitrite transporter 
protein family.  The family name suggests that the substrates for members of this 
family are formate, nitrite or both.  However, various publications show that FNT 
proteins transport, in addition to formate and/or nitrite, the hydrosulphide ion, 
bicarbonate and lactate may also be substrates of the transporter family (Suppmann 
and Sawers, 1994, Jia et al, 2009, Czyzewski and Wang, 2012, Fernandez and Galvan, 
2007, and Rycovska et al, 2012). 
 
The results presented in Chapter 3 of this thesis show that, when a synthetic codon-
optimised pfnita gene (pfnita_opt) for expression in the lower eukaryote Aspergillus 
nidulans was transformed into this fungus no expression of the P. falciparum protein 
occurred (Figure 3.10).  The original rationale was that the pfnita gene could be 
expressed in A. nidulans for the purposes of the complementation of a deletion mutant 
strain lacking the orthologous nitrite transporter encoding gene.  Further 
characterisation of the P. falciparum transport protein could be conveniently studied in 
this experimentally amenable model fungal organism.  It was noted that A. nidulans 
does not possess a formate transporter gene from in silico analyses and therefore 
complementation for this function could not be assessed. 
 
In addition to pfnita_opt, a further synthetic pfnita gene (pfnita_optEc) was designed 
and created for expression in the model prokaryote Escherichia coli and functional 
complementation attempts of null mutants lacking the orthologous proteins, either 
EcNirC or EcFocA.  The two synthetic codon-optimised genes, pfnita_opt or 
pfnita_optEc, were transformed into loss-of-function nitrite or formate transporter 
mutant E. coli strains and expressed under anaerobic conditions using specialised 
medium for later biochemical assays (Figure 3.12).  Although the genes were 
expressed under such optimal conditions the expression levels were lower than the re-
expressers (Figures 3.12 and 3.18).  In one experiment, however, the expression of 
pfnita_opt was unable to be verified due to technical problems associated with the 
western blots. 
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For the functional complementation of an ecnirc nitrite transporter null mutant both 
synthetic codon-optimised genes were expressed followed by protein characterisation.  
The uptake of nitrite into cells was studied by investigating the depletion of nitrite from 
media containing the bacteria.  The depletion of nitrite from the medium equates to 
the uptake of nitrite by the bacterial cells.  In two positive control strains, a WT and 
the EcNirC re-expresser, the concentration of nitrite diminished from the medium over 
a two hour time period (Figure 3.15).  In three negative control samples, null mutant, 
heat killed WT cells, and a blank control omitting cells (i.e. No Cells), the levels of 
nitrite did not differ significantly over the two hours of incubation (Figure 3.15).  From 
concomitant experiments it was clear that the strains expressing the synthetic codon-
optimised P. falciparum genes indicated that the PfNitA_optEc protein was not involved 
in the uptake of nitrite from the medium as the strain performed similarly to the 
negative controls (Figure 3.15).  Moreover statistical analysis using a one-way ANOVA 
confirmed there were no significant differences between the pfnita expressing cells and 
the three negative controls (Table 3.5).  In summary, the results presented in this 
work shows that the PfNitA permease does not transport nitrite when expressed in E. 
coli under the assay conditions presented in this thesis. 
 
In addition to a nitrite transporter, E. coli also possesses a formate transporter, ecfoca.  
The null mutant ecfoca strain was used for the functional complementation of this 
gene, coupled with the formate transport assays.  Formate is a toxic by-product of E. 
coli anaerobic glucose metabolism and is therefore excreted from the cell to prevent 
the acidification of the cell cytoplasm.  However, when the pH of the medium drops to 
pH < 6.8 the function of the permease is altered and formate is imported into the 
cytoplasm.  The transport of formate into the cells was assessed using an indirect 
assay with the lacZ gene fused to the fdhF promoter (Falke et al, 2009).  This 
promoter is only active upon formate import and the formate transport capability assay 
is based on the resulting β-galactosidase activity.  In short, a high β-galactosidase 
activity equates to formate influx.  In the positive control strain, the EcFocA re-
expresser, β-galactosidase activity was found to be markedly increased compared to 
the null mutant (Figures 3.17 and 3.19).  In two negative control strains, null mutant 
and pccir2 expressing cells, the levels of β-galactosidase activity did not differ greatly 
over the four hours of experimentation (Figure 3.19).  Unfortunately, the A. nidulans 
codon-optimised gene (pfnita_opt) was not assayed as technical problems with the 
Discussion Chapter 6 
 
[220] 
 
western blot meant that expression of the protein could not be confirmed.  Expression 
of the E. coli codon-optimised protein (PfNitA_optEc) was poor compared to the 
EcFocA re-expresser (Figure 3.18).  The tests strains expressing the synthetic codon-
optimised P. falciparum gene did not function with regard to the uptake of formate as 
the β-galactosidase activity was similar to the negative controls (Figure 3.19).  
Statistical analysis of these strains did not reveal significant differences between the 
test strains (Table 3.12).  This is potentially due to the large standard deviations 
observed in the samples.  To decrease the standard deviations, more assays would 
have to be carried out.  However, the β-galactosidase activity was slightly higher than 
the negative controls, and given the poor expression of the protein, we speculate that 
PfNitA can function in the transport of formate.  To assess this theory, further research 
would need to be carried out. 
 
S. cerevisiae is another potential organism that could be used for complementation 
assays, especially as a knock-out library is available36.  As this yeast is a eukaryotic 
organism it may carry out PTM’s that are required for the activity of the PfNitA 
transporter.  However, although found in the FNT family (due to a FNT domain37) and 
annotated as a formate-nitrite transporter on GeneDB38 the protein does not appear to 
be involved in monocarboxylate transport (Jennings and Cui, 2008 and 39).  It is 
possible that the protein plays a role in the transport of the chloride ion (Jennings and 
Cui, 2008).  Given the uncertainty of the transporters substrate, and the fact that to 
examine the substrate/s in E. coli certain metabolic pathway had to be induced, it was 
concluded that it would be too difficult to design an assay for complementation in S. 
cerevisiae. 
 
6.1.2 Subcellular localisation of PfNitA 
The subcellular localisation for PfNitA was not predicted from in silico analyses.  For 
instance, a mitochondrial or apicoplast location was not indicated by the prediction 
programs.  That no signal peptide was observed was further circumstantial evidence.  
                                                 
36 http://www-sequence.stanford.edu/group/yeast_deletion_project/deletions3.html.  Accessed on 24 
January 2013. 
37 http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?INPUT_TYPE=precalc&SEQUENCE=45270094.  
Accessed on 24 January 2013. 
38 http://old.genedb.org/genedb/Search?name=YHL008C&organism=cerevisiae.  Accessed on 24 January 
2013. 
39 http://www.yeastgenome.org/cgi-bin/locus.fpl?locus=YHL008c.  Accessed on 24 January 2013. 
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Neither does the amino acid sequence contain a PEXEL motif (Hiller et al, 2004, and 
Marti et al, 2004) to direct the protein outside of the parasite cell.  Thus, a biochemical 
investigation into the subcellular localisation of PfNitA was initiated.  Parasites were 
transfected with plasmids containing a GFP tagged or an HA tagged pfnita_opt gene 
(Figure 4.1).  Real time live fluorescence microscopy of PfNitA-GFP and 
immunofluorescence analysis (IFA) of PfNitA-HA showed that the PfNitA transporter 
was located to the parasite plasma membrane (PPM) and in some instances the 
digestive vacuole (DV) (Figures 4.4, 4.5, and 4.6).  The parasite plasma membrane 
location of the transporter suggests a role in efflux or influx of metabolites or 
compounds from the parasites.  IFA co-localisation studies presented in this thesis 
supported the PPM location but not the DV location (Figure 4.7).  This result, however, 
does not completely rule out the DV as a location for the permease.  If the over-
expressed PfNitA_opt protein is detrimental to the parasite, the protein could be 
transported to the digestive vacuole for degradation, although a proteosome would be 
the expected subcellular organelle for protein breakdown.  This is, of course, only 
speculative and would require further analysis.  In the yeast Saccharomyces cerevisiae, 
the subcellular localisation has likewise not been determined accurately for the protein 
orthologue.  Nonetheless, studies using GFP tagged proteins suggest the S. cerevisiae 
orthologue is associated with the vacuole in yeast (Paulsen et al, 1998, in Jennings and 
Cui, 2008).  No functional role has been reported for the S. cerevisiae transporter but it 
is conceivable that the proteins may have similar vacuolar functions in both S. 
cerevisiae and P. falciparum.  Overall, the research suggests the PfNitA protein is 
localised to the PPM and DVM in intraerythrocytic parasites. 
 
It is plausible that the PfNitA protein acts as a monocarboxylate transporter and is 
responsible for the passage of compounds into or out of the parasite itself.  There is 
indeed a putative monocarboxylate transporter gene present in the P. falciparum 
genome, designated PF3D7_021030040.  To the best of my knowledge, no work has 
been carried out on this gene and/or protein or orthologues in other Plasmodium 
species.  Many of the studies performed on Plasmodium transporters have been with 
proteins that are responsible for the passage of nutrients into the parasite from the 
surrounding medium (e.g. Slavic et al, 2010, and el Bissati et al, 2008).  However, very 
                                                 
40 http://plasmodb.org/plasmo/.  Accessed on 4 September 2012. 
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few studies have identified proteins that play a role in the efflux of a substrate.  An 
exception, namely the PfCRT protein, is thought to act on the efflux of chloroquine 
from the parasites DV, although this is not the sole function of the PfCRT protein 
(Martin et al, 2009a). 
 
Nitrites are found in the DV and may be involved in the detoxification of haem (Ostera 
et al, 2008 and Ostera et al, 2011).  It is possible that because the PfNitA transporter 
is present in the DVM, it functions in the transport of nitrite and/or nitrite into the DV 
and/or possibly transports haemoglobin breakdown end-products back into the parasite 
cytoplasm for use in cellular metabolism or further export between the parasite and/or 
erythrocyte. 
 
Dual localisation of proteins in P. falciparum is not unknown.  For instance the protease 
falcilysin is dually located in the digestive vacuole where it has a role in Hb degradation 
and is also found in the apicoplast where it in the degrades transit peptides leading to 
production of the full-length functional protein (Ponpuak et al, 2007).  The falcilysin 
protein is also trafficked to the mitochondrion (Ralph, 2007).  The lipoate protein ligase 
A2 (LplA2) from P. falciparum has been shown to be present in the mitochondrion and 
apicoplast (Günther, 2007).  This particular protein is involved in the metabolism of 
lipoic acid that is found in the mitochondrion and apicoplast and LplA2 is essential for 
parasite sexual development in the mosquito (Günther, 2007).  The vacuolar H+-
ATPase (V-ATPase) is observed in four organelles of the parasite namely the parasite 
plasma membrane, parasitophorus vacuole membrane, the digestive vacuole and in 
cytoplasmic vesicles (Hayashi et al, 2000).  V-ATPase is known to play a role in the 
extrusion of protons from the parasite in the maintenance of cytoplasmic pH.  
However, it should be noted that in the DV, the V-ATPase actively imports protons to 
reduce the pH of the DV (Hayashi et al, 2000).  In light of these examples, it is 
therefore possible that the Plasmodium protein is located to the two organellar 
membranes.  Given the range of anionic substrates demonstrated for orthologous 
proteins, it is also possible different substrates are transported in the different 
locations. 
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6.1.3 Knock-out of PfNitA 
Orthologues of PfNitA in E. coli and A. nidulans have previously been knocked-out 
demonstrating these orthologues are not essential to the growth of the organism.  For 
example, in A. nidulans, deletion of the annita gene does not affect growth (on 
complex medium) due to the presence of two nitrite/nitrate transporters (Unkles et al, 
2011).  In P. falciparum there are few transport proteins compared to other 
eukaryotes, and many of these could not be knocked-out successfully (e.g. Slavic et al, 
2010, el Bissati et al, 2008, and, Waller et al, 2003).  The paucity of transport proteins 
in Plasmodium species suggests such proteins may be essential to parasite survival.  
To analyse the essentiality of pfnita to intraerythrocytic parasites, gene knock-out 
studies were carried out in blood stage P. falciparum. 
 
The pfnita gene could not be disrupted in two different strains of P. falciparum by 
double cross-over recombination (Figure 4.10).  We attempted to knock-out the gene 
in the presence of an additional copy of pfnita by expressing the synthetic codon-
optimised gene from an episomal plasmid (Figure 4.12).  If pfnita is essential for 
intraerythrocytic stage parasites, a knock-out of the gene should be possible as a 
second copy is present and the protein it encodes is expressed.  This method 
employed was shown to be successful to yield a knock-out strain of P. falciparum for 
thioredoxin reductase and for the hexose transporter (Krnajski  et al, 2002, and Slavic 
et al, 2010).  The synthetic codon-optimised gene was chosen in an attempt to prevent 
recombination with the natural P. falciparum gene locus.  Despite the additional 
synthetic codon-optimised gene, the pfnita locus was not targeted as judged by the 
failure to generate a viable strain (Figure 4.12 and 4.13).  In fact, from the 
hybridisation pattern obtained after Southern analysis, it is possible instead that 
recombination between the two transfected plasmids occurred while integration at the 
intended locus did not take place.  The recombination of plasmids may be a technical 
problem and consequently would need to be rectified before future experiments could 
take place. 
 
The P. falciparum gene locus of pfnita was, however, targeted showing that this gene 
is not per se refractory to recombination (Figure 4.18).  The tagging of the 
endogenous gene was achieved using a sequence homologous only to the 3’ end of 
the pfnita gene rather than the full ORF as this tactic made certain that only one 
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functional copy of the gene was present at the recombined locus.  This approach 
showed that the changes to the gene locus through the integration of the pCHD-
Hsp86-ctml-(HA)3 plasmid was not detrimental per se to parasite survival.  Instead, 
there did appear to be a random integration event (or events), occurring at another 
gene locus, of the plasmid.  Random integration of plasmids can occur, and appear to 
be selected for when integration into the target locus leads to a growth defect 
(Günther et al, 2009, and Patzewitz, 2009).  Only a small percentage of parasites 
underwent recombination with the pCHD-Hsp86-ctml-(HA)3 plasmid suggesting there 
may be fitness costs involved.  The results obtained by Southern blot analyses for 
pCHD-Hsp86-ctml-(HA)3 recombination were somewhat ambiguous.  The data obtained 
suggested non-specific integration of the knock-out construct into the P. falciparum 
genome as well as integration at the correct locus (Figure 4.18).  The possible non-
specific integration requires further investigation including pulse field gel 
electrophoresis to investigate other loci involved.  In addition, integration at the correct 
locus should be examined by the cloning of the appropriate cell line by limiting dilution.  
As the locus could not be targeted by the pCHD-Hsp86-ctml-GFP plasmid (Figure 4.16) 
the presence of the longer C-terminal tag was possibly deleterious to the organism or 
interfered with the single cross-over required for integration, potentially due to the 
larger size of the plasmid. 
 
A second strategy pursued (but not completed) was to target the pfnita locus with a 
plasmid containing a partial gene but without any N- or C-terminal tags (Figure 4.19).  
The pHH1 based plasmid constructs were created for the purpose of a knock-out as 
well as a knock-out control.  Such plasmids recombine by single cross-over 
recombination events, for the knock-out the native locus is interrupted and two non-
functional copies of the gene inserted.  For the knock-out control, integration of the 
plasmid should result in a single functional copy of the gene and a second truncated 
copy of the gene.  In short, the knock-out control should show whether the gene locus 
is targetable in principle. 
 
6.1.4 Conclusions 
The results obtained from knock-out studies of pfnita in P. falciparum suggest that the 
pfnita gene is essential for the intraerythrocytic stages, as a strain harbouring such a 
disrupted gene appears to be unobtainable.  This would fit with available expression 
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data from the PlasmoDB database that implies pfnita is present throughout the 
intraerythrocytic development stages. 
 
The substrate for PfNitA remains elusive.  However, given the functions and reported 
substrates in other organisms as well as the likely essentiality of the gene and the 
protein locations from the results presented in this thesis, it may be speculated the 
permease functions in the removal of waste products from the growing parasite.  
Waste products may be exported from the parasite into the parasitophorus vacuole.  
The parasitophorus vacuole membrane is porous and in turn may allow the waste 
metabolites to pass into the RBC lumen from where these molecules are excreted into 
the hosts’ bloodstream, possibly through the new permeability pathways created by 
the parasite.  In these respects lactate is a possible waste metabolite as it is the main 
by-product from glucose metabolism by the parasite.  It is noteworthy that there is no 
annotated lactate transporter in the parasite genome on PlasmoDB41. 
 
6.1.5 Future work 
Formate uptake analysis 
An aspect that is of most importance is to confirm whether formate is transported by 
the PfNitA transporter as suggested by the research results presented in this thesis.  
Investigating the presence or concentration of formate in spent RPMI medium is 
complicated.  Available methods to analyse formate are not sensitive enough to detect 
relatively low medium concentrations.  The limits of the published methods are 
concentrations of 7 mg/L (Blomme et al, 2001).  Also, mass spectrometry-based 
metabolomics cannot detect molecules as small as formate (S. Sethia, personal 
communication).  If formate is transported into the parasite cell, heavy labelled 
formate could be used to follow formate metabolism in the cell as well as where its by-
products are found.  However, we hypothesise that formate would be produced as a 
toxic end-product of metabolism that would require removal from the parasite cell. 
 
To analyse the uptake or efflux of formate and other metabolites, pfnita could be 
expressed in Xenopus laevis oocytes which has been used successfully before for 
investigation of permeases.  Secondly characterisation of the uptake of a heavy 
                                                 
41 http://plasmodb.org/plasmo/.  Accessed on 4 September 2012. 
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labelled/tracer formate could be carried out in laboratory grown Plasmodium cultures.  
As well as investigating formate, the transport of other metabolic end-products such as 
acetate and lactate may be studied. 
 
Another possible line of enquiry to investigate the transportation of formate is to use 
the ‘Conditional Knock-out’ method in which a gene knock-out strain is obtained with 
an additional copy of the gene being present on an episomal plasmid.  Instead of using 
the same gene that is being targeted, as attempted in this study with the codon-
optimised copy, a specific lactate or general monocarboxylate transporter could be 
used as the complementary gene copy.  If the process was successful the results 
would indicate if the lactate transporter carries out the same function as the PfNitA 
permease.  Although lactate is an end-product of glucose metabolism in Plasmodium 
and lactic acid in the human bloodstream leads to lactic acidosis in patients, a lactate 
transporter has not been annotated in the Plasmodium genome42 as stated above. 
 
Indeed, work in the laboratory of Prof. Kiaran Kirk at the Australian National University 
(Marchetti, Martin and Kirk, personal communication and Marchetti, 2012) it has been 
shown that the PfNitA transporter is capable of transporting formate and to a lesser 
degree nitrite.  In addition to these compounds their data has also shown that lactate 
can be transported by the PfNitA transporter.  Moreover this research group has 
defined the PfNitA permease as a moncarboxylate transporter (Marchetti, 2012). 
 
Inhibitor studies 
If the functional complementation assays described in Chapter 3 are optimised, the 
strains could be used to identify potential inhibitors of the Plasmodium protein.  The 
Malaria Box43, 44 is a collection of diverse compounds that have shown to be active 
against the intraerythrocytic stages of P. falciparum but were not toxic to mammalian 
cells (Figure 6.1).  The Malaria Box contains 400 drug-like and probe-like compounds. 
 
                                                 
42 http://plasmodb.org/plasmo/.  Accessed on 4 September 2012. 
43 http://www.mmv.org/malariabox.  Accessed on 20 August 2012. 
44 https://www.ebi.ac.uk/chemblntd.  Accessed on 20 August 2012. 
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Figure 6.1: Malaria Box selection process.  Image is taken from the ‘Medicines for Malaria Venture’ 
website45. 
 
Assays in bacterial strains expressing the PfNitA protein would be carried out in the 
presence and absence of the Malaria Box inhibitors.  The prevention of substrate 
uptake would indicate the compound used inhibited the PfNitA permease.  The 
blocking of the transporter would most likely not kill the bacteria as they can survive 
without the substrate.  Therefore concentrations of compounds that are inhibitory but 
that do not kill the cells may be identified.  Potentially, the 3D structural model of 
PfNitA generated in this thesis and computer programs to map inhibitor compounds to 
this model could be used to narrow down the inhibitors investigated using the assay 
system. 
 
Knock-down using mutagenesis 
In A. nidulans, the orthologous annita gene has been subjected to a wide range of in 
vitro-generated mutations resulting in alteration of the amino acid sequence.  
Following transformation of mutant constructs into A. nidulans strains have been 
assessed for their ability to (i) grow on nitrite as the sole nitrogen source, (ii) express 
the mutant protein to WT levels and (iii) transport nitrite (Symington, 2009 and Unkles 
et al, 2011).  These studies have shown that, following mutation of four highly 
conserved asparagines residues located in the proteins transmembrane domains 
(Section 1.5.3.1, Aspergillus), one mutant in particular showed good protein expression 
and the mutation made only a slight difference to the growth of the strain on nitrite.  
This mutation, N214D, added a negative charge to the protein, but had little effect on 
the size of the amino acid side chain, and is therefore unlikely to affect the protein 
folding (Symington, 2009).  In radioactive tracer experiments, the N214D A. nidulans 
mutant strain showed reduced nitrite influx compared to that of the strain with the WT 
protein (Dr. S.E. Unkles, unpublished work). 
 
                                                 
45 http://www.mmv.org/sites/default/files/uploads/images/RandD/Selection_Process_Malaria_Box.png.  
Accessed on 20 August 2012. 
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It may be possible to exploit the data from A. nidulans, and the functional 
complementation assays described in Chapter 3 to attempt a ‘knock-down’ of the P. 
falciparum NitA transporter by creating an equivalent mutation that may reduce the 
activity of the transporter.  The E. coli complementation assays could be used to 
identify any residues that lower the level of substrate transported by the protein.  
Mutants would be generated from P. falciparum gDNA and transfected into the 
parasites.  This experimental approach relies on the effectiveness of the functional 
complementation assays and a single cross-over taking place at the correct locus.  An 
allelic exchange experiment would introduce the respective mutations into the P. 
falciparum gene and may lead to the generation of a mutant pfnita gene encoding a 
transporter with reduced transport activity.  Given the correct recombination genotype, 
the phenotype such as growth patterns could be analysed in comparison to WT and 
transfected non-mutant parasites (for instance, those generated for a knock-out 
control). 
 
6.2 PcCir2 
 
The Cir2 protein of P. chabaudi belongs to the PIR protein family.  Members of this 
family are found in all sequenced malarias although the link between the PIR’s and P. 
falciparum orthologues is questionable.  Members of the PIR family are thought to play 
a role in immune evasion as the amino acid sequences contain a so called 
hypervariable region (HVR) as discussed in Chapter 1 (Figures 1.11 and 5.2). 
 
The DNA and protein sequences of pccir2 do not resemble other non-redundant 
sequences from other species, and therefore no suggestions about the function of the 
protein family can be made.  It was our intention to obtain structural information that 
might provide clues to the function of the protein. 
 
The questions we wished to answer in this thesis were: 
 
(i) Can we produce sufficient purified protein for crystallography trials? 
 
(ii) What is the 2D or 3D structure of PcCir2 and can we hypothesise a function 
from this information? 
Discussion Chapter 6 
 
[229] 
 
6.2.1 Recombinant protein expression and purification 
To analyse the structure of PcCir2, constructs were designed with the objective to 
overexpress the protein in E. coli. The pccir2 gene was cloned into 3 expression 
plasmids each with a C-terminal His-tag for production of the full-length protein 
(Figures 5.3 and 5.9).  As the protein appeared to be insoluble, two further constructs 
that would potentially produce soluble proteins were created and designated 
PcCir2Dom and PcCir2Dom2 (Figure 5.23).  One construct was truncated at the C-
terminus before the TMD. The second domain was truncated at the N-terminus after a 
hydrophobic stretch of amino acids and at the C-terminus before the TMD. 
 
Purification of full-length PcCir2 using cobalt affinity chromatography proved difficult, 
as the recombinant protein did not appear to be particularly stable. The protein 
appeared to degrade during expression (Figure 5.4, 5.10 and 5.13) and aggregated 
during purification (Figures 5.8, 5.12, and 5.15).  Moreover, the recombinant protein 
purified with contaminating bacterial proteins (Figures 5.8, 5.12, and 5.15).  Further 
purification and protein concentration methods were not investigated. 
 
The two truncated constructs were not expressed as soluble proteins, despite many 
attemps to do so by altering expression temperatures and times, media and bacterial 
strains (Figures 5.19, 5.20, 5.21, 5.22, 5.24 and 5.25).  Therefore we were unable to 
produce protein that could be taken forwards for structural analysis and 
crystallography trials.  Soluble protein was obtained by collaborators, but the quantities 
were not sufficient for structural analyses. 
 
The PcCir2 amino acid sequence contains a single putative transmembrane domain 
(Figure 5.1).  The N-terminal of the protein is moderately hydrophobic, although it is 
not thought to be a TMD.  As with the N-termini of the RIFIN proteins (Kyes et al, 
1999), the weak hydrophobic N-terminus of PcCir2 may represent a cleavable signal 
peptide is present.  When the PcCir2 protein domains (lacking the TMD) were 
expressed in E. coli they were poorly soluble.  It is possible that this weak hydrophobic 
stretch of amino acids was responsible for the poor solubility of the protein domain.  
Potentially this hydrophobic stretch of amino acids encodes a cleavable signal peptide 
that would remain uncleaved when expressed in E. coli, and this prevented the 
production of soluble protein. 
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6.2.2 Membrane topology 
To experimentally determine the topology of the PcCir2 protein, a set of C-terminal 
fusion proteins were made for use in GFP fluorescence and PhoA activity assays as 
described by Rapp et al (2004) and Daley et al (2005).  The pccir2 sequence was 
truncated at five locations in the amino acid sequence to generate five truncated 
proteins as well as the single full-length protein (Figure 5.26). 
 
 
Figure 6.2: A putative PcCir2 structural model with putative binding sites.  The structural model 
was downloaded from the I-TASSER server and edited in PyMol.  The putative binding residues as 
suggested by I-TASSER are shown in grey, and the N-terminus is blue and C-terminus in red.  A clear TMD 
is absent from this model. 
 
Of these six proteins, one was found to be packed into E. coli inclusion bodies and was 
excluded from our studies (Figure 5.31).  The data from each of the assays was 
combined (Figure 5.30) and analysed to provide a 2D topology model.  The topology of 
the PcCir2 protein as determined experimentally has the N-terminus of the protein 
locatedintracellularly and the C-terminus on the outside.  By extention this suggests 
the hypervariable region is internal. 
 
The PcCir2 amino acid sequence was subject to analyses using the I-TASSER46 (Zhang, 
2008) server to predict the structure and possible function/s of the PcCir2 protein.  The 
I-TASSER server selects known crystal structures as templates for protein structure 
predictions given an amino acid sequence.  When the PcCir2 amino acid sequence was 
uploaded to the server, I-TASSER predicted five different structural models.  The 
                                                 
46 http://zhanglab.ccmb.med.umich.edu/I-TASSER/.  Accessed on 4 September 2012. 
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templates for these models were binding proteins and receptors.  This may imply that 
PcCir2 is a binding protein or a receptor, though there is perhaps not enough similarity 
between these proteins to be conclusive.  An I-TASSER generated model is depicted in 
Figure 6.2 with the putative binding residues indicated in grey. 
 
The topology of the PcCir2 protein places the hypervariable region inside the cell.  
Such a location could be due to a difference in the mechanisms of trafficking found in 
P. falciparum that are absent in E. coli.  P. falciparum protein trafficking is not yet fully 
understood although many mechanisms have been suggested (Charpian and 
Przyborski, 2008).  It is also believed that membrane proteins travel along a 
‘membrane system’ before they are released into the RBC (Saridaki et al, 2008).  
Nevertheless, E. coli is a host that has been used for the expression of eukaryotic 
membrane proteins. 
 
 
 
Figure 6.3:  Trafficking of proteins in Plasmodium.   A schematic diagram taken from Charpian and 
Przyborski (2008) to illustrate the various ways in which a protein can be trafficked outside of the parasite.  
Membrane proteins are associated with membrane throughout the trafficking process. 
 
The scheme presented in Figure 6.3 illustrates the ways in which Plasmodium proteins 
are thought to be trafficked outside the RBC.  The PcCir2 protein may be transported 
from the ER in a vesicle to the parasitophorus vacuole and beyond.  In the vesicle, and 
each subsequent membrane, the protein is embedded in the layer of lipids that 
comprise the vesicle, parasitophorus or plasma membranes.  Without the potential 
post-translational modification and signals of P. falciparum the nascent protein could a 
priori be inserted into the E. coli membrane in an orientation intended for the transport 
vesicle or PVM, and this membrane topology does not necessarily reflect the final 
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orientation of the PcCir2 protein.  For instance, depending on the model presented in 
Figure 6.3, the final membrane topology of Exp1 is not the same as the topology in the 
transport vesicle (Charpian and Przyborski, 2008). 
 
The BIR proteins of P. berghei were found to be associated with Maurer’s Clefts as well 
as the PfMC2 proteins of P. falciparum (del Portillo et al, 2004 and Merino et al, 2006), 
while the STEVOR proteins, also belonging to P. falciparum, are trafficked though 
Maurer’s Clefts on their way to the RBC membrane (Niang et al, 2009).  The 
membrane-associated histidine-rich protein 1 (MAHRP1) of P. falciparum is a protein 
with no significant homology to other proteins and which also contains a single TMD 
(Spycher et al, 2006).  The MAHRP1 protein is known to be exported to the RBC and is 
found in Maurer’s Clefts.  The C-terminus of MAHRP1 is located in the RBC cytoplasm, 
whilst research in this thesis suggests the N-terminus of PcCir2 is located in the RBC 
cytoplasm.  It is tempting to speculate that the PcCir2 protein is indeed a Maurer’s 
Cleft protein and the TMD is used to anchor the protein to the lipid rich Maurer’s Cleft.  
Possibly the PIR family of proteins are chaperones that transport proteins lacking a 
PEXEL/VTS motif (Hiller et al, 2004, and Marti et al, 2004) outside the parasite and to 
the surface of the RBC.  The PcCir2 protein was purified with a number of 
contaminating bacterial proteins.  If the PcCir2 protein is a binding protein it may 
interact with various E. coli proteins which were consequently co-purified by the metal 
affinity chromatography and only visible after the denaturing conditions of the protein 
electrophoresis.  The positioning of the PcCir2 protein at the surface of the erythrocyte 
or in Mauree’s Clefts would make it a promising candidate for a variable antigen given 
its exposure to the immune system and the high level of sequence variability across 
the family of CIR proteins.  Thus, one might speculate that the PIR protein family are 
chaperone proteins that reside in the Maurer’s Clefts. 
 
It has been reported that expression of eukaryotic membrane proteins with an N-
terminus out topology in E. coli (such as G-protein receptors) can cause problems with 
regard to correct targeting and membrane insertion (Junge et al, 2008).  The 
membrane protein topology prediction programs predicted PcCir2 to have an N-
terminus out topology.  It is possible that by expressing the protein in an E. coli 
heterologous system the protein is mis-targeted and inserted in the wrong orientation.  
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This could explain why the experimental model produces a ‘C-terminus out’ topology 
while the bulk of the protein and N-terminal are intracellular. 
 
6.2.3 Conclusions 
The production of PcCir2 domains and full-length protein was hampered by the 
problems that arose due to solubility and purification of the protein and its domains.  
As a result no pure protein was produced that could be used for further structural 
analysis.  The membrane topology analysis of PcCir2 gave an unexpected result in that 
the hypervariable region was found to be intracellular.  If the recombinant protein (s) 
were expressed and inserted in the E. coli inner membrane in the correct topology, we 
could speculate that the PcCir2 protein may function as a chaperone and is possibly 
present in the Maurer’s Clefts found towards the periphery of the RBC.  However, to 
fully investigate this possibility and to obtain a structural model for the PcCir2 protein, 
further work must be carried out. 
 
6.2.4 Future work 
Obtaining purified PcCir2 
To obtain full-length PcCir2 protein that can be solubilised and purified efficiently, more 
expression trials require to be carried out.  PcCir2 was expressed at high levels during 
the experimental stages of this thesis.  However, problems occurred during the 
purification process.  The use of a different tag such as a Strep-tag® or a glutathione-
S-transferase (GST) tag may aid in the purification process.  GST binds with high 
affinity to glutathione during purification, though as the GST amino acid sequence is 
211 amino acids long it is quite a large fusion protein (Thermo Scientific/Pierce47).  The 
purification process is carried out in near physiological conditions which may help to 
stabilise the PcCir2 protein and prevent the aggregation and/or degradation observed 
in the experimental work during this thesis.  However there are problems in running 
GST tagged proteins on denaturing protein gels as the GST protein degrades (Thermo 
Scientific/Pierce) leading to additional bands on the gel.  The Strep-tag® is highly 
selective for Strep-Tactin® and proteins are purified in a one step process under 
                                                 
47 http://www.piercenet.com/browse.cfm?fldID=4A8ADF29-5056-8A76-4EC6-63375BA024E7.  Accessed 
on 5 September 2012. 
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physiological conditions (IBA protocol48).  The high selectivity of the Strep-tag® for 
Strep-Tactin® may eliminate many of the contaminating proteins observed when PcCir2 
was purified, and the procedure occurring under physiological conditions.  The different 
purification tag may prevent some of the aggregation and/or degradation observed.  
Potentially, the addition of a maltose-binding protein (MBP) fusion tag to the 
recombinantly expressed PcCir2 should also be assessed.  Moreover, the MBP tag may 
assist with the solubility of the protein and prevent aggregation after purification 
(Nallamsetty and Waugh, 2007). 
 
Recombinant expression of Cir homologues 
To achieve soluble expression of a Cir domain numerous different Cir protein domains 
could be expressed.  First an alignment of many different Cir amino acid sequences 
would be created, and the putative domains selected which correspond to the putative 
ordered domain found for PcCir2.  Each of these putative domains may be cloned and 
expressed in E. coli with the intention of obtaining soluble and purified protein that 
could be used for crystallography trials.  Refinements in experimental approach may 
include expression and purification of protein domains from BIR and YIR sequences in 
order to maximise the chances of obtaining soluble purified protein. 
 
To investigate possible protein-protein interactions, a yeast two-hybrid screen could be 
carried out.  However, this would depend on the identification of potential ligands for 
the PcCir2 protein.  The use of Co-immunoprecipitation of the discussed full-length 
PcCir2 purification may provide some ‘lead’ ligands in the form of co-purified E. coli 
proteins.  Interaction proteins could then be identified using mass spectrometry 
techniques. 
 
Cir localisation 
Several questions remain regarding the subcellular localisation of PcCir proteins. 
Although PcCir proteins have been localised to the red blood cell surface, it is not clear 
which termini is present on the surface (Janssen et al, 2004).  A second question 
relates to where in the RBC/RBCm the proteins locate.  For example, are they present 
in Maurer’s Clefts?  Is there an intracellular location of any PcCir (or even PIR) 
                                                 
48 http://www.stratech.co.uk/pdf_folder/PR03_Streptag_pur_Protocol_0003.pdf.  Accessed on 5 
September 2012. 
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proteins?  To attempt to answer these questions antibodies could be designed to 
degenerate protein sequences at either termini of the protein/s.  Such antibodies 
would then be exploited for immunofluorescence analyses of the Cir proteins in P. 
chabaudi infected RBCs taken from a rodent model. 
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Appendix 1: Bacterial Growth Media 
 
2xTY     16 g/L tryptone, 10 g/L yeast extract, 5 g/L 
     sodium chloride. 
 
JC Minimal Salts Medium   4 g/L potassium dihydrogen phosphate, 10.5 
     g/L potassium hydrogen phosphate, 1 g/L 
     ammonium sulphate, 0.05 g/L magnesium 
     chloride, 2.5 g/L LB, 10 µM sodium  
     molybdate, 10 µM sodium selenate, 10 ml/L 
     sulphur free salts. (Jia et al, 2009) 
 
LB Agar    1.2 % agar (w/v) in LB medium.  
 
Luria Bertani (LB) medium  25 g/L LB powder (Invitrogen). 
 
M9 Media    200 ml/L M9 minimal salts, 2 mM magnesium 
     sulphate, 0.1 mM calcium chloride, 0.4 % 
     (w/v) glycerol, pH 6.8. 
 
M9 Minimal Salts    64 g/L disodium hydrogen phosphate, 15 g/L 
     potassium dihydrogen phosphate, 12.5 g/L 
     sodium chloride, 25 g/L ammonium chloride. 
 
Super Optimal Broth (SOB) 20 g/L tryptone, 5 g/L yeast extract, 10 mM 
     sodium chloride, 2.5 mM potassium chloride, 
     0.5 mM magnesium sulphate, 0.5 mM  
     magnesium chloride. 
 
SOB with Catabolite repression SOB medium with 20 mM glucose. 
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Sulphur free salts   82 g/L magnesium chloride, 10 g/L  
     manganese chloride, 4 g/L iron(III)chloride, 1 
     g/L calcium chloride, 20 ml hydrochloric acid 
     (Cole et al, 1974). 
 
TGYEP    10 g/L tryptone, 5 g/L yeast extract, 5 g/L 
     dipotassium hydrogen phosphate, 12 g/L 
     potassium dihydrogen phosphate, pH 6.7. 
 
Werkmans Minimal Medium  50 mM disodium hydrogen phosphate, 50 mM 
     potassium dihydrogen phosphate, 1 mM 
     magnesium sulphate, 0.1 mM calcium  
     chloride, 15 mM ammonium sulphate, 80 mM 
     glucose, pH 6.5 (Suppmann and Sawers, 
     1994).
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Appendix 2: Oligonucleotide Primers 
 
Name Sequence (5'->3') Insert/Purpose L RES 
NitAopt F CGAACTGCAGTTCCCTTTCTTC Full-length Opt NitA for pV5GPD  22 PstI 
Y212K R CGGAGAAGACTTTGCCAGCGCCGTC Opt NitA Y212K mutation  25  
Y212K F GACGGCGCTGGCAAAGTCTTCTCCG Opt NitA Y212K mutation  25  
NitAopt R ACGGTATCGATAAGCTTGATATCGAATTCGACGTCCTAGGT Full-length Opt NitA for pV5GPD 41 ClaI 
PcCir2Dom F GCACCCATGGCCAAAGATCTGTGCGAT PcCir2 Domain for pEHISTEV and pEHISGEFTEV 27 NcoI 
PcCir2Dom R CGTGCTCGAGTCAGTTTTTAAAGTTATCATAATCTTTG PcCir2 Domain for pEHISTEV and pEHISGEFTEV  38 XhoI 
PcCir2Dom2 F GCACCCATGGCAAACAACGATAGCCAGAAA PcCir2 Domain2 for pEHISTEV and pEHISGEFTEV 30 NcoI 
PcCir GFPe F GCAGCTCGCGGATGGCCAAAGATCTGTGCGATG Opt Cir2 for pGFPe and pHA-1 33 XhoI 
PcCir GFPe R CGTCGGTACCCCCACATAGCTCGCCATTTTG Opt Cir2 for pGFPe and pHA-1 31 KpnI 
PcCir2 40 R GCTCGGTACCCCGTTGGTCGGGCAATAGG Opt Cir2 40 for pGFPe and pHA-1 29 KpnI 
PcCir2 106 R GCTCGGTACCCCAAAGGTCTGGTTCGGATG Opt Cir2 106 for pGFPe and pHA-1 30 KpnI 
PcCir2 210 R CGTCGGTACCCCGTTTTTAAAGTTATCATAATCTTTC Opt Cir2 210 for pGFPe and pHA-1 37 KpnI 
PcCir2 254 R GCTCGGTACCCCGCTAATATCTTCGCTGTTATG Opt Cir2 256 for pGFPe and pHA-1 33 KpnI 
PcCir2 73 F CCACCTCGCGGATGAAAAACAACGATAGCCAG Opt Cir2 73 for pGFPe and pHA-1 32 XhoI 
NitAopt TTQ F CCAGGAATTCGCATATGCCGCCCAACAACAGCAAA Full-length Opt NitA for TTQ18  35 EcoRI 
NitAopt V5 TTQ R GAGGAAGCTTCTAGGTGGAGTGAAGACCGAGGAG Full-length Opt NitA with V5 tag for TTQ18  34 HindIII 
FocA F CCGGAATTCGCATATGAAAGCTGACAACCCTTTTG Full-length EcFocA for TTQ18 35 EcoRI 
FocA R AAAACTGCAGCATGGTGGTCGTTTTCACGCAGG Full-length EcFocA for TTQ18  33 PstI 
NirC F CCGGAATTCGCATATGTTACAGACACTAT Full-length EcNirC for TTQ18 29 EcoRI 
NirC R AAAACTGCAGCACCGGCAGCCGTTTCAGTT Full-length EcNirC for TTQ18 30 PstI 
5’ KO check int F GCATAAGCTTGTACAATTGAGTTAAGTGGATGG Check integration of 5’ pCC KO  33 HindIII 
5’ KO check int R CCAATAGATAAAATTTGTAGAG Check integration of 5’ pCC KO 22  
3’ KO check int F CATATGTTAAATATTTATTTCTC Check integration of 3’ pCC KO 23  
3’ KO check int R GGACTCTAGAGGATATCAGCGCAAACATGTGATGGA Check integration of 3’ pCC KO 36 XbaI 
PfNitA KO 750 5 F CAGGCCGCGGGAATGAATACATACTAAGAGCAGC PfNitA 5' 724 bp for pCC1/4  34 SacII 
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Name Sequence (5'->3') Insert/Purpose L RES 
PfNitA KO 750 5 R GAACCTTAAGGTGCTCATGTCAAATGGGTAC PfNitA 5' 724 bp for pCC1/4 31 AflII 
PfNitA KO 750 3 F CGAGCCATGGGCTGGTGCAATTGTTTTGGG PfNitA 3' 756 bp for pCC1/4 30 NcoI 
PfNitA KO 750 3 R GATCCCTAGGGGTGATTTGAACAACAGGACAATG PfNitA 3' 756 bp for pCC1/4 34 AvrII 
PfNitA KO 500 5 F CAGGCCGCGGGCCACCAAATAATTCCAAATATG PfNitA 5' 508 bp for pCC1/4 33 SacII 
PfNitA KO 500 5 R GAACCTTAAGCTCATCGATGCTCCTACGATTTC PfNitA 5' 508 bp for pCC1/4 33 AflII 
PfNitA KO 500 3 F CGAGCCATGGGTTAGGAAATTACTTAAGCTC PfNitA 3' 542 bp for pCC1/4 31 NcoI 
PfNitA KO 500 3 R GATCCCTAGGGTATTTTATATGCCATTAGCTC PfNitA 3' 542 bp for pCC1/4 32 AvrII 
PfNitACtml GW F CACCCTTATTTATCCTGGAGCATTTAC C - terminal PfNitA for Gateway™ Cloning  27  
PfNitA GW R ATTTCGTAATTCTATAGATAAA C - terminal PfNitA for Gateway™ Cloning  22  
PfNitA F1 CACAAATTAAGAGAAATCGTAGG Check integration of C-terminal PfNitA fragment  23  
GW int R1 CGTTTTACAACGTCTCGAGGG Check integration of C-terminal PfNitA fragment  21  
GFP mut2 R CGCGAAAGTAGTGACAAGTG Check integration of C-terminal PfNitA fragment with GFP tag 20  
NitAopt GW F CACCATGCCGCCCAACAACAG Full-length Opt NitA for Gateway™ Cloning 21  
NitAopt GW R GGTGGAGTCAAGACCGAG Full-length Opt NitA for Gateway™ Cloning 18  
CD F ATCCCTTCCTTACTACAGAATAGG Amplification of CD 24  
CD R ATCAGATTGTTGGTTGAAGAAGG Amplification of CD 23  
hDHFR F GCGCGGATCCATGCATGGTTCGCTAAAC Amplification of hDHFR 28  
hDHFR R GCGCGCTTAATCATTCTTCTCATATAC Amplification of hDHFR 27  
PfNitA pHH1 KO F GCAGAGATCTGACTTTTATATTATAAAGTGTATGC Amplification of NitA for pHH1 based knock-out and control 35 BglII 
PfNitA pHH1 KO R GCAGCTCGAGTTAGATAAAATATATGATAAAATATATTCCTATTGG Amplification of NitA for pHH1 based knock-out 46 XhoI 
PfNitA pHH1 KOcon R GCAGCTCGAGGCCATTAGCTCAATTTCGTAATTCTATAG Amplification of NitA for pHH1 based knock-out control 39 XhoI 
L= number of nucleotides.  RES = Restriction Endonuclease Site, underlined in sequence. 
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Appendix 3: Accession Numbers 
 
Accession numbers for the genes referred to in this text were obtained from the National 
Centre for Biotechnology Information (NCBI)49 or PlasmoDB50 databases and are as follows: 
 
Organism Protein Number 
P. falciparum NitA, putative formate-nitrite transporter PFC0725c 
E. coli FocB CAQ32863.1 
P. knowlesi putative transporter PKH_082480 
P. berghei putative formate-nitrite transporter PBANKA_041440 
P. chabaudi putative formate-nitrite transporter PCHAS_041530 
P. yoelii putative formate-nitrite transporter PY06388 
P. vivax putative transporter PVX_095405 
E. coli FocA CAQ31432.1 
H. influenzae formate transporter YP_247898.1 
S. typhimurium NirC AAA27040.1 
E. coli NirC CAQ33687.1 
S. boydii NirC YP_001882042.1 
B. subtilis formate-nitrite transporter NP_391685.1 
S. aureus formate-nitrite transporter YP_039761.1 
C. sticklandii fdhc protein YP_003937095.1 
M. thermautotrophicus fdhc protein AAC44819.1 
M. formicicim probable formate transporter P35839.1 
B. cereus fdhC gene product YP_085067.1 
C. albicans transporter family CAA21934.1 
S. cerevisiae YHL008C AAS56428.1 
T. gondii putative formate-nitrite transporter XP_002369729.1 
E. gracilis FocA-like AAS66886.1 
B. bovis formate-nitrite transporter family protein XP_001608703.1 
T. annulata formate-nitrite transporter XP_951799.1 
C. reinhardtii formate-nitrite transporter Nar 1.3 XP_001701278.1 
C. reinhardtii formate-nitrite transporter Nar 1.4 XP_001700148.1 
V. cholerae Chain D, Pentameric Formate Channel 3KLZ_D 
A. nidulans formate-nitrite family transporter CBF78263.1 
C. difficile Chain E, Crystal Structure Of Hsc K16s 3TE2_E 
S. typhimurium formate transporter YP_005232043.1 
P. chabaudi Cir2  PCHAS_000290 
 
  
  
  
 
 
                                                 
49 http://www.ncbi.nlm.nih.gov/guide/.  Accessed on 10 August 2012. 
50 http://plasmodb.org/plasmo/.  Accessed on 10 August 2012. 
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Appendix 4: Abbreviations 
 
General Abbreviations 
 
APS  ammonium persulphate 
ATP  adenosine triphosphate 
BCA  bicinchoninic acid 
BCIP  5-bromo-4-chloro-3-indolyl phosphate 
BCKDH  branched chain alpha-keto acid dehydrogenase 
bis  N, N’ – methylene bisacrylamide 
bp  base pair (s) 
Bla  blasticidin 
BSA  bovine serum albumen 
BSD  blasticidin-S-deaminase 
Bs  Bacillus sphaericus 
bti  Bacillus thuringiensis var. israelensis 
CBB  Coomassie Brilliant Blue 
CD  circular dichroism spectrophotometry 
cDNA  complementary deoxyribonucleic acid 
C-terminal carboxy terminal 
CQ  chloroquine 
oC  degrees centigrade 
Da  Daltons 
DABCO  1,4-Diazabicyclo[2.2.2]octane 
DAPI  4', 6-diamidino-2-phenylindole dihydrochloride 
DDT  dichlorodiphenyltrichlorethane 
DHFR  dihydrofolate reductase 
DHOD  dihydroorotate dehydrogenase 
DHPS  dihydropteroate synthase 
DIC  differential interference contrast 
DMSO  dimethyl sulphoxide 
DNA  deoxyribonucleic acid 
DSM  drug selectable marker 
DTT  dithiothreitol 
DV  digestive vacuole 
DVM  digestive vacuole membrane 
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DW  distilled water 
ECL  enhanced chemiluminescence 
EDTA  ethylenediaminetetraacetic acid 
EGTA  ethyleneglycoltetraacetic acid 
ETC  electron transport chain 
FITC  Fluorescein isothiocyanate 
FNT  formate-nitrite transporter 
g  gram (s) 
g  gravity 
gDNA  genomic deoxyribonucleic acid 
GFP  green fluorescent protein 
GOI  gene of interest 
h  hour (s) 
HAc  haemagglutinin 
HAT  human African trypanosomiasis 
Hb  haemoglobin 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His  Histadine (tag) 
HVR  hypervariable region 
IB (s)  inclusion body (ies) 
IDC  intraerythrocytic developmental cycle 
IE  infected erythrocyte (s) 
IFA  immunofluorescence analysis 
IPP  isopentenyl pyrophosphate 
IPTG  isopropyl β-D-1-thiogalactopyranoside 
iRBC  infected red blood cell (s) 
k  kilo 
kb  kilobases 
KO  knock out 
kpsi  kilo pound-force per square inch 
L  litre 
LB  Luria Bertani 
LBA  long branch attraction 
LDS  lithium dodecyl sulphate 
M  molar 
MCS  multicloning site 
MCT  monocarboylate transporter 
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µg  micro gram (s) 
µl  micro litre (s) 
µM  micro Molar 
mg  milli gram (s) 
ml  milli litre (s) 
mM  milli Molar 
min (s)  minute (s) 
MOPS  3-(N-morpholino) propanesulfonic acid 
MQ  milliQ 
NED  N-1-naphthylethylenediamine dihydrochloride 
nm  nanometers 
NO  nitric oxide 
N-terminal amino terminal 
OD  optical density 
ORF  open reading frame 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PEP  phosphoenolpyruvate 
PEXEL  Plasmodium export element 
PhoA  alkaline phosphatase 
PIPES  2-[4-(2-sulfoethyl)piperazin-1-yl]ethanesulfonic acid 
PIR  Plasmodium interspersed repeats 
pNPP  p-nitrophenyl phospate 
PPM  parasite plasma membrane 
PV  parasitophorus vacuole 
PVM  parasitophorus vacuole membrane 
PVDF  polyvinylidene fluoride 
PVM  parasitophorus vacuole membrane 
RBC  red blood cell (s) 
RBCm  red blood cell membrane 
rpm  revolutions per minute 
RPMI  Roswell Park Memorial Institute 
RT  room temperature 
s  second (s) 
SDS  sodium dodecyl sulphate 
SEM  standard error of the mean 
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SOB  super optimal broth 
SOC  super optimal broth with catabolite repression 
SOD  superoxide dismutase 
TAE  trisacetate-EDTA 
TBS  tris-buffered saline 
TBST  tris-buffered saline tween-20 
TCA  tricarboxylic acid 
TE Buffer tris-EDTA 
TEMED  N, N, N’, N’ – tetramethylethylenediamine 
TEV  tobacco etch virus (protease site) 
Tris  tris(hydroxymethyl)aminomethane 
TRITC  tetramethyl rhodamine iso-thiocyanate 
Tween-20 polyoxyethylene sorbitan 
U  unit (s) 
UTR  untranslated region 
UV  ultraviolet 
VSA  variant surface antigen (s) 
VTS  vacuolar targeting sequence 
v/v  volume per volume 
w/v  weight per volume 
WHO  World Health Organisation 
WR 99210 Walter Reed Institute anti-DHFR antifolate 99210 
2D  two dimensional 
3D  three dimensional 
3’  three prime 
5’  five prime 
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Protein Abbreviations 
PfAQP  Plasmodium falciparum aquaglyceroporin 
PfCRT  Plasmodium falciparum chloroquine resistance transporter 
PfEMP-1 Plasmodium falciparum erythrocyte membrane protein-1 
PfFT1 and 2 Plasmodium falciparum folate transporters 1 and 2 
PfMDR  Plasmodium falciparum multi drug resistance transporter 
PfMRP  Plasmodium falciparum multi resistance-associated protein 
PfNHE  Plasmodium falciparum Na+/H+ exporter 
PfHT  Plasmodium falciparum hexose transporter 
PfNitA  Plasmodium falciparum formate/nitrite transporter, putative 
PfNT/PfENT Plasmodium falciparum nucleoside transporter 
YHL008c FNT protein of S. cerevisiae 
PfNitA  FNT protein of Plasmodium falciparum 
NirC  FNT proteins of E. coli and Salmonella and Thermofilum pendens 
Nar1  FNT protein of Chlamydomonas reinhardtii 
PcCir2  Plasmodium chabaudi Cir2 
FocA/B  FNT protein of E. coli and V. cholerae 
EgFth  FNT protein of Euglena gracilis 
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Amino Acid Abbreviations 
 
A ala alanine 
R arg arginine 
N asn asparagine 
D asp aspartate 
C cys cysteine 
E glu glutamate 
Q gln glutamine 
G gly glycine 
H his histidine 
I ile isoleucine 
L leu leucine 
K lys lysine 
M met methionine 
F phe phenylalanine 
P pro proline 
S ser serine 
T thr threonine 
W trp tryptophan 
Y try tyrosine 
V val valine
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Appendix 5: Data Collected from BLASTP Database 
Searches. 
 
Query: S. cerevisiae, AAS56428.1. 
Species Gene Anotation e-value bit score max ident 
Ogataea parapolymorpha formate transporter 1, putative 8e-111 352 57 % 
Candida glabrata hypothetical protein 0.0 542 47 % 
Candida albicans transporter family 8e-116 365 45 % 
Spathaspora passalidarum putative formate transporter 1 8e-128 395 44 % 
Wickerhamomyces ciferrii putative transporter 5e-139 429 40 % 
 
Query: P. falciparum, PFC0725c. 
Species Gene Anotation e-value bit score max ident 
P. vivax transporter, putative 6e-148 421 78 % 
P. knowlesi  transporter, putative 9e-162 458 73 % 
P. berghei transporter, putative 1e-154 440 71 % 
P. yoelli formate/nitrite transporter, putative 2e-153 437 70 % 
P. chabaudi transporter, putative 2e-74 230 67 % 
 
Query: E. coli NirC, CAQ33687.1. 
Species Gene Anotation e-value bit score max ident 
Shigella flexneri putative nitrite transporter 0.0 533 99 % 
Salmonella enterica Nitrite transporter NirC 3e-177 500 93 % 
 
Query: E. coli FocA, CAQ31432.1. 
Species Gene Anotation e-value bit score max ident 
Shigella flexneri putative formate transporter 1 0.0 577 99 % 
Salmonella enterica formate transporter 0.0 562 96 % 
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Appendix 6:  Synthetic Codon-Optimised Gene Sequences 
 
pfnita_optEc 
ATGCCTCCGAATAATTCAAAATATGTTCTGGATCCGGTGAGCATTAAAAGCGTTTGTGGTGGTGAAGAAA
GCTATATTCGTTGCGTGGAATATGGCAAAAAAAAAGCCCATTATAGCAACCTGAATCTGCTGGCAAAAGC
AATTCTGGCAGGTATGTTTGTTGGTCTGTGTGCACATGCAAGCGGTATTGCCGGTGGTCTGTTCTATTAT
CATAAACTGCGTGAAATTGTTGGTGCCAGCATGAGCGTTTTTGTTTATGGTTTTACCTTTCCGATCGCCT
TCATGTGTATTATTTGTACCGGTAGCGACCTGTTTACAGGTAATACCCTGGCAGTTACCATGGCACTGTA
TGAGAAAAAAGTTAAACTGCTGGATTATCTGCGCGTGATGACCATTAGCCTGTTTGGTAATTATGTGGGT
GCAGTTAGCTTTGCCTTTTTTGTTAGCTATCTGAGCGGTGCCTTTACCAATGTTCATGCCGTTGAAAAAA
ACCATTTTTTTCAGTTTCTGAACGATATCGCCGAAAAAAAAGTGCATCACACCTTTGTTGAATGTGTTAG
CCTGGCCGTTGGTTGCAACATTTTTGTTTGTCTGGCCGTTTATTTTGTGCTGACCCTGAAAGATGGTGCA
GGTTATGTGTTTAGCGTGTTTTTTGCCGTTTATGCATTTGCCATTGCCGGTTATGAACATATTATCGCCA
ACATCTATACCCTGAATATTGCCCTGATGGTGAACACCAAAATTACCGTTTATCAGGCCTACATCAAAAA
TCTGCTGCCGACCCTGCTGGGTAACTATATTGCGGGTGCAATTGTTCTGGGTCTGCCGCTGTATTTTATC
TATAAAGAGCACTACTATAACTTTGAACGCAGCAAACGCGATAATAATGATGCACAGATGAAAAGCCTGA
GCATTGAACTGCGTAAT 
 
pfnita_opt 
ATGCCGCCCAACAACAGCAAATACGTCCTTGATCCCGTCAGCATCAAATCCGTCTGCGGCGGCGAGGAGA
GCTACATCCGATGCGTCGAATATGGTAAGAAGAAAGCCCACTATTCCAACCTGAACCTGCTCGCTAAGGC
TATCCTCGCCGGCATGTTCGTCGGCCTCTGCGCCCACGCCTCCGGCATCGCCGGCGGCCTCTTCTATTAC
CACAAGCTCCGCGAGATCGTCGGCGCCTCTATGTCCGTCTTCGTTTACGGTTTCACATTCCCTATCGCCT
TCATGTGCATCATCTGCACCGGTTCCGATCTCTTCACCGGTAACACTCTTGCCGTTACGATGGCTCTCTA
CGAGAAGAAGGTCAAGCTCCTGGACTACCTGCGCGTTATGACTATCTCTCTTTTCGGCAACTACGTCGGC
GCCGTCTCCTTCGCTTTCTTCGTCTCCTACCTCTCTGGCGCCTTCACCAACGTTCACGCCGTCGAGAAGA
ACCACTTCTTCCAATTCCTTAACGACATCGCCGAGAAGAAAGTTCACCACACTTTCGTCGAGTGCGTTTC
GCTCGCTGTCGGCTGCAACATCTTCGTCTGCCTCGCTGTCTACTTCGTCCTGACCCTCAAGGACGGCGCT
GGCTACGTCTTCTCCGTCTTCTTCGCTGTCTACGCTTTCGCCATCGCCGGTTACGAGCATATCATCGCTA
ACATATATACCCTCAACATCGCCCTCATGGTCAACACCAAGATCACCGTCTACCAGGCCTACATCAAGAA
CCTCCTGCCCACTCTGCTCGGCAACTACATCGCCGGTGCCATCGTTCTCGGCCTTCCCCTTTACTTCATC
TACAAGGAACATTATTACAACTTCGAACGCTCGAAGCGCGATAACAACGACGCCCAGATGAAGTCTCTCA
GCATCGAGCTCCGCAAC 
 
pccir2 
ATGAACAAAGATCTGTGCGATGTGATTAAAGGCATTGATGATCTGATTGAAGTGGAAGTGAAAGCGGAAG
GCATTGAAACCATTCGTGATGAACTGTTTAACACCTATTGCCCGACCAACAAAGGCGGCAAAATGCGTCA
GCAGGGCCAGGATGGCTGCTGCATTGGCTATAGCGAAACCGTGATTAGCGCGTTTATTCATCTGCAAGAA
ACCCTGAAAAACAACGATAGCCAGAAAAAACTGGATCGTGATAAACTGGCGCAGTATGCGATTCTGTGGC
TGAGCTATAAAATTAACCAGCATCCGAACCAGACCTTTGGCACCAACGATATCTACAACAACTTCAAACA
GTACGGCTACTGGAACCGTGAACATAACAACTACATCGAACAGATCAAGAAATACGTGGATATCAAAGAT
ATGACCAAACTGCATGAAGCGTTTATTCTGCTGTGCAACATGTATACCGAAATTGATGAAAACAAAAGCA
ACTGCACCAAATGCAGCCAGAAAGCGAGCGAATTTGTGAAAAAATTTGAAATTCTGAACGATGATCCGAA
CCATATTAAAGATAGCCCGTATAGCCAGATTCTGCTGACCCTGAGCAAAGATTATGATAACTTTAAAAAC
TGCTGCAACAAGAAAAAGGGTGAAAGCTGCGATTTTCCGAGCCTGCCGCAGATTAGCCCAAAGAAAAGCT
TTGCGCAGAACAGCCTGGAAAGCCCGGGCCATACCAGCGGCCATAACAGCGAAGATATTAGCAGCAAAAG
CCCGATGGCGAACAAACTGATTCCGGGCCTGCTGATTTTTGCGGCGATTCCGGTGTTTCTGGGCATTGCG
TATAAATATAGCCTGTTTGGCTTTGATAAACAGCGTCATCGTCAGTATCTGCGTGAAAAAATTAAGAAAA
TCAAAAACAAAATGGCGAGCTATGTGGC 
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Appendix 7:  Raw Data 
 
Appendix 7.1.1 
 
Nitrite uptake assay -  calculated nitrite concentration [mM] in the medium at various time 
points in each of the replicates for the control study. 
 
replicate sample 30 60 120 240 
1 4018 76 63 25 9 
 4520 80 88 70 43 
 Control 86 89 85 89 
2 4018 83 62 34 10 
 4520 80 87 81 49 
 Control 81 82 79 81 
3 4018 66 49 9 9 
 4520 89 88 81 75 
 Control 62.308 63.077 66.154 68.426 
4 4018 76 57 10 9 
 4520 83 88 81 75 
 Control 66.154 68.462 65.385 68.462 
5 4018 58.462 43.846 7.692 6.923 
 4520 68.426 67.962 61.538 57.692 
6 4018 50.769 37.692 6.923 6.923 
 4520 63.846 67.962 64.615 57.692 
7 4018 63.846 47.692 25.154 7.692 
 4520 61.538 67.962 53.846 33.077 
8 4018 58.462 48.462 19.231 6.923 
 4520 61.538 66.923 62.308 37.692 
 
Nitrite uptake assay -  calculated nitrite concentration [mM] in the medium at various time 
points in each of the five replicates. 
 
replicate sample 0 30 60 90 120 
1 4018 100.952 102.857 76.190 47.619 28.271 
 4520 102.857 100.952 101.905 100.000 90.476 
 NirC 109.524 78.095 70.476 62.857 53.333 
 FocA 85.714 85.905 75.428 72.286 68.762 
 NitA 107.619 104.762 104.762 90.470 102.857 
 NitA/Ec 83.164 86.849 84.217 85.963 84.911 
 HK 100.952 113.333 107.619 110.476 112.381 
 control 105.714 105.714 103.810 100.952 102.857 
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2 4018 90.476 76.190 56.190 24.762 9.524 
 4520 89.524 81.905 81.905 81.905 76.190 
 NirC 80.952 80.952 66.667 64.762 60.952 
 FocA 69.119 69.936 60.436 57.543 54.441 
 NitA 106.667 92.381 91.429 84.762 77.143 
 NitA/Ec 81.991 84.500 78.716 77.375 69.473 
 HK 86.667 86.667 91.429 89.524 90.476 
 control 80.952 87.619 86.667 80.000 88.571 
 
      
3 4018 94.286 87.619 74.286 59.048 50.476 
 4520 86.667 89.524 88.571 85.714 79.048 
 NirC 80.952 83.810 75.238 62.857 59.048 
 FocA 92.381 100.000 76.190 64.762 66.667 
 NitA 88.571 92.381 91.429 81.905 82.857 
 NitA/Ec 75.205 77.896 78.711 84.800 87.898 
 HK 82.857 88.571 80.952 85.714 82.857 
 control 93.333 86.667 88.571 93.333 85.714 
 
      
4 4018 88.571 59.048 14.286 8.571 9.524 
 4520 116.190 106.667 98.095 93.333 95.238 
 NirC 88.571 69.524 57.143 42.857 31.429 
 FocA 87.619 70.476 62.857 52.381 44.762 
 NitA 85.714 86.667 86.667 90.476 78.095 
 NitA/Ec 78.450 80.791 79.978 78.576 76.813 
 HK 91.429 92.381 95.238 98.095 98.095 
 control 80.000 80.952 81.905 81.905 82.857 
 
       
5 4018 75.238 77.143 60.000 34.286 12.381 
 4520 77.143 90.476 88.571 80.952 76.190 
 NirC 72.381 71.429 54.286 40.952 35.238 
 FocA 72.381 95.238 85.714 90.952 86.667 
 NitA 78.095 89.524 92.381 84.762 85.714 
 NitA/Ec 78.955 79.300 80.358 77.089 73.221 
 HK 80.000 89.524 97.143 83.810 87.619 
 control 69.524 86.667 85.714 76.190 81.905 
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Appendix 7.1.2 
 
Nitrite uptake assay statistics. 
 
Descriptives 
VAR 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
1.00 5 22.0352 17.70613 7.91842 .0501 44.0203 
2.00 5 83.4284 8.84749 3.95672 72.4428 94.4140 
3.00 5 48.0000 13.74518 6.14703 30.9331 65.0669 
4.00 5 68.7548 15.74102 7.03960 49.2097 88.2999 
5.00 5 85.3332 10.40230 4.65205 72.4170 98.2494 
6.00 5 78.4606 7.78263 3.48050 68.7972 88.1240 
7.00 5 94.2856 11.52741 5.15521 79.9724 108.5988 
8.00 5 88.3808 8.50230 3.80235 77.8238 98.9378 
Total 40 71.0848 25.70385 4.06414 62.8643 79.3053 
 
ANOVA 
VAR 
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 20957.063 7 2993.866 19.919 .000 
Within Groups 4809.768 32 150.305   
Total 25766.832 39    
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Appendix 7.2.1 
 
Formate β-galactosidase assay - calculated β-galactosidase activity (Miller Units) at various time 
points in each of the replicates for the control study. 
 
 
0 mM 0.1 mM 0.5 mM 
1 2147.37 
  
3123.08 
  
3350 
  2 2463.16 1580.95 1657.89 3507.69 2150 3947.37 3683.33 2866.67 6307.69 
3 2066.67 2189.47 3631.58 3485.71 2714.29 4666.67 3750 2753.85 5500 
4 2562.96 2216.67 3230.77 4327.27 3833.33 5214.29 2368.42 3783.33 4187.5 
20 2176.67 1994.03 
 
1547.83 1587.88 
 
1276.64 1191.6 
 24 693.33 
  
824.56 
  
788.43 
  
          
 
1 mM 2 mM RM201 
1 3366.67 
  
3366.67 
  
3165.22 
  2 3716.67 3316.67 6153.85 2477.78 3183.33 4733.33 1978.08 1602.78 5411.76 
3 2941.18 2584.62 5142.86 3100 4175 5266.67 1013.86 1230.93 5520 
4 3476.92 3533.33 4928.57 3185.71 4511.11 5500 1278.57 1239.62 4710.45 
20 1033.66 1240.37 
 
1472.16 1242.2 
 
1289.72 430.94 
 24 833.04 
  
906.42 
  
578.29 
   
Formate β-galactosidase assay - calculated β-galactosidase activity (Miller Units) at various time 
points in each of the five replicates. 
 
2 h 
 
1 2 3 4 5 
 
RM 2206.061 1895.455 1146.667 1509.302 2038.360 
 
Foc 3924.324 3961.290 4082.353 2724.138 1146.667 
 
Pf/Ec 2192.727 2400.000 2482.759 2073.333 1731.034 
 
Cir 1140.909 2009.091 2561.905 1544.000 1365.217 
 
Nir 2328.571 3208.333 2969.231 3053.846 3666.667 
3 h 
 
1 2 3 4 5 
 
RM 1137.391 1156.098 1731.915 1253.846 1623.810 
 
Foc 3158.974 3126.829 5670.588 3220.000 3244.444 
 
Pf/Ec 1850.794 1720.000 2311.765 2228.571 1737.500 
 
Cir 904.000 1610.169 2535.714 1566.667 1592.593 
 
Nir 3488.889 3936.842 2700.000 2792.000 3063.636 
4 h 
 
1 2 3 4 5 
 
RM 1125.180 1091.473 1407.273 1043.165 1378.430 
 
Foc 3390.698 4120.000 5326.316 2793.750 3420.000 
 
Pf/Ec 1888.525 1632.353 3166.667 1626.667 1857.895 
 
Cir 677.143 1642.623 2266.667 1913.514 1646.154 
 
Nir 2608.333 2727.273 3236.364 3272.727 3894.737 
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Appendix 7.2.2 
 
Formate β-galactosidase assay statistics. 
 
2 h test: 
Test of Homogeneity of Variances 
VAR 
Levene Statistic df1 df2 Sig. 
3.808 4 20 .018 
 
 
3 h test: 
Descriptives 
VAR 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
1.00 5 1380.6120 277.57507 124.13534 1035.9570 1725.2670 
2.00 5 3684.1670 1111.43253 497.04774 2304.1412 5064.1928 
3.00 5 1969.7260 280.36950 125.38505 1621.6013 2317.8507 
4.00 5 1641.8286 581.48471 260.04787 919.8200 2363.8372 
5.00 5 3196.2734 515.11714 230.36739 2556.6710 3835.8758 
Total 25 2374.5214 1087.28712 217.45742 1925.7113 2823.3315 
 
ANOVA 
VAR 
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 2.040E7 4 5098752.372 12.783 .000 
Within Groups 7977629.523 20 398881.476   
Total 2.837E7 24    
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4 h test: 
Descriptives 
VAR 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
1.00 5 1209.1042 170.55665 76.27525 997.3301 1420.8783 
2.00 5 3810.1528 969.01913 433.35853 2606.9566 5013.3490 
3.00 5 2034.4214 644.66078 288.30106 1233.9693 2834.8735 
4.00 5 1629.2202 590.35556 264.01503 896.1969 2362.2435 
5.00 5 3147.8868 512.16032 229.04506 2511.9558 3783.8178 
Total 25 2366.1571 1144.16303 228.83261 1893.8698 2838.4444 
 
ANOVA 
VAR 
 
Sum of 
Squares df Mean Square F Sig. 
Between Groups 2.344E7 4 5860151.110 14.691 .000 
Within Groups 7978012.245 20 398900.612   
Total 3.142E7 24    
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Appendix 7.3 GFP assay 
Truncation/ 
Replicate 
Final 
OD(600) 
Fluorescence 
units 
 Truncation/ 
Replicate 
Final 
OD(600) 
Fluorescence 
units 
PcCir240 0.129 9830  PcCir2254 0.115 8098 
1 0.133 8369  1 0.136 8098 
  0.108 9719    0.104 8139 
  0.109 9994    0.110 10023 
2 0.097 9988  2 0.109 10021 
  0.111 9991    0.115 10025 
  0.134 9980    0.141 10014 
3 0.122 9992  3 0.102 10017 
  0.136 9984    0.127 10016 
  0.137 9906    0.109 9933 
4 0.141 9888  4 0.116 9930 
  0.127 9899    0.118 9930 
  0.119 9993    0.118 10021 
5 0.147 9979  5 0.116 10021 
  0.130 9993    0.102 10027 
PcCir2106 0.115 4163  PcCir2 73 0.196 3720 
1 0.136 5433  1 0.227 4990 
  0.117 5127    0.180 4802 
  0.108 2675    0.189 3991 
2 0.109 2739  2 0.130 2521 
  0.123 3630    0.192 3780 
  0.143 3507    0.168 3061 
3 0.179 3805  3 0.168 3103 
  0.180 4075    0.147 2916 
  0.119 3122    0.180 2712 
4 0.133 3508  4 0.094 1058 
  0.147 3371    0.156 2249 
  0.116 3196    0.218 3972 
5 0.120 2953  5 0.170 3161 
  0.136 3160    0.218 4114 
PcCir2210 0.181 8792  PcCir2312 0.183 4099 
1 0.192 10057  1 0.152 3339 
  0.119 10058    0.205 4070 
  0.196 10090    0.181 3675 
2 0.179 10149  2 0.135 2517 
  0.191 10149    0.124 2470 
  0.159 8856    0.145 2714 
3 0.160 9470  3 0.176 2822 
  0.175 10180    0.151 2786 
  0.159 9113    0.183 2634 
4 0.172 8720  4 0.170 2702 
  0.178 10189    0.167 2654 
  0.172 8043    0.189 3177 
5 0.221 10112  5 0.209 3359 
  0.205 10108    0.194 3199 
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Appendix 7.4 PhoA assay 
Truncation/ 
Replicate OD600 OD420 
 
Truncation/ 
Replicate OD600 OD420 
PcCir240 0.139 0.002 
 
PcCir2254 0.124 0.003 
1 0.139 0.004 
 
1 0.158 0.002 
 
0.127 0.002 
  
0.16 0.002 
 
0.145 0.003 
  
0.115 0.001 
2 0.118 0.004 
 
2 0.122 0.002 
 
0.122 0.002 
  
0.117 0.002 
 
0.072 0.002 
  
0.075 0.002 
3 0.076 0.002 
 
3 0.074 0.001 
 
0.085 0.002 
  
0.11 0.003 
 
0.124 0.003 
  
0.134 0.003 
4 0.119 0.002 
 
4 0.123 0.001 
 
0.109 0.002 
  
0.088 0.004 
 
0.094 0.001 
  
0.098 0.004 
5 0.102 0.002 
 
5 0.125 0.003 
 
0.118 0.002 
  
0.076 0.002 
PcCir2106 0.138 0.003 
 
PcCir2 73 0.126 0.007 
1 0.161 0.005 
 
1 0.112 0.005 
 
0.158 0.004 
  
0.104 0.005 
 
0.173 0.003 
  
0.105 0.005 
2 0.132 0.001 
 
2 0.112 0.005 
 
0.145 0.001 
  
0.101 0.004 
 
0.096 0.002 
  
0.071 0.005 
3 0.074 0.001 
 
3 0.086 0.006 
 
0.107 0.004 
  
0.077 0.003 
 
0.12 0.004 
  
0.093 0.005 
4 0.105 0.002 
 
4 0.106 0.007 
 
0.115 0.003 
  
0.098 0.005 
 
0.095 0.003 
  
0.068 0.007 
5 0.121 0.004 
 
5 0.084 0.006 
 
0.071 0.003 
  
0.063 0.005 
PcCir2210 0.137 0.004 
 
PcCir2309 0.121 0.013 
1 0.141 0.005 
 
1 0.136 0.013 
 
0.152 0.004 
  
0.154 0.015 
 
0.111 0.002 
  
0.098 0.013 
2 0.104 0.002 
 
2 0.123 0.014 
 
0.12 0.002 
  
0.111 0.011 
 
0.093 0.003 
  
0.075 0.011 
3 0.086 0.003 
 
3 0.068 0.005 
 
0.092 0.002 
  
0.082 0.011 
 
0.102 0.001 
  
0.128 0.015 
4 0.116 0.002 
 
4 0.092 0.011 
 
0.114 0.002 
  
0.091 0.01 
 
0.1 0.003 
  
0.079 0.013 
5 0.081 0.001 
 
5 0.076 0.008 
 
0.079 0.001 
  
0.076 0.007 
 
